Activity Report
Research is in our DNA Since 1929 Activity Áreas de investigación Report Área de Trasplante de Órganos y Tejidos y Nuevas Terapias
Edita: IDIVAL Legal Deposit: SA 525-2015
Instituto de Investigación Marqués de Valdecilla Avda. Cardenal Herrera Oria s/n 39011 Santander – España 05
Contents
7 Foreword 15 Valdecilla 17 IDIVAL 19 Organisational Structure 27 Support for Researchers 43 Training 57 A few milestones in 2017 63 R&D+i at IDIVAL
97 Research Areas:
99 Organ and Tissue Transplant and New Therapies Area 131 Neuroscience Area 151 Cancer Area 191 Cross-Disciplinary Area 209 Infectious Diseases and Immune System Area 239 Metabolism, Diseases of Ageing and Lifestyle Habits Area 249 Associated Groups Activity Áreas de investigación Report Área de Trasplante de Órganos y Tejidos y Nuevas Terapias 07
Foreword
09
globalised world, Cantabria needs an international presence which allows us to maintain and improve our current level of excellence in healthcare. Similarly, we must be able to facilitate and recognise the extra efforts of the professionals in our healthcare system who are involved in research, and this recognition must be enough of an incentive to attract more highly qualified healthcare professionals. These are some of the keys to vitalising our healthcare services through research and innovation.
As I mention above, improving our treatment of patients’ problems is the core goal of healthcare research and innovation. One of the keys for dealing with the major problems facing our healthcare system is the multidisciplinary approach. In Cantabria we have experts in various disciplines who regularly work with us: engineers, physicists, economists, lawyers, and management specialists. They can all give us a competitive advantage in the development of our research and innovation projects. Here, Primary Care is an indisputable asset from the point of view of the quality of care, and it can also contribute great value in the sphere of research and innovation, as it approaches Improving the approach to health problems and most people’s healthcare problems as part of their their prevention are core goals for translational and everyday lives. innovation research in the healthcare field. Both areas are part of the identity of healthcare research This is a long-term investment which is sure to institutions like IDIVAL, which focus on these activities determine, at least partly, the sustainability of our in Spain’s leading hospitals. Treating and preventing healthcare system, and which we cannot do without. disease is undoubtedly one of the greatest tasks facing While we are aware of the limitations imposed by the our society, and finding a sustainable approach is an size of a region like ours, the Cantabrian Health Service ongoing challenge. has other very considerable development options.
The primary purpose of healthcare systems is to care Thanks to its healthcare professionals, Cantabria has for patients; however, the best international healthcare been able to consolidate IDIVAL as the benchmark centres also consider training new professionals and healthcare research institute in our region. The biomedical research to be an essential part of their challenges and possibilities it presents are enormous, activity. Balancing these three elements is not a simple matched by the ambition and determination of all our task, and requires simultaneously accommodating the professionals, who we must recognise and incentivise different views of the various institutions which must so their professionalism and hard work can give us the work closely together to do so: hospitals, universities, value of healthcare knowledge and innovation. and research centres. In our Autonomous Region teaching and research are especially important in the Marqués de Valdecilla University Hospital, one of Cantabria’s major generators of scientific knowledge, as attested by the indicators for recent years, including María Luisa Real González 2017, shown in this report. This stems from the Minister of Health of the Government of Cantabria. Hospital’s well-known past trajectory, which must President of the Board of IDIVAL continue to evolve to meet the demands of modern society.
IDIVAL must be an instrument to facilitate the approach to major healthcare-related challenges by fostering talent, innovation and internationalisation. IDIVAL contributes special value to the responsibility of training the coming generations of professionals so they can acquire the tools they need for a fully developed future career, by facilitating mobility, attracting and retaining new researchers, and training clinical personnel in aspects relating to research and innovation, in connection with leading international centres. In this
11
of this, because not many institutes enjoy support like the grants it provides for IDIVAL. In a small region, the continued excellence of IDIVAL would be impossible without this economic support.
The efforts of the current Regional Ministry to invest in high-technology at the HUMV will also enable IDIVAL to remain scientifically competitive. In 2017 it I would like to begin by congratulating the Director surpassed 2,000 impact factor points and a cumulative of IDIVAL, Galo Peralta, who was recently appointed total of 120,000 citations in international literature. As Head of the ITEMAS (healthcare technology well as the number of publications (443 in 2017), their innovation) platform of the Carlos III Health Institute. quality is also notable: over half are in the first quartile, As well as a national acknowledgement of his and the average impact factor (4.62) is excellent. management of IDIVAL, this is also a recognition of Valdecilla’s commitment to innovation, which can Despite these figures, we still have a long way to go. bring great opportunities to our institution and to As the Minister said in her foreword, according to Cantabria, a small region which can only compete in IDIVAL’s mission its research must focus on treating quality of research, not in quantity. and preventing health problems. Our research will only have meaning if it has the potential to benefit Readers examining the data in this Report will see that the public. To achieve this, more than ever, we must over 2017 IDIVAL has exceeded its goals. Everybody distance ourselves from conventional research which in the organisation, starting with its new scientific focuses more on methodology than on the problem, director, Professor Benedicto Crespo, should be and which does not offer any improvement in the well- congratulated for achieving their objectives. IDIVAL being of our patients. It is true that it is not easy to has grown in groups over 2017, and has grown by leave our comfort zone of project-based financing and considering unfairly neglected areas of healthcare change to results-based financing, and this will require (nursing, primary care) and non-healthcare areas changes in the administration’s recruitment policy (photonics engineering, healthcare law), confirming to enable us to attract real talent to our institutions, its inclusive nature. As just one example of the but this is the only way we can repay society for its success of this strategy, I would like to highlight its contributions. first patent (because it will not be the last) in prostate brachytherapy, one of the areas where HUMV is taking the lead thanks to its collaboration with the UC Photonics group. Julio Pascual Let’s talk about financing. Exactly two thirds of Managing Director of the Marqués de Valdecilla University IDIVAL’s budget comes from its own resources (private Hospital, member of the Board of Governors, and Chairman of or competitive). Here the figures speak for themselves: the Executive Committee of the IDIVAL Board of Governors more than 90 research projects and 211 clinical trials over 2017 (both figures are more than twice those for 2015). Undoubtedly, the recent regularisation to ensure transparency in clinical trial management has attracted more trials, and those trials are more complex and at earlier stages, which was a major goal for our hospital. The Government of Cantabria deserves thanks for all
13
Working to secure resources from European funds, to recruit and retain leading researchers with a high level of scientific activity, to foster research careers among young healthcare professionals, and to improve our national and international visibility should be the watchword for IDIVAL in the next few years. 2017 was a year of consolidation in the research activity and promotion of the Valdecilla biomedical I know that with the commitment and efforts of all the environment. And this strengthening of foundations actors involved, we can continue to be proud of our and recognition as the benchmark biomedical achievements, and we can be sure that the best is still research body of Cantabria may be its most important to come in our mission to benefit society. achievement of the year.
The figures for IDIVAL’s activity over the year (scientific output, attracting resources, achievements in innovation and level of internationalisation) continue Benedicto Crespo-Facorro to reflect the Institute’s leadership and attest to its Scientific Director of IDIVAL satisfactory progress. Meanwhile, IDIVAL’s milestones and new commitments include the addition of new research groups in areas like primary care, nursing, biomedical law, and photonics engineering, and a strong commitment to foster research and innovation among young professionals through PostMIR Valdecilla contracts, the mentoring programme, calls for Next- Val (Next Generation Valdecilla) projects for novice researchers, and summer internships.
As the national and international context of the Institute is highly competitive, all the agents who form part of it must share a similar vision. Only with clearly defined policies facilitating the selection and retention of the professionals best equipped for high-level research, who in many cases will undoubtedly also provide excellent clinical work, can we maintain the level of excellence required in this demanding context in national healthcare research.
Considering our present and near future, encouraged by our satisfaction with the achievements of recent years but also identifying future threats, I believe we need to commit to the coordination and functional convergence of the different institutions and bodies involved in research in the biomedical environment of Cantabria.
15
· Valdecilla
Valdecilla is the unifying brand field of biomedical sciences at the of health research institutes which Ramón Pelayo de la Marqués de Valdecilla University and in line with the points set Torriente, Marquis of Valdecilla, Hospital with the contribution out in Royal Decree 339/2004 applied to the institutions which of the University of Cantabria, of 27 February. Therefore, the he created: the Marqués de placing it at a level of national and constitution of IDIVAL implies Valdecilla University Hospital, the international excellence. strong support of its founding Marqués de Valdecilla Research institutions, the University of Institute (IDIVAL), the Valdecilla IDIVAL was conceived at the end Cantabria and the Government Virtual Hospital, and the Marqués of 2013 through an agreement of Cantabria, for health research de Valdecilla Foundation, and between the Government of in the Valdecilla setting. Taking which still maintains that original Cantabria and the University over from IFIMAV, IDIVAL was spirit of innovation, cross-border of Cantabria, as the heir of the launched in 2014 to harmoniously collaboration, and philanthropy. Marqués de Valdecilla Training integrate basic, clinical and public and Research Institute (IFIMAV). health research, encouraging The innovative spirit of the IFIMAV was established in 2002 translational research and Valdecilla brand is particularly as a research management promoting a better transfer of evident in IDIVAL, conceived unit within the Marqués de the scientific progress obtained with the goal of promoting Valdecilla Foundation and in addressing the most prevalent research and innovation in the evolved following the model health problems.
17
IDIVAL
IDIVAL promotes and manages published high-impact works in progress, and innovation in the biomedical research of the collaboration with some of the healthcare. IDIVAL’s current Marqués de Valdecilla University world’s best research groups in challenge is to maximise the Hospital and the University of various biomedical disciplines. application of research results Cantabria. It is financed by the Our impact factor was over to improve healthcare. In Government of Cantabria and the 2,000 points in 2017. We have partnership with prestigious University of Cantabria. accumulated over 120,000 institutions such as the Botín citations in international literature. Foundation, IDIVAL has launched IDIVAL encourages the an ambitious innovation development of knowledge. IDIVAL supports researchers. programme. IDIVAL promotes activities for In 2017, we launched several the development of excellent programmes to support IDIVAL is a leading institution. scientific output, and has innovation and research. IDIVAL IDIVAL was recognised by the established 19 high-impact issued grants for healthcare Carlos III Health Institute in 2015 research groups in six areas of research worth over a million as one of Spain’s Healthcare research: Cancer, Neuroscience, euros in 2017. Research Institutes. Transplants, Infection, Metabolism, and Transversal. IDIVAL is committed to society. Another 12 groups are also IDIVAL seeks to improve contributing to scientific output. translational research and promote progress in Cantabria. IDIVAL pursues excellence. Its goals include the development In 2017, IDIVAL’s researchers of knowledge, technological
19
Organisational Structure
BOARD OF Governing GOVERNORS and Advisory EXECUTIVE Bodies COMMITTEE
GENERAL SCIENTIFIC IDIVAL is governed in accordance with MANAGEMENT MANAGEMENT its statutes, published in the Official Gazette of Cantabria (BOC No. 7 of CENTRAL RESEARCH 13 January 2014), by a Board, an SUPPORT UNIT AREAS Executive Committee, a Management External Scientific Director, a Scientific Director and Council its own consulting bodies: Internal Scientific Council and External C.E.I.C. Scientific Council, appointed by the Bioethics Board. Committee Internal Scientific It is also advised by the Clinical Council Research Ethics Committee of Cantabria and the Bioethics Committee at the University of Cantabria in compliance with the legal requirements for research. Activity Organisational Structure Governing and Advisory Report Bodies
The Board of IDIVAL
In accordance with IDIVAL’s statutes, published in the Official Gazette of Cantabria of 13 January 2014, the board is the highest governing body of IDIVAL and has the highest level of representation. Among its functions are approving the budget, the action plan and the annual report of the Institute as well as appointing the directors and members of advisory bodies. In 2017, the Board was made up of the following individuals:
President: D. Piero Crespo Baraja. D. Jesús Castillo Obeso. Dª. María Luisa Real González. Professor at CSIC. Director of Specialist in Family and Community the Institute of Biomedicine and Medicine. “José Barros” Health Minister of Health and Social Services Biotechnology of Cantabria. Designated Centre (Camargo). Designated by of the Government of Cantabria. by the Rector of the University of agreement between the Minister for Cantabria. Health and the Rector of the Vice-president: University of Cantabria. D. Manuel Gómez Fleitas. Innovation Coordinator. General Surgery Dª. María del Carmen Fariñas D. Ángel Pazos Carro. Department. Marqués de Valdecilla Álvarez. Rector of the University of Cantabria. University Hospital. Professor in the Head of the Infectious Diseases Department of Medicine and Surgery. Department. Tenured Professor in the University of Cantabria. Designated by Department of Medicine and Chairs: the Managing Director of HUMV. Surgery. Designated by agreement between the Minister for Health D. María Antonia Mora González. D. Pedro José Prada Gómez. and the Rector of the University of General Director of Planning and Department Head. Radiation Oncology Cantabria. Healthcare, Ministry of Health. Department. Marqués de Valdecilla Designated by the Minister for Health. University Hospital. Designated by the Managing Director of HUMV. Secretary, non-board: Dª. María de la Cruz Reguera Andrés. D. José Antonio Riancho Moral. General Secretary. Section Head. Internal Medicine D. Joaquín Cayón de las Cuevas. Ministry of Health. Department. Marqués de Valdecilla Head of the Legal Counsel Office Designated by the Minister for Health. University Hospital. Professor in the of the Ministry of Health. Department of Medicine and Psychiatry. D. Julian Pérez Gil. University of Cantabria. Designated Manager of the Cantabrian Health by the Rector of the University of The IDIVAL Board met twice over Service. Cantabria. the year. During these meetings it appointed the new Scientific Director, D. Javier León Serrano. D. Javier Crespo García. approved the audited accounts and Vice Rector of Research and Head of the Digestive System report for 2016 and the action plan Knowledge Transfer. University of Department. Marqués de Valdecilla and budget for 2017, and renewed Cantabria. University Hospital. Professor in the its composition with the addition of Department of Medicine and Surgery. two new members to replace two University of Cantabria. Designated by D. Julio Pascual Gómez. departures. Managing Director of the Marqués de the Managing Director of HUMV. Valdecilla University Hospital. 21
Chairs: D. José Antonio Riancho Moral. Section Head. Internal Medicine Executive D. Javier León Serrano. Department. Marqués de Valdecilla Vice Rector of Research and Committee University Hospital. Professor in the Knowledge Transfer. University of Department of Medicine and Psychiatry. Cantabria. Representative of the University of Cantabria. Representative University of Cantabria. of the University of Cantabria. Dª. Mª de la Cruz Reguera Andrés. D. Luis Martínez Martínez. General Secretary. Ministry of Health. Head of the Microbiology Department. President: Representative of the Healthcare Marqués de Valdecilla University Administration. Hospital. Tenured Professor in the D. Julio Pascual Gómez. D. María Antonia Mora González. Department of Molecular Biology. President according to the statutes as General Director of Planning and University of Cantabria. Representative Managing Director of the Marqués de Healthcare, Ministry of Health. of the Healthcare Administration. Valdecilla University Hospital. Representative of the Healthcare Representative of the Healthcare Administration. Administration.
IDIVAL’s Executive Committee met once in 2017 in order to monitor the agreements signed by the Foundation in compliance with Article 33 of IDIVAL’s statutes. Activity Organisational Structure Governing and Advisory Report Bodies
Senior Management
IDIVAL’s senior management body consists of a Scientific Director and a Managing Director, Scientific Director: Managing Director: both appointed by the Board of The Scientific Director is the senior The Managing Director acts as the Governors. representative and spokesperson representative and spokesperson for the Foundation on scientific for the Foundation in its dealings matters. He directs, plans and with other institutions in relation leads the Foundation’s scientific to management activities, and policy, draws up the scientific plan manages the Institute’s internal for the Institute, and coordinates organisation and research its execution. In 2017 the Board infrastructure. The Managing appointed Benedicto Crespo Director of IDIVAL in 2017 was Facorro, Head of the Psychiatry Galo Peralta Fernández. Department at the Marqués de Valdecilla University Hospital and Professor at the University of Cantabria, as Scientific Director of IDIVAL. 23
President: Miguel López-Botet Arbona. Professor of Immunology, Pompeu External Scientific Ángel Carracedo Álvarez. Fabra University. Council Professor of Legal Medicine, University of Santiago de Josep M. Grinyó. Compostela. Senior Clinic. University Hospital of Bellvitge. University of Barcelona.
The External Scientific Council Juan Bernal Carrasco. contributes as a scientific advisor in Professor of Research at the Spanish achieving the scientific excellence National Research Council (CSIC), pursued by IDIVAL. The External Director of the Department of Chairs: Scientific Council offers opinions at Endocrine and Nervous System the request of the Board or the senior Pathophysiology. Alberto Sols Institute management of IDIVAL and advises Ana María Zubiaga Elordieta. of Biomedical Research. on the evaluation of the Institute’s Professor of Genetics, University of activity. the Basque Country, Faculty of Miguel Delgado Rodríguez. Science and Technology. Head of the Professor of Preventive Medicine and Its members were proposed by Genomics Department of the Public Health. University of Jaén. IDIVAL’s senior management and UPV/EHU. appointed by the IDIVAL Board in its Rafael Cantón Moreno. meeting on 25 February 2014. The Francesc Graus Ribas. Head of the Microbiology Department members are: Head of the Neurology Department. of the Ramón y Cajal Hospital. Hospital Clinic of Barcelona. University Associate Professor of the Department of Barcelona. IDIBAPS. of Microbiology, Faculty of Pharmacy. Complutense University Madrid. Francisco Mora Teruel. Professor of Human Physiology in the Xosé Ramón Bustelo. Faculty of Medicine at the Director of the Genomics and Complutense University of Madrid. Proteomics Unit. Centre of Cancer Professor of Molecular Physiology and Research. CSIC-University of Biophysics in the Faculty of Medicine Salamanca. at the University of Iowa. José Carlos Flórez. Jordi Vila Estapé. Chief, Diabetes Unit. Investigator, Head of the Bacteriology Department. Center for Genomic Medicine, Hospital Clinic of Barcelona. Professor Massachusetts General Hospital. of Microbiology. Autonomous Associate Professor, Harvard Medical University of Barcelona. CRESIB. School. Institute Member, Broad Institute.
The External Scientific Council met once to review IDIVAL’s new Strategic Plan, the 2016 report, the 2017 action plan, and the IDIVAL 2017 budget, and to assess new groups for incorporation. Activity Estructura Organizativa Órganos de Gobieno y Report Asesoramiento 25
María del Carmen Fariñas María Amor Hurlé González. Internal Scientific Álvarez. Representative of the University of Coordinator of the Infectious Diseases Cantabria. Professor of Pharmacology. Council and Immune System Area. Head of University of Cantabria. the Infectious Diseases Department. Marqués de Valdecilla University Javier Crespo García. Hospital. Professor in the Department Head of the Digestive System of Medicine and Psychiatry. University Department. Professor in the of Cantabria. Department of Medicine and Psychiatry. University of Cantabria. José Antonio Riancho Moral. Coordinator of the Metabolism, The Internal Scientific Council is Diseases of Ageing and Lifestyle Habits presided over by the Scientific Area. Section Head. Internal Medicine Director of IDIVAL and is made Department. Marqués de Valdecilla up of researchers appointed by the University Hospital. Professor in the Board. Department of Medicine and Psychiatry. University of Cantabria. The Internal Scientific Council of IDIVAL was appointed by the IDIVAL’s Internal Scientific Council Board at a meeting on 25 February Miguel Ángel Lafarga replaced one of its members in 2014, based on a proposal by the Coscojuela. 2017 and met 8 times. Among other Scientific Director. Representative of the University of business, it reviewed IDIVAL’s grants Cantabria. Professor of Anatomy and programme, its strategic plan, its annual Cellular Biology. report, and the projects presented to University of Cantabria. President: various competitive calls for entries, and monitored the strategic plan.
Benedicto Crespo Facorro. Scientific Director of IDIVAL. Section Head. Psychiatry Department. Marqués de Valdecilla University Hospital. Professor in the Department of Medicine and Psychiatry. University of Cantabria.
Chairs:
Marcos López Hoyos. Coordinator of the Organ and Tissue Transplant and New Therapies Area. Head of the Immunology Department. Marqués de Valdecilla University Hospital.
Fernando Rivera Herrero. Coordinator of the Cancer Area. Head of the Oncology Department. Marqués de Valdecilla University Hospital.
Javier Llorca Díaz. Coordinator of the Cross-Disciplinary Area. Professor of Preventive Medicine and Public Health. University of Cantabria. Activity Áreas de investigación Report Área de Trasplante de Órganos y Tejidos y Nuevas Terapias 27
Support for Researchers
IDIVAL’s Central Research Support Unit. This Unit is organised into six areas: Projects Area, Training and Methodological Support Area, Clinical Trial Area, Technological Support Area, Innovation Area and General Services Area.
CENTRAL SUPPORT UNIT
PROJECTS TRAINING AND CLINICAL TECHNOLOGICAL INNOVATION AREA METHODOLOGY TRIALS SERVICES AREA AREA AREA
COORDINATOR Regional funds Biobank National funds Microscopy International funds Agency Cytometry Otri Private Library Clinical Trial funds Unit Genomics Innovation Neuroimaging Support Unit Laboratory
GENERAL SERVICES
COORDINATOR
HUMAN RESOURCES
COORDINATOR Activity Support for Researchers Report Central Support Unit
This area aims to promote, enhance and disseminate research results amongst society, encouraging the The IDIVAL Human Resources interaction of researchers with the building Area corporate and social environment, the management of its patents and business creation. It carries out actions for the promotion of IDIVAL has its own facilities, located IDIVAL’s Human Resources Area innovative culture, research and within the Marqués de Valdecilla centralises aspects relating to the evaluation of technological solutions, preparation and drafting of R&D+i University Hospital complex. The Institute’s recruitment and labour projects and the search for financing, IDIVAL building measures 3,000 relations. as well as all activities needed to m2. Located inside the building are ensure that the R&D results of IDIVAL most services of the Central Support research groups and researchers Research Unit, as well as laboratory Coordinator: from the Cantabria Health Services spaces for IDIVAL groups and reach society through public-private meeting rooms. Marta Abelleira Álvarez. (IDIVAL) partnerships.
Administrative Personnel: The Innovation Area also supports strategies for innovation in patient María José San Emeterio. (IDIVAL) care and organisation through the EValTec® programme, which General Services uses human factor engineering Area techniques for assessing usability in medical technology selection Projects and implementation processes and Area process redesign. IDIVAL’s General Services Area brings together the resources needed for The Projects Area at IDIVAL administrative and legal management brings together the resources across all areas of IDIVAL. needed to manage the grants promoted by IDIVAL itself as well Research Results Transfer Office as the application, execution and (OTRI): justification of both public and private Coordinator: funds at the disposal of the IDIVAL Patricia Zorrilla de la Fuente. research groups. Julio Muela Carriles. (IDIVAL) (IDIVAL)
Technician: Technicians: Innovation Unit: Accounting: Javier Arce Saiz. (IDIVAL) Beatriz García González. (IDIVAL) Paloma Glez Álvarez. (IDIVAL) Charo González Cabria. (IDIVAL) Ana Temperán Galván. (IDIVAL)
Administrative Personnel: EValTec® Programme: Invoicing: Laura del Río Celis. (IDIVAL) Innovation Registry: Laura Herrero Urigüen. (IDIVAL) Elena Calvo Llano. (IDIVAL) Area Marina Cano Iglesias. (IDIVAL)
IDIVAL’s Innovation Area forms part of the ITEMAS Platform of the Carlos III Health Institute (ISCIII).
It also includes a Results Transfer Office (OTRI), which is part of the OTRI network. 29
Training and Methodology Support Area
IDIVAL, as part of its goal to strengthen and facilitate scientific training associated with research, provides library support to researchers and promotes, coordinates and performs training activities in this area throughout the year.
healthcare system throughout of Dr Wenceslao López Albo, the Cantabria. Its facilities consist of a first Managing Director of Casa de “Marquesa Great Hall, classroom, copy services Salud Valdecilla, under the patronage room, study room, periodicals library, of María Luisa Gómez de Pelayo, de Pelayo” video library, depositories of less Marquesa de Pelayo, the niece Library used and antique holdings, two of Ramón Pelayo de la Torriente, storerooms, and an administration Marqués de Valdecilla. Since then, and management area, located it has been considered one of in the Marqués de Valdecilla Spain’s leading specialist libraries. University Hospital. The electronic In 2016 the Library introduced a The Marquesa de Pelayo Library library, Biblioteca Virtual Marquesa new platform providing access to its is an active centre of biomedical de Pelayo, offers all its services electronic resources, as part of the information resources. Its mission is (inter-library loans, reference, etc.) IDIVAL website, notably improving its to contribute to raising the level of and online resources (organised accessibility. innovation and excellence in three according to the Haynes Pyramid) fundamental areas of Cantabria’s via the IDIVAL website, with direct public healthcare system: clinical access to its catalogue. care, teaching, and research, by an The Library was first opened in 1929, intensive use of information and Head Librarian: communication technologies. the second oldest and the first fully modern library of its kind in Spain, Mario Corral García. (IDIVAL) The Library is governed by IDIVAL designed to become a National and provides support for the public Library of Medicine, on the initiative Activity Support for Researchers Report Central Support Unit
Trial Unit. The Agency provides Clinical Trial Units (SCREN, Spanish support for the management of Clinical Research Network) of the Clinical clinical trials, and the Unit supports Carlos III Health Institute. their execution. Both bodies are Trial Area involved in advising, designing, evaluating, managing, implementing and executing clinical trials, including technical support for the Clinical Research Ethics Committee of Cantabria. The Clinical Trial Area includes a The Clinical Trial Area is part of the Clinical Trial Agency and a Clinical Platform for Clinical Research and
Clinical Trial Agency
The Agency offers its organisation Technicians: and resources to researchers to promote reliable clinical trials Blanca del Pozo Fernández. that can guarantee the quality of (IDIVAL) the study, patient safety and data Lorena Martín Guerra. reliability. It also provides support (IDIVAL) to the Clinical Research Ethics Committee of Cantabria. Lucía Lavín Alconero. (IDIVAL)
Clinical Trial Unit
measures 250 m2 and is equipped Team: to simultaneously serve up to nine patients. It began operations in Mª Blanca Sánchez Santiago. 2013 partially financed with funds (Clinical Pharmacology Department, from the Farmaindustria R&D HUMV) programme. It provides support for Mª Ángeles de Cos. highly complex clinical trials in the (Clinical Pharmacology Department, Valdecilla environment. HUMV) Javier Adín Ibarra. (Clinical Pharmacology Department, HUMV)
The IDIVAL Clinical Trial Unit, Nuria Sánchez Avelló. under the Clinical Pharmacology (HUMV) Department, located in the Marqués de Valdecilla University Hospital, 31
The Technology Support Services Coordinator: Area is made up of six units: Technology Biobank, Laser Microscopy Unit, Electron Microscopy Unit, Flow Mª José Marín Vidalled. Support Services Cytometry and Cell Sorting Unit and (IDIVAL). Area Neuroimaging Unit.
Valdecilla Biobank
Scientific Director:
Pascual Sánchez Juan. (Neurology Service, HUMV)
DNA AND FLUIDS GROUP
Coordinator:
Mª José Marín Vidalled. (IDIVAL)
The Valdecilla Biobank is a researchers whose projects Technicians: hospital biobank that manages involve the use of human human biological samples in biological samples. Inés Santiuste Torcida. (IDIVAL) order to support biomedical David Ramos Melendro. (IDIVAL) research, through the collection, In the 2018-2020 call for processing, storage and transfer financing of the ISCIII AES of samples and associated clinical Platforms, the Valdecilla Biobank SOLID SAMPLES GROUP data for research projects, all in was re-accepted as part of the the strictest conditions of quality National Registry of Biobanks Coordinator: control and confidentiality. (Plataforma Red Nacional de Biobancos, PRNB), with €93,060 Santiago Montes Moreno. The Valdecilla Biobank is in financing for this period. (Anatomical Pathology Department, authorised by the Ministry of The 2018-2020 PRNB is HUMV) Health of the Government of continuing the work begun by Cantabria, and is registered in the biobank RETIC and the 2014- Solid Samples Group Technicians: the ISCIII biobank register. It 2017 PRNB, through 5 strategic is organised into three Groups core areas: Coordination, José Bernardo Revert Arce. according to the types of samples Management and Training; (IDIVAL) handled: the DNA and Fluids Collections and Services; Group, located on the ground R&D+i; ELSI and External floor of the IDIVAL building, and Communication; and User NEUROLOGICAL TISSUES GROUP the Solid Samples Group and Attraction and Retention. the Neurological Tissues Group Coordinator: in the Anatomical Pathology The Valdecilla Biobank has held Nuria Terán Villagrá. Department of the Marqués the ISO9001:2015 certification for (Anatomical Pathology Department, de Valdecilla Hospital. They quality management since 2015. HUMV) all have sample collections of pathologies of high scientific Technician: interest while providing a variety of services through the use Saray Pereda Marcos. of their equipment, offering (IDIVAL) comprehensive support to Activity Support for Researchers Report Central Support Unit
Microscopy Unit
IDIVAL’s Microscopy Unit is on NIKON Ti microscope and is Scientific Coordinator, Laser the ground floor of the IDIVAL equipped with an epifluorescence Microscopy: building. This unit offers confocal module, incubation and micro- laser scanning microscopy, injection systems and an optical Mónica López Fanarraga. (UC) fluorescence microscopy, time- system to monitor fast processes in lapse, transmission electron live cells. Scientific Coordinator, Transmission microscopy (TEM), etc., for in- Electron Microscopy: house and external research The electronic microscopy groups, and advice on their different department has a JEOL JEM1011 Miguel Lafarga Coscojuela. applications. It also provides transmission electron microscope, (UC) specific training in microscopy equipped with a high-resolution and preparation of samples for digital camera which provides Technical manager: researchers and support staff excellent image quality. This through courses accredited by microscope permits the analysis Fidel Madrazo Toca. (IDIVAL) the Government of Cantabria’s of ultra-thin sections of cells and Commission on Continuing tissues, and the observation of Education. microorganism preparations and Scientific Coordinator: macromolecular complexes with One of the core goals of the negative stain contrasting. Mónica López Fanarraga. laser microscopy department is (UC) to contribute high performance fluorescence studies as rapidly as possible. It features the latest Supervising Technician: generation equipment consisting of two sets of image systems, a Fidel Madrazo Toca. confocal laser scanning microscope (IDIVAL) (CLSM) and a fully-automated TIRF combined Nikon A1R, which captures high-quality confocal images of cells and molecular events at high speed and sensitivity, live-cell equipment with a motorised 33
Cytometry and Cell Sorting Unit
CytoFLEX cytometer (Beckman Scientific Coordinator: Coulter) and an AutoMACS Pro Separator magnetic separator Marcos López Hoyos. (Miltenyi Biotec) for the sorting (Immunology Department, HUMV) of cell populations in sterile conditions.
The UCFSC organises an annual Technical Coordinator: The Flow Cytometry and Cell course on flow cytometry in Sorting Unit (UCFSC) is in the collaboration with the Inbiomed David San Segundo Arribas. IDIVAL building, located in the Cytometry Unit, intended for both laboratory of the Transplantation researchers and health workers, (Immunology Department, HUMV) and Autoimmunity Research accredited by the Commission group. This unit provides technical on Continuing Education of the and methodological support in Government of Cantabria. the use of flow cytometry and Technical manager: cell sorting, both for researchers at the centre and for any external David Merino Fernández. group that needs it. It has an (IDIVAL) upgraded FACSAria II cytometer/ sorter (BD Biosciences), a
Neuroimaging Unit
The neuroimaging laboratory, on the constituting a fundamental tool in 2nd floor of the IDIVAL building, has brain research. implemented and developed a wide range of techniques for analysing images of the human brain obtained by magnetic resonance imaging (MRI), which the Unit offers IDIVAL researchers and external groups in order to provide technical and methodological support in the Scientific Coordinator: design and execution of scientific studies. Benedicto Crespo Facorro. (Psychiatry Department, HUMV) The analysis techniques employed can obtain quantitative data on important cerebral variables Technicians: (volume of cerebral structures or areas, cortical thickness, gyrification Diana Tordesillas Gutiérrez. patterns, white matter structure, (IDIVAL) activity patterns, etc.) for the Roberto Roiz Santibáñez. advancement of in vivo knowledge (CIBERSAM) of the brain, and therefore, possible Víctor Ortiz de la Foz. alterations in severe mental illness, (IDIVAL) Activity Support for Researchers Report Central Support Unit
Units supported by the University of Cantabria
IDIVAL has a number of facilities Supercomputing service that the University of Cantabria offers its researchers, such Hydrobiology laboratory as materials characterisation, (Hydraulic research) chromatography, stabling and animal studies services. Chromatography service, Advanced Microscopy (IBBTEC) Animal Housing and Experimentation Services (SEEA) Mass sequencing service (IBBTEC)
Materials characterisation service (SERCAMAT)
Optical transmission microscopy service (SERMET) 35
> Ges-Val Grants. A research > Spine surgery training management training scholarship. scholarship for specialists in IDIVAL > Int-Val Grants. For research traumatology and orthopaedics, and intensification. in neurosurgery. Research > Ment-Val Grants. Mentoring > Human Factor training Grants programme for resident doctors. scholarship. > Production Grants. > InnyCron Grants. Programme supporting innovation in care for > Summer Internships. patients with chronic conditions. IDIVAL has a line of research grants > Pre-Doctorate Contracts. focusing on fostering talent. Each > Inplant programme. Programme The total amount of IDIVAL grants of these programmes has a clear to embed clinical researchers as awarded in 2017 was as follows: educational focus and the description Heads of Department at the of their activity is featured in the Marqués de Valdecilla University training section of this report. Hospital. In 2017, IDIVAL announced and > Wenceslao López Albo Post-MIR awarded the following grants: contracts programme (described in the training section of the report). > Inn-Val Grants. Awarded to > Complementary personnel for Innovation projects. projects from the National Plan. > Next-Val Grants. Awarded to > National call for “Enfermería projects for young researchers. Valdecilla” research projects.
Grants Programme Priority Budget (€) awarded
Post-MIR programme Post-Residence 329.000 3 research training
Intensification Prioritising research in healthcare personnel working in patient care 60.000 1
Mentoring Specialists in training 48.000 6
Inplant programme Attracting new Heads of Department or Section 100.000 0
Research managers Research Management training 19.322 1
Pre-doctoral programme Pre-doctoral training 247.000 4
Next-Val programme New researcher projects 100.000 12
Inn-Val programme Innovation projects 100.000 9
Prim-Val programme Primary care projects 30.000 6
InnyCron programme Chronic disease projects 100.000 8
Support programme Support for the functioning of IDIVAL groups 300.000 32
Summer Internships Undergraduates in the biomedical field 3.408 5 Activity Support for Researchers Report Central Support Unit
INN-VAL Grants
In 2015, IDIVAL launched the Inn- Project: Project: Val grant programme, focusing Quinosomes for the treatment of Design of biopolymer-functionalised on the development of innovative Leishmaniasis as a neglected disease graphene structures for the technological and healthcare model. development of neuronal cultures projects, and seeking to promote the Principal investigator: in cellular models of motor neuron transfer of knowledge to society and Mónica López Fanárraga pathology. the market, and to integrate local Financing: € 14.000. Principal investigator: agents in the Valdecilla environment. Olga Tapia Martínez In 2017 it announced the third round Project: Financing: € 12.000. of grants. The following projects Prospective study of the value of the were awarded grants in 2017: gene PRKACA as a marker of response Project: to fludarabine. Characterisation of the CREB1 Principal investigator: pathway and its role in the Carlos Pipaón González development and progression of Project: Financing: € 7.000. MCC in the age of immunotherapy. Testing a new immunotherapy Implications in diagnosis and therapy. treatment for solid tumours with Project: Principal investigator: gold nanoparticles based on Listeria Effectiveness of Intra-articular Injections José Pedro Vaqué Díez monocytogenes as a combinatorial of ASOs with Chondrogenic Effect in Financing: 10.000 €. therapy. the Treatment of Osteoarthritis: Proof of Principal investigator: Concept. Project: Carmen Álvarez Domínguez Principal investigator: Nanosensor test for fibrosis diagnosis Financing: € 14.000 José Carlos Rodríguez Rey in scleroderma patients. Financing: € 10.000 Principal investigator: Project: Ana Victoria Villar Ramos CENS-ERG safety, ergonomics and Project: Financing: 14.000 €. innovation: study of musculo-skeletal Study of the unnecessary opening of comfort in otorhinolaryngologists. surgery doors: on an intervention to Analysis of usage scenarios and improve safety. proposed product designs. Principal investigator: Principal investigator: María Sáenz Jalón David Lobo Duro Financing: € 7.000. Financing: € 12.000. 37
NEXT-VAL grants
In 2017 IDIVAL announced the Project: Project: third round of NEXT-VAL (NEXT The “progressing” patient as a new Apraxia in neurodegenerative diseases: generation VALdecilla) grants clinical entity in patients with coronary development of a quantitative for the development of one- or artery disease. Exploratory study of diagnostic tool and application two-year research projects led by possible molecular substrates. in evaluating impact on everyday novice researchers. These grants Principal investigator: activities. are intended to encourage the Tamara García Camarero Principal investigator: recruitment of new researchers in Financing: € 8.000. Carmen Lage Martínez the Valdecilla environment. The Financing: € 8.000. projects selected in 2017 were: Project: Study of new biomarkers of subclinical Project: cardiovascular and atherosclerosis risk The role of proteomic and genetic in patients with axial spondyloarthritis. biomarkers on the pathogenesis and Principal investigator: management of recurrent pregnancy Fernanda Genre loss due to unknown causes. Project: Financing: € 10.000. Principal investigator: Synthesis of 11C- methionine. A Leyre Riancho Zarrabeitia novel radiopharmaceutical for PET/ Project: Financing: € 8.000. CT exploration in the study of multiple Biomarkers of response to migraine myeloma. prevention treatment: advanced Project: Principal investigator: genetic, molecular and magnetic Spinal muscular atrophy (SMA). María de Arcocha Torres resonance markers. Principal investigator: Financing: € 8.000. Principal investigator: Olga Tapia Martínez Vicente González Quintanilla Financing: € 8.000. Project: Financing: € 10.000. Non-invasive determination through Project: biomarkers of lowered portal Project: Chronic pain is a serious social, hypertension after treatment with beta- The role of nursing consultation economic and healthcare problem, and blockers in patients with cirrhosis. in adherence to treatment and the design of preventive and curative Principal investigator: neurocognitive evolution in multiple José Ignacio Fortea Ormaechea therapies is a scientific challenge. sclerosis patients. Correlation with Financing: € 10.000. Principal investigator: molecular and neuroimaging markers. Mónica Tramullas Fernández € Project: Principal investigator: Financing: 8.000. Silvia Gutiérrez González New targets for prognosis of Financing: € 10.000. epidermoid carcinoma of the Project: oropharynx and applications in the Searching for early biomarkers of long- personalisation of the treatment. term hepatic, metabolic and endothelial Principal investigator: dysfunction in non-affective psychosis. Ana Freije León A 10-year follow-up study. Financing: € 6.000. Principal investigator: Javier Vázquez Bourgon Financing: 6.000 €. Activity Support for Researchers Report Central Support Unit
GES-VAL grants
In 2015, IDIVAL launched a grant out at IDIVAL over a period of two aspects of management, monitoring, programme for the development to three years, with a third round justification and evaluation of of a plan for training activities in announced in 2017. This programme research projects. science and health technology promotes the training of technicians research management to be carried in this field, as they learn different
INT-VAL grants
In 2016, IDIVAL introduced the from their other duties. IDIVAL funds grant in 2017 was Agustín Oterino, Int-Val programme (Intensification the part-time or full-time substitution for a 12-month period. of research - Valdecilla) to release of doctors or nurses involved in clinical practitioners with heavy research or innovation projects. The research and/or innovation workloads researcher awarded an intensification
MENT-VAL grants
In 2016, IDIVAL launched a In 2017, the selected Manuel Lozano González mentoring programme for candidates were: Department: Cardiology resident doctors at Valdecilla, intended to attract new Marina Sandra Cherchi Pepe Daniel Pablo Marcos medical professionals finalising Department: Intensive Care Department: Microbiology their training, young people Medicine with drive seeking excellence, Leandra Reguero del Cura and also as a way to provide Marina de Cos Gómez Department: Dermatology personalised specialist Department: Nephrology healthcare training and an introduction to Marlene Feo González research. Department: Intensive Care Medicine 39
Production Grants
In 2017, IDIVAL allocated funds differentiating them from the projects, the existence of novice for the operating costs of research impact factor of projects where researchers, and the responsibility groups, based on their output in authors from the group are of any group members for 2016. This grant was calculated neither the first nor last. The any IDIVAL platform were considering the impact factor of funds obtained by the group, also considered. The following each IDIVAL research group in the patents generated, RETIC or production grants were allocated projects in which an author in the CIBER membership, participation to IDIVAL groups in 2017: group is first or last, in doctoral theses and European
Group Total €
Anatomical Pathology and Molecular Pathology 8.571 Apoptosis 1.896 Cell Nucleus Biology 4.665 Cell Cycle, Stem Cells and Cancer 2.460 Cytokines and Growth Factors in Tissue Plasticity Phenomena 5.553 Cephalea Clinic and Genetics 7.479 Diagnosis and Treatment Using Imaging 3.675 Neurodegenerative Diseases 16.066 Genetic Epidemiology and Arteriosclerosis in Diseases 44.540 Epidemiology and Pathogenic Mechanisms of Infectious Diseases 18.002 Epidemiology and Public Health 9.502 Translational Haematopathology 32.521 Nanovaccines and Cellular Vaccines based on Listeria monocytogenes 5.182 Hereditary Haemorrhagic Telangiectasia Study Group 3.114 Cardiovascular Research Group 4.957 Molecular Imaging 9.389 Infection and Immunity and Digestive Pathology 11.417 Immunopathology of Rheumatic Diseases 4.086 Melatonin and Breast Cancer 1.996 Mineral and Lipid Metabolism 17.018 Clinical and Molecular Microbiology 15.210 Nanomedicine 5.771 Haematologic Neoplasms and Haematopoietic Progenitor Cell Transplantation 7.481 Neurophysiology in Epilepsy and Neurointensives 2.905 New Techniques in Abdominal Surgery 4.670 Psychiatry 15.791 Cell Signalling and Therapeutic Targets in Cancer 10.867 Transplantation and Autoimmunity 21.017 Clinical Trials, Medical Oncology and Palliative Medicine Unit 4.198 Activity Support for Researchers Report Central Support Unit
Pre-doctorate contracts
In 2017, IDIVAL partnered with • Pre-doctoral fellow: • Pre-doctoral fellow: the University of Cantabria to David Salcines Cuevas. Carmen Lage Martinez. launch the second pre-doctorate Director: Director: contract programme, in which Carmen Álvarez Domínguez Pascual Jesús Sánchez Juan. seven candidates were selected (IDIVAL) (HUMV) (four funded by IDIVAL and three by the University of Cantabria) • Pre-doctoral fellow: for a contract of up to four years Ana Belén Salido Medina. • Pre-doctoral fellow: with the goal of completing their Director: María Iglesias Escudero. doctoral theses. Juan Francisco Nistal Herrera Director: (HUMV) Marcos López Hoyos. The selected candidates and their (HUMV) thesis directors were: • Pre-doctoral fellow: José Ramón Sánchez de La • Pre-doctoral fellow: Torre. Lorenzo Joaquín Gutiérrez
Director: Avilés. Director: Jon Infante Ceberio José Carlos Rodríguez Rey. (HUMV) (UC) • Pre-doctoral fellow: Verónica Pulito Cueto. • Pre-doctoral fellow: Director: Lourdes María Valdivia Miguel Ángel González-Gay Fernández. Mantecón Director: Mónica López Fanárraga. (HUMV) (UC) 41
Summer internships
IDIVAL, in collaboration with eight-week stay during the months The students selected to work in the Institute of Biomedicine of July, August and September the IDIVAL Group laboratories in and Biotechnology of Cantabria for students in their last year of 2017 were: (IBBTEC), funds summer undergraduate or master’s degree internships for students in the studies in a biomedical subject Elena González López. biomedical and biotechnological (biology, biotechnology, nursing, Mar Portillo González. fields at the IDIVAL research group pharmacy, medicine, dentistry, Nuria García Carbonero. laboratories. The grant funds an etc.) during the internship period. Activity Áreas de investigación Report Área de Trasplante de Órganos y Tejidos y Nuevas Terapias 43
Training Activity Training Report Hospital sessions
Lozano Polo, Internal Medicine. Dr genes, environment and chance. Marisol Holanda Peña, Intensive Care Dr Javier Riancho Zarrabeitia, Medicine. Victoria Sánchez Peláez, Neurodegenerative Diseases Research Hospital Hospital Nurse. José Carlos Garrido Group, IDIVAL. Gómez, Clinical Analyses. sessions 22: Clinical safety at HUMV: Side- 16: The Healthcare Ethics Committee effect surveillance and alerts system. of the Marqués de Valdecilla Training schedule. Dr Henar Rebollo, University Hospital: a useful proposal. Head of the Preventive Medicine Dr Adín Ibarra, Healthcare Ethics Department. Dr Paz Rodríguez Cundín, This dissemination activity includes Committee. Preventive Medicine Specialist. Dr María Fe García Reija, Maxillofacial monthly scientific sessions 23: Advances in pulmonary Surgery Specialist. Susana Moya, which sees the participation of hypertension. Dr Cristina Ruisánchez Nurse, Nursing Quality, Training, and internationally renowned guests Villar, Cardiology Department. Dr José R&D+i area. and IDIVAL researchers, who run Manuel Cifrián Martínez, Pulmonology sessions within the Marqués de Department. Valdecilla University Hospital (HUMV) September: setting. April: 21: What is the meaning of the 6: Presentation of the results of enigmatic antibodies of the antigen These sessions are interspersed the HUMV’s Clinical Committees. DFS70/LEDGFp75? Dr Carlos with weekly hospital sessions at the Dr Eduardo Miñambres García, Alberto Casiano Torres, Professor of HUMV. The 2017 sessions were the Transplant Committee. Dr Isabel Microbiology, Molecular Genetics following: Martínez Rodríguez, Tissue and and Medicine, Associate Director of Tumour Committee. Dr Coral the Center for Health Disparities and Montalbán Carrasco, Nutrition Molecular Medicine, Dept. of Basic Committee. Dr Fidel Fernández, Sciences / Division of Rheumatology, Mortality Committee. Loma Linda University School of May: Medicine, Los Angeles (USA).
4: Inherited cardiovascular diseases: October: January: preventing sudden death. Dr Víctor Expósito García, Cardiology 5: Healthcare protocol for victims of 19: Commitment to quality at HUMV: Department. sexual assault or sexual abuse. Dr Ana Best In Class Awards 2016. Dr Julio 11: Wunderlich syndrome secondary Isabel Merino Fernández, Doctor of Pascual Gómez, Managing Director to the rupture of the iliac vein. Dr Obstetrics and Gynaecology. HUMV. Concepción Fariñas Álvarez, Alejandro González Castro, Intensive Quality Coordinator. Care Medicine. Dr Julia García Reyero, 19: The open plan ICU: its role in Anatomical Pathology. our hospital. Dr Ana María Ruiz Ruiz, February: Intensive Care / Intermediate Care 18: What can clinical immunology Department. 2: Haematopoietic transplants: historic contribute to the study of recurrent milestones, future expectations reproductive failure? Dr Silvia and results. Dr Enric Carreras, Sánchez-Ramón, Clinical Immunology November: Haematologist, Hospital Clínic Department. Hospital Clínico San Fundación Josep Carreras. Carlos, Complutense University of 2: Desensitisation unit: when allergic Madrid. 9: Clinical anatomy. Dr Toresano, drug reactions do not limit therapy. Leticia de las Vecillas Sánchez, López Internal Medicine, and Dr Mazorra, June: Anatomical Pathology. Albo intern. Allergology Department Specialist 16: Thoughts on sustainability. 1: A summary of emergency Dr Adín Ibarra, Healthcare Ethics healthcare. Presentation of the new 9: Valdecilla on the road to IHAN Committee. Dr Toresano, Internal edition of the Valdecilla emergency accreditation: initiative to humanise Medicine, and Dr Mazorra, Anatomical healthcare handbook. Dr Héctor childbirth and maternity care. Dr Pathology. Alonso Valle, A&E Department. Pilar Gortázar Árias, Neonatologist, Dr María Andrés Gómez, A&E Paediatrics Department. Chair of the March: Department. Dr Samuel Gómez Ruiz, IHAN Committee of the Marqués de Head of A&E Department. Dr Gonzalo Valdecilla University Hospital. Pérez Roji, Deputy Medical Director. 2: Homage to Dr Agustín Gutiérrez. 16: Clinicopathological classification A multidisciplinary approach to acute 8: HCV can be eliminated by 2021. of neurodegenerative diseases and ischaemic stroke: the latest triumph of Dr Javier Crespo García, Head of the presentation of the Valdecilla Biobank neuroscience. Dr Juan Miguel Macho Digestive System Department. Brain Bank. Dr Gabor G. Kovacs of Fernández, Hospital Clinic Barcelona. the Neurology Institute of the Medical Thoughts on blood samples for 15: Amyotrophic lateral sclerosis: University of Vienna. analytical determinations. Dr José Luis an unfortunate combination of 45
23: Acute Renal Failure: from clinical December: to molecular diagnosis. Dr Claudio Ronco, Director of the Nephrology, 14: Amyloidosis as a diagnostic Dialysis and Transplantation challenge: a case study. Sara Marcos Department of the Renal Research González, R-3, Anatomical Pathology. Institute, Hospital Bortolo Vicenza Pablo Legarra Oroquieta, R-5, (Italy). Cardiology.
Workshop: Researching with patents. Fundamentals of optical and electronic microscopy. Patricia Zorrilla, Innovation area Training (OTRI), IDIVAL. 23 May. Sample preparation. 3rd edition. David related to San Segundo (Immunology Dept. Specialist, HUMV), Maria José Marín (Technological Services Coordinator, support unit 4th Flow Cytometry Course. departments IDIVAL). 23-27 October. David San Segundo (Immunology Healthcare financing opportunities Dept. Specialist, HUMV), Paz López of the H2020 programme. Includes activities for researchers Mato (Inbiomed), María José Marín (Coordinator of Technological Services provided by Institute departments. Paloma González (Innovation area, at IDIVAL). Clinical and research IDIVAL). In 2017, the following dissemination techniques and applications. 15 - 18 activities were provided under this May. line:
Visits by Baccalaureate and Pint of Science Festival. compulsory secondary education students. This science festival is held in several Dissemination countries around the world at the Over 2017 five different schools same time, and encourages the activities visited and were given demonstrations general public to talk to researchers in of how the different technological an informal setting: the pub. services work.
Researchers’ Night.
IDIVAL participates in this event organised in Santander by the University of Cantabria, which is held at the same time in around 300 cities in 24 European and neighbouring countries. Activity Training Report Hospital sessions
Master’s Degree in the Study and Treatment of Pain.
Collaborations Rey Juan Carlos University and Research with Universities University of Cantabria. methodology
Master’s Degree: Introduction to Mental Health Research.
In 2017 IDIVAL had 119 associate University of Cantabria; Complutense professors in its research groups and University of Madrid; Autonomous This section includes in-house training in the Marqués de Valdecilla University University of Barcelona; University of activities and programmes organised Hospital, and 12 tenured professors Barcelona and University of Cádiz in and financed directly by IDIVAL. and 8 full professors also providing collaboration with CIBERSAM. In 2017, this section included the healthcare. following research methodology Master’s Degree in Genetic, activities: In terms of training in the various fields Nutritional and Environmental related to research, IDIVAL researchers Factors in Growth and have collaborated in the organisation Development. 1st edition of the IDIVAL course and implementation of training within on good clinical practice. different master’s degree programmes: University of Cantabria. 2-6 October. Course Director: Galo Peralta. Master’s Degree in Integrated Duration: 10 hours. Management and Research in Chronic Wounds. 2nd edition of the IDIVAL course University of Cantabria. on good clinical practice. 27 November - 1 December Master’s Degree in Healthcare Course Director: Galo Peralta. Master’s Degree in Molecular Biology Research. Duration: 10 hours. and Biomedicine. University of Cantabria. Research Methodology course. University of Cantabria and University of the Basque Country Director: 16-20 October. Dolores Delgado (Professor of UIMP meeting: Healthcare Research Course Director: Galo Peralta. Immunology. Department of Molecular Institutes: towards effective Duration: 20 hours. Biology. University of Cantabria). translation. Directors: Jesús Fernández Crespo Master’s Degree in Healthcare and (Director General of the Carlos III Social Services Management. Health Institute), Alfonso Beltrán (Deputy Director General of Director: David Cantarero Prieto International Research Programmes (University Professor in the Area of and Institutional Relations, Carlos Applied Economics, Area of Public Tax III Health Institute), Galo Peralta Authority, Department of Economics Fernández (Managing Director of of the University of Cantabria). IDIVAL). 3-5 July. Annual landmark University of Cantabria. meeting in which IDIVAL collaborates with the Carlos III Health Institute. 47
residents, internal pharmaceutical in Occupational Medicine, and 10 residents, internal biology residents, nurses specialising in Obstetrics and Specialist internal chemistry residents and Gynaecology. internal midwifery nursing residents. Training In 2017, the Marqués de Valdecilla The medical specialisations accredited University Hospital offered 82 places in the Marqués de Valdecilla University in 39 specialisations. The Marqués Hospital and the number of places de Valdecilla University Hospital also offered in the last call for specialised The Marqués de Valdecilla University participated in the training of the 20 health training (Order SSI/876/2017) Hospital is accredited to train places offered for specialisation in were: internal medical residents in various Family and Community Medicine specialisations, internal psychology for the Santander Area, a specialist
Specialisation Nº Specialisation Nº
Allergology 1 Intensive Care Medicine 3 Clinical Analyses 1 Internal Medicine 5 Pathological Anatomy 3 Nuclear Medicine 1 Anaesthesiology and Reanimation 5 Microbiology and Parasitology 1 Gastroenterology 2 Nephrology 2 Clinical Biochemistry 1 Pulmonology 2 Cardiology 3 Neurosurgery 1 Cardiovascular Surgery 0 Clinical Neurophysiology 2 General and Digestive Surgery 3 Neurology 2 Oral and Maxillofacial Surgery 1 Obstetrics and Gynaecology 3 Orthopaedic Surgery and Traumatology 2 Ophthalmology 1 Thoracic Surgery 0 Medical Oncology 2 Medical-Surgical Dermatology 1 Radiation Oncology 1 Endocrinology and Nutrition 1 Otorhinolaryngology 1 Hospital Pharmacy 2 Paediatrics and Specific Areas 5 Clinical Pharmacologist 2 Clinical Psychology 1 Haematology and Haemotherapy 2 Psychiatry 3 Immunology 1 Radiodiagnostics 3 Occupational Medicine 1 Hospital Radiophysics 1 Family and Community Medicine 20 Rheumatology 2 Physical Medicine and Rehabilitation 1 Urology 1 Activity Training Report Hospital sessions
innovation, known as Post-MIR Marqués de Valdecilla University Wenceslao López Albo contracts, is Hospital of up to three years in specifically for residents who have duration that should include a Training completed their specialisation. It stay at one or various renowned new has been active since 2003 as a way international centres. to promote training, attracting and In 2017, IDIVAL offered grants clinical consolidating talent in the Marqués for a two-year contract to three de Valdecilla University Hospital specialists; the Post-MIR Valdecilla researchers environment. contracts of a further eight specialists were active at some This nationwide call invites recently- point during 2017. trained specialists from any centre IDIVAL’s training programme in in the country to develop a research healthcare-related research and programme supervised by the
2017 Call
Carlos José Velasquez Rodríguez Luis Javier Ruiz Guerrero Miriam Sánchez Escamilla Neurosurgery specialist, trained at Healthcare innovation project for the Immunotherapy to combat lymphoid HUMV. creation of an Inherited Cardiovascular neoplasms through T lymphocytes with Tutor: José Luis Fdez. Luna. Diseases Unit (UECF); cardiomyopathy, a designer antigen receptor. Project: New prognosis markers in aortopathy and channelopathy, Tutor: Arancha Bermúdez high-grade gliomas and feasibility study preventing sudden death and Residency abroad: Haematopoietic for developing an outpatient neuro- cardiopathy in sport. transplant programme. Memorial Sloan oncological surgery programme at Tutor: Jesús Zarauza. Kettering Cancer Center, New York. HUMV. Residency abroad: Department of Duration: 24 months. Residency abroad: Division of Hereditary Cardiovascular Diseases, Neurosurgery, Toronto Western St George’s Hospital. Hospital, Canada. London. Duration: 24 months. Duration: 24 months.
49
2016 Call
Arantza Onaindia Pérez in the National Hospital for Neurology, Women’s Hospital (Boston, USA) Anatomical Pathology specialist, Neurosurgery and Psychiatry, UCL Duration: 18 months. trained at HUMV. Institute of Neurology (London), Johns Tutor: Miguel Ángel Piris. Hopkins Hospital (Baltimore), Imagerie Project: Application of new molecular interventionnelle oncologique et Rosa Fabregat Borrás techniques to routine diagnosis of viscérale – NHC (Strasbourg). Specialist in Radiation Oncology cancer patients. Duration: 18 months. trained in the HUMV. Residency abroad: University of Texas Tutor: Pedro Prada. MD Anderson Cancer Center. Project: Intraoperative radiotherapy Duration: 18 months. Leticia de las Vecillas Sánchez as a treatment of care innovation Allergy specialist, trained at HUMV. in the Public Health System of Marta Drake Pérez Tutor: Fernando Rodríguez. Cantabria. Technical and clinical Radiodiagnostics specialist, Project: Creation of a unit for characteristics, methodology, trained at HUMV. desensitisation to chemotherapy drugs dosimetry and quality control. Tutor: Gerardo Lopez Rasines. and biological agents. Prospective Stays: Gregorio Marañón University Project: Innovation project in study of risk factors in the population of Hospital (Madrid) European Institute Neuromusculoskeletal Radiology. patients desensitised to chemotherapy, of Oncology (Milan). Residency abroad: Geneva University antibiotics and biological agents. Duration: 18 months. Hospital, Department of Neuroradiology Residency abroad: Brigham and
2015 Call
Maria Kislikova María Riaño Molleda Hospital Paul Brousse, Paris and Nephrology Specialist, trained at General Surgery Specialist, trained at Hammersmith Hospital, London. HUMV. HUMV. Duration: 2 years. Tutor: Ángel Martín de Francisco. Tutor: Manuel Fleitas Project: Epigenetic Regulation of Project: Training in hepatobiliary Arterial Smooth Muscle Phenotype in surgery and liver transplantation CKD-Associated Vascular Disease. and the study and application Stay abroad: Dr David Wheeler. The of solutions and machines for UCL Centre for Nephrology, University preserving abdominal solid organs for College of London. transplantation. Duration: 2 years. Stay abroad: Professeur René ADAM,
2014 Call
Paula Iruzubieta Coz intestinal microbiota in liver disease and the Institute of Cellular Medicine Digestive System Specialist, trained due to non-alcoholic fatty deposits in at Newcastle University for 12 at HUMV. obesity. months. Tutor: Javier Crespo García (Head of Stay Abroad: Cooperative Research Duration: 3 years. Digestive System Dept., HUMV). Centre in Biosciences (CIC bioGUNE 6 Project: Role of immunity and months), Freeman Hospital Newcastle Activity Training Report Hospital sessions
programmes in the Faculty of institute researcher Carmen Medicine of the University of Fariñas Álvarez). Cantabria: Doctoral theses. IDIVAL training activity is reflected Doctoral > Doctorate in Molecular in doctoral theses. In 2017, IDIVAL Biology and Biomedicine groups participated in a total of programmes (coordinated by Dolores 38 doctoral theses, either through Delgado. The programme is their direction or authorship. The quality accredited). adjoining table lists theses read or directed by IDIVAL personnel. > Doctorate in Health Sciences IDIVAL researchers participate (currently coordinated by in the two active doctoral
Author and directors Title University
Leocadio Rafael López Giménez, Cecilia Analysis of medication errors in a Cantabria Martínez Fernández Llamazares, Isabel de las neonatology unit Cuevas Terán
Giusi Alesia Sgaramella, José Luís Hernández Analysis of the plasma concentration Cantabria Hernández, Emilio Pariente Rodrigo, José of thyrotropin as a variable predicting Manuel Olmos Martínez cardiovascular disease in males over 50: the Camargo cohort
Beatriz García-Riart Monzon, Juan M. Hurlé Analysis of the microRNA profile in the Cantabria González, Juan Antonio Montero Simón elimination of skeletal progenitors of embryonic interdigital spaces
Wu Yunfen, Alfonso Vázquez Barquero Applications of T-electromyography in Cantabria the minimally invasive transpedicular implantation of screws in the lumbosacral spinal column: - a neurophysiological view
Pilar Álvarez Sáinz de la Maza, Ramón Merino Bambi, a new therapeutic target for the Cantabria Pérez, Jesús Merino Pérez treatment of autoimmune diseases
Sana Alibi Ep Othmen, Jalel Boukakida, Jesús Genomic characterisation of clinical strains of Cantabria Navas Méndez corynebacterium
Víctor Expósito García, Juan Francisco Nistal Electrical consequences of myocardial fibrosis Cantabria Herrera, María Amor Hurlé González mediated by TGFb: structural remodelling and development of auricular fibrillation
Gonzalo Fernández Ruiz, José Luis Fernández Contribution of the microenvironment to Cantabria Luna chemical resistance of glioblastoma trigger cells in models in vitro
Lucía García-Berbel Molina, Francisco Javier Determination of prognostic biomarkers in Cantabria Freire Salinas, José Javier Gómez Román intraductal mammary papillomas
Sara Lantigua Romero, Noemí Rueda Revilla, Effect of different therapeutic strategies on Cantabria Carmen Martínez-Cue Pesini the cognitive deficits and neuromorphological alterations of a Down syndrome model
María Ángeles Diego Mantecón, José Antonio Effect of the administration of selective Cantabria del Barrio del Campo, Carmen Martínez-Cue negative allosteric modulators for the subunit Pesini gabaaa5 on the cognitive processes involved in the learning and memory alterations of a Down syndrome model
Verónica Vidal Sánchez, Carmen Martínez-Cue Effect of the reduction of inhibition mediated Cantabria Pesini by the GABAAα5 and GABAB receptors on the functional and neuromorphological alterations of a Down syndrome model 51
Author and directors Title University
Marcos López Hoyos, María Teresa Arias Non-alcoholic fatty liver disease: Cantabria Loste, Emilio Fábrega García immunological, genetic and metabolic mechanisms involved in its etiopathogenesis
Mónica Rubio Lorenzo, María Isabel Pérez Comparative study of Cantabria Nuñez, Mª del Rosario García-Barredo Pérez ultrasound assisted percutaneous Achilles tendon surgery, compared to conventional open surgery, in ruptured Achilles tendon
María Teresa Sainz Olavarría, Benedicto Cross-disciplinary longitudinal study of the Cantabria Crespo Facorro morphometry of the orbitofrontal cortex in patients with first-episode non-affective psychosis. Relationship with socio- demographic, clinical and cognitive variables.
Ana Santurtún Zarrabeitia, María Teresa Temporal study of violent death and Cantabria Zarrabeitia Cimiano its association with environmental and economic variables in Spain
Carlos Rodríguez de Lope López, Jordi Bruix, Assessment and optimisation of treatment Barcelona Alejandro Forner González of small (< 2 cm) primary liver tumours
Marta López Sánchez, Miguel Ángel González- Factors associated with mortality in patients Cantabria Gay Mantecón treated with extracorporeal membrane oxygenation (ECMO) in lung transplants
María Teresa Gil Urquiza, Pedro Muñoz Cacho Factors affecting the start and continuation Cantabria of breastfeeding in Cantabria
Eusebio Real Peña, Olga María Conde Portilla Photonics and interpretation techniques Cantabria applied to the diagnosis of cardiovascular and dermatological pathologies
Marcos López Hoyos, Silvia Torices del Val, Identification of important gene variants in Cantabria Víctor Manuel Martínez Taboada the NFkappaB pathway and their functional consequences in patients with rheumatoid arthritis
Blanca Sampedro Andrada, Javier Crespo Implementation of an application in the Cantabria García electronic prescription system of the HUMV to increase VHB and VHC screening
Tamara Silió García, Paloma Salvadores The experience of patients evaluated for Cantabria Fuentes, María Carmen Ortego Maté lung transplants
Juan Manuel Odriozola Feu, José Schneider Severe maternal morbidity as an indicator Cantabria Fontán, José Ramón De Miguel Sesmero of the quality of obstetric care: analysis at Marqués de Valdecilla University Hospital (2001-2010)
Elisabet Frande Cabanes, Carmen Álvarez Cerebral Listeriosis in the mouse model: Cantabria Domínguez, Mónica López Fanárraga pathogenesis and prevention
María Dolores Alonso Mesonero, Javier Llorca Systemic Lupus Erythematosus. Cantabria Díaz, Miguel Ángel González-Gay Mantecón Epidemiology and clinical presentation in northwest Spain
Beatriz Carnero López, Javier Llorca Díaz, Rheumatic manifestations in cancer Cantabria Miguel Ángel González-Gay Mantecón patients. Prospective observational study
Glenda Mariuxi Bermúdez Pinargote, Miguel In situ follicular neoplasia and in situ Cantabria Ángel Piris Pinilla, Santiago Montes Moreno mantle cell neoplasia: incidence and clinical significance Activity Training Report Hospital sessions
Author and directors Title University
Belinda Vega Gutiérrez, José Ramos Vivas New aspects of the biology of Las Palmas de gran Photobacterium damselae subsp piscicida Canaria Pili, motility and adherence to solid surfaces.
Jorge Mata Garrido, María Teresa Berciano Organisation and dynamic of permanent Cantabria Blanco, Miguel Ángel Lafarga Coscojuela nuclear foci in the repair of DNA damage in neurons
Juan Jesús Augustin Rodríguez, Ramón The role of Bambi in regulating the humoral Cantabria Merino Pérez, Jesús Merino Pérez immune response
Rosmari De La Puerta Huertas, María Amor Participation of BMP7 (bone morphogenetic Cantabria Hurlé González, Mónica Tramullas Fernández protein 7) in pain perception and anxious behaviour
Miguel Ángel Hernández Hernández, José Persistence of cerebral electric activity Cantabria Luis Fernández Torre, José Luís Hernández after clinical diagnosis of brain death: Hernández incidence, impact and comparative analysis of the electroencephalogram compared to computed tomography angiography.
Juan Carlos Rodríguez Sanjuan, Nerea Ruiz Liver transplant from asystolic donors Cantabria controlled with ECMO.
Santiago López González, Tania Huedo A systematic review of adherence to Cantabria Medina, María Carmen Ortego Maté treatment for hypertension and the interventions designed to improve it
María Pilar García-Berbel Molina, Francisco Utility of col11a1 as a marker predicting Cantabria Javier Freire Salinas, José Javier Gómez tumour infiltration Román
Ricardo Calderón González, Carmen Álvarez Listeria monocytogenes-based vaccines Cantabria Domínguez, Mónica López Fanárraga
Roberto De La Fuente Royano, María Amor Potential clinical value of microRNA-30c Cantabria Hurlé González, Mónica Tramullas Fernández as a biomarker and therapeutic target for neuropathic pain 53
Wednesday 08/03/2017 biomarker that can discriminate ANA-associated autoimmune Progress Speaker: rheumatic disease (AARD) from non- Rufino Mondéjar García AARD patients. A cost-effectiveness Reports Río Hortega contract of the study. Anatomical Pathology Research Group at IDIVAL. Wednesday 15/11/2017 Title: Molecular Basis for targeted therapy in T-cell lymphomas. Speaker: This programme began as a David San Segundo Arribas joint initiative by the Biomedical Wednesday 22/03/2017 Immunology specialist and Research Forum of Cantabria, member of the Autoimmunity and consisting of researchers from Speaker: Transplantation research group at IDIVAL, the University of Cantabria Fernanda Genre IDIVAL. and the Institute of Biology and Sara Borrell contract of the Genetic Title: Myeloid-derived suppressor Biomedicine of Cantabria, that was Epidemiology and Arteriosclerosis cells (MDSC) and immunoregulation organised in 2017 as a continuation Research Group at IDIVAL. in transplantation. of the programme of research Title: Cardiovascular risk in seminars presented by young spondyloarthropathies. Speaker: researchers, in collaboration with María Juncal Ruiz clinical and basic researchers. Child Psychiatrist at the Hospital Wednesday 06/04/2017 Sierrallana, researcher in the first- The 2017 programme included the episode psychosis programme of following seminars, held at the Speaker: the Marqués de Valdecilla University Marqués de Valdecilla University Raquel García López Hospital, and doctorate student at Hospital. Post-doctoral researcher in the the University of Cantabria. Physiology and Pharmacology Title: Systemic immunoinflammatory Department of the University of response in patients with a first Cantabria psychotic episode. Title: Tgf-beta mediated signalling in aortic abdominal aneurysm: molecular mechanisms and Wednesday 13/12/2017 therapeutic approach. Speaker: Wednesday 03/05/2017 Wednesday 18/01/2017 Maria Kislikova Specialist in Nephrology at Marqués Speaker: Speaker: de Valdecilla University Hospital. Beatriz Abascal Bolado. Mónica Gozalo Margüello Title: Changes of elastic fibres and Pulmonology Specialist at Marqués Specialist doctor in the Microbiology epigenetic changes of vessel smooth de Valdecilla University Hospital. area. muscle cells in chronic kidney Title: Update in COPD research. Title: Influenza, the Unpredictable disease. Threat: an update. Speaker: Wednesday 17/05/2017 Wednesday 08/02/2017 Arantza Onaindia Pérez Specialist in the Anatomical Speaker: Speaker: Pathology Department at Marqués María Lázaro Díez Galo Peralta Fernández. de Valdecilla University Hospital. Pre-doctoral student in the Clinical IDIVAL Management Director. Title: A next-generation sequencing and Molecular Microbiology group. approach for direct and definitive Title: Strategic Programme Vitalising Title: Role of neutrophils in innate determination of Biallelic Cebpa Biomedical Care at Valdecilla. defence against pathogens: mutations. Acinetobacter. Wednesday 22/02/2017 Wednesday 07/06/2017 Speaker: Félix Campos Juanatey Speaker: Urology Specialist at Marqués de Juan Irure Ventura Valdecilla University Hospital. 4th-year resident in the Immunology Title: New trends and future Department of Marqués de Valdecilla directions in reconstructive University Hospital. urological surgery. Title: Anti-dfs70 antibodies, a new Activity Training Report Hospital sessions
1. Undergraduate Studies in 2. Summer internship Medicine at the University of programme. Student Cantabria. In 2013, IDIVAL launched a training Courses at the Marqués de grant programme for Valdecilla University Hospital five students studying an cover students of the Faculty undergraduate degree or of Medicine in their third, fourth, diploma in any biomedical fifth and sixth year of medical discipline (biology, studies. The following numbers biotechnology, nursing, IDIVAL’s research groups in 2017 of students were enrolled in pharmacy, medicine, dentistry, include 119 associate professors the final three years of the etc.) to spend a summer working in the Marqués de Bachelor’s Degree in Medicine working in the laboratories of Valdecilla University Hospital. The in the academic year 2017/2018 IDIVAL groups, a programme 12 tenured professors and 8 full (involving the Marqués de that has continued since then. professors from the University of Valdecilla University Hospital): The students awarded the grant Cantabria working at the Marqués 4th year of Medical Studies: 20, and the research group in which de Valdecilla University Hospital 5th year of Medical Studies: 156, they worked during the belong to IDIVAL groups. 6th year of Medical Studies 122. summer of 2017 appear in the IDIVAL grants section.
They will also be a discussion Thursday 30/03/2017 forum for young researchers and healthcare personnel in our Speaker: Santander hospitals, and for the general public, John F. Cryan and an opportunity to establish Biomedical Professor, Department of partnerships. The lectures in this Anatomy and Neuroscience, programme in 2017 were: Lectures University of Cork, Ireland. Title: The Microbiome- A Key Regulator of Brain & Behaviour Across the Lifespan. Thursday 26/01/2017 A series of lectures devoted to advancing worldwide knowledge in Speaker: Thursday 27/04/2017 Biomedicine, jointly organised by Iñaki Sanz IDIVAL and IBBTEC, and held in the Department Director at the Speaker: Marqués de Valdecilla University Emory University School of Juan Francisco Nistal Herrera Hospital. Medicine in Atlanta. Associate doctor in the Title: Immunological and Cardiovascular Surgery Prestigious researchers at the top epigenetic bases of the Department and head of the of the field worldwide are invited activation of B lymphocytes and research group on cytokines to lecture on subjects such as plasma cells in Systemic Lupus and growth factors in Oncology, Neurology, Immunology, Erythematosus. Implications for phenomena of pathological Regenerative Medicine, and diagnosis and treatment. tissue plasticity at IDIVAL. Microbiology. Title: Advances in molecular Speaker: physiopathology and new These lectures were an initiative of Javier González-Maeso therapeutic perspectives in scientists at the different research Professor, Department of Marfan syndrome. centres of Cantabria to create Physiology and Biophysics, a forum for discussing current Virginia Commonwealth Thursday 25/05/2017 advances in biomedicine, in which University School of Medicine. some of our region’s research Title: Epigenetic mechanisms groups play a leading role. involved in the treatment of Speaker: schizophrenia. Arturo Álvarez-Buylla Professor of Neurosurgery, University of California-San Francisco. Title: Adult neural stem 55
cells do not self-renew Thursday 26/10/2017 Thursday 21/12/2017 asymmetrically; how are they retained? Speaker: Speaker: Manuel Vázquez Carrera Luis M. Liz-Marzán Thursday 29/06/2017 Professor of the Pharmacology, Scientific Director of the Centre Toxicology and Therapeutic for Cooperative Research in Speaker: Chemistry Department of the Biomaterials. Christian Giske School of Pharmacy, Barcelona Title: Design of precious metal Head of the Bacteriology and University. nanomaterials (particularly gold) Mycobacteriology Department Title: Inflammation, insulin for biomedical applications, of Karolinska University resistance, and other metabolic such as new bioimaging Hospital. disorders. techniques, cell manipulation Title: Dissemination of and ultrasensitive metabolite resistance in Klebsiella detection. Thursday 30/11/2017 pneumoniae and Escherichia coli - a story of successful clones. Speaker: Galo Peralta Fernández and Thursday 28/09/2017 Benedicto Crespo Facorro Managing Director and Speaker: Scientific Director of IDIVAL. Francisco Sánchez Madrid Title: IDIVAL, present and future Scientific Director of the IIS- perspectives. Princesa. Title: Exosomes shuttling at the Immune Synapse: Mechanisms of microRNA and proteins sorting. Activity Áreas de investigación Report Área de Trasplante de Órganos y Tejidos y Nuevas Terapias 57
A few milestones in 2017 Activity A few milestones in 2017 Report Organigram
PRESENTATION 2ND CYCLE SANTANDER BIOMEDICAL LECTURES
MEETING OF THE EXTERNAL SCIENCE SCIENTIFIC WEEK COUNCIL NEW APPOINTMENT ANNOUNCEMENT SCIENTIFIC VALDECILLA OF CALL DIRECTOR 100.000 PostMIR CITATIONS IN HUMAN FACTOR LITERATURE SYMPOSIUM: NEW APPROACH PREDOCTORAL TO ORGANISING CALL HEALTHCARE PRIVATE IDIVAL-UC DONATION OF 190.000 E PROGRAMME LAUNCH Inplant BOARD MEETING
1-Jan 1-Feb 1-Mar 1-Abr 1-May 1-Jun 1-Jul 1-Aug 1-Sep 1-Oct 1-Nov 1-Dic
ANNOUNCEMENT OF CALL PROGRAMME Inn-Val VITALISING ANNOUNCEMENT AWARDING LAUNCH OF THE BIOMEDICAL OF CALL CALL BRAIN CARE AT Prim-Val Next-Val BIOBANK VALDECILLA DONATION BY BOARD VISIT TO LUCHAMOS MEETING VALDECILLA POR LA VIDA DEPUTY DIRECTOR OF RESEARCH ASSESSMENT AT ADDITION ISCIII OF FOUR MEETING NEW GROUPS UIMP-ISCIII
eVAL Tec IN THE SCS INFUSION PUMP COMPETITION 59
from a resident of the city of study showing the utility of Torrelavega, the largest single normothermic abdominal News stories private donation the institution perfusion in brain-dead patients has received to date. The to improve the number and from 2017 donation forms conditions of donated organs, part of the “collaborate” and has ruled out the existence campaign which hoped to of complications due to cerebral obtain funds from donations reperfusion. The study was and bequests for research conducted on 78 donors in the projects in the Valdecilla hospitals of Puerta de Hierro environment. (Madrid), Clínico San Carlos (Madrid), Virgen de las Nieves IDIVAL attracted four new (Granada) and the Marqués de research groups Valdecilla University Hospital.
The external scientific Inflammation and its key role in Benedicto Crespo Facorro is the council gave a positive Alzheimer’s disease new Scientific Director of IDIVAL assessment to four new research groups for inclusion The main finding of this large- Benedicto Crespo-Facorro in IDIVAL. These four groups scale international project, is Professor of Psychiatry are: the Photonics Engineering with the participation of and Deputy Director of the Group, led by Professor IDIVAL researchers from the Department of Medicine and José Miguel López Higuera; Neurodegenerative Diseases Psychiatry of the University of the Nursing Research Group Group, was the discovery of Cantabria, Santander. Section led by Professor Carmen two new genes (PLCG2 and Head of the Psychiatric Service Sarabia; the Primary Care ABI3) and a new variant of of the Marqués de Valdecilla Research Group led by Dr Pedro a gene which was already University Hospital. Head Muñoz; and the Healthcare known (TREM2) associated of the Research Group IDIVAL Law and Bioethics Group with Alzheimer’s disease. of Psychiatry, principal led by Joaquín Cayón. These These three genes form part of investigator of the group of groups mean new areas of innate immunity and are mainly Research CIBERSAM G26 research will be included in expressed in the microglia, and coordinator of the area of the Institute, such as photonic which are the immune system Psychosis in Cibersam. engineering and law, and reflect cells in the central nervous a commitment to research in system. These cells are the IDIVAL launches a pioneering primary care and nursing. main actors regulating the plan to revitalise healthcare inflammatory phenomena in research and innovation Valdecilla patents a new guidance the brain, so this discovery system for prostate brachytherapy contributes to drawing attention to this process, as one of the IDIVAL launches a grants The Radiation Oncology factors causing the disease, and plan with nine different Department at Valdecilla, led by therefore a possible target for programmes focusing on Dr Pedro Prada in collaboration the development of new drugs. fostering talent, innovation and with the Photonic Engineering internationalisation. Group at the University of IDIVAL is committed to the The plan as a whole involves a Cantabria led by Dr José Miguel European Human Resources provision of over 1 million López Higuera, has obtained Strategy for Researchers (HRS4R) euros for developing research a European-level patent for its and innovation projects in prostate brachytherapy system. The goal of the European the Valdecilla environment The system consists of software Human Resources Strategy through competitive calls which identifies the position of for Researchers (HRS4R) is to for applicants scheduled the needles used in the prostate contribute to the development throughout the year, the only tissue, improving the safety of a European employment ones of their kind in Spain in of this therapy, which does market of interest to researchers, Healthcare Research not currently have guidance promoting their equal rights and Institutes. systems of this kind. obligations throughout Europe. Over 2017, IDIVAL assessed its A private donation of The use of regional perfusion current practices and/or policies €190,000 for IDIVAL devices increases the number of and identified their weaknesses organs suitable for transplant compared to the 40 principles IDIVAL was bequeathed assets of the Charter & Code, and valued at around €190,000 The IDIVAL Transplants and described the measures it will Autoimmunity Group led a take in an Action Plan. Activity Algunos hitos de 2017 Report News stories from 2017
Advances in the understanding of journal Nature Molecular vasculitis associated with ANCA early-stage Parkinson’s disease Psychiatry, developed by (anti-neutrophil cytoplasmic the international consortium antibodies). A collaboration with the ENIGMA, it was based on the Neurology and Nuclear prospective meta-analysis of IDIVAL launches a biobank for Medicine departments of magnetic resonance scans of brains the Marqués de Valdecilla 1,963 people with schizophrenia University Hospital identified and 2,359 control subjects all IDIVAL launched the the alterations produced in over the world. Valdecilla Brain Biobank, the brains of Parkinson’s which will receive, process, disease patients in its earliest The world’s first study of the and store brains and issue stages, which will help in the complete genome (GWAS) of IgA biological samples donated by understanding of these first vasculitis patients and individuals without stages, even before symptoms neurological defects for use in appear. The results were 308 Spanish patients with research projects. published in the prestigious IgA vasculitis were recruited This brain bank is coordinated journal ‘Neurology’, the official (currently the largest cohort by Dr Nuria Terán from publication of the American of patients with this illness the Anatomical Pathology Academy of Neurology. for genetic studies) and 1,018 Department, and is part of healthy individuals as controls. the Valdecilla Biobank, whose Generalised alterations in the The results obtained in this scientific director is Dr Pascual cerebral white matter of patients study describe the involvement Sánchez-Juan, and which has with schizophrenia of the HLA (human leukocyte all the resources necessary antigen) class II region in to ensure the quality and The largest analysis of cerebral the pathophysiology of IgA utility of these samples in white matter to date included vasculitis, confirming the great scientific research projects of researchers from IDIVAL’s importance of the immune proven quality, attesting to its Psychiatry Research Group, system in the development compliance with the ethical and produced evidence for the of this disease. The data and legal standards governing overall effect of schizophrenia also link IgA vasculitis with research with human on brain interconnections. other class II vasculitis such samples. Published in the prestigious as giant cell arteritis and the 61
A new method for treating IDIVAL applies human factor fulminant hepatic failure due to engineering to the assessment of paracetamol overdose healthcare technologies
The results of this study, IDIVAL’s Innovation Support published in Nature Unit, together with teams Communications, show from the Valdecilla Virtual that gene therapy to block Hospital, assessed the usability the mitochondrial protein of different infusion pumps in MCJ avoids hepatic toxicity a tender to provide infusion caused by paracetamol in pumps for the entire Cantabrian mice, opening up a new area Health Service. of therapy for paracetamol The teams designed simulated poisoning, which causes over realistic scenarios and analysed 30,000 hospitalisations a year in how 25 professionals from the the USA. IDIVAL’s participation three hospitals in the region in this project, led by the CIC used the pumps, identifying bioGUNE, was made possible potential safety problems, by the Digestive System which were used as one of the Department of the Marqués de criteria for selecting the pumps, Valdecilla University Hospital, and which will also be used with a López Albo contract for to develop implementation a collaborative residence at that strategies to improve safety in centre leading directly to this the use of this equipment. work. Activity Áreas de investigación Report Área de Trasplante de Órganos y Tejidos y Nuevas Terapias 63
IDIVAL R&D+i activity Activity IDIVAL R&D+i activity Report IDIVAL financing in 2017
IDIVAL R&D+i activity
Revenue
IDIVAL recorded total revenue representing 31% of total revenue. national and international levels of €6.96 million in 2017. The remaining revenue (69%) (€2.41 million) and the private Revenue from the Government came from public and private agreements and contracts signed of Cantabria was €2.17 million, competitive programmes at during the year (€2.36 million)
IDIVAL REVENUE 2014-2017 Amount
Government of Cantabria 2.169.500 Competitive calls 2.407.347 National R&D+i Plan 2.129.541 European Commission Programmes 89.253 Private competitive grants 188.549 Private contracts and agreements 2.357.100 Clinical trials 1.182.394 Service contracts 325.107 Collaboration agreements 198.235 Donations 651.365 Provision of services 22.849
TOTAL REVENUE 6.956.796
ORIGIN OF REVENUE, 2017 Percentage Distribution 34% 31% Government of Cantabria
Competitive calls
Private contracts and agreements 35% 65
Expenditure
IDIVAL’s expenditure is essentially In 2017, it allocated a total of The IDIVAL grant programme allocated to developing self-funded €2.83 million to developing represented expenditure of €1.09 research projects, to the IDIVAL projects with specific funding, million (Post-MIR Valdecilla research grant programme and to €2.05 million to structural costs, López Albo contracts, productivity, structural costs (support personnel, and €0.17 million to investments. co-financing of projects and in-house research personnel and contracts, etc.). operational costs).
Personnel
In 2017, IDIVAL had 31 Research Groups made up of researchers, Researcher Programmes Number collaborators and technical personnel, all pertaining to the Miguel Servet Programme (ISCIII): 3 Marqués de Valdecilla University IDIVAL Researchers: 6 Hospital and the University of Cantabria. Four of these research groups joined in 2017 Research Training Programme Number after the assessment of the External Scientific Council. Of the 31 research groups, 19 are Rio Hortega Programme (ISCIII): 2 consolidated, 3 emerging, 9 associated, and 1 newly created. Sara Borrell Programme (ISCIII): 2 Wenceslao López Albo Programme (IDIVAL): 9 Of these, 20 are directed by head researchers involved with clinical activity, 8 by researchers of the Contracts for Research Projects Number University of Cantabria, 2 by Institute researchers, and 1 by Ministry of Health personnel. IDIVAL-funded contracts 47
These groups had a total of 631 National Plan contracts: 47 members active at some point in Privately-funded contracts: 49 2017, 59 of whom were Principal Investigators on projects developed through competitive funding in Support Services Number active national or international calls over the last five years (2013-2017). Scren Programme (ISCIII): 2 Personnel contracted by IDIVAL during 2017 belong to the following Biobank network (ISCIII): 2 programmes: ITEMAS Platform (ISCIII): 3 Infrastructure technicians (ISCIII): 1 IDIVAL support personnel: 12 Activity IDIVAL R&D+i activity Report IDIVAL financing in 2017
Publications
In terms of production activity, in 2017 (excluding conference last author is from IDIVAL. IDIVAL researchers have papers published in journals). In published 443 indexed papers 246 papers (49.9%), the first or
Impact factor
In 2017, the cumulative impact percentage of publications with an published in 2017 had an impact factor of IDIVAL group publications impact factor in the first quartile factor in the first decile of the was 2047 (JCR 2016), the was 48%, and 91 (20.5%) papers specialisation.
Citaciones
The first article authored by Joint Surgery, 1930; 12: 280-288. 2017 the Valdecilla brand had Valdecilla researchers was cited in Throughout 2017, there were accumulated over 120,000 citations, 1930 and 1941. This was the paper 14,079 citations of the Valdecilla and more than 200 works exceeded published by Dr González Aguilar: brand, according to data from the 100 citations, with the number of González-Aguilar J. Contribution to ISI Web of Knowledge platform annual citations continuing to rise. the pathogeny of tendon tumours (using the descriptor “Valdecilla” of giant cells. Journal of Bone and in the affiliation field). Thus, by
IDIVAL publications in 2017, distributed by quartile
200 214 175
150
125
100
75 93 88 50 48 25
0 Q1 Q2 Q3 Q4 67
Evolution of the total impact factor
2000 2047 1750 1949 1915 1.788 1795 1500
1250
1000
750
500
250
0 2013 2014 2015 2016 2017
Evolution of impact factor distribution by quartile
Year Q1 Q2 Q3 Q4 Total N % N % N % N % 2012 188 51,6% 69 19,0% 64 17,6% 43 11,81% 364 2013 170 44,2% 98 25,5% 63 16,4% 54 14,0% 385 2014 171 52,1% 73 22,3% 56 17,1% 28 8,5% 328 2015 207 49,1% 99 23,5% 72 17,1% 44 10,4% 422 2016 199 40,4% 142 28,8% 80 16,2% 72 14,6% 493 2017 214 48,3% 93 21% 88 19,9% 48 11% 443
214 200 207 199 175 170 171 150
125 142
100 98 99 93 75 88 80 73 72 72 50 63 56 54 48 25 44 28 0 Q1 N Q2 N Q3 N Q4 N
2013 2014 2015 2016 2017 Activity IDIVAL R&D+i activity Report IDIVAL financing in 2017
IDIVAL publications in 2017 by impact factor
(Excluding those derived from multi-centre collaborations)
Magazine FI (JCR 2016) Nº Sum FI Quartile Decile
ACS CHEM NEUROSCI 3,883 1 3,883 1 2
ACTA CRYSTALLOGRAPHICA 2,032 1 2,032 2 5
SECTION B-STRUCTURAL SCIENCE CRYSTAL ENGINEERING AND MATERIALS ACTA NEUROCHIRURGICA 1,881 1 1,881 2 5
ACTA PSYCHIAT SCAND 6,79 1 6,79 1 1
ACTAS UROL ESP 1,181 3 3,543 4 8
ADDICTION 5,789 1 5,789 1 1
AIDS 5,003 1 5,003 1 2
ALIMENTARY PHARMACOLOGY 7,286 1 7,286 1 1 & THERAPEUTICS
ALLERGY 7,361 1 7,361 1 1
AM J TRANSPLANT 6,165 2 12,33 1 1
AMERICAN JOURNAL OF CARDIOLOGY 3,398 2 6,796 2 4
AMERICAN JOURNAL OF DERMATOPATHOLOGY 1,095 2 2,19 4 8
AMERICAN JOURNAL OF GASTROENTEROLOGY 9,566 1 9,566 1 1
AMERICAN JOURNAL OF HEMATOLOGY 5,275 3 15,825 1 2
AMERICAN JOURNAL OF HUMAN GENETICS 9,025 1 9,025 1 1
AMERICAN JOURNAL OF MEDICAL GENETICS 2,259 1 2,259 3 6 PART A
AMERICAN JOURNAL OF PATHOLOGY 4,057 1 4,057 1 2
AMERICAN JOURNAL OF PHYSIOLOGY. 3,611 1 3,611 1 2 RENAL PHYSIOLOGY
AMERICAN JOURNAL OF RESPIRATORY AND 13,204 1 13,204 1 1 CRITICAL CARE MEDICINE
ANGEWANDTE CHEMIE-INTERNATIONAL 11,994 1 11,994 1 1
EDITION
ANN RHEUM DIS 12,811 5 64,055 1 1
ANN TRANSPL 1,252 1 1,252 3 7
ANN VASC SURG 1,145 1 1,145 3 8
ANNALS OF HEMATOLOGY 3,083 2 6,166 2 5
ANNALS OF INTENSIVE CARE 3,656 1 3,656 2 3
ANNALS OF ONCOLOGY 11,855 1 11,855 1 1
ANNALS OF THORACIC SURGERY 3,7 1 3,7 1 2
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY 4,302 1 4,302 1 2
APPL NURS RES 1,379 1 1,379 2 3
APPL SPECTROSC 1,529 1 1,529 2 5
ARCH ARGENT PEDIATR 0,403 1 0,403 4 10
ARCH BRONCONEUMOL 2,979 4 11,916 2 4 69
Magazine FI (JCR 2016) Nº Sum FI Quartile Decile
ARCHIVOS ESPANOLES DE UROLOGIA 0,323 2 0,646 4 10
ARTHRIT CARE RES 3,319 2 6,638 2 4
ARTHRITIS & RHEUMATOLOGY 6,918 1 6,918 1 1
ARTHRITIS RESEARCH & THERAPY 4,121 4 16,484 2 3
ASIAN JOURNAL OF ANDROLOGY 2,996 1 2,996 1 2
AUTOIMMUNITY REVIEWS 8,961 1 8,961 1 1
BEHAVIOURAL BRAIN RESEARCH 3,002 1 3,002 2 4
BEST PRACT RES CL HA 2 1 2 3 7
BIOLOGY OF BLOOD AND MARROW 4,704 3 14,112 1 2 TRANSPLANTATION BIOMATERIALS 8,402 1 8,402 1 1
BLOOD 13,164 2 26,328 1 1
BLOOD TRANSFUS-ITALY 1,607 1 1,607 4 8
BMC CARDIOVASC DISOR 1,832 1 1,832 3 7
BMC INFECTIOUS DISEASES 2,768 2 5,536 2 5
BMC MEDICAL GENETICS 2,198 1 2,198 3 6
BMJ OPEN 2,369 1 2,369 1 3
BONE MARROW TRANSPLANTATION 3,874 3 11,622 2 3
BRAIN IMAGING BEHAV 3,985 1 3,985 2 3
BREAST CANCER RESEARCH AND TREATMENT 3,626 1 3,626 2 4
BRITISH JOURNAL OF CANCER 6,176 3 18,528 1 2
BRITISH JOURNAL OF DERMATOLOGY 4,706 1 4,706 1 1
BRITISH JOURNAL OF HAEMATOLOGY 5,67 3 17,01 1 2
CANCER EPIDEMIOL 2,343 1 2,343 2 4
CANCER MEDICINE 3,362 1 3,362 2 5
CARDIOVASC PATHOL 2,359 2 4,718 2 4
CARDIOVASC TOXICOL 2,712 2 5,424 2 5
CATHETERIZATION AND CARDIOVASCULAR 2,602 2 5,204 2 5 INTERVENTIONS
CELL DEATH DIS 5,965 1 5,965 1 3
CEPHALALGIA 3,609 2 7,218 1 3
CHRONIC RESPIRATORY DISEASE 1,818 1 1,818 3 8
CIR ESPAN 1,276 4 5,104 3 7
CLIN EXP DERMATOL 1,589 1 1,589 3 6
CLIN EXP RHEUMATOL 2,634 5 13,17 3 6
CLIN NUCL MED 3,64 1 3,64 1 2
CLIN PSYCHOL REV 8,897 1 8,897 1 1 Activity IDIVAL R&D+i activity Report IDIVAL financing in 2017
Magazine FI (JCR 2016) Nº Sum FI Quartile Decile
CLIN RHEUMATOL 2,365 1 2,365 3 7
CLINICAL & TRANSLATIONAL ONCOLOGY 2,353 11 25,883 3 7
CLINICAL CARDIOLOGY 2,757 1 2,757 2 5
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 7,398 2 14,796 1 2
CLINICAL INFECTIOUS DISEASES 8,216 3 24,648 1 1
CLINICAL REVIEWS IN ALLERGY & IMMUNOLOGY 5,263 1 5,263 1 2
COLORECTAL DIS 2,689 1 2,689 2 3
CRYSTALS 1,566 1 1,566 3 6
CURR ONCOL REP 2,608 1 2,608 3 6
CURR PAIN HEADACHE R 2,051 1 2,051 3 7
CURRENT MEDICINAL CHEMISTRY 3,249 1 3,249 2 3
CURRENT OPINION IN NEUROLOGY 4,699 1 4,699 1 2
DIABETES RESEARCH AND CLINICAL PRACTICE 3,639 1 3,639 2 4
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS 2,401 1 2,401 3 6 DISEASE
DIGESTIVE DISEASES AND SCIENCES 2,875 1 2,875 2 5
DRUG DISCOV TODAY 6,369 1 6,369 1 1
ECHOCARDIOGR-J CARD 1,314 1 1,314 4 9
EJSO-EUR J SURG ONC 3,522 1 3,522 1 2
EMERGENCIAS 3,028 1 3,028 1 2
ENFERMEDADES INFECCIOSAS Y 1,714 5 8,57 3 8 MICROBIOLOGIA CLINICA
EPIGENETICS-US 4,394 1 4,394 1 3
EUR ARCH OTO-RHINO-L 1,66 1 1,66 2 5
EUR J CELL BIOL 3,712 1 3,712 2 5
EUR J NUCL MED MOL I 7,277 1 7,277 1 1
EUR J NUTR 4,37 1 4,37 1 2
EUR J TRAUMA EMERG S 0,895 1 0,895 3 8
EUR RADIOL 3,967 1 3,967 1 2
EUR RESPIR J 10,569 2 21,138 1 1
EUR SURG RES 1,382 1 1,382 3 7
EUROINTERVENTION 5,165 2 10,33 1 2
EUROPEAN ARCHIVES OF PSYCHIATRY 3,569 1 3,569 2 3 AND CLINICAL NEUROSCIENCE
EUROPEAN HEART JOURNAL 19,651 1 19,651 1 1
EUROPEAN JOURNAL OF CANCER 6,029 2 12,058 1 2
EUROPEAN JOURNAL OF INTERNAL MEDICINE 2,96 3 8,88 1 2
EXPERT OPINION ON ORPHAN DRUGS 0,559 1 0,559 4 10
FASEB JOURNAL 5,498 1 5,498 1 1
FORENSIC SCI INT-GEN 3,911 2 7,822 1 1 71
Magazine FI (JCR 2016) Nº Sum FI Quartile Decile
FRONTIERS IN CELLULAR AND INFECTION 4,3 1 4,3 1 2 MICROBIOLOGY
FRONTIERS IN IMMUNOLOGY 6,429 1 6,429 1 2
FRONTIERS IN MICROBIOLOGY 4,076 1 4,076 1 3
FRONTIERS IN NEUROENDOCRINOLOGY 9,425 1 9,425 1 1
FUTURE ONCOL 2,131 1 2,131 3 8
GASTRIC CANCER 5,454 1 5,454 1 2
GASTROENT HEPAT-BARC 0,917 3 2,751 4 10
GASTROENTEROLOGY 18,392 2 36,784 1 1
GYNECOLOGIC ONCOLOGY 4,959 1 4,959 1 1
HAEMATOLOGICA 7,702 2 15,404 1 1
HEALTH AND QUALITY OF LIFE OUTCOMES 2,143 1 2,143 2 4
HEALTH ECON POLICY L 1,675 1 1,675 2 5
HELICOBACTER 3,429 1 3,429 2 3
HEMATOLOGICAL ONCOLOGY 3,118 1 3,118 2 4
HEPATOLOGY 13,246 4 52,984 1 1
IEEE T MED IMAGING 3,942 1 3,942 1 1
IEEE TRANSACTIONS ON MAGNETICS 1,243 1 1,243 3 7
IMMUNOLOGY LETTERS 2,86 1 2,86 3 6
INDIAN J DERMATOL VE 1,948 1 1,948 2 5
INFLAMMATORY BOWEL DISEASES 4,525 1 4,525 1 2
INT J ENV RES PUB HE 2,101 1 2,101 2 3
INT J MOL SCI 3,226 1 3,226 2 4
INTENSIVE CARE MEDICINE 12,015 2 24,03 1 1
INTERNATIONAL JOURNAL OF 4,307 1 4,307 1 2 ANTIMICROBIAL AGENTS
INTERNATIONAL JOURNAL OF CANCER 6,513 1 6,513 1 2
INTERNATIONAL JOURNAL OF CARDIOLOGY 6,189 1 6,189 1 2
INTERNATIONAL JOURNAL OF CARDIOVASCULAR 1,896 1 1,896 3 6 IMAGING
INTERNATIONAL JOURNAL OF COLORECTAL DISEASE 2,426 1 2,426 2 4
INTERNATIONAL JOURNAL OF LEGAL MEDICINE 2,382 1 2,382 1 2
INTERNATIONAL JOURNAL OF NANOMEDICINE 4,3 1 4,3 1 2
J AM SOC NEPHROL 8,966 1 8,966 1 1
J CANCER RES CLIN 3,503 1 3,503 2 4
J CLIN LIPIDOL 5,812 4 23,248 1 1
J CLIN VIROL 3,051 1 3,051 2 5
J CROHNS COLITIS 5,813 1 5,813 1 2
J DERMATOL TREAT 1,89 1 1,89 2 5
J HEMATOL ONCOL 6,35 1 6,35 1 1 Activity IDIVAL R&D+i activity Report IDIVAL financing in 2017
Magazine FI (JCR 2016) Nº Sum FI Quartile Decile
J IMMUNOASS IMMUNOCH 0,727 1 0,727 3 8
J INVEST DERMATOL 6,287 1 6,287 1 1
J MECH BEHAV BIOMED 3,11 1 3,11 2 3
J MICROBIOL METH 1,79 1 1,79 3 7
J NEPHROL 2,153 1 2,153 2 5
J NEUROSURG SCI 1,522 2 3,044 3 6
J NEUROSURG-PEDIATR 2,17 1 2,17 2 4
J OPTICS-UK 1,741 1 1,741 2 5
J ORTHOP RES 2,692 1 2,692 1 3
J VASC SURG 3,536 1 3,536 1 2
JACC-CARDIOVASC INTE 8,841 4 35,364 1 1
JOURNAL OF AFFECTIVE DISORDERS 3,432 1 3,432 1 2
JOURNAL OF ALZHEIMERS DISEASE 3,731 2 7,462 2 3
JOURNAL OF ANATOMY 2,182 1 2,182 1 2
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY 5,071 2 10,142 1 1
JOURNAL OF BIOMEDICAL OPTICS 2,53 1 2,53 2 4
JOURNAL OF BONE AND MINERAL METABOLISM 2,423 2 4,846 3 6
JOURNAL OF CLINICAL MICROBIOLOGY 3,712 2 7,424 2 3
JOURNAL OF CLINICAL ONCOLOGY 24,008 1 24,008 1 1
JOURNAL OF CLINICAL PATHOLOGY 2,687 1 2,687 2 3
JOURNAL OF COMMUNICATIONS TECHNOLOGY 0,446 1 0,446 4 10 AND ELECTRONICS
JOURNAL OF CUTANEOUS PATHOLOGY 1,317 1 1,317 3 7
JOURNAL OF GASTROENTEROLOGY 0,165 2 0,33 4 10
JOURNAL OF HAND SURGERY-BRITISH AND 0,844 1 0,844 3 7 EUROPEAN VOLUME
JOURNAL OF HEPATOLOGY 12,486 2 24,972 1 1
JOURNAL OF HOSPITAL INFECTION 3,126 1 3,126 2 4
JOURNAL OF INFECTION 4,201 1 4,201 1 2
JOURNAL OF INFECTION AND CHEMOTHERAPY 1,826 1 1,826 3 7
JOURNAL OF INTERVENTIONAL CARDIAC 1,826 1 1,826 3 7 ELECTROPHYSIOLOGY
JOURNAL OF LIGHTWAVE TECHNOLOGY 3,671 2 7,342 1 2
JOURNAL OF MAGNETISM AND MAGNETIC 2,63 1 2,63 2 4 MATERIALS
JOURNAL OF MATERIALS CHEMISTRY C 5,256 1 5,256 1 2
JOURNAL OF MEDICAL ECONOMICS 1,576 1 1,576 2 5
JOURNAL OF MEDICAL GENETICS 5,451 1 5,451 1 2
JOURNAL OF MOLECULAR AND CELLULAR 5,68 1 5,68 1 2 CARDIOLOGY
JOURNAL OF MOLECULAR MEDICINE-JMM 4,686 1 4,686 1 2 73
Magazine FI (JCR 2016) Nº Sum FI Quartile Decile
JOURNAL OF NANOPARTICLE RESEARCH 2,02 1 2,02 2 5
JOURNAL OF NEUROLOGY 3,389 2 6,778 2 4
JOURNAL OF NEUROLOGY NEUROSURGERY AND 7,349 2 14,698 1 1 PSYCHIATRY
JOURNAL OF NEUROSURGERY 4,059 1 4,059 1 1
JOURNAL OF NON-CRYSTALLINE SOLIDS 2,124 3 6,372 1 2
JOURNAL OF PINEAL RESEARCH 10,391 1 10,391 1 1
JOURNAL OF THE NEUROLOGICAL SCIENCES 2,295 2 4,59 3 6
JOURNAL OF THORACIC DISEASE 2,365 1 2,365 3 7
JOURNAL OF TRAUMA NURSING 0,852 1 0,852 3 7
JOURNAL OF VIRAL HEPATITIS 4,122 2 8,244 1 3
LABMEDICINE 1,265 1 1,265 4 8
LANCET 47,831 1 47,831 1 1
LEUKEMIA 11,702 1 11,702 1 1
LIVER INTERNATIONAL 4,116 3 12,348 1 3
LIVER TRANSPLANTATION 3,91 1 3,91 1 2
MATURITAS 3,255 1 3,255 1 2
MED INTENSIVA 1,231 7 8,617 4 10
MEDICINA CLINICA 1,125 16 18 3 6
MEDICINE 1,803 2 3,606 2 4
MODERN PATHOLOGY 5,728 2 11,456 1 1
MUSCLE NERVE 2,605 1 2,605 2 5
NANOSCALE 7,367 1 7,367 1 1
NAT MED 29,886 1 29,886 1 1
NAT REV CARDIOL 14,299 1 14,299 1 1
NAT REV RHEUMATOL 12,188 1 12,188 1 1
NATURE COMMUNICATIONS 12,124 3 36,372 1 1
NATURE GENETICS 27,959 2 55,918 1 1
NEFROLOGIA 1,183 6 7,098 4 8
NEUROBIOLOGY OF DISEASE 5,02 2 10,04 1 2
NEUROCIRUGIA 0,548 1 0,548 4 10
NEUROIMAGE 5,835 1 5,835 1 1
NEUROLOGIA 2,103 1 2,103 3 6
NEUROLOGY 7,592 2 15,184 1 1
NEUROMUSCULAR DISORD 2,969 1 2,969 2 4
NEUROPEPTIDES 2,486 1 2,486 3 6
NEUROSURGICAL REVIEW 2,06 1 2,06 2 5
NEW ENGLAND JOURNAL OF MEDICINE 72,406 2 144,812 1 1
NUCL MED COMMUN 1,472 1 1,472 3 7 Activity IDIVAL R&D+i activity Report IDIVAL financing in 2017
Magazine FI (JCR 2016) Nº Sum FI Quartile Decile
OCUL IMMUNOL INFLAMM 2,453 1 2,453 2 4
ONCOGENE 7,519 2 15,038 1 1
ONCOL LETT 1,39 1 1,39 4 9
ONCOLOGIST 4,962 2 9,924 1 3
ONCOLOGY REPORTS 2,662 1 2,662 3 6
ONCOTARGET 5,168 2 10,336 1 3
OSTEOARTHR CARTILAGE 4,742 1 4,742 1 1
OSTEOPOROSIS INTERNATIONAL 3,591 1 3,591 2 4
OTOLOGY & NEUROTOLOGY 2,024 1 2,024 2 4
P R HEALTH SCI J 0,581 1 0,581 4 10
PATHOLOGY INTERNATIONAL 1,465 1 1,465 3 8
PATHOLOGY RESEARCH AND PRACTICE 1,543 1 1,543 3 7
PEDIATR DERMATOL 0,99 1 0,99 4 9
PHYSICAL REVIEW B 3,836 1 3,836 2 3
PLOS ONE 2,806 15 42,09 1 3
PREV MED 3,434 1 3,434 1 2
PROCEEDINGS OF THE NATIONAL ACADEMY OF 9,661 1 9,661 1 1 SCIENCES OF THE UNITED STATES OF AMERICA
PSYCHIATRY RESEARCH-NEUROIMAGING 1,878 1 1,878 2 4
PSYCHOPHARMACOLOGY 3,308 1 3,308 2 3
RESPIRATORY MEDICINE 3,217 1 3,217 2 4
RESUSCITATION 5,23 1 5,23 1 1
REV PORT CARDIOL 1,195 1 1,195 4 9
REV SCI INSTRUM 1,515 1 1,515 3 6
REVISTA CLINICA ESPAÑOLA 0,971 2 1,942 3 7
REVISTA DE NEUROLOGIA 0,743 2 1,486 4 10
REVISTA DE PSIQUIATRIA Y SALUD MENTAL 2,227 2 4,454 2 5
REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS 1,401 4 5,604 4 9
REVISTA ESPANOLA DE QUIMIOTERAPIA 0,75 1 0,75 4 10
REVISTA MEXICANA DE FISICA 0,482 1 0,482 4 9
RHEUMATOL INT 1,824 4 7,296 3 7
RNA BIOL 3,9 1 3,9 2 3
ROM J MORPHOL EMBRYO 0,67 2 1,34 4 10
SCHIZOPHR RES 3,986 3 11,958 1 2
SCI JUSTICE 1,992 1 1,992 2 3
SCIENTIFIC REPORTS 4,259 14 59,626 1 2
SEMIN ARTHRITIS RHEU 4,498 3 13,494 1 2
SEMIN LIVER DIS 5,5 1 5,5 1 2
SENSORS-BASEL 2,677 1 2,677 1 2 75
Magazine FI (JCR 2016) Nº Sum FI Quartile Decile
SLEEP MED 3,391 1 3,391 2 3
TEACHING AND TEACHER EDUCATION 2,183 1 2,183 1 2
THERAPEUTIC ADVANCES IN NEUROLOGICAL 4,192 1 4,192 1 2 DISORDERS
THERAPEUTICS AND CLINICAL RISK MANAGEMENT 2,2 1 2,2 2 5
THROMBOSIS AND HAEMOSTASIS 5,627 1 5,627 1 1
TRANSPL INFECT DIS 1,719 1 1,719 3 8
TRANSPL INT 3,079 1 3,079 1 3
TRANSPLANTATION 3,678 4 14,712 1 2
TUMOR BIOL 3,65 1 3,65 2 4
TURK J MED SCI 0,71 1 0,71 4 9
VIRCHOWS ARCHIV 2,848 1 2,848 2 3
WORLD NEUROSURG 2,592 3 7,776 2 4
ZYGOTE 1,053 1 1,053 4 9
TOTAL GENERAL 443 2047,147 Activity IDIVAL R&D+i activity Report IDIVAL financing in 2017
IDIVAL R&D+i activity
The number of works by IDIVAL research groups and their impact factors are shown in the following table:
GROUP No of works Total IF
Anatomical pathology and molecular pathology 13 30,626 Apoptosis 2 9,701 Cell nucleus biology 6 25,057 Cell cycle, stem cells and cancer 4 18,856 Cytokines and growth factors in the phenomena 10 61,819 of pathological tissue plasticity Cephalea clinic and genetics 7 17,557 Healthcare law and bioethics 1 1,675 Diagnosis and treatment using imaging 7 13,478 Neurodegenerative diseases 19 101,860 Genetic epidemiology and arteriosclerosis 57 441,455 in systemic inflammatory diseases Epidemiology and pathogenic mechanisms of infectious diseases 29 93,662 Epidemiology and public health 20 68,865 Translational haematopathology 20 85,632 Molecular imaging 17 46,242 Infection and immunity and digestive pathology 42 251,828 Photonics engineering 7 18,599 Immunopathology of rheumatic diseases 3 9,641 Cardiovascular research 21 119,378 Nursing research 8 19,125 Melatonin and breast cancer 3 15,323 Mineral and lipid metabolism 34 110,070 Clinical and molecular microbiology 24 58,337 Nanomedicine 18 63,375 Nanovaccines and cellular vaccines based on Listeria 2 12,535 monocytogenes and their applications in biomedicine Haematologic neoplasms and haematopoietic 30 160,6 progenitor cell transplantation Neurophysiology in epilepsy and neurointensives 1 1,231 New techniques in abdominal surgery 6 16,310 Psychiatry 22 123,012 Community healthcare 3 8,483 Cell signalling and therapeutic targets in cancer 14 36,957 Transplantation and autoimmunity 37 116,026 Clinical trials, medical oncology and palliative medicine unit 29 128,544 77
Drug-Coated Balloon: Lancet 2017. 390: 1700-1712. “Scoring to Win”. FI: 47,831(Q1) Some JACC Cardiovasc Interv 2017. 10: 1341-1343. 10. Ibi D, de la Fuente Revenga M, representative FI: 8,841(Q1) Kezunovic N, Muguruza C, Saunders JM, Gaitonde SA, Moreno JL, Ijaz MK, articles 5. Escaned J, Collet C, Ryan N, Luigi Santosh V, Kozlenkov A, Holloway T, De Maria G, Walsh S, Sabate M, Seto J, García-Bea A, Kurita M, Mosley Davies J, Lesiak M, Moreno R, Cruz- GE, Jiang Y, Christoffel DJ, Callado LF, Gonzalez I, Hoole SP, Ej West N, Piek Russo SJ, Dracheva S, López-Giménez 1. Alonso C, Fernández-Ramos D, JJ, Zaman A, Fath-Ordoubadi F, Stables JF, Ge Y, Escalante CR, Meana JJ, Varela-Rey M, Martínez-Arranz I, RH, Appleby C, van Mieghem N, van Akbarian S, Huntley GW, González- Navasa N, Van Liempd SM, Lavin Geuns RJ, Uren N, Zueco J, Buszman Maeso J. JL, Mayo R, Ilisso CP, de Juan VG, P, Iñiguez A, Goicolea J, Hildick-Smith Antipsychotic-induced Hdac2 Iruarrizaga-Lejarreta M, delaCruz-Villar D, Ochala A, Dudek D, Hanratty C, transcription via NF-?B leads to L, Mincholé I, Robinson A, Crespo Cavalcante R, .., Banning AP. synaptic and cognitive side effects. J, Martín-Duce A, Romero-Gomez Clinical outcomes of state-of- NAT NEUROSCI 2017. 20: 1247-1259. M, Sann H, Platon J, Van Eyk J, the-art percutaneous coronary FI: 17,839(Q1) Aspichueta P, Noureddin M, Falcón- revascularization in patients with de Pérez JM, Anguita J, Aransay AM, novo three vessel disease: 1-year 11. Iturrioz-Rodríguez N, González- Martínez-Chantar ML, Lu SC, Mato JM. results of the SYNTAX II study. Eur Domínguez E, González-Lavado E, Metabolomic Identification Heart J 2017. 38: 3124-3134. Marín-Caba L, Vaz B, Pérez-Lorenzo M, of Subtypes of Nonalcoholic FI: 19,651(Q1) Correa-Duarte MA, Fanarraga ML. Steatohepatitis. A Biomimetic Escape Strategy for Gastroenterology 2017. 6. Fernández Carrillo C, Lens S, Llop Cytoplasm Invasion by Synthetic FI: 18,392(Q1) E, Pascasio JM, Crespo J, Arenas J, Particles. Fernández I, Baliellas C, Carrión JA, de Angew Chem Int Ed Engl 2017. 56: 2. Barbier-Torres L, Iruzubieta P, la Mata M, Buti M, Castells L, Albillos 13736-13740. Fernández-Ramos D, Delgado TC, A, Romero M, Turnes J, Pons C, FI: 11,994(Q1) Taibo D, Guitiérrez-de-Juan V, Varela- Moreno-Planas JM, Moreno-Palomares Rey M, Azkargorta M, Navasa N, JJ, Fernández-Rodriguez C, García- 12. Lens S, Alvarado E, Mariño Z, Fernández-Tussy P, Zubiete-Franco I, Samaniego J, Prieto M, Fernández Londoño MC, LLop E, Martinez J, Simon J, Lopitz-Otsoa F, Lachiondo- Bermejo M, Salmerón J, Badia E, Fortea JI, Ibañez L, Ariza X, Baiges Ortega S, Crespo J, Masson S, McCain Salcedo M, Herrero JI, Granados R, Blé A, Gallego A, Bañares R, Puente MV, Villa E, Reeves H, Elortza F, Lucena M, Mariño Z, Calleja JL. A, Albillos A, Calleja JL, Torras X, MI, Hernández-Alvarez MI, Zorzano A, Treatment of hepatitis C virus Hernández-Gea V, Bosch J, Villanueva Andrade RJ, Lu SC, Mato JM, Anguita infection in patients with cirrhosis C, Forns X, García-Pagán JC. J, Rincón M, Martínez-Chantar ML. and predictive value of model for Effects of All-Oral Anti-Viral The mitochondrial negative regulator end-stage liver disease: Analysis of Therapy on HVPG and Systemic MCJ is a therapeutic target for data from the Hepa-C registry. Hemodynamics in Patients With acetaminophen-induced liver injury. Hepatology 2017. 65: 1810-1822. Hepatitis C Virus-Associated Nat Commun 2017. 8: 2068-0. FI: 13,246(Q1) Cirrhosis. FI: 12,124(Q1) Gastroenterology 2017. 7. Gladman D, Rigby W, Azevedo FI: 18,392(Q1) 3. Curiel-Olmo S, Mondejar R, Almaraz VF, Behrens F, Blanco R, Kaszuba C, Mollejo M, Cereceda L, Marès R, A, Kudlacz E, Wang C, Menon S, 13. Martínez C, Gayoso J, Canals Derdak S, Campos-Martin Y, Batlle A, Hendrikx T, Kanik KS. C, Finel H, Peggs K, Dominietto A, Gonzalez de Villambrosía S, Gut M, Tofacitinib for Psoriatic Arthritis Castagna L, Afanasyev B, Robinson Blanc J, Traverse-Glehen A, Verney A, in Patients with an Inadequate S, Blaise D, Corradini P, Itälä-Remes Baseggio L, Camacho FI, Wotherspoon Response to TNF Inhibitors. M, Bermúdez A, Forcade E, Russo D, A, Stamatopoulos K, Xochelli A, N Engl J Med 2017. Potter M, McQuaker G, Yakoub-Agha I, Papadaki T, Kanellis G, Ponzoni M, 377: 1525-1536. Scheid C, Bloor A, Montoto S, Dreger Garcia-Cosio M, Vaque JP, Beltran S, FI: 72,406(Q1) P, Sureda A, Lymphoma Working Party Gut I, Piris MA, Martinez N. of the European Group for Blood and Splenic diffuse red pulp small 8. González-Gay MA, Matteson EL, Marrow Transplantatio. B-cell lymphoma displays increased Castañeda S. Post-Transplantation expression of cyclin D3 and Polymyalgia rheumatica. Cyclophosphamide-Based recurrent CCND3 mutations. Lancet 2017. 390: 1700-1712. Haploidentical Transplantation as Blood 2017. 129: 1042-1045. FI: 47,831(Q1) Alternative to Matched Sibling or FI: 13,164(Q1) Unrelated Donor Transplantation 9. González-Gay MA, Matteson EL, for Hodgkin Lymphoma: A Registry 4. De la Torre Hernández JM, Puri R, Castañeda S. Study of the Lymphoma Working Alfonso F. Polymyalgia rheumatica. Party of the European Society for Activity IDIVAL R&D+i activity Report IDIVAL financing in 2017
Blood and Marrow Transplantation. 17. Sierra M, Martínez-Rodríguez I, NT, Pandiella A, Lafarga M, Leon J, J Clin Oncol 2017. 35: 3425-3432. Sánchez-Juan P, González-Aramburu I, Martinez-Climent JA, Sanz-Moreno V, FI: 24,008(Q1) Jiménez-Alonso M, Sánchez-Rodríguez Fernandez-Luna JL. 14. Oller J, Méndez-Barbero N, Ruiz A, Berciano J, Banzo I, Infante J. ODZ1 allows glioblastoma to EJ, Villahoz S, Renard M, Canelas Prospective clinical and DaT- sustain invasiveness through a LI, Briones AM, Alberca R, Lozano- SPECT imaging in premotor LRRK2 Myc-dependent transcriptional Vidal N, Hurlé MA, Milewicz D, G2019S-associated Parkinson upregulation of RhoA. Oncogene Evangelista A, Salaices M, Nistal JF, disease. 2017. 36: 1733-1744. Jiménez-Borreguero LJ, De Backer J, Neurology 2017. 89: 439-444. FI: 7,519(Q1) Campanero MR, Redondo JM. FI: 7,592(Q1) Nitric oxide mediates aortic 20. Zubiete-Franco I, Fernández-Tussy disease in mice deficient in the 18. Sims R, van der Lee SJ, Naj P, Barbier-Torres L, Simon J, Fernández- metalloprotease Adamts1 and in a AC, Bellenguez C, Badarinarayan N, Ramos D, Lopitz-Otsoa F, Juan VG, mouse model of Marfan syndrome. Jakobsdottir J, Kunkle BW, Boland Davalillo SL, Duce AM, Iruzubieta P, NAT MED 2017. 23: 200-212. A, Raybould R, Bis JC, Martin ER, Taibo D, Crespo J, Caballeria J, Villa E, FI: 29,886(Q1) Grenier-Boley B, Heilmann-Heimbach Aurrekoetxea I, Aspichueta P, Varela- S, Chouraki V, Kuzma AB, Sleegers K, Rey M, Lu SC, Mato JM, Beraza N, 15. Ruisanchez C, Sarralde JA, Vronskaya M, Ruiz A, Graham RR, Olaso Delgado TC, Martínez-Chantar ML. Gonzalez-Fernandez C, Dominguez MJ. R, Hoffmann P, Grove ML, Vardarajan Deregulated neddylation in liver Sudden dysfunction of veno- BN, Hiltunen M, Nöthen MM, White CC, fibrosis. venous extracorporeal membrane Hamilton-Nelson KL, Epelbaum J, Maier Hepatology 2017. 65: 694-709. oxygenation caused by intermittent W, .., Schellenberg GD. FI: 13,246(Q1) cannula obstruction: the key role of Rare coding variants in PLCG2, echocardiography. ABI3, and TREM2 implicate Intensive Care Med 2017. 43: 1055- microglial-mediated innate immunity 1056. in Alzheimer’s disease. FI: 12,015(Q1) Nat Genet 2017. 49: 1373-1384. FI: 27,959(Q1) 16. Sánchez-Juan P, Seshadri S. Dynamic measurements of 19. Talamillo A, Grande L, Ruiz- ß-amyloid accumulation: The early Ontañon P, Velasquez C, Mollinedo P, effect of APOE. Torices S, Sanchez-Gomez P, Aznar Neurology 2017. 89: 986-987. A, Esparis-Ogando A, Lopez-Lopez C, FI: 7,592(Q1) Lafita C, Berciano MT, Montero JA, Vazquez-Barquero A, Segura V, Villagra 79
Research Projects
R&D+i national plan grants active or awarded in 2017
Active Grants as prognostic factors in idiopathic 11. BFU2014-54754-P. normal pressure hydrocephalus. Berciano Blanco, Mª Teresa, CARLOS III HEALTH INSTITUTE. Miguel Ángel Lafarga Coscojuela Throughout 2017, IDIVAL groups 2014-2016. Acetylation regulation of the maintained 42 active projects in the survival factor of motoneurons: its R&D+i National Plan, 15 research 6. PI13/01310. importance in snRNP biogenesis contracts, and 3 European projects. José Ramos Vivas and the assembly of CAJAL nuclear Clinically relevant host-pathogen bodies. MINECO. key interaction in Acinetobacter 2015-2017. species. CARLOS III HEALTH INSTITUTE. 2014-2016. 12. BFU2014-54026-P. Juan Hurle González 7. PI13/01760. Biological mechanism and new José Luis Fernández Luna significance of the interdigital Projects Prognostic and therapeutic cell death responsible for the relevance in ODZ 1 glioblastoma, separation of the fingers during a new target in cancer. CARLOS III limb development. 2015-2017. 1. SAF2013-46292-R HEALTH INSTITUTE. 2014-2016. Benedicto Crespo Facorro. 13. PI14/00378. New candidate genes for the 8. PI13/01884. Manuel Antonio Arias Rodríguez response to antipsychotic treatment Eugenio Carrasco Marín Study of serological factors and in schizophrenia: evidence from Defects in innate immunity and cellular activation as potential gene expression studies. coinfection with respiratory viruses: early markers of chronic antibody- MINECO. 2014-2017 the perfect storm to develop mediated rejection in renal invasive pneumococcal disease transplants. CARLOS III HEALTH 2. SAF2013-47416-R in children? CARLOS III HEALTH INSTITUTE. 2015-2017.
Miguel Ángel Piris Pinilla. INSTITUTE. 2014-2016. Aggressive lymphomas: treatment 14. PI14/00900. guided by molecular diagnosis. 9. PI13/01249. Alberto Gandarillas Solinis MINECO. 2014-2016 Juan Martino González New Routes and Strategies Preservation of areas involved in Towards Squamous Cell Cancer. 3. SAF2013-42012-P. the verbal working memory to CARLOS III HEALTH INSTITUTE.
Samuel Cos Corral. prevent sequelae in glioma surgery 2015-2017. Sensitising effects of melatonin for in eloquent areas. CARLOS III chemotherapy and radiotherapy: a HEALTH INSTITUTE. 15. PI14/00918. study of the molecular changes that 2014-2016. Diana Tordesillas Gutiérrez modulate this process. PAFIP neurocognition: Long-term MINECO. 2014-2016. 10. PI13/01191. longitudinal study (10 years) of María del Carmen Fariñas Álvarez cognitive functioning in patients 4. SAF2013-47434-R. Intestinal colonisation by with schizophrenia spectrum
María Amor Hurle González multiresistant enterobacteriaceae psychosis. MicroRNAs in neuropathic pain: in patients with renal and liver CARLOS III HEALTH INSTITUTE. molecular biomarkers and targeted transplants: multicentre cohort 2015-2017. therapies. MINECO. 2014-2016. study and randomised, controlled, open clinical trial CARLOS III 16. PI14/01911. 5. PI13/01008. HEALTH INSTITUTE. Luis Martínez Martínez Eloy Manuel Rodríguez Rodríguez 2014-2016. Heteroresistance and Persistence Alzheimer’s disease biomarkers in carbapenem-resistant Klebsiella Activity IDIVAL R&D+i activity Report IDIVAL financing in 2017
pneumoniae. CARLOS III HEALTH 24. PIE15/00079. INSTITUTE. 2017-2019. INSTITUTE. 2015-2017. Javier Crespo García Personalized Medicine in HCV 32. PI16/01397 17. PI15/00009. infection: understanding and Santiago Montes Moreno Alain Antonio Ocampo Sosa predicting hepatic and systemic Targeted exonic next generation Functional identification and responses in the era of the new sequencing for the molecular characterisation of new components antiviral drugs. CARLOS III HEALTH diagnosis and cell free tumor DNA of type VI secretion systems and the INSTITUTE. 2016-2018. analysis as a screening method for molecular basis of their regulation patients with DLBCL. CARLOS III in clinical strains of Pseudomonas 25. PIE15/00081. HEALTH INSTITUTE. aeruginosa. CARLOS III HEALTH Miguel Ángel Piris Pinilla 2017-2019. INSTITUTE. 2016-2018. Discovery, Validation and 33. PI16/01415 Implementation of Biomarkers for María del Carmen Fariñas Álvarez 18. PI15/00521. Precision Oncology. CARLOS III Impact of intestinal colonisation by Manuel Olmos Martínez HEALTH INSTITUTE. 2016-2019. multiresistant enterobacteriaceae Study of bone and mineral in systemic infections, graft-versus- metabolism of the post-menopausal 26. RTC-2015-3786-1. host disease (GVHD), and mortality female and male population aged 50 Javier Gómez Román in patients receiving transplants of and over receiving care from a health Development of anti-CCR9 allogeneic hematopoietic progenitor centre in Cantabria. CARLOS III therapeutic antibodies for the cells (Alo-HCT). CARLOS III HEALTH HEALTH INSTITUTE. 2016-2018. personalised treatment of tumours- TERPERAN. MINECO. 2016-2018. INSTITUTE. 2017-2019. 19. PI15/00525. 27. DTS15/00238 34. PI16/01535 Miguel Ángel González Mantecón Olga María Conde Portilla María Victoria Francia Gil Genetic markers of atherosclerotic Fusioderm, fusion of photonic Induction of conjugative disease in Rheumatoid Arthritis. technologies for dermatological pheromone-induced plasmid CARLOS III HEALTH INSTITUTE. diagnosis. CARLOS III HEALTH transfer. CARLOS III HEALTH 2016-2018. INSTITUTE 2016-2017. INSTITUTE. 20. PI15/01224. 2017-2019. 28. PI16/00156 Juan Francisco Nistal Herrrera José Pedro Vaque Diez 35. PI16/01585 Bone morphogenetic protein 7 New mechanisms in aggressive Marcos López Hoyos (BMP7): Potential therapeutic target skin cancers: Applications to the Utility of the study of in the pathological remodelling of the diagnosis, prognosis and treatment Myeloid-Derived Suppressor Cells cardiovascular system. CARLOS III of therapy-resistant melanoma and (MDSC) when monitoring kidney HEALTH INSTITUTE. 2016-2018. Merkel-cell carcinoma. CARLOS III transplants. CARLOS III HEALTH 21. PI15/02138. HEALTH INSTITUTE. 2017-2019. INSTITUTE. 2017-2019. Javier Crespo García 29. PI16/00915 RIANCHO Endothelial dysfunction, subclinical 36. PI16/01652 José Antonio Moral atheromatous disease and Pascual Sánchez Juan Study of mesenchymal stem cells cardiomyopathy in patients with Study of rare variant genes in osteoporosis: Role of long HCV infection. Characterisation and associated with Alzheimer’s disease non-coding RNAs (lncRNAs) and potential reversibility with direct in the Spanish population. CARLOS III regenerative potential. CARLOS III antiviral agents. CARLOS III HEALTH HEALTH INSTITUTE. 2017-2019. HEALTH INSTITUTE INSTITUTE. 2016-2018. 2017-2019. 37. PI16/01656 22. PI15/01285. Julio Francisco Jiménez Bonilla 30. PI16/01103 Agustín Oterino Durán 5-Year study of a population with José Ramos Vivas Epigenetic modifications induced Mild Cognitive Impairment (MCI) Integrated biology of infection by adverse childhood experiences previously evaluated with 11C-PIB and antimicrobial resistance of and endothelial damage in chronic and 18F-FDG PET/TAC. CARLOS III Acinetobacter baumannii and A. migraines: case-control study. HEALTH INSTITUTE. 2017-2019. pittii. CARLOS III HEALTH INSTITUTE. Murine experimental model creation. 2017-2019. CARLOS III HEALTH INSTITUTE. 38. PI16/01717 2016-2018. Manuel Martínez Taboada 31. PI16/01294 Study of the role of BAMBI, a Ángel Piris Pinilla 23. PI15/00069. regulator of TGF beta signalling, as Aggressive lymphomas: Interaction Javier Llorca Díaz a pathogenic factor and prognostic between the tumour genome and the Integration of genetic big data and marker in rheumatoid arthritis. microenvironment as a determinant clinical data: survival with breast cancer CARLOS III HEALTH INSTITUTE. of progression and response to in the MCC-Spain study. CARLOS III 2017-2019. HEALTH INSTITUTE. 2016-2018. therapy. CARLOS III HEALTH 81
39. CP16/00033 6. CD15/00095 Active European Projects in 2017 Raquel López Mejías Fernanda Genre Cardiovascular risk assessment in Sara Borrell contracts. CARLOS III patients with rheumatoid arthritis: HEALTH INSTITUTE. 1. EU12/01- PSYSCAN. the relevance of genetic markers. 2016-2019 Benedicto Crespo Facorro CARLOS III HEALTH INSTITUTE Translating neuroimaging findings 2017-2019. 7. CM15/00186 from research into clinical practice. Rufino Mondejar García 7PM. European Commission. 40. PI16/00496 Rio Hortega contracts. CARLOS III Mónica López Fanárraga HEALTH INSTITUTE. 2. EU13/01- PRECISESADS. Design and evaluation of multi- 2016-2018 Miguel Ángel González-Gay therapeutic nano-dispensers based Molecular Reclassification to Find on carbon nanotubes to treat 8. INT15/00096 Clinically Useful Biomarkers for tumours. CARLOS III HEALTH Benedicto Crespo Facorro Systemic Autoimmune Diseases. INSTITUTE. 2017-2019. Contracts for intensification of FP7, Innovative Medicines Initiative. research activity in the SNS European Commission. 41. SAF2016-76046-R CARLOS III HEALTH INSTITUTE Benedicto Crespo Facorro 2016 3. EU16/10 Stratified treatment in schizophrenia: Carlos Fernandez Viadero integrating results of the human 9. BA15/00053 CHRODIS PLUS: Action on chronic and cellular transcriptome in Santiago Montes Moreno diseases antipsychotic treatment strategies. Grants for the mobility of healthcare MINECO. faculty. CARLOS III HEALTH 2017-2019. INSTITUTE 2016
42. SAF2016-75195-R 10. PTA2015-11501-I Jesús Merino Pérez Saray Pereda Marcos BAMBI, a regulator of TGF beta Research support technician signalling, in cutaneous inflammation contract. and differentiation of Human CD4 T MINECO. Lymphocytes. 2017-2019
11. MS16/00033 Research and Mobility Contracts Raquel López Mejías Miguel Servet Type I contract. CARLOS III HEALTH INSTITUTE 1. MS12/03149 2017-2021 Alain Antonio Ocampo Sosa. Miguel Servet Type I contracts, 12. CM16/00051 CARLOS III HEALTH INSTITUTE. Javier Riancho Zarrabeitia. 2013-2017 Rio Hortega contract. CARLOS III HEALTH INSTITUTE 2017-2018 2. CD13/00088 Cristina Pérez Menéndez 13. CM16/00034 Sara Borrell contracts. CARLOS III Manuel Delgado Alvarado HEALTH INSTITUTE. 2014-2017 Rio Hortega contract. CARLOS III HEALTH INSTITUTE 2017-2018 3. CPII14/00016 José Ramos Vivas 14. INT16/00133 Miguel Servet Type II contracts. Miguel Ángel González-Gay CARLOS III HEALTH INSTITUTE. Mantecón. 2015-2017. Contracts for intensification of research activity in the SNS 4. BES-2014-070615 CARLOS III HEALTH INSTITUTE Fulgencio Ruso Julve. 2017 Grants for pre-doctorate contracts. MINECO 2015-2019. 15. BA16/00021 José María de la Torre Hernández. 5. GIS15/00017 Scholarship for a 1-year Aroa Sanz Carreira residence at the Massachusetts Healthcare Research Management Institute of Technology. Contracts in IIS. CARLOS III HEALTH CARLOS III HEALTH INSTITUTE. 2016-2018 INSTITUTE 2017 Activity IDIVAL R&D+i activity Report IDIVAL financing in 2017
Grants awarded
In 2017, IDIVAL researchers received a positive response on 10 projects 5. PI17/01307 10. PT17/0017/0039 in the National Plan and 4 European Alberto Gandarillas Solinis Benedicto Crespo Facorro projects: Therapeutic targets: common causes Platform for Clinical Research and of genomic instability and malignancy Clinical Trial Units (Scren) CARLOS III in squamous cancer, for application HEALTH INSTITUTE. 2018-2020. in personalised medicine. CARLOS III 1. CPII17/00011 HEALTH INSTITUTE. 2018-2020. Alain Antonio Ocampo Sosa 11. EU17/15 Miguel Servet Type II contracts, 6. PI17/01399 Benedicto Crespo Facorro CARLOS III HEALTH INSTITUTE. José Luis Fenández Luna COST Action CA15211 Atmospheric 2018-2020. Contribution of the hypoxia-odz1 Electricity Network: coupling with the axis to the invasive capacity of Earth System, climate and biological 2. DTS17/00055 glioblastoma. CARLOS III HEALTH systems Olga María Conde Portilla INSTITUTE. 2018-2020. Design and development of a 12. EU17/24 multimodal device for intraoperative 7. PI17/01688 Mónica Fanarraga López cardiovascular diagnosis (IntraCardio). Carlos Pipaon González COST Action BM1401 European CARLOS III HEALTH INSTITUTE. 2018- The role of neddylation in chronic Network on RAMAN-BASED 2019. lymphocytic leukaemia, its value Applications for clinical diagnosis for prognosis and therapeutic (Raman4clinics) 3. PI17/00156 applications. CARLOS III HEALTH José Luis Fernández Torre INSTITUTE. 2018-2020. 13. EU17/12 Intracortical electroencephalography Miguel Ángel González-Gay in coma patients with acute brain 8. PT17/0005/0036 IMPROVEMENT (improving the damage. CARLOS III HEALTH Francisco Peralta Fernández outcome in myositis spectrum INSTITUTE. 2018-2020. Platform for Innovation in Medical and diseases: core set variables Healthcare Technologies (ITEMAS) harmonization and use from children 4. PI17/00936 CARLOS III HEALTH INSTITUTE. 2018- to adulthood) project Jon Infante Ceberio 2020. Study of motor, genetic and imaging 14. EU17/23 biomarkers in prodromal Parkinson’s 9. PT17/0015/0019 José María de la Torre disease associated with the G2019S Pascual Sánchez Juan MIT-La Caixa: Integrated mutation in LRRK2. CARLOS III Biobanks Platform. CARLOS III Characterization For Calcific Aortic HEALTH INSTITUTE. 2018-2020. HEALTH INSTITUTE. Stenosis Will Change Treatment 2018-2020. Strategies 83
During 2017, IDIVAL authorised its area of influence. a total of 68 clinical trials and Clinical 49 post-authorisation studies to The list of major clinical trials be performed in the Marqués de approved in 2017 is shown in the trials Valdecilla University Hospital and adjoining table.
List of trials with contracts signed in 2017
Researcher Clinical Trial
Benedicto Crespo Facorro Study assessing the effect of ALKS 3831, compared to olanzapine, on bodyweight in young adults with schizophrenia, schizophreniform disorders, or bipolar disorder 1 with the disease in the initial phase.
Sonia González de Villambrosía Phase II study of TAK-659 in patients with relapsed/refractory diffuse large B-cell Pellón lymphoma after two or more previous lines of chemotherapy.
Juan García Rivero Phase IIb randomised (stratified), double-blind (open for promoter), parallel-group, placebo-controlled dose-finding study of Nemiralisib (GSK2269557) added to the standard treatment compared to the standard treatment alone, in patients diagnosed with an acute, moderate or severe exacerbation of their chronic obstructive pulmonary disease (COPD).
Mónica López Duarte Randomised, open, controlled phase 3 adaptive trial to investigate the effectiveness, safety and tolerability of the antibody BiTE® blinatumomab as a consolidation treatment compared to conventional consolidation chemotherapy in paediatric subjects with precursor B-cell acute lymphoblastic leukaemia (ALL) in the first high-risk relapse.
Fernando Rivera Herrero Phase I/II study of the safety, tolerability and effectiveness of INCAGN01876 in combination with immunotherapy in subjects with advanced or metastasised malignant neoplasms.
Lucrecia Yáñez San Segundo Phase III randomised, double-blind, placebo-controlled study of itacitinib or placebo in combination with corticosteroids for the first-line treatment of acute graft-versus-host disease.
Susana Armesto Alonso Open clinical study to assess the long-term effectiveness and safety of dimethyl fumarate in adults with moderate-to-severe chronic plaque psoriasis in clinical practice (DIMESKIN 1) STUDY.
López-Brea Piqueras, Multicentre phase III/IV study with a single treatment group to investigate the long-term Marta Francisca safety and effectiveness of atezolizumab (tecentriq) in previously treated patients with locally advanced or metastatic non-small-cell lung cancer (TAIL).
Eloy Manuel Rodríguez Rodríguez Multicentre, randomised, double-blind, placebo-controlled, parallel-group phase III study to assess the effectiveness and safety of crenezumab in patients with prodromal to mild Alzheimer’s disease.
Eva Martínez de Castro Apixaban for the treatment of venous thromboembolism in cancer patients: A randomised, open, prospective study, blind for the evaluator - the CARAVAGGIO study.
Carlos López López Epidemiological, retrospective, longitudinal study to characterise the natural history of patients with advanced differentiated thyroid carcinoma in Spain and Portugal. “ERUDIT” study.
Ricardo Blanco Alonso Phase II multicentre, randomised, double-blind, placebo-controlled study to assess the safety and effectiveness of RO7123520 as a complementary treatment in patients with active moderate or severe rheumatoid arthritis with an inadequate response to TNF-a inhibitors.
José Manuel Cifrián Martínez Quality of life in patients with pulmonary hypertension (HAP and HPTEC) and their perception of the quality of care received.
David Iturbe Fernández Double mask, multicentre, placebo-controlled clinical trial to investigate the effectiveness and safety of 12 months of therapy with inhaled Promixin® (sodium colistimethate) for the treatment of patients with bronchiectasis not due to cystic fibrosis and with a chronic Pseudomonas aeruginosa (P Aeruginosa) infection. Activity IDIVAL R&D+i activity Report Clinical Trials
Researcher Clinical Trial
Pascual Jesús, Sánchez Juan Multicentre, randomised, double-blind, placebo-controlled study with 4 parallel groups over 26 weeks to assess the safety, tolerability and anti-inflammatory effect of three oral doses of Sativex® in patients with mild Alzheimer’s type cognitive impairment or early-stage Alzheimer’s type dementia.
Juan García Rivero Multicentre, randomised, double-blind, parallel-group study with active control over 52 weeks to compare the effectiveness and safety of QVM149 with QMF149 in patients with asthma.
María Aránzazu Bermúdez Pilot phase Ib/IIa clinical trial of the inhibitor of the Hedgehog signalling pathway, Glasdegib, Rodríguez in patients with chronic graft-versus-host disease resistant to second-line treatment.
Javier Crespo García Phase II, multicentre, double-blind, parallel-group, placebo-controlled trial to investigate the safety, tolerability, pharmacodynamics and pharmacokinetics of different oral doses of BI 1467335 over 12 weeks of treatment, compared to a placebo in patients with clinical evidence of EHNA.
Ricardo Blanco Alonso Phase III, multicentre, randomised, double-blind, placebo-controlled trial of gilteritinib, an FLT3 inhibitor, administered as a maintenance treatment after an allotransplantation in patients with acute myeloid leukaemia with FLT3/ITD.
Monserrat Rivero Tirado Phase IIb, double-blind, randomised, placebo-controlled, parallel-group dose-finding study of PF-06651600 and PF-06700841 via oral as induction therapy and chronic treatment in patients with moderate or severe ulcerative colitis.
Javier Crespo García Phase III, randomised, double-blind, placebo-controlled study to assess the safety and effectiveness of selonsertib in patients with nonalcoholic steatohepatitis (NASH) and bridging fibrosis (F3).
Laura Sánchez Moreno Phase III prospective, multicentre, open, randomised clinical trial of Hemopatch application to prevent postoperative air leak after pulmonary resection in high-risk patients.
Carlos López López Pilot phase II randomised multicentre study to assess the effectiveness and safety of treatment with FOLFIRI-aflibercept compared to an initial treatment with FOLFIRI- aflibercept (during 6 cycles) followed by maintenance with 5FU-aflibercept in elderly patients with metastatic colorectal cancer (mCRC) after failure of an oxaliplatin regime.
Carlos López López Phase 2 multicentre study of nivolumab in combination with ipilimumab for adult patients with advanced childhood solid tumours.
Juan Ignacio Villa Blanco SKIPPAIN (Fast pain relief in patients with axial spondyloarthritis induced by secukinumab) Multicentre, randomised, double-blind, placebo-controlled study over 24 weeks to assess the effectiveness and safety of secukinumab in the control of spinal pain in patients with axial spondyloarthritis.
Javier Gonzalo Ocejo Viñals Assessment of the effectiveness and toxicity in use of intravenous gammaglobulin for treating infections in patients with hypogammaglobulinemia IGG after solid organ transplantation.
José Manuel Cifrián Martínez Dose-finding study of the effectiveness and safety of bardoxolone methyl in patients with pulmonary hypertension.
Fernando Rivera Herrero Phase I / II study with nab-paclitaxel (Abraxane®) and gemcitabine followed by modified FOLFOX (AG-mFOLFOX) in patients with untreated metastatic cancer of the pancreas.
Marta Francisca López-Brea Phase III multicentre, randomised, placebo-controlled study of atezolizumab (antibody anti- Piqueras pd-l1) in monotherapy and in combination with platinum-based chemotherapy in patients with previously untreated, locally advanced or metastatic urothelial carcinoma.
Ramón Agüero Balbín Randomised, double-blind (open for the promoter), placebo-controlled, multicentre, dose- finding study to assess the effectiveness and safety of Danirixín tablets, administered twice a day, compared to a placebo, over 24 weeks in adult participants with chronic obstructive pulmonary disease (COPD).
Juan García Rivero Multicentre, randomised, double-blind trial in parallel groups to assess the effectiveness and safety of PT009 compared to PT005 in exacerbation of COPD during a 52-week treatment period, in subjects with COPD ranging from moderate to very severe. 85
Researcher Clinical Trial
José Manuel Cifrián Martínez Extension access programme to assess the long-term safety of bardoxolone methyl in patients with pulmonary hypertension.
Bermúdez Rodríguez, Phase 2, randomised, double mask, placebo-controlled study to assess the effectiveness María Aránzazu and tolerability of Entospletinib, a selective SYK inhibitor, in combination with systemic corticosteroids as a first line treatment in patients with chronic graft-versus-host disease (GVHD).
Javier Crespo García Effects on mortality of the administration of albumen in patients with cirrhosis and hepatic encephalopathy.
Francisco Jesús González Vílchez Double-blind, randomised, placebo-controlled, multicentre study to assess the effectiveness and safety of omecamtiv mecarbil in the mortality and morbidity of subjects with chronic cardiac insufficiency with a low ejection fraction.
José Manuel Cifrián Martínez Randomised, double-blind, placebo-controlled study to assess the effectiveness and safety of oral treatment with nintedanib during at least 52 weeks in patients with interstitial lung disease associated with systemic sclerosis (SSc-ILD).
Marta Francisca López-Brea Phase III randomised, multicentre, open, comparative trial to determine the effectiveness Piqueras of durvalumab or durvalumab and tremelimumab in combination with platinum-based chemotherapy as a first line treatment in patients with small cell lung cancer (SCLC) in advanced disease (stage IV).
Borja Suberviola Cañas Randomised, double-blind, placebo-controlled study of Aerucin® as adjuvant therapy to antibiotics in the treatment of pneumonia due to P Aeruginosa.
Javier Crespo García Phase III, randomised, double-blind, placebo-controlled study to assess the safety and effectiveness of selonsertib in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH).
Ángel Luis Martín de Francisco Double-blind, randomised, placebo-controlled study to assess the effect of SNF472 on the Hernández progress of cardiovascular calcification alongside the standard treatment in patients with end-stage renal disease (ESRD) subjected to haemodialysis (HD).
José Manuel Cifrián Martínez, Prospective multicentre, randomised study to assess the effect of rivaroxaban on Ángela María Puente Sánchez rechannelling portal vein thrombosis and on survival in patients with cirrhosis and portal vein thrombosis.
Francisco Jesús González Vílchez Multicentre, randomised, double-blind, prospective study to assess the effect of sacubitril/ valsartán vs. enalapril on everyday activity, using a wrist actigraph on adult patients with chronic cardiac insufficiency.
Montserrat Rivero Tirado Proof of concept study of BI 655130 as a complementary treatment for patients with active mild to moderate ulcerative colitis during treatment with a TNF inhibitor.
José Manuel Cifrián Martínez Phase II multicentre, international, double-blind, two-group, randomised, placebo-controlled trial of pirfenidone on patients with unclassifiable progressive fibrosing EPI.
Borja Suberviola Cañas Phase Ib/IIa randomised, double-blind, parallel-group, placebo-controlled, multicentre study to assess the safety and effectiveness of expanded allogeneic adipose tissue-derived stem cells (eASCs) Cx611 for the intravenous treatment of adult patients with severe bacterial pneumonia acquired in the community and admitted to intensive care units.
Benedicto Gutiérrez Escalada Prevalence study of glycaemic alterations in dyslipidemic patients receiving care in cardiology clinics.
María del Carmen Fariñas Álvarez Phase Ib randomised, double-blind, placebo-controlled, multiple ascending dose study to investigate the safety, tolerability and pharmacokinetics of DSTA4637S in patients with Staphylococcus aureus bacteremia who are receiving conventional treatment with antibiotics.
Álvaro Terán Lantarón Multicentre randomised study comparing plastic prostheses and self-expanding metal prostheses in endoscopic ultrasound-guided transmural drainage of encapsulated pancreatic necrosis.
Ana de Juan Ferré Phase Ib/II study to assess the effectiveness and tolerability of PM01183 in combination with olaparib in patients with advanced solid tumours. Activity IDIVAL R&D+i activity Report Clinical Trials
Researcher Clinical Trial
Agustín Oterino Durán Multicentre, double-blind, randomised study of 12 weeks of treatment to compare the effectiveness and safety of AMG 334 70 mg subcutaneous once a month compared to a placebo in adult patients with episodic migraine where 2 to 4 prophylactic treatments have failed (LIBERTY).
Marta Fernández Sampedro Impact of the eradication of asymptomatic bacteriuria on the reduced incidence of early periprosthetic infection in patients with fractured femur requiring hip hemiarthroplasty.
María Ferri Molina Phase IB-II clinical trial of oral melatonin gel for the prevention and treatment of oral mucositis in patients with cancer of the head and neck treated with radio-chemotherapy.
Carlos López López Phase II clinical trial of Durvalumab (MEDI4736) plus Tremelimumab for treatment of patients with advanced gastroenteropancreatic or pulmonary neuroendocrine tumours (DUNE Trial).
Marta Francisca López-Brea Phase III open multicentre study of brigatinib (AP26113) compared to crizotinib in patients Piqueras with ALK-positive advanced lung cancer.
Javier Crespo García Phase III multicentre, randomised, double-blind, placebo-controlled study to assess the safety and effectiveness of Elafibranor in patients with nonalcoholic steatohepatitis (NASH) and fibrosis.
Ricardo Blanco Alonso, Multicentre, randomised, double-blind study with active control to assess the effectiveness in week 52 of subcutaneous secukinumab in monotherapy compared to subcutaneous adalimumab in monotherapy in patients with active psoriatic arthritis.
Javier Crespo García Investigation of the effectiveness and safety of three dosage levels of subcutaneous semaglutide administered once a day, compared to a placebo, in subjects with nonalcoholic steatohepatitis. Clinical trial over 72 weeks.
Ricardo Blanco Alonso MAXIMISE (Treatment of axial psoriatic arthritis with Secukinumab), multicentre, randomised, double-blind, placebo-controlled study over 52 weeks to assess the effectiveness and safety of secukinumab 150 mg or 300 mg s.c. in patients with active psoriatic arthritis and axial skeletal problems who do not respond appropriately to non- steroidal anti-inflammatories (NSAIDs).
Javier Crespo García Randomised, double-blind, multidose, placebo-controlled study to assess the effectiveness, safety and tolerability of the administration of GSK2330672 in the treatment of pruritus in patients with primary biliary cholangitis.
José Manuel López Vega Phase II randomised, open, multicentre study to assess the effect of oral metronomic Vinorelbine compared to the best support treatment as maintenance therapy after first line taxane-based chemotherapy in patients with endocrine-resistant HER-2 negative breast cancer.
María Aránzazu Bermúdez Ponatinib and chemotherapy in young adults with acute lymphoblastic leukaemia with Rodríguez newly diagnosed Philadelphia chromosome.
Juan Carlos Ruíz San Millán Prospective assessment of donor-specific cellular alloresponse for the minimisation of immunosuppression in de novo kidney transplants.
Javier Crespo García Randomised, double-blind, placebo-controlled, multicentre proof-of-concept study to explore dose range over 24 weeks of IVA337 treatment in adult patients with nonalcoholic steatohepatitis (NASH). A randomized, double-blind, placebo-controlled, multicentre, dose-range, proof-of-concept, 24-week treatment study of IVA337 in adult subjects with nonalcoholic steatohepatitis (NASH).
Benedicto Crespo Facorro Placebo-controlled trial in subjects at Ultra-high Risk for Psychosis with Omega-3 fatty acids in Europe (PURPOSE).
Lucrecia Yáñez San Segundo A Phase 3 Randomized Study of the Efficacy and Safety of Posaconazole versus Voriconazole for the Treatment of Invasive Aspergillosis in Adults and Adolescents (Phase 3; Protocol No. MK-5592-069).
Beatriz Payá González Long-term open extension study with dose flexibility of vortioxetine in children and adolescents aged 7 to 18 with major depressive disorder (MDD).
Beatriz Payá González Long-term open extension study without interrupting the treatment, with dose flexibility, of vortioxetine in children and adolescents aged 7 to 17 with major depressive disorder (MDD).
Mónica González Martínez Rapid maxillary expansion in the treatment of residual paediatric sleep apnea after adenoidectomy: Randomised, controlled clinical trial. 87
4. Carretero G, Puig L, Carrascosa JM, reumatoide que no puede utilizar Ferrándiz L, Ruiz-Villaverde R, de la metotrexato. Clinical Cueva P, Belinchon I, Vilarrasa E, Del Recommendations by the Spanish Rio R, Sánchez-Carazo JL, López- Society of Rheumatology for practice Ferrer A, Peral F, Armesto S, Eiris N, the management of patients Mitxelena J, Vilar-Alejo J, A Martin M, diagnosed with rheumatoid arthritis guidelines Soria C; from the Spanish Group of who cannot be treated with Psoriasis. methotrexate. Redefining the therapeutic objective Reumatol Clin. 2017 May - in psoriatic patients candidates for Jun;13(3):127-138. In 2017, IDIVAL researchers biological therapy. 9. González A, Lluch A, Aba E, Albanell participated in the following J Dermatolog Treat. 2017 Nov 21:1-13. J, Antón A, Álvarez I, Ayala F, Barnadas clinical practice guidelines and 5. Gago-Veiga AB, Díaz de Terán J, A, Calvo L, Ciruelos E, Cortés J, de consensus documents. The González-García N, González-Oria la Haba J, López-Vega JM, Martínez relevance of these guidelines C, González-Quintanilla V, Minguez- E, Muñoz M, Peláez I, Redondo A, as recommendations developed Olaondo A, Santos-Lasaosa S, Viguera Rodríguez Á, Rodríguez CA, Ruíz A, systematically to help professionals Romero J, Pozo-Rosich P. Llombart A. and patients make decisions about How and when to refer patients A definition for aggressive disease the most suitable healthcare and diagnosed with secondary headache in patients with HER-2 negative to select the most appropriate and other craniofacial pain in the metastatic breast cancer: an expert diagnostic or therapeutic options Emergency Department and Primary consensus of the Spanish Society of when addressing a health Care: Recommendations of the Medical Oncology (SEOM). problem is unquestionable. Spanish Society of Neurology’s Clin Transl Oncol. 2017 May;19(5):616- Headache Study Group. 624. Neurologia. 2017 Sep 1. pii: S0213- 10. González-Billalabeitia E, Sepúlveda 4853(17)30269-4. JM, Maroto P, Aparicio J, Arranz JA 1. Arikan Abelló F, Ley Urzaiz L, 6. García-Marco JA, Delgado J, Esteban E, Gironés R, López-Brea M, Fernández Alén J, Martín Láez R; Hernández-Rivas JA, Ramírez Payer Mendez-Vidal MJ, Pinto A, Sastre J, de Vascular Pathology Working Á, Loscertales Pueyo J, Jarque I, Prado DS, Terrasa J, Vázquez S, Powles Group of the Sociedad Española Abrisqueta P, Giraldo P, Martínez R, T, Beyer J, Castellano D, Del Muro XG; de Neurocirugía. [Antithrombotic Yáñez L, Terol MJ, González M, Bosch Spanish Germ Cell Cancer Group treatment consensus protocol F; en nombre del Grupo Español de and the Spanish Oncology (anticoagulation and antiplatelet Leucemia Linfocítica Crónica (GELLC). Genitourinary Group. Consensus therapy) during the perioperative Update of the Grupo Español de Recommendations from the Spanish and periprocedural period in Leucemia Linfocítica Crónica clinical Germ Cell Cancer Group on the Use neurosurgery]. guidelines of the management of of High-dose Chemotherapy in Germ Neurocirugia (Astur). 2017 Nov - chronic lymphocytic leukemia. Cell Cancer. Dec;28(6):284-293. Med Clin (Barc). 2017 Apr Eur Urol Focus. 2017 Apr;3(2-3):280- 2. Cappellini MD, Comin-Colet J, de 21;148(8):381.e1-381.e9. 286. Francisco A, Dignass A, Doehner W, 7. García-Marco JA, Delgado J, 11. González-Billalabeitia E, Sepúlveda Lam CS, Macdougall IC, Rogler G, Hernández-Rivas JA, Ramírez Payer JM, Maroto P, Aparicio J, Arranz JA, Camaschella C, Kadir R, Kassebaum Á, Loscertales Pueyo J, Jarque I, Esteban E, Gironés R, López-Brea M, NJ, Spahn DR, Taher AT, Musallam Abrisqueta P, Giraldo P, Martínez R, Mendez-Vidal MJ, Pinto A, Sastre J, KM; IRON CORE Group. Yáñez L, Terol MJ, González M, Bosch de Prado DS, Terrasa J, Vázquez S, Iron deficiency across chronic F; en nombre del Grupo Español de Powles T, Beyer J, Castellano D, Del inflammatory conditions: Leucemia Linfocítica Crónica (GELLC). Muro XG; Spanish Germ Cell Cancer International expert opinion Update of the Grupo Español de Group and the Spanish Oncology on definition, diagnosis, and Leucemia Linfocítica Crónica clinical Genitourinary Group. management. guidelines of the management of Consensus Recommendations Am J Hematol. 2017 Oct;92(10):1068- chronic lymphocytic leukemia. from the Spanish Germ Cell Cancer 1078. Med Clin (Barc).2017 Apr Group on the Use of High-dose 3. Caresia Aroztegui AP, García Vicente 21;148(8):381.e1-381.e9. Chemotherapy in Germ Cell Cancer. AM, Alvarez Ruiz S, Delgado Bolton Eur Urol Focus. 2017 Apr;3(2-3):280- 8. García-Vicuña R, Martín-Martínez RC, Orcajo Rincon J, Garcia Garzon JR, 286. MA, Gonzalez-Crespo MR, Tornero- de Arcocha Torres M, Garcia-Velloso Molina J, Fernández-Nebro A, MJ; Oncology Task Force of the 12.Hernández-Tejedor A, Peñuelas O, Blanco-García FJ, Blanco-Alonso R, Spanish Society of Nuclear Medicine Sirgo Rodríguez G, Llompart-Pou JA, Marsal-Barril S; en representación and Molecular Imaging. 18F-FDG PET/ Palencia Herrejón E, Estella A, Fuset del Comité Científico del trabajo de CT in breast cancer: Evidence-based Cabanes MP, Alcalá-Llorente MA, Recomendaciones de la Sociedad recommendations in initial staging. Ramírez Galleymore P, Obón Azuara Española de Reumatología para el Tumour Biol. 2017 B, Lorente Balanza JA, Vaquerizo manejo clínico del paciente con artritis Oct;39(10):1010428317728285. Alonso C, Ballesteros Sanz MA, Activity IDIVAL R&D+i activity Report Clinical practice guidelines
García García M, Caballero López J, 14. Hidalgo M, Álvarez R, Gallego L, Turon F, Villanueva C, Zarrabeitia R, Socias Mir A, Serrano Lázaro A, Pérez J, Guillén-Ponce C, Laquente B, García-Pagán JC. Villares JM, Herrera-Gutiérrez ME. Macarulla T,Muñoz A, Salgado M, Vera Vascular diseases of the liver. Recommendations of the Working R, Adeva J, Alés I, Arévalo S, Blázquez Clinical Guidelines from the Catalan Groups from the Spanish Society of J, Calsina A,Carmona A, de Madaria E, Society of Digestology and the Intensive and Critical Care Medicine Díaz R, Díez L, Fernández T, de Paredes Spanish Association for the Study of and Coronary Units (SEMICYUC) for BG, Gallardo ME, González I, Hernando the Liver. the management of adult critically ill O, Jiménez P, López A, López C, Gastroenterol Hepatol. 2017 patients. López-Ríos F, Martín E, Martínez J, Oct;40(8):538-580. Med Intensiva. 2017 Jun - Martínez A, Montans J, Pazo R, Plaza 16. Pérez-Vázquez P, Franco-Gutiérrez Jul;41(5):285-305. JC, Peiró I, Reina JJ, Sanjuanbenito A, V, Soto-Varela A, Amor-Dorado JC, Yaya R, Carrato A. 13. Caresia Aroztegui AP, García Martín-Sanz E, Oliva-Domínguez M, Consensus guidelines for diagnosis, Vicente AM, Alvarez Ruiz S, Delgado Lopez-Escamez JA. treatment and follow-up of patients Bolton RC, Orcajo Rincon J, Garcia Practice Guidelines for the Diagnosis with pancreatic cancer in Spain. Garzon JR, de Arcocha Torres M, and Management of Benign Clin Transl Oncol. 2017 Jun;19(6):667- Garcia-Velloso MJ; Oncology Task Paroxysmal Positional Vertigo 681. Force of the Spanish Society of Nuclear Otoneurology Committee of Spanish Medicine and Molecular Imaging. 15. Martín-Llahí M, Albillos A, Bañares Otorhinolaryngology and Head and 18F-FDG PET/CT in breast cancer: R, Berzigotti A, García-Criado MÁ, Neck Surgery Consensus Document. Evidence-based recommendations in Genescà J, Hernández-Gea V, Llop- Acta Otorrinolaringol Esp. 2017 Aug initial staging. Herrera E, Masnou-Ridaura H, Mateo 18. pii: S0001-6519(17)30135-8. Tumour Biol. 2017 Oct;39(10):10104 J, Navascués CA, Puente Á, Romero- Gutiérrez M, Simón-Talero M, Téllez 89
Research (RETIC) Platforms and that would be difficult to achieve Biomedical Research Centre in a context of more restricted RETICS and Networks (CIBER) in which IDIVAL execution. groups participate. CIBER with the IDIVAL participates in four CIBERs, participation These organisational structures seven RETICS and three other formed by a variable set of platforms The three platforms in of IDIVAL multidisciplinary centres and which IDIVAL participates (the research groups in biomedicine aim ITEMAS Platform, the Biobank to conduct cooperative research Platform and the Scren Platform) The Carlos III Health Institute projects of general interest, centred provide cross-disciplinary support, has promoted various Thematic on a common specific area for the forming part of the researcher Networks for Cooperative achievement of scientific objectives support services.
CIBER / RETIC / Platform IDIVAL Group or Unit IP
Mental Health CIBER (CIBERSAM) Psychiatry Benedicto Crespo Facorro
Neurodegenerative Disease CIBER Neurodegenerative Jon Infante Ceberio (CIBERNED) Diseases
Epidemiology and Public Health CIBER (CIBERESP) Epidemiology and Public Health Javier Llorca Díaz
Bioengineering, Biomaterials and Nanomedicine CIBER Photonics engineering José Miguel López Higuera (CIBER-BBN)
Spanish Network for Research in Infectious Diseases Epidemiology and Pathogenic Carmen Fariñas Álvarez (REIPI) and Molecular Mechanisms of Infectious Diseases and Clinical Microbiology
Network for Maternal and Children’s Health and Marqués de Valdecilla María Jesús Cabero Development (RED SAMID) University Hospital
Thematic Network for Multiple Sclerosis Cephalea Clinic Agustín Oterino Durán and Genetics
Renal Research Network (REDinREN) Transplantation and autoimmunity Marcos López Hoyos
Research Network for Inflammation and Rheumatic Genetic epidemiology and Miguel Ángel Glez Gay Disease (RIER) atherosclerosis in systemic inflammatory diseases
Biobank Platform Central Support Unit Pascual Sánchez Juan
Platform for Innovation in Healthcare Central Support Unit Galo Peralta Fernández (ITEMAS)
Platform for Clinical Research and Clinical Trials Central Support Unit Benedicto Crespo Facorro (Scren) Activity IDIVAL R&D+i activity Report Innovation
Innovation
Introduction
Innovation is a key element of Conde), and a project from the regional economic development. call for FIPSE Viability Studies From the point of view of society, Cultura Apoyo a la (Development of a nanoplasmonic innovation in the healthcare sector Innovadora Innovación sensor for detecting circulating means continuous improvement tumour cells in the blood of cancer of the efficiency and productivity patients, José Luis Fernández Captación Colaboración of national health systems, de público- Luna). significantly improving patients’ financiación privada quality of life. • The idea: New therapy for melanoma by the researcher In Cantabria we are lucky enough Transferecia Mercado Carmen Álvarez was a finalist in the to have the Marqués de Valdecilla Merck Oncology Innovation grants University Hospital, which as well programme, and the IDEA2 Global as attracting healthcare expertise programme of the Massachusetts can be regarded as one of the Institute of Technology. region’s economic driving forces, Oncología Radioterápica of the as it transforms this knowledge brachytherapy grid developed by • The innovation management tool into value. the Valdecilla Radiation Oncology developed by IDIVAL and Semicrol, Department in collaboration with Fundanet Innova, is now consolidated IDIVAL’s innovation area consists the Photonics Engineering Group of as the benchmark tool on the ITEMAS of 5 people, structured as the the University of Cantabria. platform. Research Results Transfer Office (OTRI) and the Innovation Unit, • Promoting innovation projects and forms part of EValTec®. in the Innovation Area after winning a project in the call for Some of its milestones in 2017 applicants Healthcare Technological were: Development by the ISCIII (design and development of a • Presentation at the Congress of multimodal device for intraoperative the Sociedad Española de cardiovascular diagnosis, Olga
ITEMAS platform
and communication with the rest of currently finances the contracts of 3 society. The main tool of ITEMAS is of the professionals in the Area. the creation of Innovation Support Units (UAI) in hospitals. In 2017, IDIVAL has steadily ITEMAS is the Platform for participated in online activities, Innovation in Medical and Health These provide the resources and leading the Alliances workgroup Technologies (ITEMAS) promoted help needed so that healthcare and organising the annual assembly and financed by the Carlos III professionals can turn their in the Marqués de Valdecilla Health Institute (ISCIII). ITEMAS is ideas and discoveries into reality University Hospital. a support structure for healthcare for patients, creating a more innovation, which exists to help sustainable National Health System. the innovation ideas of healthcare professionals generate value for the Through its Innovation Unit, system, by favouring technology IDIVAL has been a node of this transfer, the culture of innovation, Platform since it began in 2010, and 91
Transfer
For innovation and the Since the establishment of 2 utility model applications to transfer of research results the OTRI, the following have the Spanish Office of Patents to the market to be effective been presented: and Brands (OEPM). and have an impact on society, it is necessary to 1 Community Design create an economic and legal 20 Spanish patent applications application to the Office for environment conducive to to the Spanish Office of Harmonisation in the Internal innovation and economic Patents and Brands (OEPM). Market (OHIM). development. IDIVAL adheres to Industrial 15 international patent 3 Spanish brand applications Property Regulations, which applications through the to the Spanish Office of govern the management Patent Cooperation Treaty Patents and Brands (OEPM). and use of intellectual and (PCT). industrial property rights and transfers to the market within 3 European patent the area of responsibility of applications to the European the Healthcare Administration Patent Office (EPO). of Cantabria.
Of these, the following were processed in 2017:
Application no. Title Applicants Inventor
U201700120 “Device supporting cathetere SCS Marta Rubio Cuevas insertion guidance” Manuel Iglesias Peramato
PCT/ES2017/070103 “Use of a GNP-LLO91-99 complex IDIVAL/SCS Carmen Álvarez Domínguez for cancer treatment Ricardo Calderón González and prevention” Elisabet Frande Cabanes Sonsoles Yáñez Díaz Eva Ferrández Fernández Soledad Penadés Ullate Marco Marradi Isabel García Martín
P201730464 “Method for predicting the therapeutic CSIC/UC/ Benedicto Crespo Facorro response to antipsychotic drugs” IDIVAL/CIBER Jesús Vicente Sainz Maza
EP17382162 “System and device for positioning IDIVAL/SCS/UC/ José Luis Fernández Luna medical needles” TEKNIKER/ Ana Talamillo Cancelo CELLBIOCAN Fernando Moreno García Francisco González Fernández Ruth Díez Ahedo Santos Merino Álvarez Deitze Otaduy del Paso
PCT/ES2017/000089 “Method for predicting the clinical IDIVAL-UC-SCSVHIR- José Luis Fernández Luna response to treatment with IdiPAZ Víctor Manuel Martínez Taboada anti-inflammatory agents” Silvia Torices del Val Marcos López Hoyos Pedro Muñoz Cacho Ignacio Varela Egocheaga Alejandro Balsa Criado Sara Marsal Barril Antonio Julià Cano Activity IDIVAL R&D+i activity Report Innovation
Application no. Title Applicants Inventor
EP17382519 “Cartridge, device and procedure for the IDIVAL/SCS/UC/ José Luis Fernández Luna Cancelo detection, capture, identification TEKNIKER/ Fernando Moreno García and counting of circulating tumour cells” CELLBIOCAN Francisco González Fernández Ángela Inmaculada Barreda Gómez Aritz Juarros Laskurain Santos Merino Álvarez Deitze Otaduy del Paso Alfredo Franco Pérez Francisco Aguirre Yagüe
PCT/ES2017/ “Dynamic abdominal wall traction SCS Federico Castillo Suescun 0700817 device for open abdominal wound”
For all applications, transfer and contact work with potential licensees has been performed or is currently under way.
Innovation support
IDIVAL’s innovation research and innovation, 4. Transfer: This phase management complies with and the latest publications includes ideas that have UNE standard 166.002:2014, produced in the Valdecilla generated some type of and its management system environment. This newsletter commercial activity, e.g., has been certified by DNV. will be available on the contact with companies or IDIVAL website and emailed potential licensees. Its main activities are: to subscribers. 5. Market: This phase includes ideas in any of Promotion of the Culture the following situations: of Innovation Innovation Funnel a) Licensed to industry. To promote the culture of The innovation projects innovation in the Valdecilla managed by IDIVAL are b) Generated a spin-off. environment, IDIVAL classified into FIVE phase, organises a series of defined below: c) Forms part of an courses and workshops that exclusive agreement encourage creativity and 1. Capture: In this phase, with a company. teamwork, issues reports, the ideas that the unit and provides training on captured in 2017 are d) Implemented in a specific aspects of the considered, as well as healthcare centre (in innovation process, etc. those captured in previous the case of healthcare The Innovation Unit has years that did not advance and organisational participated in various to a later stage. innovations). activities presented in the training section. 2. Analysis: In this phase, proposals for Technological Surveillance which market research, Newsletter patentability reports, or product value or technical IDIVAL publishes a regular feasibility reports are being newsletter on technological carried out are considered. surveillance which covers the bases of competitive 3. Development: This financing for public and phase includes ideas private research and being developed in the innovation projects, internal form of prototypes, and external symposia standardisations and/or relating to relevant trials. 93
• In 2017, the Innovation Area managed 44 ideas, distributed among the five stages as follows:
0 5 10 15 20 25 30 35 40 45 50
Capture Assessment Development Transfer Market
• According to the innovation funnel, ideas are distributed as follows:
7 14 7 13 3 IDEAS EVALUATION DEVELOPMENT TRANSFER MARKET
Healthcare Materials and devices Image Pharmaceuticals Biotechnology and Innovation in care ICT molecular diagnosis or organisation Activity IDIVAL R&D+i activity Report Innovation
EValTec®
EValTec® is a project which In 2017 it worked with the in the use of technology in the applies human factor Cantabrian Health Service (SCS) different units and hospitals. engineering as a tool for in the technical assessment of At present EValTec is ready to assessment and implementation volumetric and syringe infusion face new challenges, such as of medical technology. It is the pumps in the context of a public competing for funding, working result of the collaboration of tender to acquire these systems with medical technology HUMV, the Valdecilla Virtual for a price of over 1 million development companies to Hospital (HvV) and IDIVAL, euros, in the first action by favour the development of more and its team is made up of Spain in this field. Human factor usable and safer devices, and professionals from the different methods were applied to assess the possibility of evaluating new institutions. them, such as heuristics and technologies in the Cantabrian usability tests. 25 professionals Health System. It has an alliance with participated in the usability Medstar Health Research test from units like the Day Institute- National Center for Hospital, ICU, neonatal ICU, and Human Factors in Healthcare, anaesthesia, the three hospitals Washington, a centre of in the region. recognised international prestige. This assessment provided the opportunity for a deeper examination of the technology and how it can adapt to the needs of the different units where it will be used, so EValTec® considers the human EValTec also collaborated in its factor to be a tool for making implementation, developing changes in organisations and a strategy based on training improving patient safety. facilitators, leading professionals 95
Organization Chart Groups and areas
· Cancer
Translational Hematopathology. RR: S. Montes Moreno Clinical and Molecular Pathology. RR: Javier Gómez-Román Apoptosis. RR: J. Hurlé González Melatonin and Breast Cancer. RR: S. Cos Corral Cellular Signaling and Therapeutic Targets. RR: J. L. Fernández-Luna Cellular Cycle, Stem Cells and Cancer. RR: A. Gandarillas Solinis New Techniques in Abdominal Surgery. RR: M. Gómez-Fleitas Oncologic Clinical Trials Unit. RR: F. Rivera Herrero Molecular Imaging. RR: J. I. Banzo Marraco Nanomedicine. RR: M. López Fanarraga · Neurosciences
Neurodegenerative Diseases. RR: Jon Infante Ceberio Psychiatry. RR: B Crespo Facorro Nuclear Cell Biology. RR: M. A. Lafarga Coscojuela Epilepsy Neurophysiology and Brain Intensive Care. RR: J. L. Fernández-Torre Clinical and Genomics Research in Headache. RR: A. Oterino Durán
· Transplantation
Autoimmunity and Transplantation. RR: M. López Hoyos Hematological Neoplasms and Bone Marrow Transplantation. RR: E. Conde García Cytokines, Growth Factors and Illness Tissue Plasticity. RR: J. F. Nistal Herrera
Cardiovascular Research Group. RR: J. A. Vázquez de Prada Nursing Research. C. Sarabia Cobo Community Health. P. Muñoz Cacho Community Health. P. Infection Immunity and Digestive Diseases.RR: J. Crespo García Bioethics and Law. J. Cayón de las Cuevas Bioethics and Law. Photonic Engineering. J. M. López Higuera Epidemiology and Public Health. J. Llorca Díaz · Infection and Immunity
Rheumatic Diseases Immunopathology. RR: J. Merino Pérez Clinical and Molecular Microbiology. RR: J. Calvo Montes Genetic Epidemiology and Atherosclerosis in Rheumatic Diseases. RR: M. A. González-Gay Epidemiology and Pathogenic Mechanisms of Infectious Diseases. RR: C. Fariñas Álvarez Genomics, Proteomics and Vaccines. RR: C. Álvarez-Domínguez
· Metabolism, Aging and Life Style
Mineral and Lipid Metabolism. RR: J. González-Macías Imaging Diagnosis and Therapeutics. RR: J. A. Parra Blanco
Responsable Researcher Consolidated Groups Associated Groups RR. · Transversal Area Emerging Groups New Groups
· Research areas Activity Report 99
· Organ Transplants and Tissue and New Therapies Area
Marcos López Hoyos. Coordinator of the Transplant Area of Organs and Tissues and New Therapies.
Head of Immunology Service. University Hospital Marqués de Valdecilla. Memoria Research areas Organ Transplants and Tissue and de Actividad New Therapies Area
Group Responsible Juan Francisco • Cytokines and Growth Factors Nistal Herrera Cardiovascular Surgery in Pathological Tissue Plasticity Servicie University Hospital Phenomena Marqués de Valdecilla University of Cantabria
Researchers María Amor Hurlé González Carmen Martínez-Cue Pesini
Contributors Manuel Cobo Belaustegui Víctor Expósito García Susana García Cerro Raquel García López Aritz Gil Ongay Carlos Juárez Crespo Miguel Fernando Llano Cardenal Luis Javier Ruiz Guerrero Valentín Tascón Quevedo Mónica Tramullas Fernández Verónica Vidal Sánchez
Consolidated group Nurses Elena Martín Delgado Roberto Moreta Sánchez
Predoctoral María Carcelen Labrador Raquel Frances Romero Ana Belén Salido Medina
Technicians Ana María Cayón Gómez María de las Nieves García Iglesias María Eva García Iglesias
beta (TGF-βs, activin and BMPs) in is a response of pathological the molecular pathophysiology of significance in these patients. myocardial remodelling secondary We are studying the molecular Research to haemodynamic stress and in mechanisms of myocardial altered development. remodelling in this context Lines using samples of myocardium of 1. 1. Pathological plasticity patients with aortic stenosis, a of myocardium subjected to murine experimental model of this 1. Pathological plasticity of pressure overload. Aortic stenosis pathology and cell cultures. myocardium. is the most frequent valvular cause for surgery in our area We are analysing the involvement and is associated with a left of transforming growth factors ventricular hypertrophy which 101
1.2. Developmental variations TGF-ßs in adaptive processes in 2. Luczynski P, Tramullas M, Viola M, and pathological plasticity of chronic opioid therapy; d) The Shanahan F, Clarke G, O’Mahony S, myocardium in Down syndrome. involvement of TGF-ßs in the Dinan TG, Cryan JF. The Ts65Dn mouse (trisomy hypoesthesia of experimental Microbiota regulates visceral pain of an area of chromosome 16 Down syndrome. in the mouse. homologous to the human 21) is Elife. 2017;6. an experimental model of Down F.I.:7,725. [doi:10.7554/eLife.25887] 3.2. Pathological neuronal syndrome that reproduces its plasticity in learning and memory phenotypic characteristics. We 3. Kurusamy S, López-Maderuelo circuits. We are analysing the are studying the involvement D, Little R, Cadagan D, Savage AM, mechanisms that connect the of the TGF-ß family in cardiac Ihugba JC, Baggott RR, Rowther TGF-ß family with cognitive development variations found in FB, Martínez-Martínez S, Arco PG, variations and neurodegenerative this model. Murcott C, Wang W, Francisco Nistal disease in Down syndrome. J, Oceandy D, Neyses L, Wilkinson RN, Cartwright EJ, Redondo JM, 2. Pathological plasticity of the Armesilla AL. Down syndrome causes more aortic wall. We are analysing the Selective inhibition of plasma cases of mental retardation involvement of transforming growth membrane calcium ATPase 4 and all patients develop an factors beta in the molecular improves angiogenesis and vascular Alzheimer-type neuropathology pathophysiology of the remodelling reperfusion. early on. Deficits in the synthesis of the aortic wall in relation to J Mol Cell Cardiol. 2017;109:38-47. and transport of trophic factors aneurysm formation. Progressive F.I.:5,680. [doi:10.1016/j. could mediate these variations. dilation of the aorta carries high yjmcc.2017.07.001] Furthermore, the TGF-ß family is rates of morbidity and mortality. We involved in the pathophysiology of are studying the role of TGF-ßs in 4. García-Cerro S, Rueda N, Vidal experimental Alzheimer’s disease. the molecular pathophysiology of V, Lantigua S, Martínez-Cué C. We intend to evaluate the role of the pathological remodelling of the Normalizing the gene dosage TGF-ß in the cognitive variations aortic wall in aneurysm formation. of Dyrk1A in a mouse model of found in the Ts65Dn mouse and Down syndrome rescues several We intend to: evaluate different therapeutic Alzheimer’s disease strategies. phenotypes. 1) Establish signalling pathways Neurobiol Dis. 2017;106:76-88. involved in the vascular chronic F.I.:5,020. [doi:10.1016/j. inflammatory process responsible nbd.2017.06.010] for progressive aortic dilatation; 5. Fariñas MC, Campo A, Duran R, 2) Identify biomarkers to assess the Sarralde JA, Nistal JF, Gutiérrez-Díez risk of rupture and assist in surgery JF, Fariñas-Álvarez C. indication; Risk factors and outcomes for 3) Establish new therapeutic targets nosocomial infection after prosthetic vascular grafts. J Vasc Surg. 2017;66:1417-1426. F.I.:3,536. [doi:10.1016/j. 3. Pathological plasticity in the • PUBLICATIONS: jvs.2017.06.078] central nervous system. 6. Sanchez-Barcelo, Emilio J., Rueda, IMPACT FACTOR | 61,819 3.1 Pathological neuronal plasticity Noemi, Mediavilla, Maria D., Martinez- of the nociceptive system. The Cue, Carmen, Reiter, Russel J. mechanisms linking TGF- ßs and Clinical Uses of Melatonin in modulation of pain transmission, Neurological Diseases and Mental basally and in pathological plasticity Original articles and Behavioural Disorders. models of the nociceptive system, Curr Med Chem. 2017;24:3851-3878. are being analysed. F.I.:3,249. [doi:10.2174/09298673246 1. Oller J, Méndez-Barbero N, Ruiz 66170718105557] Chronic neuropathic pain is EJ, Villahoz S, Renard M, Canelas LI, Briones AM, Alberca R, Lozano- highly resistant to conventional 7. Corrales A, Parisotto EB, Vidal V, Vidal N, Hurlé MA, Milewicz D, drug treatment. We have García-Cerro S, Lantigua S, Diego M, Evangelista A, Salaices M, Nistal JF, demonstrated the involvement of Wilhem Filho D, Sanchez-Barceló EJ, Jiménez-Borreguero LJ, De Backer J, the TGF-ß family in processing Martínez-Cué C, Rueda N. Campanero MR, Redondo JM. the physiological nociceptive Pre- and post-natal melatonin Nitric oxide mediates aortic signal. We intend to study: a) administration partially regulates disease in mice deficient in the Molecular mechanisms involving brain oxidative stress but does metalloprotease Adamts1 and TGF-ß in neuropathic pain, and not improve cognitive or in a mouse model of Marfan experimental inflammatory pain; histological alterations in the syndrome. b) The interaction between TGF- Ts65Dn mouse model of Down NAT MED. 2017;23:200-212. ßs and the endogenous opioid syndrome. F.I.:29,886. [doi:10.1038/nm.4266] system; c) The involvement of Behav Brain Res. 2017;334:142-154. Memoria Research areas Organ Transplants and Tissue and de Actividad New Therapies Area
F.I.:3,002. [doi:10.1016/j. de síndrome de down. • PROJECTS bbr.2017.07.022] Director/es: Noemí Rueda Revilla, Carmen Martínez-Cue Pesini. 8. Holmes AA, Romero J, Levsky JM, UNIVERSIDAD DE CANTABRIA. Projects Haramati LB, Phuong N, Rezai-Gharai L, Cohen S, Restrepo L, Ruiz-Guerrero 2. Victor Expósito García. L, Fisher JD, Taub CC, Di Biase L, Consecuencias eléctricas de la 1. Juan Francisco Nistal Herrera. Garcia MJ. Circumferential strain fibrosis miocárdica mediada por Papel de la adiponectina y acquired by CMR early after TGF-B: remodelado estructural y su relación con TGF-ß en el acute myocardial infarction adds desarrollo de fibrilación auricular. remodelado miocárdico inducido incremental predictive value to Director/es: Juan Francisco Nistal por la sobrecarga de presión en la late gadolinium enhancement Herrera, María Amor Hurlé González. estenosis aórtica y en su regresión imaging to predict late myocardial UNIVERSIDAD DE CANTABRIA. postquirúrgica. remodeling and subsequent risk of PI12/00999. INSTITUTO DE SALUD sudden cardiac death. 3. Verónica Vidal Sánchez. CARLOS III. MINISTERIO DE J Interv Card Electrophysiol. Efecto de la reducción de la ECONOMÍA Y COMPETITIVIDAD. 2017;50:211-218. inhibición mediada por los F.I.:1,826. [doi:10.1007/s10840-017- receptores GABAA?5 y GABAB 2. Juan Francisco Nistal Herrera. 0296-9] sobre las alteraciones funcionales Proteína morfogenética del hueso y neuromorfológicas en un modelo 7 (BMP7): Posible diana terapéutica 9. Ruisanchez C, Alonso A, Carballo B, de síndrome de down. en el remodelado patológico del Gil A, Lerena P, Sarralde JA, Ruano FJ. Director/a: Carmen Martínez-Cue Pesini. sistema cardiovascular. Incidental tricuspid valve UNIVERSIDAD DE CANTABRIA. PI15/01224. INSTITUTO DE SALUD fibroelastoma associated with CARLOS III. MINISTERIO DE patent foramen ovale in a young ECONOMÍA Y COMPETITIVIDAD. female: Straightforward diagnosis but controversial management. Thesis Addressed Echocardiography. Clinical Trials 2017;34:1399-1400. 1. María Ángeles Diego Mantecón. F.I.:1,314. [doi:10.1111/echo.13539] Efecto de la administración de moduladores alostéricos 1. Francisco jesús gonzález vílchez. 10. Arnáiz-García ME, Arnáiz- negativos selectivos para la Estudio multicéntrico, aleatorizado, García AM, Gutierrez-Diez F, Nistal subunidad GABAAA5 sobre los doble ciego, de grupos paralelos, JF, González-Santos JM, Pulitani I, procesos cognitivos implicados con control activo, para evaluar Amado-Diago C, Arnáiz J. en las alteraciones de aprendizaje la eficacia y seguridad de LCZ696 Mutilating Purpura Fulminans in an y memoria de un modelo de comparado con valsartan, sobre Adult with Meningococcal Sepsis. síndrome de down. la morbilidad y mortalidad en P R HEALTH SCI J. Director/es: José Antonio Del Barrio Del pacientes con insuficiencia 2017;36:179-182. Campo, Carmen Martínez-Cue Pesini. cardiaca (Clase II-IV NYHA) con F.I.:0,581. UNIVERSIDAD DE CANTABRIA. fracción de eyección preservada. CLCZ696D2301. NOVARTIS 2. Rosmari De La Puerta Huertas. FARMACEUTICA, S.A. Participación de BMP7 (BONE Reviews MORPHOGENETIC PROTEIN 7) en la percepción del dolor y las conductas ansiosas. 1. García R, Merino D, Gómez JM, Director/es: María Amor Hurlé Nistal JF, Hurlé MA, Cortajarena AL, González, Mónica Tramullas Villar AV. Fernández. UNIVERSIDAD DE Extracellular heat shock protein CANTABRIA. 90 binding to TGFß receptor I participates in TGFß-mediated 3. Roberto De La Fuente collagen production in myocardial Royano. Valor clínico potencial fibroblasts. de MICRORNA-30C como Cell Signal. 2016;28:1563-1579. biomarcador y diana terapéutica F.I.:4,191. [doi:10.1016/j. para el dolor neuropático. cellsig.2016.07.003] Director/es: María Amor Hurlé González, Mónica Tramullas Fernández. Authorship Thesis UNIVERSIDAD DE CANTABRIA.
1. Sara Lantigua Romero. Efecto de distintas estrategias terapéuticas sobre los déficits cognitivos y las alteraciones neuromorfólogicas de un modelo 103 Memoria Research areas Organ Transplants and Tissue and de Actividad New Therapies Area
Group Responsible José Antonio Vázquez de Prada Tiffe Cardiology Service • Cardiovascular research Marqués de Valdecilla Group University of Cantabria
Researchers Iván Olavarri de Miguel
Contributors José María Cuesta Cosgaya José María De la Torre Hernández Mónica Fernández-Valls Gómez Tamara García Camarero María Teresa García Unzueta Francisco Jesús González Vílchez Bernardo Alio Lavín Gómez Dae Hyun Lee Hwang Piedad Lerena Sáenz Javier Ruano Calvo Cristina Ruisánchez Villar Fermín Sainz Laso Gabriela Veiga Fernández Manuel Jesús Zarauza Navarro Clinic group José Javier Zueco Gil
Technicians María Cristina Obregón Rodríguez
1. Cardiovascular Therapy. d.Preconditioning in acute coronary syndromes. a. Immunosuppression in Heart Research Transplantation, specifically the 2. Cardiovascular Diagnosis: clinical implementation of new Lines immunosuppressive approaches a. Genetics in mitral valve prolapse with proliferation signal inhibitors (mTOR inhibitors). b. Prevalence and clinical significance The Cardiovascular Research Group is of Coronary aneurysms. actively working in the fields of Heart b. Drug eluting stents, especially Failure and Heart Transplantation, in the setting of left main disease. 3. Multimodality Cardiac Interventional Cardiology and the Imaging. different modalities of Cardiac Imaging c. Percutaneous Structural Heart (2D and 3D echocardiography, Disease Interventions a. Diagnosis and characterizaction coronary angiography -including IVUS of Cardiac Allograft Vasculopathy and optical coherence-, coronary CT · Atrial septal defects closure with intravascular ultrasonography angiography and Magnetic resonance · Transcatheter aortic valve (IVUS), optical coherence and Imaging). implantations (TAVI) virtual histology. · Prosthetic leaks closure -Left Our main areas of research are: atrial appendage closure b. Transesophageal three- 105
Figure. Three-dimensional echocardiogram demonstrating mitral valve prolapse
dimensional echocardiography N, Zueco J, Buszman P, Iñiguez A, the Melatonin Adjunct in the acute in atrial septal defects and mitral Goicolea J, Hildick-Smith D, Ochala myocaRdial Infarction treated with valve prolapse. A, Dudek D, Hanratty C, Cavalcante Angioplasty trial. R,..., Banning AP. J Pineal Res. 2017;62. c. Three-dimensional Clinical outcomes of state-of- F.I.:10,391. [doi:10.1111/jpi.12374] echocardiography evaluation of the-art percutaneous coronary the mitral annulus. revascularization in patients with 4. Alfonso F, Cuesta J, Pérez- de novo three vessel disease: Vizcayno MJ, García Del Blanco d. Strain and strain-rate in diabetic 1-year results of the SYNTAX II B, Rumoroso JR, Bosa F, Pérez and oncologic cardiomyopathy study. de Prado A, Masotti M, Moreno Eur Heart J. 2017;38:3124-3134. R, Cequier A, Gutiérrez H, García F.I.:19,651. [doi:10.1093/eurheartj/ Touchard A, López-Mínguez JR, ehx512] Zueco J, Martí V, Velázquez M, Morís C, Bastante T, García-Guimaraes M, 2. Ruisanchez C, Sarralde JA, Rivero F, Fernández C, Interventional Gonzalez-Fernandez C, Dominguez Cardiology Working Group of the MJ. Spanish Society of Cardiology. Sudden dysfunction of veno- Bioresorbable Vascular Scaffolds venous extracorporeal membrane for Patients With In-Stent oxygenation caused by Restenosis: The RIBS VI Study. intermittent cannula obstruction: JACC Cardiovasc Interv. the key role of echocardiography. 2017;10:1841-1851.F.I.:8,841. • PUBLICATIONS: Intensive Care Med. 2017;43:1055- [doi:10.1016/j.jcin.2017.06.064] 1056. IMPACT FACTOR | 119,378 F.I.:12,015. [doi:10.1007/s00134-017- 5. Amat-Santos IJ, Cortés C, 4704-5] Nombela Franco L, Muñoz-García AJ, Suárez De Lezo J, Gutiérrez- 3. Dominguez-Rodriguez A, Abreu- Ibañes E, Serra V, Larman M, Original articles Gonzalez P, de la Torre-Hernandez Moreno R, De La Torre Hernandez JM, Gonzalez-Gonzalez J, Garcia- JM, Puri R, Jimenez-Quevedo P, Camarero T, Consuegra-Sanchez L, Hernández García JM, Alonso-Briales 1. Escaned J, Collet C, Ryan N, Del Mar Garcia-Saiz M, Aldea-Perona JH, García B, Lee DH, Rojas P, Sevilla Luigi De Maria G, Walsh S, Sabate A, Virgos-Aller T, Azpeitia A, Reiter T, Goncalves R, Vera S, Gómez M, Davies J, Lesiak M, Moreno R, RJ, MARIA investigators. Effect I, Rodés-Cabau J, San Román Cruz-Gonzalez I, Hoole SP, Ej West of intravenous and intracoronary JA. Prosthetic Mitral Surgical N, Piek JJ, Zaman A, Fath-Ordoubadi melatonin as an adjunct to Valve in Transcatheter Aortic F, Stables RH, Appleby C, van primary percutaneous coronary Valve Replacement Recipients: Mieghem N, van Geuns RJ, Uren intervention for acute ST-elevation A Multicenter Analysis. JACC myocardial infarction: Results of Cardiovasc Interv. Activity Research areas Organ Transplants and Tissue and Report New Therapies Area
2017;10:1973-1981. In-Stent Restenosis (from the RIBS Pt-Cr everolimus-eluting stent with F.I.:8,841. [doi:10.1016/j. IV and V Randomized Trials). Am J resorbable abluminal polymer in jcin.2017.07.045] Cardiol. 2017;119:983-990. clinical practice. A randomized trial. F.I.:3,398. [doi:10.1016/j. Catheter Cardiovasc Interv. 2017;90. 6. de la Torre Hernandez JM, amjcard.2016.12.006] F.I.:2,602. [doi:10.1002/ccd.26843] Rumoroso JR, Subinas A, Gonzalo N, Ojeda S, Pan M, Martín Yuste V, 10. Dominguez-Rodriguez A, Abreu- 14. Tenorio J, Álvarez I, Riancho- Suárez A, Hernández F, Teruel L, Moreu Gonzalez P, de la Torre-Hernandez Zarrabeitia L, Martos-Moreno GÁ, J, Cubero JM, Cascón JD, Vinhas H, JM, Consuegra-Sanchez L, Piccolo Mandrile G, de la Flor Crespo M, Lozano Í, Martin Moreiras J, Pérez de R, Gonzalez-Gonzalez J, Garcia- Sukchev M, Sherif M, Kramer I, Prado A, Goicolea J, Escaned J. Camarero T, Del Mar Garcia-Saiz M, Darnaude-Ortiz MT, Arias P, Gordo G, Percutaneous intervention in chronic Aldea-Perona A, Reiter RJ, MARIA Dapía I, Martinez-Villanueva J, Gómez total coronary occlusions caused Investigators. R, Iturzaeta JM, Otaify G, García- by in-stent restenosis: procedural Usefulness of Early Treatment With Unzueta M, Rubinacci A, Riancho JA, results and long-term clinical Melatonin to Reduce Infarct Size in Aglan M, Temtamy S, Hamid MA, outcomes in the TORO (Spanish Patients With ST-Segment Elevation Argente J, Ruiz-Pérez VL, Heath KE, registry of chronic TOtal occlusion Myocardial Infarction Receiving Lapunzina P. secondary to an occlusive in-stent Percutaneous Coronary Intervention Molecular and clinical analysis of RestenOsis) multicentre registry. (From the Melatonin Adjunct in the ALPL in a cohort of patients with EuroIntervention. 2017;13. Acute Myocardial Infarction Treated suspicion of Hypophosphatasia. F.I.:5,165. [doi:10.4244/ With Angioplasty Trial). Am J Med Genet A. EIJ-D-16-00764] Am J Cardiol. 2017;120:522-526. 2017;173:601-610. F.I.:3,398. [doi:10.1016/j. F.I.:2,259. [doi:10.1002/ajmg.a.37991] 7. García Del Blanco B, Jiménez amjcard.2017.05.018] Quevedo P, Diaz JD, Hernández F, 15. Santurtún A, Riancho JA, Rumoroso JR, Sabaté M, de la Torre 11. Núñez-Gil IJ, Nombela-Franco Santurtún M, Richard C, Colorado MM, Hernandez JM, Serrador A, Pérez de L, Bagur R, Bollati M, Cerrato García Unzueta M, Zarrabeitia MT. Prado A, Goicolea J, Trillo R, Pan M. E, Alfonso E, Liebetrau C, De la Genetic DNA profile in urine and Spain: coronary and structural heart Torre Hernandez JM, Camacho B, hair follicles from patients who have interventions from 2010 to 2015. Mila R, Amat-Santos IJ, Alfonso undergone allogeneic hematopoietic EuroIntervention. 2017;13:F.I.:5,165. F, Rodríguez-Olivares R, Camacho stem cell transplantation. [doi:10.4244/EIJ-D-16-00834] Freire SJ, Lozano Í, Jiménez Díaz VA, SCI JUSTICE. 2017;57:336-340. Crespo-Facorro B, Ortiz-Garcia de la Piraino D, Latini RA, Feltes G, Linares F.I.:1,992. [doi:10.1016/j. Foz V, Suarez-Pinilla P, Valdizan EM, JA, Mancone M, Ielasi A, Sánchez- scijus.2017.05.003] Pérez-Iglesias R, Amado-Señaris JA, Grande Flecha A, Fernández Cisnal Teresa Garcia-Unzueta M, Labad J, A, Ugo F, Jiménez Mazuecos JM, 16. Ruisanchez C, Carballo B, Lerena P. Correll C, Ayesa-Arriola R. Effects Omedè P, Pavani M, Villablanca PA, Cystic mass in the left ventricle: of aripiprazole, quetiapine and ..., CAAR Investigators. suspected thrombus with ziprasidone on plasma prolactin Rationale and design of a inhomogeneous appearance. levels in individuals with first episode multicenter, international and Int J Cardiovasc Imaging. nonaffective psychosis: Analysis of a collaborative Coronary Artery 2017;33:1149-1150. randomized open-label 1year study. Aneurysm Registry (CAAR). F.I.:1,896. [doi:10.1007/s10554-017- Schizophr Res. 2017;189:134-141 Clin Cardiol. 2017;40:580-585. 1096-0] F.I.:3,986. [doi:10.1016/j. F.I.:2,757. [doi:10.1002/clc.22705] schres.2017.01.046] 17. De la Torre Hernández JM, 12. Ferko N, Ferrante G, Hasegawa Sadaba Sagredo M, Telleria Arrieta 8. García-Hoyos M, García-Unzueta JT, Schikorr T, Soleas IM, Hernandez M, Gimeno de Carlos F, Sanchez MT, de Luis D, Valero C, Riancho JA. JB, Sabaté M, Kaiser C, Brugaletta S, Lacuesta E, Bullones Ramírez JA, Diverging results of areal and de la Torre Hernandez JM, Galatius Pineda Rocamora J, Martin Yuste volumetric bone mineral density in S, Cequier A, Eberli F, de Belder A, V, Garcia Camarero T, Larman M, Down syndrome. Serruys PW, Valgimigli M. Cost- Rumoroso JR. Osteoporos Int. 2017;28:965-972 effectiveness of percutaneous Antithrombotic treatment during F.I.:3,591. [doi:10.1007/s00198-016- coronary intervention with cobalt- coronary angioplasty after failed 3814-1] chromium everolimus eluting stents thrombolysis: strategies and versus bare metal stents: Results prognostic implications. Results 9. Alfonso F, Pérez-Vizcayno MJ, from a patient level meta-analysis of the RESPIRE registry. BMC García Del Blanco B, García-Touchard of randomized trials. Catheter Cardiovasc Disord. A, López-Mínguez JR, Sabaté M, Cardiovasc Interv. 2017;89:994-1002. 2017;17:212-212. Zueco J, Melgares R, Hernández R, F.I.:2,602. [doi:10.1002/ccd.26700] F.I.:1,832. [doi:10.1186/s12872-017- Moreno R, Domínguez A, Sanchís 0636-9] J, Moris C, Moreu J, Cequier A, 13. de la Torre Hernandez JM, Garcia Romaguera R, Rivero F, Cuesta J, Camarero T, Lee DH, Sainz Laso F, 18. Ruisanchez C, Alonso A, Carballo B, Gonzalo N, Jiménez-Quevedo P, Veiga Fernandez G, Pino T, Rubio S, Gil A, Lerena P, Sarralde JA, Ruano FJ. Cárdenas A, Fernández C, Spanish Legarra P, Valdivia JR, Zueco Gil J. Incidental tricuspid valve Society of Cardiology. Procedural resources utilization and fibroelastoma associated with Usefulness of Drug-Eluting Balloons clinical outcomes with bioresorbable patent foramen ovale in a young for Bare-Metal and Drug-Eluting everolimus-eluting scaffolds and female: Straightforward diagnosis 107
but controversial management. reestenosis de un stent metálico la aparición de acontecimientos Echocardiography. convencional. ESTUDIO RIBS V. cardiovasculares en pacientes que 2017;34:1399-1400. Versión A05 de 1 de marzo de 2010. han experimentado recientemente F.I.:1,314. [doi:10.1111/echo.13539] RIBS V (AAG-I-H-0920). FUNDACIÓN un síndrome coronario agudo. MÉDICA PARA LA INVESTIGACIÓN EFC11570. SANOFI AVENTIS, S.A.. Editorials Y DESARROLLO EN EL ÁREA CARDIOVASCULAR. 10. José Antonio Vázquez de Prada Tiffe. 1. de la Torre Hernandez JM, Puri R, 5. José Javier Zueco Gil. Estudio multicéntrico, aleatorizado, Alfonso F. Eficacia y seguridad de la doble doble ciego, basado en eventos, Drug-Coated Balloon: Scoring to antiagregación comparada con la que compara la eficacia y seguridad Win. combinación de anticoagulación + de Rivaroxaban oral con placebo JACC Cardiovasc Interv. doble antiagregación en pacientes en la reducción del riesgo de 2017;10:1341-1343.F.I.:8,841. con fibrilación auricular de bajo- muerte, infarto de miocardio o [doi:10.1016/j.jcin.2017.05.019] moderado riesgo sometidos a ictus, en pacientes con insuficiencia implementación de un stent cardiaca crónica y enfermedad 2. Puri R, de la Torre Hernandez JM, coronario. MUSICA-2. GARCÍA arterial coronaria significativa Auffret V. DORADO, DAVID. tras una hospitalización por Routine Surveillance Coronary exacerbación de la insuficiencia Angiography Post-PCI: Should We 6. Francisco Jesús González Vílchez. cardiaca. RIVAROXHFA3001/ ReACT and Change Our Routine?. Estudio multicéntrico, doble ciego, BAY59-7939/16302. JANSSEN R&D JACC Cardiovasc Interv. aleatorizado y controlado con IRELAND. 2017;10:118-120. placebo para evaluar la eficacia F.I.:8,841. [doi:10.1016/j. y seguridad de la administración 11. Francisco Jesús González Vílchez. jcin.2016.11.020] por vía intravenosa de dosis Estudio multicéntrico, aleatorizado, intermitentes de levosimendán doble ciego, de grupos paralelos, Clinical Trials en pacientes ambulatorios con con control activo, para evaluar la insuficiencia cardíaca crónica eficacia y seguridad de LCZ696 avanzada. IMIM-LEV-0901. comparado con valsartan, sobre la CONSORCI MAR PARC DE SALUT morbilidad y mortalidad en pacientes 1. José Javier Zueco Gil. DE BARCELONA. con insuficiencia cardiaca (Clase Estudio de resultados en pacientes II-IV NYHA) con fracción de eyección tras la implantación de stends 7. José María de la Torre Hernández. preservada. CLCZ696D2301. Endeavor frente a Cypher. Estudio Daño por isquémica-reperfusión: NOVARTIS FARMACEUTICA, S.A.. prospectivo, multicéntrico, nuevos datos en el conocimiento aleatorizado, de 2 brazos y abierto, de los mecanismos de acción 12. José Javier Zueco Gil. versión final 1.0 de 12 de abril responsables de la cardioprotección Registro de pacientes con de 2007. Hoja de Información conferida por el beta-bloqueo en Dispositivo Biorreabsorbible en la al Paciente y Consentimiento el infarto agudo de miocardio. práctica clínica habitual. Estudio Informado, versión 1.5 de 16 de Traslación de resultados pre- Repara. COR-BVS-2013-01. noviembre de 2007,. PROTECT. clínicos al cuidado humano, Ensayo SOCIEDAD ESPAÑOLA DE MEDTRONIC IBERICA, S.A. METOCARD-CNIC. METOCARD. CARDIOLOGÍA SEC. FUNDACIÓN BIOMÉDICA GALICIA 2. José María de la Torre Hernández. SUR. 13. Francisco Jesús González Vílchez. Stent Xience o Visión Intervención Ensayo clínico fase II, multicéntrico, en angina en ancianos. Estudio 8. José Javier Zueco Gil. aleatorizado en grupos paralelos, XIMA (incluye la Enmienda 1),. Evaluación clínica para comparar doble ciego, controlado con placebo, TOR-XIM-2008-03. FUNDACIÓN la seguridad, la eficacia y el de búsqueda de dosis para explorar UNIVERSIDAD EMPRESA. rendimiento del sistema de armazón los efectos farmacodinámicos, vascular biorreabsorbible liberador la seguridad, la tolerabilidad y la 3. José Javier Zueco Gil. de everolimus ABSORBTM frente farmacocinética de cuatro regímenes Estudio prospectivo, multicéntrico al sistema de stent coronario de dosis distintos del estimulador y aleatorizado (balón de paclitaxel liberador de everolimus XIENCETM oral sGC BAY1021189, durante vs stent farmacoactivo) del en el tratamiento de pacientes con 12 semanas, en pacientes con tratamiento percutáneo de los cardiopatía isquémica causada por descompensación de la insuficiencia pacientes con reestenosis de lesiones de novo en las arterias cardiaca y la fracción de eyección un stent farmacoactivo. RIBS coronarias nativas. 10-393. ABBOT preservada. BAY1021189/15829. IV (AAG-I-H-0919). FUNDACIÓN CARDIOVASCULAR SYSTEMS BAYER HEALTHCARE AG. MÉDICA PARA LA INVESTIGACIÓN INC C/C ABBOTT VASCULAR Y DESARROLLO EN EL ÁREA INTERNATIONAL BVBA. 14. José Javier Zueco Gil. CARDIOVASCULAR. Ensayo clínico de un brazo 9. José Antonio Vázquez de Prada para evaluar la eficacia de 4. José Javier Zueco Gil. Tiffe. las intervenciones coronarias Estudio prospectivo, multicéntrico y Ensayo aleatorizado, doble ciego, percutáneas (ICP) en la enfermedad aleatorizado (balón de paclitaxel vs controlado con placebo y con grupos coronaria de 3 vasos (E3V) de stent farmacoactivo)del tratamiento paralelos para evaluar el efecto nueva aparición mediante la percutáneo de los pacientes con de SAR236553/REGN727 sobre aplicación del Score SYNTAX II, Activity Research areas Report Organ Transplants and Tissue and New Therapies Area
el uso de guía de presión para la derivadas de la médula ósea Europeo Multinacional sobre evaluación funcional y el uso de (CMN-MO) sobre la mortalidad por la Previención de Episodios IVUS como guía del procedimiento, cualquier causa en el infarto agudo Tromboembólicos en Fibrilación e implantación de un stent liberador de miocardio. BAMI-01. QUEEN Auricular. DSE-ANT-2011-01. DAIICHI de everolimus con recubrimiento MARY AND WESTFILED COLLEGE. SANKYO, INC. abluminal biodegradable. ECRI-002. EUROPEAN CARDIOVASCULAR 21. José María de la Torre Hernández. 3. Francisco Jesús González Vílchez. RESEARCH INSTITUTE-2 (ECRI-2). Intervención Coronaria Percutánea Estudio multicéntrico, observacional, con el Stent con Liberación de retrospectivo para evaluar la 15. José Javier Zueco Gil. Fármaco Angiolite: Estudio de conversión de la formulación Estudio prospectivo, aleatorizado, Tomografía de Coherencia Óptica. estándar de tacrolimus (Prograf(c)) a multicéntrico para evaluar la ANCHOR. IVASCULAR, S.L.U.. tacrolimus de liberación prolongada seguridad y eficacia del sistema del (Advagraf(c)) en pacientes stent liberador de sirolimus en el 22. José Javier Zueco Gil. con trasplante cardiaco. AST- tratamiento de pacientes con hasta Ensayo Clínico aleatorizado TAC-2013-01. ASTELLAS PHARMA, dos lesiones arteriales coronarias de para comparar la eficacia del S.A. novo. BIOFLOW IV. BIOTRONIK SE Stent Angiolite frente a un stent & CO. KG. farmacoactivo de segunda 4. José Antonio Vázquez de Prada Tiffe. generación como Xience en Registro internacional prospectivo 16. José María de la Torre Hernández. pacientes con indicación de y multicéntrico de pacientes Ensayo clínico, randomizado, doble intervención coronaria percutánea. hombres y mujeres que han sido ciego y controlado con placebo, de la ANGIOLITE. CARDIVA 2, S.L. diagnosticados recientemente melatonina intravenosa como terapia con fibrilación auricular y reciben adyuvante a la reperfusión primaria 23. José María de la Torre Hernández. tratamiento con Rivaroxabán. con angioplastia transluminal “Estudio TWILIGHT- Ticagrelor con TRI08890. THE TROMBOSIS percutánea en pacientes con infarto Aspirina o sola en pacientes de alto RESEARCH INSTITUTE. agudo de miocardio. Melatonina/05. riesgo después de una intervención DOMINGUEZ RODRIGUEZ, coronaria”. ISSBRIL0345. ICAHN 5. Fermín Sainz Laso. ALBERTO. SCHOOL OF MEDICINE AT MOUNT Registro de paciEntes con SINAI. disPositivo biorreAbsorbible en la 17. José María de la Torre Hernández. pRáctica clínica hAbitual: medida Acceso radial frente a acceso 24. Francisco Jesús González Vílchez. de costes, efectividad, QALYs, y femoral y bivalirudina frente a Estudio multicéntrico, aleatorizado, eficiencia. COR-BVS-2016-01. heparina no fraccionada con o sin doble ciego, prospectivo para evaluar inhibidores de la glucoproteína IIb/ el efecto de sacubitril/valsartán vs. 6. Fermín Sáinz Laso. IIIa como estrategia global para enalapril en la actividad física diaria Estudio observacional minimizar las complicaciones utilizando un actígrafo de muñeca en postautorización PRESSUREwire: hemorrágicas en pacientes pacientes adultos con insuficiencia ?Evaluación práctica de la reserva de con síndrome coronario agudo cardíaca crónica”. CLCZ696B3301. fracción de flujo (FFR) y los índices sometidos a tratamiento invasivo. NOVARTIS FARMACEUTICA, S.A. alternativos asociados durante las RFBU11-I. SOCIETA ITALIANA DI intervenciones clínicas habituales. CARDIOLOGIA INVASIVA GISE. 25. Francisco Jesús González Vílchez. CRD-795 / SJM-CIP-10136. SJM Estudio doble ciego, aleatorizado, INTERNATIONAL INC. 18. José María de la Torre Hernández. controlado con placebo y Ensayo multinacional, aleatorizado, multicéntrico para evaluar la eficacia 7. Fermín Sainz Laso. doble ciego, controlado con placebo, y la seguridad de omecamtiv Estudio observacional para evaluar el efecto de ticagrelor mecarbil en la mortalidad y postautorización Registro 90 mg dos veces al día sobre la morbilidad de sujetos con prospectivo, de brazo único, incidencia de muerte cardiovascular, insuficiencia cardíaca crónica con multicéntrico, observacional, de infarto de miocardio o ictus en fracción de eyección reducida. utilización de stent liberador de pacientes con diabetes mellitus tipo 20110203. AMGEN, S.A. zotarolimus RESOLUTE-ONYX™ 2. D513BC00001. ASTRAZENECA AB. en el intervencionismo coronario Postmarketing Studies percutáneo en vasos pequeños. 19. José Javier Zueco Gil. and Other DISCO 9. FUNDACIÓN DE Terapia antiplaquetaria doble de INVESTIGACIÓN SANITARIA EN corta duración con la endoprótesis 1. Francisco Jesús González Vílchez. LEÓN FIS LEÓN. recubierta de everolimus Synergy® Estudio epidemiológico para II en pacientes mayores de 75 años evaluar el manejo del tratamiento sometidos a revascularización con esteroides en pacientes con coronaria percutánea. El ensayo trasplante cardiaco realizado en la SENIOR. 10-389. CENTRE era actual de la inmunosupresión EUROPÉEN DE RECHERCHE en España. AST-EST-2010-01. CARDIOVASCULAIRE CERC. ASTELLAS PHARMA, S.A.
20. José María de la Torre Hernández. 2. Manuel Jesús Zarauza Navarro. Efecto de la infusión intracoronaria Estudio Observacional Registro de células madre mononucleares 109 Activity Research areas Report Organ Transplants and Tissue and New Therapies Area
Group Responsible Javier Crespo García Digestive Service • Infection, Immunity and University Hospital Marqués de Valdecilla Digestive Diseases University of Cantabria
José Ignacio Fortea Ormaechea María José García García Patricia Huelín Álvarez Paula Iruzubieta Coz Francisco Javier Jiménez Pérez Susana Llerena Santiago Luis Martín Ramos Susana Menéndez Secades María Moris Folgueroso Helena Pisonero Fraga Ángela María Puente Sánchez Montserrat Rivero Tirado Carlos Rodríguez de Lope López Carlos José Sánchez Ovejero Álvaro Terán Lantarón Consolidated group Nurses Lidia Amigo Cabria Researchers Beatriz Castro Senosiain María Rita Millor Rojo José Pedro Vaqué Díez Marta Cobo Martín Antonio Cuadrado Lavín Technicians Joaquín de La Peña García Lorena Cayón Estrada Contributors Ainhoa Díaz Pérez Ángel Estebanez Gallo María Teresa Arias Loste Emilio Fábrega García Laura García Laso Joaquín Cabezas González Tatiana Fernández Lanas Agustín García Blanco Fernando Casafont Morencos Pedro Luis Fernández Gil María Elena Pérez García
the innate immune system in the producing endothelial dysfunction, Research spontaneous clearance of C virus subclinical atheromatosis, disorder infection, as well as the evolution of mineral and bone metabolism or Lines towards chronicity and its implication neurocognitive manifestations and its in response / failure to treatment with potential reversibility after curing the new direct acting antiviral agents infection with the new ADD agents. 1. Hepatitis C. (ADIs). Regarding the therapeutic Finally, we intend to study whether failure, the viral variants associated regression occurs in liver fibrosis To know the real epidemiology of with resistance will also be studied. after the response to DDA and the hepatitis C virus infection in our In addition, we will study whether pathogenic role of the enzyme Lisil- country. To evaluate the role of the hepatitis C virus is capable of oxidase like 2 (LOXL2) in this process.. 111
2. Molecular characterization of is an inherited, autosomal recessive specific cases of human cancer. pathology of lipid metabolism • PUBLICATIONS: characterized by accumulation in Potential implications in diagnosis lysosomes, especially in the liver of IMPACT FACTOR | 251,828 and therapy. Oncogenic signaling cholesterol and triglyceride esters, mechanisms that control initiation, which may erroneously be diagnosed progression and response to therapy. in the adult as HDSH. This pathology Study from a personalized point of is due to mutations of the LAL view, advanced cases of human gene (LIPA), of which more than 40 Original articles cancer that at present lack effective mutations have been described. We therapies. Currently we have research intend to evaluate whether the active 1. Lens S, Alvarado E, Mariño Z, projects in liver cancer as well as screening by mass sequencing of the Londoño MC, LLop E, Martinez J, some types of aggressive skin cancers LIPA gene in adults with a diagnosis Fortea JI, Ibañez L, Ariza X, Baiges such as advanced melanoma, Merkel of GDHD could be relevant from a A, Gallego A, Bañares R, Puente cell carcinoma and cutaneous T-cell clinical point of view. A, Albillos A, Calleja JL, Torras X, lymphoma. Hernández-Gea V, Bosch J, Villanueva 4. Alcoholic liver C, Forns X, García-Pagán JC. 3. Fatty Liver Disease disease. Effects of All-Oral Anti-Viral (EHDG). Therapy on HVPG and Systemic To study the pathophysiological Hemodynamics in Patients With Obesity and insulin resistance mechanisms of acute alcoholic Hepatitis C Virus-Associated are associated with a chronic hepatitis and the search for Cirrhosis. Gastroenterology. inflammatory state. Current evidence molecular targets. Analysis of the 2017;153 indicates that the activation of the hepatic transcriptome in patients F.I.:18,392. [doi:10.1053/j. signal transduced at the level of the with alcoholic liver disease for the gastro.2017.07.016] innate immune system by receptors development of molecular signatures such as TLRs and NLRs plays a of gene expression. 2. Alonso C, Fernández-Ramos D, decisive role in the genesis of this Varela-Rey M, Martínez-Arranz I, inflammatory state. Both receptor 5. Liver cirrhosis and portal Navasa N, Van Liempd SM, Lavin families, together with RLRs, make up hypertension. JL, Mayo R, Ilisso CP, de Juan VG, what we know as pattern recognition Iruarrizaga-Lejarreta M, delaCruz- receptors (PRRs). However, the role To characterize the natural history of Villar L, Mincholé I, Robinson A, played by PRRs in the pathogenesis of hepatic cirrhosis and factors that may Crespo J, Martín-Duce A, Romero- HDD is largely unknown. It is possible influence the portal pressure gradient. Gomez M, Sann H, Platon J, Van that differences in the gene and To evaluate the long-term role of new Eyk J, Aspichueta P, Noureddin M, protein expression of these peripheral, oral anticoagulants in the survival hepatic and fatty receptors between and development of complications of Falcón-Pérez JM, Anguita J, Aransay obese and non-obese subjects portal hypertension in patients with AM, Martínez-Chantar ML, Lu SC, translate into a different susceptibility liver cirrhosis. Mato JM. Metabolomic Identification to the development of fatty liver of Subtypes of Nonalcoholic disease. 6. Liver transplantation. Steatohepatitis. Gastroenterology. 2017;152. On the other hand, the severity of To study non-invasive blood F.I.:18,392. [doi:10.1053/j. the histological lesion of GHTD has biomarkers of clinical events related gastro.2017.01.015] been associated with the concomitant to liver transplantation (rejection, presence of hypopnea sleep apnea infection, vascular pathology, biliary 3. Villanueva, Candid, Graupera, syndrome. The role that intermittent disease, and short- and long-term Isabel, Aracil, Carles, Alvarado, hypoxia plays in the development survival of the graft). Edilmar, Minana, Josep, Puente, of liver injury has been studied Angela, Hernandez-Gea, Virginia, previously. However, there are no 7. Cholestatic and autoimmune Ardevol, Alba, Pavel, Oana, Colomo, studies aimed at evaluating the effect liver disease. Alan, Concepcion, Mar, Poca, Maria, of hypercapnia maintained at the Torras, Xavier, Rene, Josep M., hepatic level. For this reason, we Characterize the natural history and Guarner, Carlos. intend to analyze the effect of chronic physiopathological mechanisms of A Randomized Trial to Assess hypercapnia, with or without added cholestatic and autoimmune liver Whether Portal Pressure Guided hypoxemia, at the liver level with ex diseases. Therapy to Prevent Variceal vivo models of primary culture of Rebleeding Improves Survival in immortalized hepatocytes, by analysis Cirrhosis. of gene expression associated with Hepatology. 2017;65:1693-1707. glucose and lipid metabolism and F.I.:13,246. [doi:10.1002/hep.29056] regulatory genes of the immune response, as well as assessing the 4. Zubiete-Franco I, Fernández- inflammatory response induced Tussy P, Barbier-Torres L, Simon J, in these cells by the infusion of Fernández-Ramos D, Lopitz-Otsoa lipopolysaccharide. F, Juan VG, Davalillo SL, Duce AM, Iruzubieta P, Taibo D, Crespo J, The partial deficiency of the Caballeria J, Villa E, Aurrekoetxea I, lysosomal acid lipase (LAL) enzyme Aspichueta P, Varela-Rey M, Lu SC, Activity Research areas Organ Transplants and Tissue and Report New Therapies Area
Mato JM, Beraza N, Delgado TC, Use of Direct-acting Drugs Hepatitis Sáez-Royuela F, Arenas J, Rincón Martínez-Chantar ML. C Collab. Effectiveness, safety and D, Prieto M, Jorquera F, Sanchez Deregulated neddylation in liver clinical outcomes of direct-acting Ruano JJ, Navascués CA, Molina fibrosis. antiviral therapy in HCV genotype E, Moya AG, Moreno-Planas JM, Hepatology. 2017;65:694-709 1 infection: Results from a Spanish Spanish Group for the Study of the F.I.:13,246. [doi:10.1002/hep.28933] real-world cohort. Use of Direct-acting Drugs Hepatitis J Hepatol. 2017;66:1138- C Collab. 5. Albillos A, Zamora J, Martínez 1148.F.I.:12,486. [doi:10.1016/j. Real-World Effectiveness and J, Arroyo D, Ahmad I, De-la-Peña jhep.2017.01.028] Safety of Oral Combination Antiviral J, Garcia-Pagán JC, Lo GH, Sarin Therapy for Hepatitis C Virus S, Sharma B, Abraldes J, Bosch J, 9. Fernández I, Muñoz-Gómez R, Genotype 4 Infection. Garcia-Tsao G, Baveno cooperation. Pascasio JM, Baliellas C, Polanco Clin Gastroenterol Hepatol. 2017;15. Stratifying risk in the prevention N, Esforzado N, Arias A, Prieto F.I.:7,398. [doi:10.1016/j. of recurrent variceal hemorrhage: M, Castells L, Cuervas-Mons V, cgh.2017.02.020] Results of an individual patient meta- Hernández O, Crespo J, Calleja JL, analysis. Forns X, Londoño MC. 13. Huelin, Patricia, Piano, Salvatore, Hepatology. 2017;66:1219-1231. Efficacy and tolerability of interferon- Sola, Elsa, Stanco, Marialuisa, Sole, F.I.:13,246. [doi:10.1002/hep.29267] free antiviral therapy in kidney Cristina, Moreira, Rebeca, Pose, transplant recipients with chronic Elisa, Fasolato, Silvano, Fabrellas, 6. Fernández Carrillo C, Lens S, Llop hepatitis C. Nuria, de Prada, Gloria, Pilutti, Chiara, E, Pascasio JM, Crespo J, Arenas J, J Hepatol. 2017;66:718-723. Graupera, Isabel, Ariza, Xavier, Fernández I, Baliellas C, Carrión JA, de F.I.:12,486. [doi:10.1016/j. Romano, Antonietta, Elia, Chiara, la Mata M, Buti M, Castells L, Albillos jhep.2016.12.020] Cardenas, Andres, Fernandez, Javier, A, Romero M, Turnes J, Pons C, Angeli, Paolo, Gines, Pere. Moreno-Planas JM, Moreno-Palomares 10. Barbier-Torres L, Iruzubieta P, Validation of a Staging System for JJ, Fernández-Rodriguez C, García- Fernández-Ramos D, Delgado TC, Acute Kidney Injury in Patients With Samaniego J, Prieto M, Fernández Taibo D, Guitiérrez-de-Juan V, Varela- Cirrhosis and Association With Bermejo M, Salmerón J, Badia E, Rey M, Azkargorta M, Navasa N, Acute-on-Chronic Liver Failure. Salcedo M, Herrero JI, Granados R, Blé Fernández-Tussy P, Zubiete-Franco I, Clin Gastroenterol Hepatol. M, Mariño Z, Calleja JL. Simon J, Lopitz-Otsoa F, Lachiondo- 2017;15:438-438. Treatment of hepatitis C virus Ortega S, Crespo J, Masson S, F.I.:7,398. [doi:10.1016/j. infection in patients with cirrhosis McCain MV, Villa E, Reeves H, Elortza cgh.2016.09.156] and predictive value of model for F, Lucena MI, Hernández-Alvarez MI, end-stage liver disease: Analysis Zorzano A, Andrade RJ, Lu SC, Mato 14. Buti M, Calleja JL, Lens S, Diago of data from the Hepa-C registry. JM, Anguita J, Rincón M, Martínez- M, Ortega E, Crespo J, Planas R, Hepatology. 2017;65:1810-1822. Chantar ML. Romero-Gómez M, Rodríguez FG, F.I.:13,246. [doi:10.1002/hep.29097] The mitochondrial negative regulator Pascasio JM, Fevery B, Kurland D, MCJ is a therapeutic target for Corbett C, Kalmeijer R, Jessner W. 7. Curiel-Olmo S, Mondejar R, acetaminophen-induced liver injury. Simeprevir in combination with Almaraz C, Mollejo M, Cereceda L, Nat Commun. 2017;8:2068-2068. sofosbuvir in treatment-naïve and Marès R, Derdak S, Campos-Martin F.I.:12,124. [doi:10.1038/s41467-017- -experienced patients with hepatitis Y, Batlle A, Gonzalez de Villambrosía 01970-x] C virus genotype 4 infection: a Phase S, Gut M, Blanc J, Traverse-Glehen III, open-label, single-arm study A, Verney A, Baseggio L, Camacho 11. Lens S, Fernández I, Rodríguez- (PLUTO). FI, Wotherspoon A, Stamatopoulos Tajes S, Hontangas V, Vergara Aliment Pharmacol Ther. K, Xochelli A, Papadaki T, Kanellis M, Forné M, Calleja JL, Diago M, 2017;45:468-475. G, Ponzoni M, Garcia-Cosio M, Llaneras J, Llerena S, Torras X, F.I.:7,286. [doi:10.1111/apt.13883] Vaque JP, Beltran S, Gut I, Piris MA, Sacristán B, Roget M, Fernández- Martinez N. Rodríguez CM, Navascués MC, 15. González-Vela MC, Curiel-Olmo Splenic diffuse red pulp small B-cell Fuentes J, Sánchez-Ruano JJ, Simón S, Derdak S, Beltran S, Santibañez lymphoma displays increased MÁ, Sáez-Royuela F, Baliellas C, M, Martínez N, Castillo-Trujillo A, expression of cyclin D3 and Morillas R, Forns X, Spanish Group Gut M, Sánchez-Pacheco R, Almaraz recurrent CCND3 mutations. Blood. for the Study of the Use of Direct- C, Cereceda L, Llombart B, Agraz- 2017;129:1042-1045.F.I.:13,164. acting Drugs Hepatitis C Collab. Doblas A, Revert-Arce J, López [doi:10.1182/blood-2016-11-751024] Interferon-Free Therapy in Elderly Guerrero JA, Mollejo M, Marrón PI, Patients With Advanced Liver Ortiz-Romero P, Fernandez-Cuesta 8. Calleja JL, Crespo J, Rincón D, Disease. L, Varela I, Gut I, Cerroni L, Piris MA, Ruiz-Antorán B, Fernandez I, Perelló Am J Gastroenterol. 2017;112:1400- Vaqué JP. C, Gea F, Lens S, García-Samaniego 1409. Shared Oncogenic Pathways J, Sacristán B, García-Eliz M, Llerena F.I.:9,566. [doi:10.1038/ajg.2017.157] Implicated in Both Virus-Positive and S, Pascasio JM, Turnes J, Torras X, UV-Induced Merkel Cell Carcinomas. Morillas RM, Llaneras J, Serra MA, 12. Crespo J, Calleja JL, Fernández J Invest Dermatol. 2017;137:197-206. Diago M, Fernández Rodriguez C, I, Sacristan B, Ruiz-Antorán B, F.I.:6,287. [doi:10.1016/j. Ampuero J, Jorquera F, Simon MA, Ampuero J, Hernández-Conde M, jid.2016.08.015] Arenas J, Navascues CA, Bañares García-Samaniego J, Gea F, Buti M, R, Muñoz R, Albillos A, Mariño Z, Cabezas J, Lens S, Morillas RM, 16. García V, Calvo M, Martín Spanish Group for the Study of the Salcines JR, Pascasio JM, Turnes J, Arranz MD, Rivero M, Domènech E, 113
Barreiro-de Acosta M, García Planella programme for Spanish patients Liver Int. 2017;37:290-298. E, Gutiérrez A, Romero C, Cea-Calvo with genotype 1/4 chronic hepatitis F.I.:4,116. [doi:10.1111/liv.13182] L, Juliá B. P603 C virus infection. Hospitalisation risk and J Viral Hepat. 2017;24:226-237. 25. D’Avola D, Cuervas-Mons V, reintervention after ileocolonic F.I.:4,122. [doi:10.1111/jvh.12637] Martí J, Ortiz de Urbina J, Lladó resection with anastomosis in L, Jimenez C, Otero E, Suarez F, patients with Crohn’s disease. 21. Alonso S, Riveiro-Barciela Rodrigo JM, Gómez MA, Fraga E, Results from the PRACTICROHN M, Fernandez I, Rincón D, Real Lopez P, Serrano T, Rios A, Fábrega study. Y, Llerena S, Gea F, Olveira A, E, Herrero JI. J CROHNS COLITIS. 2017;11. Fernandez-Carrillo C, Polo B, Carrión Cardiovascular morbidity and F.I.:5,813. [doi:10.1093/ecco-jcc/ JA, Gómez A, Devesa MJ, Baliellas mortality after liver transplantation: jjx002.727] C, Castro Á, Ampuero J, Granados R, The protective role of mycophenolate Pascasio JM, Rubín A, Salmeron J, mofetil. 17. Massey V, Cabezas J, Bataller R. Badia E, Planas JM, Lens S, Turnes Liver Transpl. 2017;23:498-509. Epigenetics in Liver Fibrosis. J, Montero JL, Buti M, Esteban R, F.I.:3,910. [doi:10.1002/lt.24738] SEMIN LIVER DIS. 2017;37:219-230. Fernández-Rodríguez CM. F.I.:5,500.[doi:10.1055/s-0037-1605371] Effectiveness and safety of 26. Carrillo CF, Crespo G, de la sofosbuvir-based regimens plus an Revilla J, Castells L, Buti M, Montero 18. Taxonera C, Rodríguez C, NS5A inhibitor for patients with HCV JL, Fábrega E, Fernández I, Serrano- Bertoletti F, Menchén L, Arribas J, genotype 3 infection and cirrhosis. Millán C, Hernández V, Calleja JL, Sierra M, Arias L, Martínez-Montiel Results of a multicenter real-life Londoño MC. P, Juan A, Iglesias E, Algaba A, cohort. Successful Continuation of Manceñido N, Rivero M, Barreiro- J Viral Hepat. 2017;24:304-311. HCV Treatment After Liver de Acosta M, López-Serrano P, F.I.:4,122. [doi:10.1111/jvh.12648] Transplantation. Argüelles-Arias F, Gutierrez A, Transplantation. 2017;101:1009-1012. Busquets D, Gisbert JP, Olivares 22. De Gottardi A, Trebicka J, Klinger F.I.:3,678. [doi:10.1097/ D, Calvo M, Alba C, Collaborators. C, Plessier A, Seijo S, Terziroli B, TP.0000000000001596] Clinical Outcomes of Golimumab Magenta L, Semela D, Buscarini as First, Second or Third Anti-TNF E, Langlet P, Görtzen J, Puente A, 27. Salcedo M, Prieto M, Castells L, Agent in Patients with Moderate-to- Müllhaupt B, Navascuès C, Nery F, Pascasio JM, Alvarez JLM, Fernández Severe Ulcerative Colitis. Inflamm Deltenre P, Turon F, Engelmann C, I, Sánchez-Antolín G, González- Bowel Dis. Arya R, Caca K, Peck-Radosavljevic Diéguez L, García-Gonzalez M, Otero 2017;23:1394-1402. M, Leebeek FW, Valla D, Garcia- A, Lorente S, Espinosa MD, Testillano F.I.:4,525. [doi:10.1097/ Pagan JC, VALDIG Investigators. M, González A, Castellote J, Casafont MIB.0000000000001144] Antithrombotic treatment with F, Londoño MC, Pons JA, Molina direct-acting oral anticoagulants Pérez E, Cuervas-Mons V, Pascual 19. Graupera, Isabel, Coll, Mar, Pose, in patients with splanchnic vein S, Herrero JI, Narváez I, Vinaixa C, Elisa, Elia, Chiara, Piano, Salvatore, thrombosis and cirrhosis. Llaneras J, Sousa JM, Bañares R. Sola, Elsa, Blaya, Delia, Huelin, Liver Int. 2017;37:694-699. Efficacy and safety of daclatasvir- Patricia, Sole, Cristina, Moreira, F.I.:4,116. [doi:10.1111/liv.13285] based antiviral therapy in hepatitis Rebeca, de Prada, Gloria, Fabrellas, C virus recurrence after liver Nuria, Juanola, Adria, Morales-Ruiz, 23. Mariño Z, Pascasio-Acevedo transplantation. Role of cirrhosis and Manuel, Sancho-Bru, Pau, Villanueva, JM, Gallego A, Diago M, Baliellas C, genotype 3. A multicenter cohort Candid, Gines, Pere. Morillas R, Prieto M, Moreno JM, study. Adipocyte Fatty-Acid Binding Protein Sánchez-Antolín G, Vergara M, Forné Transpl Int. 2017;30:1041-1050. is Overexpressed in Cirrhosis and M, Fernández I, Castro MÁ, Pascual F.I.:3,079. [doi:10.1111/tri.12999] Correlates with Clinical Outcomes. S, Gómez A, Castells L, Montero Sci Rep. 2017;7. JL, Crespo J, Calleja JL, García- 28. Castro B, Rivero M, Crespo J, F.I.:4,259. [doi:10.1038/s41598-017- Samaniego J, Carrión JA, Del Carmen Riancho JA, Valero C. 01709-0] Arencibia A, Blasco A, López-Núñez Influence of anti-TNF therapy on C, Sánchez-Ruano JJ, Gea-Rodríguez bone metabolism in patients with 20. Perelló C, Carrión JA, Ruiz- F, Giráldez Á, Cabezas J, Hontangas inflammatory bowel disease. Antorán B, Crespo J, Turnes J, V, ..., Forns X. Eur J Intern Med. 2017;39. Llaneras J, Lens S, Delgado M, High efficacy of Sofosbuvir plus F.I.:2,960. [doi:10.1016/j. García-Samaniego J, García-Paredes Simeprevir in a large cohort of ejim.2017.01.024] F, Fernández I, Morillas RM, Rincón Spanish cirrhotic patients infected D, Porres JC, Prieto M, Lázaro Ríos with genotypes 1 and 4. 29. Riveiro-Barciela M, Tabernero M, Fernández-Rodríguez C, Hermo Liver Int. 2017;37:1823-1832. D, Calleja JL, Lens S, Manzano ML, JA, Rodríguez M, Herrero JI, Ruiz P, F.I.:4,116. [doi:10.1111/liv.13470] Rodríguez FG, Crespo J, Piqueras Fernández JR, Macías M, Pascasio B, Pascasio JM, Comas C, Gutierrez JM, Moreno JM, Serra MÁ, Arenas 24. Cheong J, Galanko JA, Arora ML, Aguirre A, Suárez E, García- J, Real Y, Jorquera F, ..., Spanish S, Cabezas J, Ndugga NJ, Lucey Samaniego J, Rivero M, Acero D, Collaborative Group for the Study of MR, Hayashi PH, Barritt AS, Bataller Fernandez-Bermejo M, Moreno the Use of Hepatitis C Direct-Actin. R. Reduced impact of renal failure D, Sánchez-Pobre P, de Cuenca B, Effectiveness and safety of on the outcome of patients with Moreno-Palomares JJ, Esteban R, ombitasvir, paritaprevir, ritonavir ± alcoholic liver disease undergoing Buti M. dasabuvir ± ribavirin: An early access liver transplantation. Effectiveness and Safety of Entecavir Activity Research areas Organ Transplants and Tissue and Report New Therapies Area
or Tenofovir in a Spanish Cohort 35. Espinet Coll E, Nebreda Durán J, Criado MÁ, Genescà J, Hernández- of Chronic Hepatitis B Patients: López-Nava Breviere G, Ducóns Gea V, Llop-Herrera E, Masnou- Validation of the Page-B Score to García J, Rodríguez-Téllez M, Crespo Ridaura H, Mateo J, Navascués CA, Predict Hepatocellular García J, Marra-López Valenciano C. Puente Á, Romero-Gutiérrez M, Carcinoma. Multicenter study on the safety of Simón-Talero M, Téllez L, Turon F, Dig Dis Sci. 2017;62:784-793. bariatric endoscopy. Villanueva C, Zarrabeitia R, García- F.I.:2,875. [doi:10.1007/s10620-017- Rev Esp Enferm Dig. 2017;109:350- Pagán JC. 4448-7] 357. Vascular diseases of the liver. F.I.:1,401. [doi:10.17235/ Clinical Guidelines from the 30. Gutiérrez-de-Juan V, López de reed.2017.4499/2016] Catalan Society of Digestology and Davalillo S, Fernández-Ramos D, the Spanish Association for the Barbier-Torres L, Zubiete-Franco I, 36. Aguiar D, Martínez-Urbistondo Study of the Liver. Fernández-Tussy P, Simon J, Lopitz- D, Baroja-Mazo A, de la Mata M, Gastroenterol Hepatol. Otsoa F, de Las Heras J, Iruzubieta Rodríguez-Perálvarez M, Rubín A, 2017;40:538-580. P, Arias-Loste MT, Villa E, Crespo J, Puchades L, Serrano T, Montero J, F.I.:0,917. [doi:10.1016/j. Andrade R, Lucena MI, Varela-Rey Cuadrado A, Casafont F, Salcedo gastrohep.2017.03.011] M, Lu SC, Mato JM, Delgado TC, M, Rincón D, Pons JA, Herrero JI. Martínez-Chantar ML. Real-World Multicenter Experience 41. Iborra M, Pérez-Gisbert J, A morphological method for of Immunosuppression Minimization Bosca-Watts MM, López-García A, ammonia detection in liver. Among 661 Liver Transplant García-Sánchez V, López-Sanromán PLoS One. 2017;12: Recipients. A, Hinojosa E, Márquez L, García- F.I.:2,806. [doi:10.1371/journal. Ann Transplant. 2017;22:265-275. López S, Chaparro M, Aceituno M, pone.0173914] F.I.:1,252. Calafat M, Guardiola J, Belloc B, Ber Y, Bujanda L, Beltrán B, Rodríguez- 31. Mondejar R, Pérez C, Onaindia 37. Buti M, Calleja JL, García- Gutiérrez C, Barrio J, Cabriada JL, A, Martinez N, González-Rincón J, Samaniego J, Serra MÁ, Crespo Rivero M, Camargo R, van Domselaar Pisonero H, Vaqué JP, Cereceda L, J, Romero M, Simón MÁ, Turnes M, Villoria A, Schuterman HS, Hervás Santibañez M, Sánchez-Beato M, J, Blasco AJ, Lázaro P, Robbins D, Nos P, Spanish Working Group on Piris MA. S, Razavi H, en representación Crohn’s Disease and Ulcerative Colitis Molecular basis of targeted therapy del Grupo para el Estudio y (GETECCU). in T/NK-cell lymphoma/leukemia: Modelización Epidemiológica de la Effectiveness of adalimumab for A comprehensive genomic and Elimination of hepatitis C in Spain: the treatment of ulcerative colitis immunohistochemical analysis of a Adaptation of a mathematical model in clinical practice: comparison panel of 33 cell lines. based on the public health strategic between anti-tumour necrosis factor- PLoS One. 2017;12:F.I.:2,806. plan for addressing hepatitis C in the naïve and non-naïve patients. [doi:10.1371/journal.pone.0177524] National Health System. J Gastroenterol. 2017;52:788-799. Med Clin (Barc). 2017;148:277-282. F.I.:0,165. [doi:10.1007/s00535-016- 32. Crespo J, Esteban R, Torres C, F.I.:1,125. [doi:10.1016/j. 1274-1] Oyagüez I, Casado MÁ, Buti M. medcli.2016.12.018] Cost-effectiveness of a hepatitis 42. Iborra M, Gisbert JP, Bosca- B virus screening strategy to 38. Gisbert JP, Molina-Infante J, Watts MM, López-García A, prevent reactivation in patients with Amador J, Bermejo F, Bujanda L, García-Sánchez V, López-Sanromán hematologic neoplasms. Calvet X, Castro-Fernández M, A, Hinojosa E, Márquez L, García- Rev Esp Enferm Dig. 2017;109:619- Cuadrado-Lavín A, Elizalde JI, Gene López S, Chaparro M, Aceituno M, 626. E, Gomollón F, Lanas Á, de Argila Calafat M, Guardiola J, Belloc B, Ber F.I.:1,401. [doi:10.17235/ CM, Mearin F, Montoro M, Pérez-Aisa Y, Bujanda L, Beltrán B, Rodríguez- reed.2017.4693/2016] Á, Pérez-Trallero E, McNicholl AG. Gutiérrez C, Barrio J, Cabriada JL, Erratum to IV Spanish Consensus Rivero M, Camargo R, van Domselaar 33. Crespo J, Jorquera Plaza F. Conference on Helicobacter pylori M, Villoria A, Schuterman HS, Hervás Gastroenterology, a historical infection treatment [Gastroenterol D, Nos P, Spanish Working Group on specialty with a great future. Hepatol 39 (2016) 697-721]. Crohn’s Disease and Ulcerative Colitis Rev Esp Enferm Dig. 2017;109:611- Gastroenterol Hepatol. (GETECCU). 613. 2017;40:378-378. Erratum to: Effectiveness of F.I.:1,401. [doi:10.17235/ F.I.:0,917. [doi:10.1016/j. adalimumab for the treatment of reed.2017.5193/2017] gastrohep.2017.02.004] ulcerative colitis in clinical practice: comparison between anti-tumour 34. Puente Á, Cabezas J, López 39. Llerena S, Cabezas J, Iruzubieta necrosis factor-naïve and non- Arias MJ, Arias MT, Estébanez Á, P, Crespo J. naïve patients. Casafont F, Fábrega E, Crespo J. Resistance to hepatitis C virus. 2017;52:875-877.F.I.:0,165. Influence of sustained viral response Implications and therapeutic options. [doi:10.1007/s00535-016-1293-y] on the regression of fibrosis and Gastroenterol Hepatol. portal hypertension in cirrhotic HCV 2017;40:484-494. patients treated with antiviral triple F.I.:0,917. [doi:10.1016/j. Authorship Thesis therapy. gastrohep.2017.04.007] Rev Esp Enferm Dig. 2017;109:17-25. 1. Carlos Rodríguez De Lope López. F.I.:1,401. [doi:10.17235/ 40. Martín-Llahí M, Albillos A, Evaluación y optimización del reed.2016.4235/2016] Bañares R, Berzigotti A, García- tratamiento de los tumores 115
hepáticos primarios de pequeño 4. Javier Crespo García. la hipertensión portal en cirrosis tamaño (< 2 cm). Personalized Medicine in HCV compensada mediante el uso Director/es: Jordi Bruix, Alejandro infection: understanding and de vasodilatadores hepáticos Forner Gonzalez. UNIVERSIDAD DE predicting hepatic and systemic selectivos. BARCELONA. responses in the era of the new SIMPRO 2010. INSTITUT DE antiviral drugs. PIE15/00079. RECERCA DE L´HOSPITAL DE LA 2. María Teresa Arias Loste. INSTITUTO DE SALUD CARLOS SANTA CREU I SANT PAU. Enfermedad hepática por III. MINISTERIO DE ECONOMÍA Y depósito de grasa no alcohólica: COMPETITIVIDAD. 4. Javier Cespo García. mecanismos inmunológicos, Registro del seguimiento a largo genéticos y metabólicos implicados 5. Javier Cespo García. plazo de sujetos que lograron una en su etiopatogenia. Characterization of direct antiviral respuesta virológica sostenida Director/es: Marcos López agents (DAAs) treatment failure. al tratamiento en los ensayos Hoyos, Emilio Fábrega García. A therapeutic approach to HCV promovidos por Gilead en sujetos UNIVERSIDAD DE CANTABRIA. based on personalized medicine. con infección por hepatitis C GILEAD16/13. GILEAD SCIENCES, S.L. crónica. Thesis Addressed GS-US-248-0122. GILEAD 6. José Pedro Vaqué Díez. Nuevos SCIENCES, INC. mecanismos en cánceres 1. Blanca Sampedro Andrada. agresivos de la piel: Aplicaciones 5. Javier Cespo García. Implementación de una aplicación al diagnóstico, pronóstico y terapia Estudio fase 3 de daclatasvir en en el sistema de prescripción de melanoma resistente a terapia combinación con peginterferón electrónica del humv para y carcinoma de células de Merkel. lambda 1a y ribavirina (RBV) o incrementar el cribado VHB Y VHC. PI16/00156. telaprevir en combinación con Director/a: Javier Crespo García. INSTITUTO DE SALUD CARLOS peginterferón alfa-2a y RBV en UNIVERSIDAD DE CANTABRIA. III. MINISTERIO DE ECONOMÍA Y pacientes con hepatitis C crónica COMPETITIVIDAD. con genotipo 1b que no han recibido tratamiento previo o recidivantes previos al tratamiento Clinical Trials con alfa/RBV. • PROJECTS AI452-021. BRISTOL-MYERS SQUIBB 1. Antonio Cuadrado Lavín. INTERNATIONAL CORPORATION Projects Ensayo clínico unicéntrico, (BMSIC). simple ciego y aleatorizado de comparación de la eficacia 6. Javier Cespo García. 1. Antonio Cuadrado Lavín. erradicadora de primera línea Ensayo clínico aleatorizado de Terapia erradicadora de primera frente a Helicobacter pylori entre fase III para evaluar la eficacia línea de la infección por la triple terapia convencional oral y la seguridad del régimen en Helicobacter Pylori: Ensayo clínico con claritromicina, amoxicilina y combinación de MK 5172/MK 8742 abierto, randomizado, multicéntrico omeprazol (CAO) durante 10 días en sujetos que han presentado de tres brazos comparando la triple frente a triple terapia alternativa fracaso con un tratamiento previo terapia clásica frente a una terapia oral con levofloxacino, con interferón pegilado y ribavirina secuencial modificada y una terapia amoxicilina y omeprazol (LAO) (P/R) con infección crónica por el concomitante. durante 10 días. VHC GT1, GT4, GT5 y GT6. 5172- EC11-528. MINISTERIO DE HPL08001HCLAD. HOSPITAL DE 068. SANIDAD Y CONSUMO. LAREDO. MERCK, SHARP&DOHME CORP. (MERCK). 2. María Teresa Arias Loste. 2. Montserrat Rivero Tirado. Implicación de diferentes Estudio de Fase III, de grupos 7. Javier Cespo García. factores de la inmunidad innata y paralelos, controlado con placebo, Estudio abierto y multicéntrico para adaptativa en la etiopatogenia de la doble ciego, aleatorizado, evaluar los resultados a largo plazo enfermedad hepática por depósito multicéntrico, internacional, para con ABT 450/ritonavir/ABT 267 graso en pacientes con obesidad investigar la seguridad y eficacia (ABT 450/r/ABT 267) y ABT 333 con mórbida. FEAD12/08. FUNDACION de los comprimidos de liberación o sin ribavirina (RBV) en adultos ESPAÑOLA DEL APARATO modificada de propionil-L-carnitina con infección crónica por el virus DIGESTIVO “FEAD”. clorhidrato (ST 261) en pacientes de la hepatitis C (VHC) de genotipo afectados por colitis ulcerosa leve 1 (TOPAZ I). 3. Javier Crespo García. bajo tratamiento oral estable. M14-423. ABBVIE DEUTSCHLAND Disfunción endotelial, ateromatosis ST261 DM 11 006. SIGMA-TAU GMBH&CO K.G. subclínica y miocardiopatía en INDUSTRIE FARMACEUTICHE pacientes con infección por RIUNITE S.P.A. 8. Javier Cespo García. VHC. Caracterización y potencial Ensayo clínico de fase II, aleatorizado reversibilidad con agentes 3. Joaquín de la Peña García. y abierto para estudiar la eficacia y antivirales directos. PI15/02138. Estudio multicéntrico, la seguridad de la combinación de INSTITUTO DE SALUD CARLOS aleatorizado, doble-ciego, MK-5172 y MK-3682 con MK-8742 III. MINISTERIO DE ECONOMÍA Y controlado con placebo, para la o MK-8408 en sujetos con infección COMPETITIVIDAD. prevención de la progresión de crónica por el VHC de GT1, GT2 y Activity Research areas Report Organ Transplants and Tissue and New Therapies Area
GT4. MK3682-011. 14. Javier Cespo García. GS-US-384-1944. GILEAD MERCK, SHARP&DOHME CORP. Estudio de fase II, abierto, SCIENCES, INC. (MERCK). multicéntrico, aleatorizado para evaluar la eficacia y seguridad 20. Javier Cespo García. 9. Javier Cespo García. de la combinación a dosis fija Estudio de fase III, aleatorizado, Estudio de Seguimiento a Largo (CDF) de sofosbuvir/velpatasvir y doble ciego, controlado con Plazo para Evaluar la Durabilidad la CDF de sofosbuvir/velpatasvir placebo para evaluar la seguridad y de la Respuesta Virológica y/o los más ribavirina en pacientes con eficacia de selonsertib en pacientes Patrones de Resistencia Viral de infección crónica por el VHC de con esteatohepatitis no alcohólica Sujetos con Hepatitis C Crónica genotipo 3 y cirrosis. (EHNA) y fibrosis en puentes (F3). que Han sido Tratados Previamente GS-US-342-2097. GILEAD GS-US-384-1943. GILEAD con MK-5172 en un Ensayo Clínico SCIENCES, INC. SCIENCES, INC. Previo. 5172-017. MERCK, SHARP&DOHME 15. Javier Cespo García. 21. Javier Cespo García. CORP. (MERCK). Ensayo multicentrico, aleatorizado, Ensayo fase II, multicéntrico, doble doble ciego y controlado con ciego, aleatorizado, de grupos 10. Javier Cespo García. placebo para evaluar emricasán (idn paralelos y controlado con placebo Estudio Fase 3, multicéntrico, 6556), un inhibidor de la caspasade para investigar la seguridad, abierto, con una sola rama de administración oral, en sujetos con tolerabilidad, farmacodinámica y tratamiento para investigar la fibrosis por esteatohepatitis no farmacocinética de distintas dosis eficacia y seguridad de un régimen alcohólica (ehna). orales de BI 1467335 durante de tratamiento de 12 semanas IDN-6556-12. PPD GLOBAL LTD. 12 semanas de tratamiento, en de Simeprevir en combinación comparación con placebo en con Sofosbuvir en pacientes con 16. Javier Cespo García. pacientes con evidencia clínica de infección crónica por el virus Ensayo multicéntrico, aleatorizado, EHNA. de la hepatitis C de genotipo 4, doble ciego y controlado con 1386.4. BOEHRINGER INGELHEIM que no han recibido tratamiento placebo para evaluar emricasán, ESPAÑA, S.A.. previo o previamente tratados. un inhibidor de la caspasa de TMC435HPC3021. JANSSEN R&D administración oral, en sujetos con Postmarketing Studies IRELAND. cirrosis por esteatohepatitis no and Other alcohólica (EHNA) e hipertensión 11. Javier Cespo García. portal grave. 1. Montserrat Rivero Tirado. Ensayo de eficacia, IDN-6556-14. PPD GLOBAL LTD. Registro no intervencionista inmunogenicidad y seguridad de la de larga duración para evaluar vacuna de toxoides de Clostridium 17. Javier Cespo García. la seguridad y la efectividad difficile en sujetos en riesgo de Estudio de fase III, multicéntrico, de HUMIRA® (adalimumab) en desarrollar infección por C. difficile. aleatorizado, doble ciego, pacientes con colitis ulcerosa (CU) H-030-014. controlado con placebo para moderada activa o muy activa evaluar la eficacia y seguridad (LEGACY). ABB-ADA-2013-01. 12. Javier Cespo García. de Elafibranor en pacientes con ABBVIE SPAIN, S.L.U. Estudio de fase 3, multicéntrico, esteatohepatitis no alcohólica aleatorizado, con doble (EHNA) y fibrosis. 2. Montserrat Rivero Tirado. enmascaramiento, a largo plazo GFT505-315-1. Estudio observacional y controlado con placebo para postautorización de seguridad ... evaluar la seguridad y la eficacia 18. Javier Cespo García. of Golimumab in UC Using the del ácido obeticólico en sujetos con Investigación sobre la eficacia y Spanish ENEIDA Registry. esteatohepatitis no alcohólica. la seguridad de tres niveles de MK8259-042-00. 747-303. INTERCEPT dosis de semaglutida subcutánea PHARMACEUTICALS INC.. administrada una vez al día frente a placebo en sujetos con 13. Javier Cespo García. esteatohepatitis no alcohólica. Estudio fase I, doble ciego, Ensayo clínico de 72 semanas de aleatorizado, controlado con duración, aleatorizado, doble-ciego, placebo, de primera controlado con placebo, con tres administración en humanos de grupos paralelos, multicéntrico, JNJ-56136379 administrado vía multinacional. oral para examinar la seguridad, NN9931-4296. NOVO NORDISK tolerabilidad y farmacocinética PHARMA, S.A.. tras dosis únicas ascendentes y un régimen de dosis múltiple en 19. Javier Cespo García. voluntarios sanos (Parte I), y tras Estudio en fase III, aleatorizado, varios regímenes de dosis múltiple doble ciego y controlado con en sujetos con hepatitis B crónica placebo para evaluar la seguridad (Parte II). y la eficacia de selonsertib en 56136379HPB1001. pacientes con cirrosis compensada JANSSEN SCIENCES IRELAND UC.. debida a esteatohepatitis no alcohólica (EHNA). 117 Activity Research areas Report Organ Transplants and Tissue and New Therapies Area
Group Responsible Carlos • Haematologic Neoplasms Richard Espiga and Haematopoietic Stem Hematology Service University Hospital Cells Transplantation Marqués de Valdecilla University of Cantabria
María Aránzazu Bermúdez Rodríguez Sara Bravo Navas Mª de Las Mercedes Colorado Araujo Sonia González De Villambrosía Pellón Andrés Insunza Gaminde Mónica López Duarte Guillermo Martín Sánchez Carmen Montes Gaisán Javier Núñez Céspedes Carlos Richard Espiga Consolidated group Iñigo Romón Alonso Miriam Sánchez Escamilla Lucrecia Yáñez San Segundo Researchers Carlos Pipaón González Nurses María del Carmen Contributors García Casquero Cristina Amunárriz Águeda José Luis Arroyo Rodríguez Technicians María Ana Batlle López María Pilar González Echezarreta
Chronic lymphatic leukemia: analysis Research on treatment regimens Research of post-transduction modifications, in patients with newly diagnosed prognostic value study and therapeutic myeloma as well as application of new lines applications. Study of resistance to drugs in multiple myeloma in refractory purine analogs mediated by kinases. relapse. Phase III trials
Line 1. Cellular biology of Molecular biology and genetics of SMD: Application of new treatment regimens hemopathies prospective tracking of alterations in the in patients with elderly myeloblastic FA-BRACA pathway. leukemia. Phase III trials Prognostic significance of BCL6 and MYC expression in lymphomas. The LIne 2. diagnostic and therapeutic Application of new treatment regimens expression of MYC and BCL6 seems innovation including proteosome inhibitors, to have a prognostic and therapeutic monoclonal antibodies and liposomal importance in NHL. This line is being Research on the application of new formulations in lymphoid pathology. developed in collaboration with the drugs in relapsed / refractory chronic group of Pathological Anatomy and lymphatic leukemia or with high-risk Clinical application of immunotherapy group of Molecular Biology of Faculty of cytogenetic alterations (17p13 and / or with lymphocytes with modified Medicine of UC of Cantabria. 11q23). Phase II and Phase III trials. T receptor (CAR-T) in lymphoid 119
neoplasms, cells mesenchymal for for Blood and Marrow Transplantatio. Transplantation the treatment of GVHD of allogeneic Post-Transplantation Group. Clin Infect Dis. 2017;65:1819-1828. transplantation and Cell populations Cyclophosphamide-Based F.I.:8,216. [doi:10.1093/cid/cix646] against CMV and EBV viruses Haploidentical Transplantation as Alternative to Matched Sibling or 5. Asensio E, López-Hoyos M, Line 3. transplantation of Unrelated Donor Transplantation Romón Í, Ontañón J, San Segundo D. hematopoyetic progenitors for Hodgkin Lymphoma: A Registry Assessment of Spanish Panel Study of the Lymphoma Working Reactive Antibody Calculator and Clinical results of allo-TPH in patients Party of the European Society for Potential Usefulness. with different neoplastic pathologies Blood and Marrow Transplantation. Front Immunol. 2017;8:540-540. J Clin Oncol. 2017;35:3425-3432. F.I.:6,429. [doi:10.3389/ Extracorporeal phototherapy as F.I.:24,008. [doi:10.1200/ fimmu.2017.00540] treatment of acute or chronic steroid- JCO.2017.72.6869] resistant CHF. 6. Rubio MT, D’Aveni-Piney M, 2. Salar A, Domingo-Domenech Labopin M, Hamladji RM, Sanz MA, Investigate the usefulness of the CMN E, Panizo C, Nicolás C, Bargay J, Blaise D, Ozdogu H, Daguindeau infusion of the patient treated with Muntañola A, Canales M, Bello JL, E, Richard C, Santarone S, Irrera G, metopsi-psoralen and submitted to Sancho JM, Tomás JF, Rodríguez Yakoub-Agha I, Yeshurun M, Diez- extracorporeal phototherapy. MJ, Peñalver J, Grande C, Sánchez- Martin JL, Mohty M, Savani BN, Blanco JJ, Palomera L, Arranz Nagler A. Cooperative clinical research on TCPH. R, Conde E, García M, García JF, Impact of in vivo T cell depletion Our casuistry is incorporated into Caballero D, Montalbán C. in HLA-identical allogeneic stem national and international databases, Long-term results of a phase 2 study cell transplantation for acute allowing a large number of cases to be of rituximab and bendamustine for myeloid leukemia in first complete accumulated for retrospective studies. mucosa-associated lymphoid tissue remission conditioned with a lymphoma. fludarabine iv-busulfan myeloablative Investigation on the application of Blood. 2017;130:1772-1774. regimen: a report from the EBMT specific anti-CMV vaccine in patients F.I.:13,164. [doi:10.1182/ Acute Leukemia Working Party. J with hematopoietic allograft to reduce blood-2017-07-795302] HEMATOL ONCOL. complications associated with it. Phase 2017;10:31-31. III trial. 3. Curiel-Olmo S, Mondejar R, F.I.:6,350. [doi:10.1186/s13045-016- Almaraz C, Mollejo M, Cereceda L, 0389-4] Study of different modalities of Marès R, Derdak S, Campos-Martin immunosuppression, including post- Y, Batlle A, Gonzalez de Villambrosía 7. Montes-Moreno S, Martinez- transplant cyclophosphamide in high- S, Gut M, Blanc J, Traverse-Glehen Magunacelaya N, Zecchini-Barrese T, risk allogeneic transplantation. A, Verney A, Baseggio L, Camacho Gonzalez de Villambrosía S, Linares FI, Wotherspoon A, Stamatopoulos E, Ranchal T, Rodriguez-Pinilla M, K, Xochelli A, Papadaki T, Kanellis Batlle A, Cereceda-Company L, G, Ponzoni M, Garcia-Cosio M, Revert-Arce JB, Almaraz C, Piris MA. Vaque JP, Beltran S, Gut I, Piris MA, Plasmablastic lymphoma phenotype Martinez N. is determined by genetic alterations Splenic diffuse red pulp small B-cell in MYC and PRDM1. lymphoma displays increased Mod Pathol. 2017;30:85-94. expression of cyclin D3 and F.I.:5,728. [doi:10.1038/ recurrent CCND3 mutations. modpathol.2016.162] Blood. 2017;129:1042-1045. 8. Alonso-Álvarez S, Magnano L, F.I.:13,164. [doi:10.1182/ Alcoceba M, Andrade-Campos • PUBLICATIONS: blood-2016-11-751024] M, Espinosa-Lara N, Rodríguez G, Mercadal S, Carro I, Sancho JM, 4. Averbuch D, Tridello G, Hoek J, Moreno M, Salar A, García-Pallarols F, IMPACT FACTOR | 160,6 Mikulska M, Akan H, Yanez San Arranz R, Cannata J, Terol MJ, Teruel Segundo L, Pabst T, Özçelik T, AI, Rodríguez A, Jiménez-Ubieto A, Klyasova G, Donnini I, Wu D, Gülbas González de Villambrosia S, Bello JL, Z, Zuckerman T, Botelho de Sousa López L, Monsalvo S, Novelli S, de Original articles A, Beguin Y, Xhaard A, Bachy E, Cabo E, Infante MS, Pardal E, García- Ljungman P, de la Camara R, Rascon Álvarez M, Delgado J, González M, J, Ruiz Camps I, Vitek A, Patriarca F, ..., Caballero MD. 1. Martínez C, Gayoso J, Canals Cudillo L, Vrhovac R, Shaw PJ, Wolfs Risk of, and survival following, C, Finel H, Peggs K, Dominietto A, T, O’Brien T, Avni B, ..., Cesaro S. histological transformation in Castagna L, Afanasyev B, Robinson Antimicrobial Resistance in follicular lymphoma in the rituximab S, Blaise D, Corradini P, Itälä-Remes Gram-Negative Rods Causing era. A retrospective multicentre M, Bermúdez A, Forcade E, Russo Bacteremia in Hematopoietic study by the Spanish GELTAMO D, Potter M, McQuaker G, Yakoub- Stem Cell Transplant Recipients: group. Agha I, Scheid C, Bloor A, Montoto Intercontinental Prospective Study Br J Haematol. 2017;178:699-708. S, Dreger P, Sureda A, Lymphoma of the Infectious Diseases Working F.I.:5,670. [doi:10.1111/bjh.14831] Working Party of the European Group Party of the European Bone Marrow Activity Research areas Report Organ Transplants and Tissue and New Therapies Area
9. Montalbán C, Díaz-López A, Am J Hematol. 2017;92: 16. Cabrero M, Martin A, Briones J, Dlouhy I, Rovira J, Lopez-Guillermo F.I.:5,275. [doi:10.1002/ajh.24813] Gayoso J, Jarque I, López J, Grande A, Alonso S, Martín A, Sancho JM, C, Heras I, Arranz R, Bernal T, Perez- García O, Sánchez JM, Rodríguez 13. Puiggros A, Collado R, Calasanz Lopez E, López-Godino O, Conde E, M, Novelli S, Salar A, Gutiérrez MJ, Ortega M, Ruiz-Xivillé N, Rivas- Caballero D. A, Rodríguez-Salazar MJ, Bastos Delgado A, Luño E, González T, Phase II Study of Yttrium-90- M, Domínguez JF, Fernández R, Navarro B, García-Malo M, Valiente Ibritumomab Tiuxetan as Part of Gonzalez de Villambrosia S, Queizan A, Hernández JÁ, Ardanaz MT, Piñan Reduced-Intensity Conditioning (with JA, Córdoba R, de Oña R, López- MÁ, Blanco ML, Hernández-Sánchez Melphalan, Fludarabine ± Thiotepa) Hernandez A, Freue JM, Garrote M, Batlle-López A, Salgado R, Salido for Allogeneic Transplantation in H, López L, Martin-Moreno AM, M, Ferrer A, Abrisqueta P, Gimeno E, Relapsed or Refractory Aggressive B Rodriguez J, Abraira V, ..., Abella E, Ferrá C, Terol MJ, Ortuño F, Cell Lymphoma: A GELTAMO Trial. GELTAMO-IPI Project Costa D, Moreno C, Carbonell F, ..., Biol Blood Marrow Transplant. Investigators. Espinet B. 2017;23:53-59. Validation of the NCCN-IPI for diffuse Patients with chronic lymphocytic F.I.:4,704. [doi:10.1016/j. large B-cell lymphoma (DLBCL): the leukemia and complex karyotype bbmt.2016.10.003] addition of 2 -microglobulin yields a show an adverse outcome even more accurate GELTAMO-IPI. in absence of TP53/ATM FISH 17. Robin M, Porcher R, Zinke- Br J Haematol. 2017;176:918-928. deletions. Cerwenka W, van Biezen A, Volin L, F.I.:5,670. [doi:10.1111/bjh.14489] Oncotarget. 2017;8:54297-54303. Mufti G, Craddock C, Finke J, Richard F.I.:5,168. [doi:10.18632/ C, Passweg J, Peniket A, Maertens 10. Sánchez-Carrera D, Bravo-Navas oncotarget.17350] J, Sucak G, Gedde-Dahl T, Vitek A, S, Cabezón E, Arechaga I, Cabezas Nagler A, Blaise D, Beelen D, Maillard M, Yáñez L, Pipaón C. 14. Heidenreich S, Ziagkos D, de N, Schwerdtfeger R, de Witte T, Fludarabine resistance Wreede LC, van Biezen A, Finke Kroger N. mediated by aminoglycoside-3’- J, Platzbecker U, Niederwieser D, Allogeneic haematopoietic stem cell phosphotransferase-IIa and the Einsele H, Bethge W, Schleuning transplant in patients with lower structurally related eukaryotic cAMP- M, Beelen DW, Tischer J, Nagler A, risk myelodysplastic syndrome: a dependent protein kinase. Glass B, Maertens J, Yáñez L, Beguin retrospective analysis on behalf of FASEB J. 2017;31:3007-3017. Y, Sill H, Scheid C, Stelljes M, Ganser the Chronic Malignancy Working F.I.:5,498. [doi:10.1096/ A, Zachée P, Selleslag D, de Witte T, Party of the EBMT. fj.201601245R] Robin M, Kröger N. Bone Marrow Transplant. Allogeneic Stem Cell Transplantation 2017;52:209-215. 11. Baptista MJ, Granada I, for Patients Age = 70 Years with F.I.:3,874. [doi:10.1038/ Morgades M, Calasanz MJ, Canals Myelodysplastic Syndrome: A bmt.2016.266] J, Robles De Castro D, Luño E, Retrospective Study of the MDS Ruiz-Xivillé N, Rodríguez-Hernández Subcommittee of the Chronic 18. Kwon M, Bautista G, Balsalobre I, González T, Terol MJ, Valiente A, Malignancies Working Party of the P, Sánchez-Ortega I, Montesinos P, Ortuño F, Garcia-Malo MD, Piñan EBMT. Biol Blood Marrow Bermúdez A, de Laiglesia A, Herrera MÁ, Carla Oliveira A, Talavera M, Transplant. 2017;23:44-52. P, Martin C, Humala K, Zabalza A, Buño I, Batlle-López A, Moreno C, F.I.:4,704. [doi:10.1016/j. Torres M, Bento L, Corral LL, Heras I, Ferra C, Solé F. bbmt.2016.09.027] Serrano D, Buño I, Anguita J, Regidor Monosomal karyotype in chronic C, Duarte R, Cabrera R, Gayoso J, lymphocytic leukemia: Association 15. Jiménez-Ubieto A, Grande C, Diez-Martin JL. with clinical and biological Caballero D, Yáñez L, Novelli S, Haplo-Cord transplantation compared features and potential prognostic Hernández-Garcia MT, Manzanares to haploidentical transplantation with significance. M, Arranz R, Ferreiro JJ, Bobillo S, post-transplant cyclophosphamide in Am J Hematol. 2017;92: Mercadal S, Galeo A, Jiménez JL, patients with AML. F.I.:5,275. [doi:10.1002/ajh.24754] Moraleda JM, Vallejo C, Albo C, Pérez Bone Marrow Transplant. E, Marrero C, Magnano L, Palomera 2017;52:1138-1143. 12. Ramos F, Robledo C, Pereira L, Jarque I, Martínez-Sánchez P, F.I.:3,874. [doi:10.1038/bmt.2017.36] A, Pedro C, Benito R, de Paz R, Martín A, Coria E, López-Guillermo Del Rey M, Insunza A, Tormo M, A, Salar A, Lahuerta JJ, GELTAMO 19. Scheid C, de Wreede L, van Díez-Campelo M, Xicoy B, Salido (Grupo Español de Linfomas y Biezen A, Koenecke C, Göhring E, Sánchez-Del-Real J, Arenillas Trasplantes de Médula Ósea) G, Volin L, Maertens J, Finke J, L, Florensa L, Luño E, Del Cañizo Cooperative Stu. Passweg J, Beelen D, Cornelissen JJ, C, Sanz GF, Hernández-Rivas JM, Autologous Stem Cell Itälä-Remes M, Chevallier P, Russell Spanish Group for Myelodysplastic Transplantation for Follicular N, Petersen E, Milpied N, Richard Syndromes (GESMD).. Lymphoma: Favorable Long- Espiga C, Peniket A, Sierra J, Mufti G, Multidimensional assessment Term Survival Irrespective of Crawley C, Veelken JH, Ljungman P, of patient condition and Pretransplantation Rituximab Cahn JY, Alessandrino EP, de Witte T, mutational analysis in peripheral Exposure. Robin M, Kröger N. blood, as tools to improve outcome Biol Blood Marrow Transplant. Validation of the revised IPSS prediction in myelodysplastic 2017;23:1631-1640. at transplant in patients with syndromes: A prospective F.I.:4,704. [doi:10.1016/j. myelodysplastic syndrome/ study of the Spanish MDS bbmt.2017.05.021] transformed acute myelogenous group. leukemia receiving allogeneic stem 121
cell transplantation: a retrospective Cruz F, Morales A, Rodriguez-Salazar 29. García-Marco JA, Delgado J, analysis of the EBMT chronic MJ, Valiente S, Pérez-Ceballos E, de Hernández-Rivas JA, Ramírez Payer malignancies working party. Bone Oteyza JP, García-Sanz R, Hodgkin Á, Loscertales Pueyo J, Jarque I, Marrow Lymphoma Subcommittee of Spanish Abrisqueta P, Giraldo P, Martínez Transplant. 2017;52:1519-1525. Group of Lymphoma and Bone R, Yáñez L, Terol MJ, González F.I.:3,874. [doi:10.1038/ Marrow Trans. M, Bosch F, en nombre del Grupo bmt.2017.171] Comorbidities, not age, are Español de Leucemia Linfocítica predictive of survival after Crónica (GELLC). Update of the 20. Steegmann JL, Colomer D, autologous hematopoietic Grupo Español de Leucemia Gómez-Casares MT, García-Gutiérrez cell transplantation for relapsed/ Linfocítica Crónica clinical guidelines V, Ortí G, Ramírez-Payer A, Olavarria refractory Hodgkin’s lymphoma in of the management of chronic E, Vall-Llovera F, Giraldo P, Conde patients older than 50 years. lymphocytic leukemia. E, Vallansot R, López-Lorenzo JL, Ann Hematol. 2017;96:9-16. Med Clin (Barc). 2017;148: Palomera L, Álvarez-Larrán A, Conesa F.I.:3,083. [doi:10.1007/s00277-016- F.I.:1,125. [doi:10.1016/j. V, Bautista G, Casas L, Giles F, 2832-6] medcli.2016.12.030] Hochhaus A, Casado-Montero LF. An analysis of the kinetics of 24. Irure J, Asensio E, Rodrigo Reviews molecular response during the first E, Romón Í, Gómez J, Arias M, trimester of treatment with nilotinib López-Hoyos M, San Segundo D. in newly diagnosed chronic myeloid Improvement in the definition of 1. Conde Diez S, de Las Cuevas leukemia patients in chronic phase. anti-HLA antibody profile in highly Allende R, Conde García E. J Cancer Res Clin Oncol. sensitized patients. Current status of iron metabolism: 2017;143:2059-2066. PLoS One. 2017;12: Clinical and therapeutic implications. F.I.:3,503. [doi:10.1007/s00432-017- F.I.:2,806. [doi:10.1371/journal. Med Clin (Barc). 2445-z] pone.0171463] 2017;148:218-224. F.I.:1,125. [doi:10.1016/j. 21. Jiménez-Ubieto A, Grande C, 25. Santurtún A, Riancho JA, medcli.2016.10.047] Caballero D, Yáñez L, Novelli S, Arozamena J, López-Duarte M, Hernández MT, Manzanares M, Zarrabeitia MT. Arranz R, Ferreiro JJ, Bobillo S, Indel analysis by droplet digital Books and Book Chapters Mercadal S, Galego A, Jiménez JL, PCR: a sensitive method Moraleda JM, Vallejo C, Albo C, Pérez for DNA mixture detection and 1. Montes Moreno, Santiago, Mollejo E, Marrero C, Magnano L, Palomera chimerism analysis. Villanueva, Manuela, Fraga, Máximo, L, Jarque I, Coria E, Rodriguez A, Int J Legal Med. García, Juan Fernando, José Luis, Villar, Martín A, López-Guillermo A, Salar 2017;131:67-72.F.I.:2,382. Martinez, Antonio, Rodríguez Pinilla, A, Lahuerta JJ, GELTAMO (Grupo [doi:10.1007/s00414-016-1422-4] Socorro María, Mayordomo Aranda, Español de Linfomas y Trasplantes de Empar, Batlle López, María Ana, Médula Ósea) cooperative stu. 26. Santurtún A, Riancho JA, Rozman, María, García Sanz, Ramón. Progression-free survival at 2 Santurtún M, Richard C, Colorado Recomendaciones para el years post-autologous transplant: MM, García Unzueta M, Zarrabeitia estudio histopatológico, a surrogate end point for overall MT. Genetic DNA profile in urine and inmunohistoquimico, citogenético y survival in follicular lymphoma. hair follicles from patients who have molecular e informe diagnostico de Cancer Med. 2017;6:2766-2774. undergone allogeneic hematopoietic los procesos neoplasicos linfoides. F.I.:3,362. [doi:10.1002/cam4.1217] stem cell transplantation. Consenso SEAP_SEHH-GOTEL. SCI JUSTICE. 2017;57:336-340. Libro blanco de anatomía patológica 22. García-Noblejas A, Cannata- F.I.:1,992. [doi:10.1016/j. de la SEAP. 2017.65. Ortiz J, Conde E, González Barca scijus.2017.05.003] E, Gutiérrez N, Rojas R, Vidal MJ, Ramírez MJ, Jiménez-Ubieto A, 27. Romon I, Lozano M. García-Ruiz JC, Sancho JM, López A, Quality indicators for Transfusion • PROJECTS Ríos Rull P, Novelli S, Albo C, Debén Medicine in Spain: a survey among G, López-Guillermo A, Nicolás C, hospital transfusion services. González de Villambrosia S, Mercadal Blood Transfus. 2017;15:207-214. Projects S, Martín García-Sancho A, Arranz R. F.I.:1,607. [doi:10.2450/2016.0018-16] Autologous stem cell transplantation (ASCT) in patients with mantle cell 28. Monfá E, San Segundo D, San 1. Carlos Pipaón González. lymphoma: a retrospective study Millán JC, Sanabria J, Albines Z, Papel de la neddilación en Leucemia of the Spanish lymphoma group Rodrigo E, Romón I, Asensio E, Arias Linfática Crónica, su valor pronóstico (GELTAMO). M, López-Hoyos M. y aplicaciones terapéuticas. Ann Hematol. 2017;96:1323-1330. Intermediate steroid PI17/01688. Instituto de Salud F.I.:3,083. [doi:10.1007/s00277-017- withdrawal Carlos III. Ministerio de Economía y 2998-6] after renal transplantation Competitividad. and anti-HLA antibodies 23. Martínez C, Jorge AS, Pereira (HLA-Abs) development. Clinical Trials A, Moreno M, Núñez J, Gayoso J, Nefrologia. 2017;37:415-422. Gonzalez-Medina J, Revilla N, Sampol F.I.:1,183. [doi:10.1016/j. 1. Sonia González de Villambrosía A, Domingo-Domenech E, de la nefro.2017.02.002] Pellón. Activity Research areas Organ Transplants and Tissue and Report New Therapies Area
Estudio fase III, multicéntrico, candidata frente a Herpes Zóster gE/ (Vidaza®) frente a Fludarabina y abierto, aleatorizado de imatinib AS01B de GSK Biologicals cuando Citarabina (Esquema Fluga) en frente a nilotinib, en pacientes se administra por vía intramuscular pacientes ancianos con leucemia adultos con leucemia mieloide en una pauta de dos dosis a adultos mieloide aguda de nuevo crónica cromosoma Filadelfia receptores de trasplante autólogo diagnóstico. positivo (Ph+) en fase crónica (LMC- de progenitores hematopoyéticos FLUGAZA. FUNDACIÓN PETHEMA FC) de nuevo diagnóstico, versión (TPH). 115523 ZOSTER-002. HOSPITAL CLÍNICO SAN CARLOS, 19 de junio de 2007. Modificación GLAXOSMITHKLINE, S.A.. SERV. HEMATOLOGÍA. internacional nº 2 de 19 de junio de 2007,. CAMN107A2303. 6. CARMEN MONTES GAISÁN. 11. Lucrecia Yáñez San Segundo. NOVARTIS FARMACEUTICA, S.A.. Estudio fase III nacional, Estudio de fase 3, aleatorizado, multicéntrico, abierto, aleatorizado, multicéntrico y abierto para evaluar 2. Lucrecia Yáñez San Segundo. de tratamiento de inducción la no inferioridad de ACP 196 frente Estudio Fase III, abierto, con bortezomib/ lenalidomida/ a Ibrutinib en sujetos con leucemia multicéntrico, aleatorizado, de tres dexametasona (VRD-GEM), seguido linfocítica crónica de alto riesgo brazos para comparar la eficacia de altas dosis de quimioterapia con tratados previamente. y la seguridad de RO5072759 + melfalán-200 (MEL-200) vs. busulfán- ACE-CL-006. ACERTA PHARMA, BV.. clorambucilo (GClb), rituximab + melfalán (BUMEL) y consolidación clorambucilo (RClb) o clorambucilo con VRD-GEM para pacientes con 12. Lucrecia Yáñez San Segundo. (Clb) en monoterapia en pacientes mieloma múltiple sintomático de Estudio de fase 3, aleatorizado, con comorbilidades y LLC no nuevo diagnóstico menores de multicéntrico, abierto, con tres tratados previamente. BO21004. 65 años. GEM2012MENOS65. grupos, de Obinutuzumab en ROCHE FARMA, S.A.U.. FUNDACIÓN PETHEMA HOSPITAL combinación con Clorambucilo, CLÍNICO SAN CARLOS, SERV. ACP 196 en combinación con 3. María Aránzazu Bermúdez HEMATOLOGÍA. Obinutuzumab y ACP 196 en Rodríguez. monoterapia, en sujetos con Estudio de fase III, multicéntrico, 7. María Aránzazu Bermúdez leucemia linfocítica crónica sin aleatorizado, abierto, para comparar Rodríguez. tratamiento previo. la eficacia y seguridad de la Estudio de fase 3 aleatorizado, doble ACE-CL-007. ACERTA PHARMA, BV.. Pomalidomida en combinación con ciego y controlado con placebo dosis bajas de Dexametasona frente para evaluar la eficacia protectora 13. Lucrecia Yáñez San Segundo. a dosis altas de Dexametasona y la seguridad de una vacuna A Phase 3 Randomized Study of the en pacientes con Mieloma terapéutica, ASP0113, en receptores Efficacy and Safety of Posaconazole múltiple Refratario o Recidivante y seropositivos para el citomegalovirus versus Voriconazole for the Refractario, Vs. de 15 de octubre (CMV) sometidos a alotrasplante de Treatment of Invasive Aspergillosis de 2010, incluyendo los cambios células hematopoyéticas (ATCH). in Adults and Adolescents (Phase 3; implentados con la enmienda 1, 0113-CL-1004. Protocol No. MK-5592-069). HIP y CI para Espeña, Vs de 14 de ASTELLAS PHARMA GLOBAL 5592-069. MERCK, diciembre de 2010, basaso en la Vs DEVELOPMENT, INC. SHARP&DOHME CORP. maestra inglesa de 15 de octubre de (MERCK). 2010. CC-4047-MM-003. 8. María Ana Batlle López. CELGENE CORPORATION. Estudio fase II aleatorizado y 14. Mª de las Mercedes Colorado multicéntrico de dos brazos de Araujo. 4. María Aránzazu Bermúdez tratamiento (R-COMP versus Estudio de fase III, doble ciego, Rodríguez. R-CHOP) en pacientes de edad controlado con placebo de Estudio Abierto, multicéntrico, avanzada (>60años) con /infama quizartinib (AC220) administrado de grupo único, para estudiar difuso de células B grandes en combinación con quimioterapia la seguridad y eficacia de (LDCBG)/Linfoma folicular grado IIIb de inducción y consolidación, y Pomalidomida (cc-4047) en no localizado de nuevo diagnóstico. administrado como terapia de monoterapia en pacientes con GEL-R-COMP-2013. DYNAMIC mantenimiento a sujetos de 18 a 75 mieloma múltiple refractario o SCIENCE, S.L.. años con leucemia mielógena aguda recidivante y refractario, Vs. de 15 FLT3-ITD (+) de nuevo diagnóstico de octubre de 2010, incluyendo 9. Lucrecia Yáñez San Segundo. (QuANTUM First). los cambios implentados con la Estudio de fase 3, aleatorizado, AC220-A-U302. DAIICHI SANKYO, enmienda 1, HIP y CI para Espeña, doble ciego, controlado con INC. Vs de 14 de diciembre de 2010, placebo, en el que se evalúa la basaso en la Vs maestra inglesa de eficacia y seguridad de idelalisib 15. María Aránzazu Bermúdez 15 de octubre de 2010. CC-4047- en combinación con bendamustina y Rodríguez. MM-003/C. rituximab, en pacientes con Estudio de fase 2, aleatorizado, con CELGENE CORPORATION. leucemia linfocítica crónica doble enmascaramiento y controlado previamente sin tratar. con placebo para evaluar la eficacia 5. Lucrecia Yáñez San Segundo. GS-US-312-0123. GILEAD y la tolerabilidad del Entospletinib, Ensayo clínico fase III, aleatorizado, SCIENCES, INC. un inhibidor selectivo de SYK, en observador-ciego, controlado con combinación con corticoesteroides placebo, multicéntrico, para evaluar 10. Mª de las Mercedes Colorado sistémicos como tratamiento de la eficacia profiláctica, seguridad Araujo. primera línea en pacientes con e inmunogenicidad de la vacuna Aleatorizado, abierto de Azacitidina enfermedad crónica de injerto contra 123
huésped (EICHc). mielomonocítica crónica (LMMC), clínicos que conducen a la toma de GS-US-406-1840. GILEAD en función del momento de inicio de decisiones terapéuticas en pacientes SCIENCES, INC. tratamiento activo. con mielofibrosis.”. Estudio CEL-SMD-2012-01. CELGENE S.L.. TRATABILIDAD. GEM-MIE-2014-01. Postmarketing GRUPO ESPAÑOL Studies and Other 3. Carmen Montes Gaisán. DE ENFERMEDADES Registro observacional post- MIELOPROLIFERATIVAS CRÓNICAS 1. Mónica López Duarte. autorización para evaluar el impacto PH NEGATIVAS GEMFIN. Programa de Registro Europeo de clínico del inicio de la terapia Evoltra®: LLA pediátrica. antitumoral de rescate en pacientes 5. Andrés Insunza Gaminde. GEN-CLO-2010-01. GENZYME con mieloma múltiple (MM) en EPAS Estudio Post-autorización EUROPE, B.V.. recaída biológica asintomática de seguridad (EPAS) prospectivo, frente al inicio del tratamiento en el no intervencionista, diseñado 2. Andrés Insunza Gaminde. momento de la recaída sintomática. como Registro de Enfermedad Estudio observacional post- CEL-MIE-2012-02. CELGENE S.L.. de pacientes con síndromes autorización para evaluar la mielodisplásicos (SMD) de bajo evolución en la práctica clínica 4. Sonia González de Villambrosía riesgo (IPSS bajo e intermedio-1) con habitual de pacientes recién Pellón. delección 5q aislada y dependencia diagnosticados de síndrome Estudio observacional prospectivo transfusional. CC-5013-MDS-010. mielodisplásico (SMD) o leucemia para identificar los aspectos CELGENE INTERNATIONAL SARL. Activity Research areas Report Organ Transplants and Tissue and New Therapies Area
Group Responsible Marcos López Hoyos Immunology Service • Transplantation and Marqués de Valdecilla Autoimmunity University Hospital
Juan Carlos Ruíz San Millán David San Segundo Arribas Mara Serrano Jorge Alberto Suárez Rodríguez Silvia Torices del Val Rosalia Valero San Cecilio Ana Victoria Villar Ramos
Consolidated group Nurses Mª Consuelo Agüeros Blanco Montserrat González García Raquel Pelayo Alonso Researchers María del Camino Lara Belmar Vega Villa Llamazares Manuel Antonio Arias Rodríguez Adalberto Benito Hernández María Eugenia Cuadrado Victor Manuel Martínez Taboada Gema Fernández Fresnedo Eduardo Miñambres García María Milagros Heras Vicario Predoctoral Emilio Rodrigo Calabia María Kislikova Luis Martin Penagos María Iglesias Escudero Contributors Ana Rosa Palanca Cuñado Lorena Álvarez Rodríguez Rosa Palomar Fontanet Technicians María De Los Ángeles Vicente Celestino Piñera Haces José Óscar García Ruíz Ballesteros Sanz Mª Ángeles Ramos Barrón Sandra Raso Torres Paloma Barreda Monteoliva Emilio Rodrigo Calabia María José Ortíz González
solid organ transplantation (rejection, Together with our own studies, we Research infection, immunosuppression participated in REDINREN (Research conversion, short-term and long- Network on Renal Diseases: RD16 lines term graft survival). This line focuses / 0009/027). At the same time, on soluble and cellular markers we have transferred the study of related to the immune response in biomarkers to lung transplantation Line 1: transplantation of solid allotransplantation and more recently. since it is a very potent clinical activity organs In addition, we included the study in our center, which has already of molecular profiles predictive allowed us to obtain results quickly, 1. Non-invasive blood and urine of failure of renal function and which have demonstrated specific biomarkers of clinical events related to increase of fibrosis in initial stages. differences between kidney and lung 125
transplantation. Soluble markers of funding from the Mutua Madrileña nanosensors as a tool in the diagnosis humoral rejection. This line of research Foundation. of patients with systemic diseases has made it possible to transfer to of unknown etiology such as the clinic the monitoring of anti- Line 2: inflammation and scleroderma. We intend to perform HLA antibodies in desensitization autoimmune diseases the concept test, implementation and treatments in renal transplants of tuning of the prototype diagnostic test patients hypersensitized with live 1. Inflammatory diseases associated plate for its application in the clinical donors. Thanks to this line, our center with aging (giant cell arteritis, environment. attracts patients from other regions polymyalgia rheumatica and and has allowed us to be part of the rheumatoid arthritis of onset in the national cross-renal donation program. elderly). These syndromes, which This line of work is also included in are very prevalent in the elderly the REDINREN program and we lead population, are mainly treated within the network. We consider this with corticosteroids, which are line one of the greatest potential of accompanied by a high toxicity. clinical transference. Studies investigate the role of cytokines, regulatory cells and 2. Immunoregulation in kidney and alterations of innate immunity, with lung transplantation. To evaluate the ultimate goal of developing less the effect that changes in blood and toxic and more effective therapies. tissues of cellular populations with We used cellular markers (phenotypic immunoregulatory capacity may and functional), serological and have on the long-term evolution genetic (expression and genetic of the transplant in general and of polymorphisms). More recently we • PUBLICATIONS: the renal in particular. In the case have started a line of work on arthritis of renal transplantation we have in connection with FIS-funded FG- IMPACT FACTOR | 116,026 found a clear influence of the level of beta signaling. pharmacological immunosuppression on the number and function of 2. Antiphospholipid syndrome. The regulatory T cells. In addition, in lung role that the innate immune response transplantation we have verified how (specifically the TLR) and the different Original articles a certain number of regulatory T cells immunoregulatory populations in blood prior to transplantation play may play in the pathogenesis of a prognostic role in the incidence this disease is studied. We also 1. Álvaro-Gracia JM, Jover JA, of rejection. This line together with analyzed the clinical results of the García-Vicuña R, Carreño L, Alonso the previous one receives regular Unit of Autoimmune Gravidarum A, Marsal S, Blanco F, Martínez- competitive financing from the ISCIII. Pathology and performed a beta Taboada VM, Taylor P, Martín-Martín study to evaluate new methods of C, DelaRosa O, Tagarro I, Díaz- 3. Intensive treatment of donors measurement of diagnostic antibodies González F. to increase the number of grafts in this pathology. In particular, we Intravenous administration of suitable for transplantation. Intensive are validating the usefulness of new expanded allogeneic adipose- treatment of multiorgan donors immunoglobulin isotypes (IgA) against derived mesenchymal stem cells based on specific ventilatory therapy, phospholipids as well as the value in refractory rheumatoid arthritis extrapulmonary water-guided of other antibodies against other (Cx611): results of a multicentre, hemodynamic goals, and hormone phospholipids not included in the dose escalation, randomised, single- therapy increases the number of diagnostic criteria so far. blind, placebo-controlled phase Ib/IIa transplant-able pulmonary grafts. clinical trial. This increase in the number of 3. Biomarkers. The group has a large Ann Rheum Dis. 2017;76:196-202. available pulmonary grafts is due library associated with clinical data F.I.:12,811. [doi:10.1136/ to the improvement in oxygenation collected since 1997. This library annrheumdis-2015-208918] of the lungs in the period between allows the study and validation death and organ harvesting. This of new markers involved in the 2. Talamillo A, Grande L, Ruiz- specific treatment is associated diagnosis, prognosis and response Ontañon P, Velasquez C, Mollinedo P, with an increase in the rest of to the treatment of autoimmune Torices S, Sanchez-Gomez P, Aznar organs to improve the perfusion and pathology. In addition, we have all A, Esparis-Ogando A, Lopez-Lopez oxygenation of all of them. the type of tests necessary for the C, Lafita C, Berciano MT, Montero development and serological studies JA, Vazquez-Barquero A, Segura V, The use of regional normothermic of autoimmunity. As a result of the Villagra NT, Pandiella A, Lafarga M, perfusion to deceased donors by exploitation of this library we have Leon J, Martinez-Climent JA, Sanz- circulatory criteria has allowed to defined new diagnostic uses of Moreno V, Fernandez-Luna JL. reduce the ischemic damage of antibodies not explored until now ODZ1 allows glioblastoma to the grafts due to the deleterious (anti-PR3) in pathologies such as sustain invasiveness through a effect of the cardiac arrest, and inflammatory bowel disease with Myc-dependent transcriptional to simultaneously extract and IDIVAL’s group of digestive pathology. upregulation of RhoA. successfully transplant all types of Oncogene. 2017;36:1733-1744. grafts (lungs, liver, Pancreas and Also using this library, we began to F.I.:7,519. [doi:10.1038/onc.2016.341] kidneys). Both lines of research have take the first steps in an ambitious developed multicentric studies with project that proposes the use of 3. Asensio E, López-Hoyos M, Activity Research areas Report Organ Transplants and Tissue and New Therapies Area
Romón Í, Ontañón J, San Segundo 8. Riancho-Zarrabeitia L, Daroca G, M, Calvo-Alén J, Fernández-Nebro D. Assessment of Spanish Panel Muñoz P, López-Hoyos M, Haya A, A, Alonso F, Rodríguez-Lozano B, Reactive Antibody Calculator and Martínez-Taboada VM. García Vadillo JA, Menor R, Narváez Potential Usefulness. Serological evolution in women with FJ, Erausquin C, García-Aparicio Á, Front Immunol. 2017;8:540-540. positive antiphospholipid antibodies. Tomero E, Manrique-Arija S, Horcada F.I.:6,429. [doi:10.3389/ Semin Arthritis Rheum. L, Uriarte E, Gil S, Blanco R, López- fimmu.2017.00540] 2017;47:397-402. González R, Boteanu A, Freire M, F.I.:4,498. [doi:10.1016/j. Galisteo C, Rodríguez-Gómez M, 4. Miñambres E, Suberviola B, semarthrit.2017.05.001] ..., SJOGRENSER and RELESSER Dominguez-Gil B, Rodrigo E, Ruiz- researchers and EAS-SER GROUP. San Millan JC, Rodríguez-San Juan 9. Lázaro-Díez M, Chapartegui- Comorbidities in Patients With JC, Ballesteros MA. González I, Redondo-Salvo S, Leigh Primary Sjögren’s Syndrome and Improving the Outcomes of Organs C, Merino D, Segundo DS, Navas J, Systemic Lupus Erythematosus: A Obtained From Controlled Donation Icardo JM, Acosta F, Ocampo-Sosa A, Comparative Registries-Based Study. After Circulatory Death Donors Martínez-Martínez L, Ramos-Vivas J. Arthritis Care Res (Hoboken). Using Abdominal Normothermic Human neutrophils phagocytose and 2017;69:38-45. Regional Perfusion. kill Acinetobacter baumannii and A. F.I.:3,319. [doi:10.1002/acr.23015] Am J Transplant. 2017;17:2165-2172. pittii. F.I.:6,165. [doi:10.1111/ajt.14214] Sci Rep. 2017;7:4571-4571. 14. Ballesteros MA, Chicote Álvarez F.I.:4,259. [doi:10.1038/s41598-017- E, Mora Cuesta VM. 5. Villares JMP, Rubio JJ, Río FD, 04870-8] An unusual case of Miñambres E. bronchoaspiration of a foreign body Validation of a new proposal to avoid 10. Domínguez-Gil B, Coll E, Elizalde J, in a polytraumatized patient. donor resuscitation in controlled Herrero JE, Pont T, Quindós B, Marcelo Arch Bronconeumol. donation after circulatory death with B, Bodí MA, Martínez A, Nebra A, 2017;53:398-398. normothermic regional perfusion. Guerrero F, Manciño JM, Galán J, F.I.:2,979. [doi:10.1016/j. RESUSCITATION. 2017;117:46-49. Lebrón M, Miñambres E, Matesanz R, arbres.2016.12.005] F.I.:5,230. [doi:10.1016/j. ACCORD-Spain study group. resuscitation.2017.05.030] Expanding the Donor Pool Through 15. Rello J, Bello I, de Vicente R, Intensive Care to Facilitate Organ Hermira Anchuelo A, Ballesteros MÁ, 6. Martin-Lorenzo M, Gonzalez- Donation: Results of a Spanish Iranzo R, Rellán L, Riera J, Robles JC, Calero L, Ramos-Barron A, Sanchez- Multicenter Study. EMPRET Study investigators. Niño MD, Gomez-Alamillo C, García- Transplantation. 2017;101: Risk Factors for Mortality in 272 Segura JM, Ortiz A, Arias M, Vivanco F.I.:3,678. [doi:10.1097/ Patients With Lung Transplant: A F, Alvarez-Llamas G. TP.0000000000001701] Multicenter Analysis of 7 Intensive Urine metabolomics insight into Care Units. acute kidney injury point to oxidative 11. Arias M, Serón D, Herrero I, Rush Arch Bronconeumol. stress disruptions in energy DN, Wiebe C, Nickerson PW, Ussetti 2017;53:421-426. generation and H 2 S availability. P, Rodrigo E, de Cos MA. F.I.:2,979. [doi:10.1016/j. J Mol Med (Berl). 2017;95:1399- Subclinical Antibody-Mediated arbres.2016.12.019] 1409. Rejection. F.I.:4,686. [doi:10.1007/s00109-017- Transplantation. 2017;101: 16. Torices S, Alvarez-Rodríguez L, 1594-5] F.I.:3,678. [doi:10.1097/ Varela I, Muñoz P, Balsa A, López- TP.0000000000001735] Hoyos M, Martinez-Taboada V, 7. Rúa-Figueroa Í, López-Longo J, Fernández-Luna JL. Galindo-Izquierdo M, Calvo-Alén 12. Carmona A, Agüera ML, Luna Evaluation of Toll-like-receptor J, Del Campo V, Olivé-Marqués A, Ruiz C, Buendia P, Calleros L, Garcia- gene family variants as prognostic Pérez-Vicente S, Fernández-Nebro Jerez A, Rodríguez-Puyol M, Arias M, biomarkers in rheumatoid arthritis. A, Andrés M, Erausquin C, Tomero Arias-Guillen M, de Arriba G, Ballarin J, Immunol Lett. 2017;187:35-40. E, Horcada L, Uriarte E, Freire M, Bernis C, Fernandez E, Garcia-Rebollo F.I.:2,860. [doi:10.1016/j. Montilla C, Sánchez-Atrio A, Santos S, Mancha J, Del Peso G, Perez E, Poch imlet.2017.04.011] G, Boteanu A, Díez-Álvarez E, E, Portoles JM, Rodriguez-Puyol D, Narváez J, Martínez-Taboada V, Silva- Sánchez-Villanueva R, Sarro F, Torres 17. Perrotti PP, Aterido A, Fernández- Fernández L, Ruiz-Lucea E, Andreu A, Martin-Malo A, Aljama P, Ramirez R, Nebro A, Cañete JD, Ferrándiz C, JL, Hernández-Beriain JÁ, Gantes M, Carracedo J. Tornero J, Gisbert JP, Domènech E, Hernández-Cruz B, Pérez-Venegas J, Markers of endothelial damage in Fernández-Gutiérrez B, Gomollón F, Pecondón-Español Á, ..., patients with chronic kidney disease García-Planella E, Fernández E, Sanmartí Pego-Reigosa JM. Incidence, on hemodialysis. R, Gratacós J, Martínez-Taboada VM, associated factors and clinical Am J Physiol Renal Physiol. Rodríguez-Rodríguez L, Palau N, Tortosa impact of severe infections in a 2017;312: R, Corbeto ML, Lasanta ML, Marsal S, large, multicentric cohort of patients F.I.:3,611. [doi:10.1152/ Julià A, IMID Consortium. with systemic lupus ajprenal.00013.2016] Genetic variation associated with erythematosus. cardiovascular risk in autoimmune Semin Arthritis Rheum. 13. Rúa-Figueroa I, de Castro diseases. 2017;47:38-45. MF, Andreu JL, Sanchez-Piedra PLoS One. 2017;12: F.I.:4,498. [doi:10.1016/j. C, Martínez-Taboada V, Olivé A, F.I.:2,806. [doi:10.1371/journal. semarthrit.2017.01.010] López-Longo J, Rosas J, Galindo pone.0185889] 127
18. Irure J, Asensio E, Rodrigo F.I.:2,153. [doi:10.1007/s40620-016- 2017;41:285-305. E, Romón Í, Gómez J, Arias M, 0355-9] F.I.:1,231. [doi:10.1016/j. López-Hoyos M, San Segundo D. medin.2017.03.004] Improvement in the definition of 23. González-López MA, Hernández anti-HLA antibody profile in highly JL, Vilanova I, Mata C, López-Escobar 28. Chico-Fernández M, Llompart- sensitized patients. M, González-Vela MC, López-Hoyos Pou JA, Sánchez-Casado M, PLoS One. 2017;12: M, González-Gay MA, Blanco R. Ballesteros-Sanz MÁ. F.I.:2,806. [doi:10.1371/journal. Thyroid autoimmunity in patients Severe traumatic disease register in pone.0171463] with hidradenitis suppurativa: a case- Spain. control study. Med Intensiva. 2017;41:324-325. 19. Suberviola B, Rellan L, Riera Clin Exp Dermatol. 2017;42:642-644. F.I.:1,231. [doi:10.1016/j. J, Iranzo R, Garcia Campos A, F.I.:1,589. [doi:10.1111/ced.13153] medin.2017.02.011] Robles JC, Vicente R, Miñambres E, Santibanez M. 24. Parker AR, Skold M, Ramsden 29. Belmar Vega L, Rodrigo Calabria Role of biomarkers in early DB, Ocejo-Vinyals JG, López-Hoyos E, Gutiérrez Fernández G, Casanova infectious complications after lung M, Harding S. Rituerto D, González Sánchez FJ, transplantation. The Clinical Utility of Measuring Armiñanzas Castillo C, Roiz Mesones PLoS One. 2017;12: IgG Subclass Immunoglobulins MP, Arias Rodriguez M. F.I.:2,806. [doi:10.1371/journal. During Immunological Investigation Actinomyces viscosus infection in a pone.0180202] for Suspected Primary Antibody kidney-pancreas trasplanted patient. Deficiencies. Nefrologia. 2017;37:431-432. 20. Torrente-Segarra V, Corominas Lab Med. 2017;48:314-325. F.I.:1,183. [doi:10.1016/j. H, Sánchez-Piedra C, Fernández- F.I.:1,265. [doi:10.1093/labmed/ nefro.2017.01.001] Castro M, Andreu JL, Martínez- lmx058] Taboada VM, Olivé A, Rosas J, 30. Monfá E, San Segundo D, San Sánchez-Alonso F, SJOGRENSER 25. Suberviola B, Rodrigo E, Millán JC, Sanabria J, Albines Z, Study Group of the Spanish Society González-Castro A, Serrano M, Heras Rodrigo E, Romón I, Asensio E, Arias of Rheumatology. Fibromyalgia M, Castellanos-Ortega Á. M, López-Hoyos M. prevalence and associated factors in Association between exposure to Intermediate steroid withdrawal primary Sjögren’s syndrome patients angiotensin-converting enzyme after renal transplantation and in a large cohort from the Spanish inhibitors and angiotensin receptor anti-HLA antibodies (HLA-Abs) Society of Rheumatology registry blockers prior to septic shock and development. (SJOGRENSER). Clin Exp Rheumatol. acute kidney injury. Nefrologia. 2017;37:415-422. 2017;35 Med Intensiva. 2017;41:21-27. F.I.:1,183. [doi:10.1016/j. Suppl 105:28-34.F.I.:2,634. F.I.:1,231. [doi:10.1016/j. nefro.2017.02.002] medin.2016.07.010] 21. Torrente-Segarra V, Salman 31. Belmar Vega L, de Francisco AL, Monte TC, Rúa-Figueroa I, 26. Domínguez-Gil B, Coll E, Pont Bada da Silva J, Galván Espinoza L, Sánchez-Alonso F, López-Longo FJ, T, Lebrón M, Miñambres E, Coronil Fernández Fresnedo G. Galindo-Izquierdo M, Calvo-Alén A, Quindós B, Herrero JE, Liébanas New oral anticoagulants in patients J, Olivé-Marqués A, Ibañez-Ruán C, Marcelo B, Sanmartín AM, with chronic kidney disease. J, Horcada L, Sánchez-Atrio A, Matesanz R, en representación Nefrologia. Montilla C, Melero González RB, del Consorcio ACCORD-España. 2017;37:244-252. Díez-Álvarez E, Martinez-Taboada V, End-of-life practices in patients with F.I.:1,183. [doi:10.1016/j. Andreu JL, Fernández-Berrizbeitia devastating brain injury in Spain: nefro.2016.08.006] O, Hernández-Beriain JÁ, Gantes implications for organ donation. M, Hernández-Cruz B, Pecondón- Med Intensiva. 2017;41:162-173. 32. Belmar L, López-Hoyos M, Irure Español Á, Marras C, Bonilla G, F.I.:1,231. [doi:10.1016/j. J, Rodrigo E, Martin de Francisco ÁL, Pego-Reigosa JM, RELESSER Study medin.2016.07.011] Fernández-Fresnedo G. Group of the Spanish Society of Paraneoplastic pauci-immune Rheumatology (SER) and the Study. 27. Hernández-Tejedor A, Peñuelas glomerulonephritis in a patient with Juvenile- and adult-onset systemic O, Sirgo Rodríguez G, Llompart-Pou lung carcinoma. lupus erythematosus: a comparative JA, Palencia Herrejón E, Estella A, Nefrologia. 2017;37:539-541. study in a large cohort from the Fuset Cabanes MP, Alcalá-Llorente F.I.:1,183. [doi:10.1016/j. Spanish Society of Rheumatology MA, Ramírez Galleymore P, Obón nefro.2016.10.012] Lupus Registry (RELESSER). Clin Exp Azuara B, Lorente Balanza JA, Rheumatol. Vaquerizo Alonso C, Ballesteros 33. Belmar Vega L, Fernández- 2017;35:1047-1055. Sanz MA, García García M, Caballero Díaz C, Palmou Fontana N, Rodrigo F.I.:2,634. López J, Socias Mir A, Serrano Calabia E, Martin Penagos L, Arias Lázaro A, Pérez Villares JM, Herrera- Rodríguez M, Fernández 22. Ballesteros MA, Duerto Álvarez Gutiérrez ME. Fresnedo G. J, Martín-Penagos L, Rodrigo E, Recommendations of the Working Pulmonary hemorrhage in a patient Arias M, Miñambres E. Influence Groups from the Spanish Society of with IgA nefropathy. of specific thoracic donor therapy Intensive and Critical Care Medicine Nefrologia. 2017;37:347-349. on kidney donation and long-term and Coronary Units (SEMICYUC) for F.I.:1,183. [doi:10.1016/j. kidney graft survival. the management of adult critically ill nefro.2016.12.001] J Nephrol. 2017;30:869-875. patients. Med Intensiva. Activity Research areas Report Organ Transplants and Tissue and New Therapies Area
34. Demetrio Pablo R, Muñoz P, RD12/0021/0007. con dos ramas de tratamiento para López-Hoyos M, Calvo V, Riancho L, INSTITUTO DE SALUD CARLOS investigar la función renal en un Martínez-Taboada VM. III. MINISTERIO DE ECONOMÍA Y régimen inmunosupresor basado Thrombocytopenia as a thrombotic COMPETITIVIDAD. en advagraf® con o sin sirolimus risk factor in patients with en pacientes receptores de un antiphospholipid antibodies without 2. Víctor Manuel Martínez Taboada. trasplante renal. PMR-EC-1212. disease criteria. Identificación de variantes génicas ASTELLAS PHARMA, S.A. Med Clin (Barc). 2017;148:394-400. relevantes de la vía de NFkB y sus F.I.:1,125. [doi:10.1016/j. consecuencias funcionales en 2. Juan Carlos Ruíz San Millán. medcli.2016.11.026] pacientes con artritis reumatoide. Tratamiento con inmunoglobulinas Influencia en el desarrollo y y rituximab en el rechazo crónico 35. Llompart-Pou JA, Chico- pronóstico de la enfermedad. humoral en el transplante: Estudio Fernández M, Sánchez-Casado M, FER13/13. FUNDACIÓN ESPAÑOLA multicéntrico, prospectivo, Salaberria-Udabe R, Carbayo-Górriz DE REUMATOLOGÍA F.E.R., randomizado y controlado con C, Guerrero-López F, González- FUNDACIÓN ESPAÑOLA DE placebo. Robledo J, Ballesteros-Sanz MÁ, REUMATOLOGÍA F.E.R.. TRITON. SERÓN MICAS, DANIEL. Herrán-Monge R, Servià-Goixart L, León-López R, Val-Jordán E. 3. Eduardo Miñambres García. 3. Gema Fernández Fresnedo. Scoring severity in trauma: Manejo del donante multiorgánico Ensayo multicéntrico internacional, comparison of prehospital scoring focalizado en el incremento de aleatorizado, doble ciego, con systems in trauma ICU patients. la donación pulmonar. Estudio grupos paralelos y controlado con Eur J Trauma Emerg Surg. multicéntrico. FMM13/06. placebo del efecto de atrasentan 2017;43:351-357. FUNDACIÓN MUTUA MADRILEÑA. sobre los resultados renales de F.I.:0,895. [doi:10.1007/s00068-016- INVESTIGACIÓN MÉDICA. sujetos con diabetes tipo 2 y 0671-8] nefropatía” SONAR: ensayo de 4. Manuel Antonio Arias Rodríguez. nefropatía diabética con atrasentan. Estudio de factores serológicos y M11-352. Reviews de activación celular como posibles ABBVIE INC. marcadores precoces del rechazo 1. Cappellini MD, Comin-Colet J, de crónico mediado por anticuerpos 4. Juan Carlos Ruíz San Millán. Francisco A, Dignass A, Doehner W, en trasplante renal. PI14/00378. Estudio multicéntrico, aleatorizado, Lam CS, Macdougall IC, Rogler G, INSTITUTO DE SALUD CARLOS abierto a 24 meses, sobre la Camaschella C, Kadir R, Kassebaum III. MINISTERIO DE ECONOMÍA Y seguridad y eficacia de everolimus NJ, Spahn DR, Taher AT, Musallam COMPETITIVIDAD. con control de la concentración KM, IRON CORE group. combinado con dosis reducida Iron deficiency across chronic 5. Marcos López Hoyos. de inhibidor de la calcineurina inflammatory conditions: Utilidad del estudio de las Células vs. micofenolato combinado con International expert opinion Mieloides Supresoras (MDSC) en la dosis estándar de inhibidor de la on definition, diagnosis, and monitorización del trasplante renal. calcineurina en trasplante renal de management. PI16/01585. novo - Avanzando en los resultados Am J Hematol. 2017;92:1068-1078. INSTITUTO DE SALUD CARLOS de eficacia y seguridad en trasplante F.I.:5,275. [doi:10.1002/ajh.24820] III. MINISTERIO DE ECONOMÍA Y renal con un régimen basado en COMPETITIVIDAD. everolimus. Estudio TRANSFORM. CRAD001A2433. Thesis Addressed 6. Victor Manuel Martínez Ttaboada. NOVARTIS FARMACEUTICA, S.A. Estudio del papel BAMBI, un 1. María Teresa Arias Loste. regulador de la señalización por 5. Gema Fernández Fresnedo. Enfermedad hepática por depósito TGFbeta, como factor patogénico Estudio aleatorizado, doble ciego, de grasa no alcohólica: mecanismos y marcador pronóstico en la artritis motivado por los acontecimientos, inmunológicos, reumatoide. PI16/01717. controlado con placebo y genéticos y metabólicos implicados INSTITUTO DE SALUD CARLOS multicéntrico, de los efectos de en su etiopatogenia. III. MINISTERIO DE ECONOMÍA Y la canagliflozina en los resultados Director/es: Marcos López Hoyos, COMPETITIVIDAD. renales y cardiovasculares en Emilio Fábrega García. sujetos con diabetes mellitus UNIVERSIDAD DE CANTABRIA. 7. Marcos López Hoyos. tipo 2 y nefropatía diabética. Red de Investigación de 28431754DNE3001. Enfermedades Renales. JANSSEN-CILAG INTERNATIONAL, NV. RD16/0009/0027. • PROJECTS INSTITUTO DE SALUD CARLOS Postmarketing III. MINISTERIO DE ECONOMÍA Y Studies and Other COMPETITIVIDAD. Projects Clinical Trials 1. Gema Fernández Fresnedo. Estudio multicéntrico, prospectivo, 1. Manuel Antonio Arias Rodríguez. observacional, para el análisis Red de Investigación en 1. Juan Carlos Ruíz San Millán. de factores de progresión de Enfermedades Renales. Estudio clínico abierto, multicéntrico, la enfermedad renal crónica 129
en pacientes diabéticos vs no 2. Juan CarlosRuíz San Millán. Estudio multicéntrico posterior a la diabéticos. Seguimiento a largo plazo de adultos autorización. PROGRESER. GRUPO ESPAÑOL que recibieron alotransplantes AST-TAC-2013-02. ASTELLAS PARA EL ESTUDIO DE LA de riñón e hígado y que han PHARMA EUROPE BV. NEFROLOGÍA DIABÉTICA participado previamente en un GEENDIAB. ensayo con Tacrolimus (Advagraf). Activity Report 131
· Neuroscience Area
Benedicto Crespo Facorro Coordinator of the Neuroscience Area.
Section Chief, Psychiatry. University Hospital Marqués de Valdecilla. Professor of the Department of Medicine and Psychiatry. University of Cantabria Activity Research Areas Report Neuroscience Area
Group Responsible Miguel Ángel Lafarga Coscojuela Department of Anatomy and Cell Biology School of Medicine • Nuclear Cell Biology University of Cantabria
Contributors María Soledad Castillo Iglesias Nazel Diban Gómez Olga Tapia Martínez Ane Urtiaga Mendía
Predoctoral Jorge Mata Garrido Josep Oriol Narcis Majos
Jointly Responsible María Teresa Berciano Blanco
Consolidated group
cause of genetic-based mortality with its target proteins, affecting the Research in the childhood. In addition to cellular localization SMNs and snRNPs and snoRNPs, of the protein and its ability to lines another essential component of CB nuclear CBs . is the coilin nucleating protein. The fundamental objective of this line Línea 2. Importance of dysfunction is to analyze the mechanisms that of nuclear compartments of spinal Línea 1. Role of motor neuron regulate the molecular assembly motor neurons in the cellular and survival factor (SMN) acetylation of the CB and its importance molecular pathophysiology of spinal in the Cajal nuclear body assembly in the SMA. We have recently muscular atrophy (SMA) in murine (Cajal body, CB): importance in spinal shown that the SMN protein is a model SMNd7. As discussed above, muscular atrophy (SMA). The core of substrate of SUMO1 and that its mutation or deletion of the SMN1 Cajal (CB, Fig. 1) is the nuclear power conjugation with SUMO is another gene in SMA produces a severe plant that directs the final assembly factor regulating the formation of deficiency of the functional SMN and quality control of the snRNPs CBs. We are currently studying the protein, leading to degeneration and snoRNPs (small nuclear nucleolar impact of another post-translational and death of spinal neurons. In the ribonucleoproteins) involved in the modification of SMN, acetylation, pathophysiology of SMA, three splicing of pre-mRNAs And in the on the assembly of snRNPs and essential mechanisms exist at maturation of pre-rRNAs. snoRNPs and the formation of CBs. the level of spinal motoneurons: splicing dysfunction of pre-mRNAs, The mutation in the gene encoding Our preliminary experiments axonal transport alterations and one of its essential proteins, indicate that SMN is acetylated dysfunction of the neuromuscular SMN (Survival Motor Neuron), is by acetyltranferase and CBP synapse. All of them contribute responsible for spinal muscular analysis with mass spectrometry to neurodegeneration and, atrophy (SMA), which causes motor demonstrates that acetylation consequently, to atrophy and neuron degeneration and is the main modifies the interactions of the SMN muscular paralysis. 133
Our research focuses on deepening new horizon that should allow to Arozamena J, Berciano MT, Lafarga the nuclear mechanisms affected identify neural genes very vulnerable M, Riancho JA. by the disease, which results in an to DNA damage or difficult to repair, Generation and characterization alteration of the nuclear metabolism whose accumulation of lesions may of two immortalized human of the RNAs in the motoneurons be involved in neurodegenerative osteoblastic cell lines useful for (Fig. 2). SMA has reported a deficit diseases. epigenetic studies. in the assembly of snRNPs for J Bone Miner Metab. the spliceosome, the molecular 2017;35:150-160. machinery that governs the splicing F.I.:2,423. [doi:10.1007/s00774-016- of pre-mRNAs. The Cajal nuclear 0753-z] body (CB) is a nuclear power plant that governs the assembly and • PUBLICATIONS: nuclear trafficking of snRNPs and Reviews snoRNPs to the spliceosome and IMPACT FACTOR | 25,057 nucleolus, respectively. 1. Berciano J, Sedano MJ, Pelayo- Negro AL, García A, Orizaola P, Gallardo In this context, we consider that the E, Lafarga M, Berciano MT, Jacobs BC. loss of CBs and their interactions Proximal nerve lesions in with the nucleolus, required for the Original articles early Guillain-Barré syndrome: transport of snoRNPs involved in implications for pathogenesis and nucleolar processing of rRNAs, are 1. Talamillo A, Grande L, Ruiz- disease classification. responsible for the severe disruption Ontañon P, Velasquez C, Mollinedo P, J Neurol. 2017;264:221-236. of splicing and biogenesis of F.I.:3,389. [doi:10.1007/s00415-016- ribosomes in the motoneurons of The Torices S, Sanchez-Gomez P, Aznar 8204-2] SMA. To investigate these nuclear A, Esparis-Ogando A, Lopez-Lopez mechanisms we used the transgenic C, Lafita C, Berciano MT, Montero mouse SMNd7 as a model of SMA JA, Vazquez-Barquero A, Segura V, Authorship Thesis type I, the most severe that causes Villagra NT, Pandiella A, Lafarga M, the degeneration of motor neurons Leon J, Martinez-Climent JA, Sanz- 1. Jorge Mata Garrido, María Teresa and death of animals between Moreno V, Fernandez-Luna JL. Berciano Blanco, Miguel Ángel postnatal days 13 and 16. ODZ1 allows glioblastoma to Lafarga Coscojuela. sustain invasiveness through a Organización y Dinámica de los Línea 3. Neuronal response to Myc-dependent transcriptional Focos Nucleares Permanentes de DNA damage: importance in upregulation of RhoA. Reparación del Daño del DNA en neurodegeneration. There is growing Oncogene. 2017;36:1733-1744. Neuronas. evidence in the literature that defects F.I.:7,519. [doi:10.1038/onc.2016.341] Universidad de Cantabria. in DNA repair and the consequent accumulation of DNA lesions play 2. Tapia O, Narcís JO, Riancho J, an important role in the molecular Tarabal O, Piedrafita L, Calderó J, Books and Book Chapters pathophysiology of multiple Berciano MT, Lafarga M. neurodegenerative processes. Cellular bases of the RNA 1. Riancho Zarrabeitia, Javier, Ruiz metabolism dysfunction in motor Soto, María, Terán Villagra, Nuria, Our goal is to analyze the nuclear neurons of a murine model of spinal Berciano Blanco, José Ángel, processing of DNA damage in muscular atrophy: Role of Cajal Berciano Blanco, María Teresa, normal, ganglionic and cerebral bodies and the nucleolus. Neurobiol Lafarga Coscojuela, Miguel Ángel. cortex neurons irradiated with X-rays Dis. 2017;108:83-99.F.I.:5,020. Compensatory motor neuron (4 Gy) to induce DNA double-strand [doi:10.1016/j.nbd.2017.08.004] response to chromatolysis in the breaks. Lafarga M, Tapia O, Romero AM, murine hSOD1-G93-A model of Berciano MT. Cajal bodies in amytrophic lateral esclerosis. In this model we have observed that neurons. Compensatory Mechanisms in most of the neuronal DNA breaks RNA Biol. 2017;14:712-725. Neurodegenerative Disorders. are repaired in the first 24 hours, but F.I.:3,900. [doi:10.1080/15476286.20 2017. de libros there are persistent foci of unrepaired 16.1231360] DNA that remain for months in a specific nuclear compartment. We 3. Brun S, Abella N, Berciano MT, • PROJECTS have characterized the structural, Tapia O, Jaumot M, Freire R, Lafarga molecular and spatial organization M, Agell N. Projects of this nuclear compartment as well SUMO regulates p21Cip1 as its transcriptional repression (Fig. intracellular distribution and with 3). In addition we are characterizing p21Cip1 facilitates multiprotein 1. María Teresa Berciano Blanco. with ChIP-seq techniques DNA complex formation in the nucleolus Regulación por acetilación del sequences enriched in the “persistent upon DNA damage. factor de supervivencia de las foci” of cortical neurons. We have PLoS One. 2017;12: neuronas motoras: su importancia identified 17 sequences associated F.I.:2,806. [doi:10.1371/journal. en la biogénesis de snrnps y en el with genes essential for neuronal pone.0178925] ensamblaje de cuerpos nucleares de homeostasis whose dysfunction cajal. BFU2014-54754-P. is related to pictures of human MINISTERIO DE ECONOMIA Y neuropathology. This line opens a 4. Pérez-Campo FM, May T, Zauers J, Sañudo C, Delgado-Calle J, COMPETITIVIDAD Activity Research Areas Report Neuroscience Area
Group Responsible Agustín Oterino Durán Neurology Service University Hospital • Cephalea Clinic and Marqués de Valdecilla Genetics
Researchers Julio Pascual Gómez
Contributors Jesús Castillo Obeso Vicente González Quintanilla Rosa María Martínez Nieto Silvia Montes Gómez Enrique Jesús Palacio Portilla Estrella Quintela Obregón María Toriello Suárez
Nurses Silvia Gutiérrez González
Associated group
grouped in 132 families, confirming Study of vascular damage associated the existence of a genetic factor in with Multiple Sclerosis by analysing the pathogenesis of migraines as circulating endothelial cells: the related to sex hormones; we further correlation of endothelial activation Research researched the association of genes with the severity and stage of the Lines of the folate metabolic pathway and disease. migraines, confirming the association of migraines with aura and high homocysteine levels. We have 1. Genetics of migraines. recently demonstrated that there is significant endothelial activation The group has maintained its in migraine sufferers and that this epidemiological-clinical and basic activation is more pronounced in research activity (mainly in genetic chronic migraines. Furthermore, • PUBLICATIONS: association studies) in the field of we demonstrated that there are cephalalgias. Within this first aspect, variants of certain subunits of GABA we should highlight the demonstration associated with migraines in general. IMPACT FACTOR | 17,557 of the dose-dependent association between migraines and tobacco, 2. Clinical and Genetic Research in and studies focusing on proving the Multiple Sclerosis. usefulness of new neuromodulators Original articles (topiramate and zonisamide) in In this line of research we are the treatment of refractory chronic developing sub-programmes which 1. Ramón C, Cernuda-Morollón E, migraines. In the field of genetics, include: the epistatic interaction of genes Pascual J. related to oestrogen metabolism in HLA haplotype study regarding the Calcitonin gene-related peptide in migraines (oestrogen receptor ESR2) origin within the region. Influence of peripheral blood as a biomarker for has been described in 594 subjects HLA on multiple sclerosis. migraine. 135
Curr Opin Neurol. 2017;30:281-286. MC, Izquierdo G, Martinez-Gines EMR200575-001. MERCK KGAA. F.I.:4,699. [doi:10.1097/ ML, Saiz A, Comabella M, Casanova- 2. Agustín Oterino Durán. WCO.0000000000000440] Estruch B, Brieva L, Arroyo R, Estudio de fase 3, aleatorizado, Rodriguez-Antiguedad A. doble ciego, controlado con placebo, 2. Riesco N, Cernuda-Morollón E, Review of the novelties from the en el que se evalúa LY2951742 en Martínez-Camblor P, Pérez-Alvarez AI, 32nd ECTRIMS Congress, 2016, pacientes con migraña episódica - Verano L, García-Cabo C, Serrano- presented at the 9th Post-ECTRIMS Estudio EVOLVE-2. Pertierra E, Pascual J. Meeting (I). I5Q-MC-CGAH. LILLY, S.A.. Relationship between serum Rev Neurol. 2017;65:31-40. levels of VIP, but not of CGRP, and F.I.:0,743. 3. Agustín Oterino Durán. cranial autonomic parasympathetic Estudio de fase 3, aleatorizado, symptoms: A study in chronic 3. Fernandez O, Oterino A, Oreja- doble ciego, controlado con placebo, migraine patients. Guevara C, Prieto JM, Mendibe-Bilbao en el que se evalúa LY2951742 en Cephalalgia. 2017;37:823-827. MM, Garcia-Merino JA, Ramio-Torrenta pacientes con migraña crónica - F.I.:3,609. L, Ginestal R, Meca-Lallana JE, Estudio REGAIN. [doi:10.1177/0333102416653232] Romero-Pinel L, Munoz D, Oliva- I5Q-MC-CGAI. LILLY, S.A.. Nacarino P, Calles-Hernandez MC, 3. Matharu M, Pascual J, Nilsson Izquierdo G, Martinez-Gines ML, Saiz 4. Agustín Oterino Durán. Remahl I, Straube A, Lum A, Davar A, Comabella M, Casanova-Estruch Ensayo de fase 3 de grupos G, Odom D, Bennett L, Proctor C, B, Brieva L, Arroyo R, Rodriguez- paralelos, doble ciego, aleatorizado y Gutierrez L, Andrews E, Johannes C. Antiguedad A. controlado con placebo, para evaluar Utilization and safety of Review of the novelties from the la eficacia y la seguridad de ALD403 onabotulinumtoxinA for the 32nd ECTRIMS Congress, 2016, administrado por vía intravenosa prophylactic treatment of chronic presented at the 9th Post-ECTRIMS en pacientes con migraña crónica. migraine from an observational Meeting (II). ALD403-CLIN-011. ALDER study in Europe. Rev Neurol. 2017;65:75-84. BIOPHARMACEUTICALS, INC. Cephalalgia. 2017;37:1384-1397. F.I.:0,743. F.I.:3,609. 5. Agustín Oterino Durán. [doi:10.1177/0333102417724150] • PROJECTS Estudio multicéntrico, doble ciego, aleatorizado, de 12 semanas de 4. Pascual J. tratamiento para comparar la Differences between chronic Projects eficacia y seguridad de AMG 334 migraine with and without 70 mg subcutáneo una vez al mes medication overuse. frente a placebo en pacientes Neurologia. 2017;32:341-342. 1. Agustín Oterino Durán. adultos con migraña episódica F.I.:2,103. [doi:10.1016/j. Modificaciones epigenéticas que han fracasado entre 2-4 nrl.2015.06.020] inducidas por experiencias adversas tratamientos profilácticos (LIBERTY). infantiles y daño endotelial en la CAMG334A2301. NOVARTIS 5. Gago-Veiga AB, Santos-Lasaosa migraña crónica: estudio de casos FARMACEUTICA, S.A.. S, Cuadrado ML, Guerrero ÁL, Irimia y controles. Creación de modelo P, Láinez JM, Leira R, Pascual J, experimental murino. PI15/01285. Postmarketing Studies Sanchez Del Río M, Viguera J, Pozo- INSTITUTO DE SALUD CARLOS and Other Rosich P. III. MINISTERIO DE ECONOMÍA Y Evidence and experience with COMPETITIVIDAD. 1. Agustín Oterino Durán. onabotulinumtoxinA in chronic Estudio retrospectivo sobre la migraine: Recommendations for 2. Agustín Oterino Durán. adherencia al consenso español para daily clinical practice. Red Temática de Esclerosis Múltiple. el tratamiento de la espasticidad por Neurologia. 1;F.I.:0,000. RD16/0015/0023. esclerosis múltiple en España. [doi:10.1016/j.nrl. 2017.09.008] INSTITUTO DE SALUD CARLOS ALM-EEM -2016-01. ALMIRALL, S.A. III. MINISTERIO DE ECONOMÍA Y Reviews COMPETITIVIDAD. 2. Agustín Oterino Durán. Estudio observacional, no intervencionista, para evaluar los 1. Riesco N, Cernuda-Morollón E, Clinical Trials cambios en la calidad de vida en Pascual J. pacientes tratados con teriflunomida Neuropeptides as a Marker for Chronic 1. Agustín Oterino Durán. en práctica. clínica habitual. SAN- Headache. Estudio de fase II, multicéntrico, TER-2015-02. SANOFI AVENTIS, S.A. Curr Pain Headache Rep. 2017;21:18-18. aleatorizado, de grupos paralelos, F.I.:2,051. [doi:10.1007/s11916-017- con enmascaramiento de los 3. Agustín Oterino Durán. 0618-8] evaluadores para evaluar Estudio observacional, global y la eficacia, la seguridad y la multicéntrico para recoger información 2. Fernandez O, Oterino A, Oreja- tolerabilidad de las dosis de 0,5, 3, sobre seguridad y documentar la Guevara C, Prieto JM, Mendibe- 10 y 20 mg del acetato de utilización del fármaco Tecfidera® Bilbao MM, Garcia-Merino JA, plovámero en comparación con (fumarato de dimetilo) en su uso Ramio-Torrenta L, Ginestal R, Meca- Copaxone en pacientes con en la práctica médica rutinaria del Lallana JE, Romero-Pinel L, Munoz D, esclerosis múltiple remitente tratamiento de la esclerosis múltiple Oliva-Nacarino P, Calles-Hernandez recidivante. (ESTEEM). 109MS401. Activity Research Areas Report Neuroscience Area
Group Responsible Jon Infante Ceberio Neurology Service University Hospital • Neurodegenerative Marqués de Valdecilla diseases
María Isabel González Aramburu Andrés González Mandly Carmen Lage Martínez José Ignacio Mateo Fernández Ana Lara Pelayo Negro Ana Pozueta Cantudo Javier Riancho Zarrabeitia María José Sedano Tous Consolidated group María Sierra Peña José Luis Vázquez Higuera Researchers Nurses José Ángel Berciano Blanco Eloy Manuel Rodríguez Rodríguez Martha Kazimierczak Pascual Jesús Sánchez Juan Predoctoral José Ramón Contributors Sánchez de la Torre Elena Carmen Gallardo Agromayor Antonio García García Technicians María García Martínez Mª del Coro Andrea González Suárez Sánchez Quintana
the pathogenic relevance of Tooth disease (CMT) harbouring Research inflammatory oedema in proximal NEFL mutations, either E397K lines nerves, particularly in spinal nerves. or N98S, we have re-defined This notion is applicable to both the corresponding phenotypes, demyelinating and axonal forms which should be classified in the of the syndrome (figure 1). Our category of dominant intermediate 1 . Peripheral neuropathy. contributions to GBS nosology have CMT. We have reported the first been compiled in a monographic electrophysiological recording of T In a prospective study of six early textbook (see publications 2015). reflex in CMT1A duplication, which Guillain-Barré syndrome (GBS) is a simple and painless diagnostic In two pedigrees of Charcot-Marie- patients, we have demonstrated method, particularly useful for at- 137
risk children. In collaboration with 2. Hereditary Ataxias. 3. Parkinson’s disease. Dr Albena Jordanova (Department of Genetics, University of Antwerp, We have continuedwith the We have demonstrated that Belgium), we have continue SCANatural History Study within the serum uric acid levels are not evaluating a large CMT2 pedigree, EUROSCA project (for more details associatedwith the risk of dementia categorized as CMT2G by linkage http:// www.ataxia-study-group.net/ in Parkinson’s disease.We have analysis. Using next-generation html/studies/eurosca). Also, within participated in two international sequencing technology, we have the EUROSCA group we have collaborative studies analyzing found a pathogenic LRSAM1 continued with the prospective the temporal profile of non- missense mutation indicating follow-up of patients with dominant motor symptoms in idiopathic that the syndrome should be ataxia included in the RISCA project. and LRRK2G2019S associated reclassified as a novel CMT2P We have participated in a follow-up Parkinson’s disease (PD). Through phenotype. In two review papers, study of a longitudinal cohort of a blood transcriptomic analysiswe we have addressed the role of patients with SCA1, 2, 3 and 6 (see have identified 13 candidate imaging techniques in the diagnosis references of our group published genes por PD in sporadic cases, of inflammatory and inherited in 2005). asymptomatic carriers of the neuropathies. G2019S mutation and controls.
Figure 1. Picture taken from the paper by Berciano et al (JNNP 2016; 87: 563-5. Epub 2015 May 13) showing electrophysiological and imaging findings in a patient with the paraparetic and axonal form of GBS. (A) Tibial nerve motor conduction velocity (MCV) study on day 4 after onset showing normal compound muscle action potential (CMAP) morphology, both on distal (ankle to abductor hallucis [AH] muscle) and proximal stimulation (popliteal fossa [PF] to AH); proximal CMAP amplitude is 14.4 mV, and distal CMAP amplitude is 18.9 mV (normal, = 3); MCV is 47 m/s (normal, = 41). (B) On day 12, note severe CMAP amplitude reduction to 1.7 mV, both on distal and proximal stimulation. Comparatively with the previous study, at this stage there was a mild slowing of MCV (passing from 47 m/s to 39.4 m/s) and prolongation of F-wave latency (55.5 ms; normal, = 55), which seems to be proportional to the observed CMAP reduction. Post contrast sagittal (C) and coronal (D) T1-weighted, fat-saturation MR images of the lower thoracic and lumbosacral spine, performed on day 4, showing diffusely thickened cauda equine (arrowheads), which in the axial image (L1 level) selectively involves the anterior roots (E, arrows); CM indicates conus medullaris. (F) Sagittal sonogram of the right ventral rami of C6-C7 cervical nerves (callipers) performed on day 3; note their characteristic homogeneous hypoechoic texture with partial loss of the surrounding perineural hyperechoic rims. (G) Short-axis sonogram the right ventral ramus of the C7 spinal nerve showing the cross sectional area (dotted green tracing) measuring 27.47 mm2 (control, 12.29 ± 5.3 mm2)2. Note blurred margins and the absence of the physiologic hyperechoic rim. Asterisks indicate the posterior tubercle of the seventh transverse vertebral process Activity Research Areas Report Neuroscience Area
As member of the EMSA-SG group J Neurol Neurosurg Psychiatry. (www.emsa-sg. org/), we have • PUBLICATIONS: 2017;88:846-863. participated in a study that discards F.I.:7,349. [doi:10.1136/jnnp-2016- 313960] the pathogenic role of mutations in IMPACT FACTOR | 101,860 COQ2 in MSA 5. Tapia O, Narcís JO, Riancho J, In collaboration with the Neurology Tarabal O, Piedrafita L, Calderó J, Department of Toulouse Purpam Berciano MT, Lafarga M. Hospital (INSERM), we are Original articles Cellular bases of the RNA participating in an ongoing project metabolism dysfunction in motor to identify clinical and preclinical neurons of a murine model of 1. Artículos Originales Sims R, van (multimodal MRI) biomarkers in der Lee SJ, Naj AC, Bellenguez C, spinal muscular atrophy: Role of LRRK2- PD Badarinarayan N, Jakobsdottir J, Cajal bodies and the nucleolus. Neurobiol Dis. 2017;108:83-99. 4. Alzheimer’s disease. Kunkle BW, Boland A, Raybould R, F.I.:5,020. [doi:10.1016/j. Bis JC, Martin ER, Grenier-Boley B, nbd.2017.08.004] Our group is a founder member of Heilmann-Heimbach S, Chouraki V, the Spanish consortium of dementia Kuzma AB, Sleegers K, Vronskaya Sivera R, Frasquet M, Lupo V, (DEGESCO). As a consequence of M, Ruiz A, Graham RR, Olaso R, 6. García-Sobrino T, Blanco-Arias P, this collaboration, in the framework Hoffmann P, Grove ML, Vardarajan Pardo J, Fernández-Torrón R, de of CIBERNED, we have published BN, Hiltunen M, Nöthen MM, White Munain AL, Márquez-Infante C, in 2015 an association between CC, Hamilton-Nelson KL, Epelbaum Villarreal L, Carbonell P, Rojas-García MAPT gene variants and different J, Maier W, ..., Schellenberg GD. R, Segovia S, Illa I, Frongia AL, neurodegenerative conditions in a Rare coding variants in PLCG2, ABI3, Nascimento A, Ortez C, García- sample of 11572 subjects.In the line and TREM2 implicate microglial- Romero MDM, Pascual SI, Pelayo- of Alzheimer’s disease biomarkers mediated innate immunity in Negro AL, Berciano J, Guerrero A, we are carrying out PET-PIB and Alzheimer’s disease. Nat Genet. Casasnovas C, Camacho A, Esteban PET-FDG studies to: 2017;49:1373-1384. J, Chumillas MJ, Barreiro M, Díaz C, F.I.:27,959. [doi:10.1038/ng.3916] 1) patients with AD, Palau F, ..., Sevilla T. Distribution and genotype- 2. Sierra M, Martínez-Rodríguez I, 2) patientswith mild cognitive Sánchez-Juan P, González-Aramburu phenotype correlation of GDAP1 impairment and I, Jiménez-Alonso M, Sánchez- mutations in Spain. Sci Rep. 2017;7:6677-6677. Rodríguez A, Berciano J, Banzo I, 3) healthy controls.We are preparing F.I.:4,259. [doi:10.1038/s41598-017- Infante J. Prospective clinical and an article describing our clinical 06894-6] DaT-SPECT imaging in premotor experience in the use of amyloid- LRRK2 G2019S-associated Parkinson PET and we have collaborated 7. Guadalupe T, Mathias SR, vanErp disease. with our data in international TG, Whelan CD, Zwiers MP, Abe Y, Neurology. 2017;89:439-444. consortiums producing a double Abramovic L, Agartz I, Andreassen F.I.:7,592. [doi:10.1212/ publication in JAMA describing OA, Arias-Vásquez A, Aribisala BS, WNL.0000000000004185] the prevalence of brain amyloid Armstrong NJ, Arolt V, Artiges deposits in healthy subjects and E, Ayesa-Arriola R, Baboyan VG, 3. Fledrich R, Mannil M, Leha A, Banaschewski T, Barker G, Bastin subjects with mild cognitive Ehbrecht C, Solari A, Pelayo-Negro ME, Baune BT, Blangero J, Bokde impairment. AL, Berciano J, Schlotter-Weigel AL, Boedhoe PS, Bose A, Brem S, B, Schnizer TJ, Prukop T, Garcia- 5. Prionopathies. Brodaty H, Bromberg U, Brooks S, Angarita N, Czesnik D, Haberlová J, Büchel C, ..., Francks C. In 2015 we have published a Mazanec R, Paulus W, Beissbarth Human subcortical brain genome wide association study T, Walter MC, Triaal C, Hogrel JY, Dubourg O, Schenone A, Baets J, asymmetries in 15,847 people (GWAs) with the largest sample worldwide reveal effects of age and of patients recruited so far (1543 De Jonghe P, Shy ME, Horvath R, Pareyson D, Seeman P, Young P, sex. samples from patients with BRAIN IMAGING BEHAV. Sereda MW. sporadic Creutzfeldt Jakob disease, 2017;11:1497-1514. Biomarkers predict outcome in coming from 7 European countries F.I.:3,985. [doi:10.1007/s11682-016- Charcot-Marie-Tooth disease 1A. and Australia, and 4203 controls). 9629-z] This study has been carried out in J Neurol Neurosurg Psychiatry. 2017;88:941-952.F.I.:7,349. the framework of a collaborative Riancho J, Pozueta A, Santos M, [doi:10.1136/jnnp-2017-315721] 8. European project, JPND DEMTEST. Lage C, Carril JM, Banzo I, Martínez- Rodriguez I, Gorno-Tempini M, 4. Rossor, Alexander M., Carr, Aisling Sánchez-Juan P. Logopenic S., Devine, Helen, Chandrashekar, Aphasia Hoskote, Pelayo-Negro, Ana Lara, due to a Strategic Stroke: New Pareyson, Davide, Shy, Michael E., Evidence from a Single Case. J Alzheimers Dis. 2017;57:717-721. Scherer, Steven S., Reilly, Mary M. F.I.:3,731. [doi:10.3233/JAD-161267] Peripheral neuropathy in complex inherited diseases: an approach to 9. Riancho J, Vázquez-Higuera JL, diagnosis. Pozueta A, Lage C, Kazimierczak M, 139
Bravo M, Calero M, Gonalezález A, Med Clin (Barc). 2017;149:417-418. Olivopontocerebellar Atrophy. Rodríguez E, Lleó A, Sánchez-Juan P. F.I.:1,125. [doi:10.1016/j. Olivopontocerebellar Atrophy. MicroRNA Profile in Patients with medcli.2017.04.018] 2017. Alzheimer’s Disease: Analysis of miR-9-5p and miR-598 in Raw and Exosome Enriched Cerebrospinal Reviews Fluid Samples. • PROJECTS J Alzheimers Dis. 2017;57:483-491. 1. Berciano J, García A, Gallardo E, F.I.:3,731. [doi:10.3233/JAD-161179] Peeters K, Pelayo-Negro AL, Álvarez- Paradelo S, Gazulla J, Martínez- Projects 10. Moreno F, Indakoetxea B, Tames M, Infante J, Jordanova A. Barandiaran M, Caballero MC, Intermediate Charcot-Marie-Tooth 1. José Ángel Berciano Blanco. Gorostidi A, Calafell F, Gabilondo A, disease: an electrophysiological Validation of prognostic and disease Tainta M, Zulaica M, Martí Massó JF, reappraisal and systematic biomarkers for Charcto-Marie-Tooth López de Munain A, Sánchez-Juan review. disease 1A (CMTA1). AFM11/06. P, Lee SE. J Neurol. 2017;264:1655-1677. MAX-PLANCK-INSTITUTE FOR The unexpected co-occurrence of F.I.:3,389. [doi:10.1007/s00415-017- EXPERIMENTAL MEDICINE. GRN and MAPT p.A152T in Basque 8474-3] JON INFANTE CEBERIO. Selección families: Clinical and pathological de genes candidato para la characteristics. 2. Berciano J, Sedano MJ, Pelayo- enfermedad de Parkinson idiopática PLoS One. 2017;12: Negro AL, García A, Orizaola P, a través del análisis diferencial F.I.:2,806. [doi:10.1371/journal. Gallardo E, Lafarga M, Berciano MT, del transcriptoma entre pacientes pone.0178093] Jacobs BC. y portadores asintomáticos de Proximal nerve lesions in mutaciones en LRRK2. PI11/00228. 11. Santurtún A, Ruiz PB, López- early Guillain-Barré syndrome: INSTITUTO DE SALUD CARLOS Delgado L, Sanchez-Lorenzo A, implications for pathogenesis III. MINISTERIO DE ECONOMÍA Y Riancho J, Zarrabeitia MT. Stroke: and disease classification. COMPETITIVIDAD. Temporal Trends and Association J Neurol. 2017;264:221-236. with Atmospheric Variables F.I.:3,389. [doi:10.1007/s00415-016- 2. Pascual Jesús Sánchez Juan. and Air Pollutants in Northern 8204-2] Estudio Multimodal de Spain. CARDIOVASC TOXICOL. 3. Berciano J. Biomarcadores de enfermedad de 2017;17:360-367. Spinal nerve involvement in early Alzheimer en Deterioro Cognitivo F.I.:2,712. [doi:10.1007/s12012-016- Guillain-Barré syndrome: Postoperatorio. PI12/02288. 9395-6] The Haymaker and Kernohan’s INSTITUTO DE SALUD CARLOS legacy. J III. MINISTERIO DE ECONOMÍA Y 12. Nieto-Reyes A, Duque R, Neurol Sci. 2017;382:1-9. COMPETITIVIDAD. Montaña JL, Lage C. F.I.:2,295. [doi:10.1016/j. Classification of Alzheimer’s Patients jns.2017.09.017] 3. Pascual Jesús Sánchez Juan. through Ubiquitous Computing. Plataforma de Biobancos. Sensors (Basel). 2017;17: PT13/0010/0024. F.I.:2,677. [doi:10.3390/s17071679] Publishers INSTITUTO DE SALUD CARLOS III. MINISTERIO DE ECONOMÍA Y 13. Berciano J, Gallardo E, 1. Sánchez-Juan P, Seshadri S. COMPETITIVIDAD. Orizaola P, Marco de Lucas E, García Dynamic measurements of -amyloid A, Pelayo-Negro AL, Sedano MJ. accumulation: The early effect of 4. Pascual Jesús Sánchez Juan. Comment on paraparetic APOE . Estudio de variantes raras en Guillain-Barré syndrome: Neurology. 2017;89:986-987. genes asociados a Enfermedad de Non-demyelinating reversible F.I.:7,592. [doi:10.1212/ Alzheimer en población española. conduction failure restricted to the WNL.0000000000004344] PI16/01652. lower limbs. INSTITUTO DE SALUD CARLOS Muscle Nerve. III. MINISTERIO DE ECONOMÍA Y 2017;55:445-446. Books and Book Chapters COMPETITIVIDAD. F.I.:2,605. [doi:10.1002/mus.25425] 1. Riancho Zarrabeitia, Javier, Ruiz 5. Jon Infante Ceberio. 14. Riancho J, Jiménez-López Y, Soto, María, Terán Villagra, Nuria, Estudio de biomarcadores Sánchez-de la Torre JR, Pardina- Berciano Blanco, José Ángel, motores, genéticos y de imagen Vilella L, Sánchez-Juan P. Berciano Blanco, María Teresa, en la enfermedad de Parkinson How much do Spanish clinicians Lafarga Coscojuela, Miguel Ángel. prodrómica asociada a la mutación know about dementia?. Compensatory motor neuron G2019S de LRRK2. PI17/00936. J Neurol Sci. 2017;372:468-470. response to chromatolysis in the INSTITUTO DE SALUD CARLOS F.I.:2,295. [doi:10.1016/j. murine hSOD1-G93-A model of III. MINISTERIO DE ECONOMÍA Y jns.2016.11.002] amytrophic lateral esclerosis. COMPETITIVIDAD. Compensatory Mechanisms in 15. Holanda Peña M, Chicote Álvarez Neurodegenerative Disorders. 6. Pascual Jesús Sánchez Juan. E, Vázquez Higuera JL. 2017. Plataforma de Biobancos. Fulminant reversible cerebral vasoconstriction syndrome. 2. Berciano Blanco, José Ángel. Activity Research Areas Report Neuroscience Area
PT17/0015/0019. INSTITUTO DE SALUD CARLOS 3. Eloy Manuel Rodríguez Rodríguez. pacientes con esclerosis múltiple III. MINISTERIO DE ECONOMÍA Y Estudio en fase III, multicéntrico, remitente recurrente tratados COMPETITIVIDAD. aleatorizado, doble ciego, controlado con alemtuzumab (Lemtrada®) en con placebo y de grupos paralelos condiciones de práctica clínica para evaluar la eficacia y seguridad habitual. Clinical Trials de crenezumab en pacientes SAN-ALE-2015-03. GENZYME con enfermedad de alzheimer de EUROPE, B.V.. 1. Andrés González Mandly. prodrómica a leve. BN29553. Registro internacional prospectivo, ROCHE FARMA, S.A.U.. 3. María Sierra Peña. de observación, multicéntrico, de Estudio observacional un solo grupo, con inscripción Postmarketing Studies postautorización Calidad de vida y consecutiva y posterior a la and Other lesiones accidentales en el paciente comercialización del desviador con epilepsia y crisis tónico-clónicas de flujo Surpass en arterias 1. Andrés González Mandly. generalizadas (Estudio QUIN-GTC). intracraneales. Estudio clínico prospectivo, EST-EPI-2016-01. SURMOUNT. STRYKER multicéntrico, aleatorizado y LABORATORIOS DR. ESTEVE, S.A.. NEUROVASCULAR. comparativo para comparar la seguridad y eficacia de dos técnicas 2. Eloy Manuel Rodríguez Rodríguez. de reducción de fracturas vertebrales Estudio en Fase III, multicéntrico, por compresión (fvc): el sistema aleatorizado, doble ciego, controlado spinejack® y el balón óseo inflable con Placebo y de grupos paralelos kyphx xpander. EU2014-05. para evaluar la eficacia y seguridad VEXIM, S.A. FRANCE. de crenezumab en pacientes con enfermedad de Alzheimer de 2. María José Sedano Tous. prodrómica a leve. BN29552. Estudio observacional, no ROCHE FARMA, S.A.U.. intervencionista para evaluar los cambios en la calidad de vida en 141 Activity Research Areas Report Neuroscience Area
Group Responsible José Luis Fernández Torre Neurophisiology Service • Neurophysiology in Epilepsy University Hospital Marqués de Valdecilla and Neurointensive care
Researchers Mª Blanca Sánchez Santiago
Contributors Francisco Javier Adin Ibarra Miguel Ángel Hernández Hernández Ana María Ruiz Ruiz
Technicians María Paz Polo Sobrón
Associated group
> Multimodal neuromonitoring > Toxic encephalopathy in including intracortical electrodes in neurocritical patients. acute brain injury patients. Research > The use of bilateral bispectral > EEG patterns and prognosis in index (BIS) in the diagnosis of lines hipoxic-ischemic encephalopathy. nonconvulsive status epilepticus in comatose patients. > Post-anoxic myoclonic status epilepticus. Stimulus-induced > Experimental models of status > Refractory nonconvulsive status postanoxic myoclonus. epilepticus. EEG phases of status epilepticus. epilepticus in humans. > Utility of EEG in the diagnosis of > Super-refractory or malignant brain death. nonconvulsive status epilepticus. 143
• PUBLICATIONS: Persistencia de actividad eléctrica Capítulo 8. Nervioso. Casos cerebral tras el diagnóstico clínico de prácticos para el aprendizaje de la muerte encefálica: incidencia, Fisiología Médica. Escanero Marcén IMPACT FACTOR | 1,231 impacto y análisis comparativo JF, Ganfornina Álvarez MD, Gual del electroencefalograma frente Sala A, Pales Argullós JL, Sánchez- a la angiografía por tomografía Barceló E, y Sánchez Romero D, computarizada. editores. Director/es: José Luis Fernández Ediciones Universidad de Valladolid. Original articles Torre, José Luís Hernández 2017:201-233. ISNB:978-84-8448- Hernández. 922-1. 1. Holanda Peña MS, Talledo NM, UNIVERSIDAD DE CANTABRIA. Ots Ruiz E, Lanza Gómez JM, Ruiz Ruiz A, Gar-cía Miguelez A, Gómez Marcos V, Domínguez Artiga Books´s chapter MJ, Hernández Hernán-dez MÁ, • PROJECTS Wallmann R, Llorca Díaz J, Grupo 1. Fernández-Torre JL, Galdón Castillo A. HU-CIC. Estudio EEG en pacientes con crisis Satisfaction in the Inten-sive epiléptica o epilepsia en situaciones Projects Care Unit (ICU). Patient opinion de urgencia. La epilepsia en as a cornerstone. Med Intensiva. situaciones de urgencia.Sociedad 1. José Luis Fernández Torre. 2017;41:78-85. Andaluza de Epilepsia (SADE). Electroencefalografía intracortical F.I.:1,231. [doi:10.1016/j. Sánchez Álvarez JC, ed. Ediciones en pacientes en coma con daño medin.2016.06.007] Panamericana. 2017:49-64 cerebral agudo. PI17/00156. INSTITUTO DE SALUD CARLOS 2. Conde Ederra MV, Fernández-Torre Authorship Thesis III. MINISTERIO DE ECONOMÍA Y JL, Ganfornina Álvarez MD, Gasull COMPETITIVIDAD. 1. Miguel Ángel Hernández Casanova X, Guerra Sánchez M, Hernández. Sánchez Romero D. Activity Research Areas Report Neuroscience Area
Group Responsible Benedicto Crespo Facorro Psichiatry Service University Hospital Marqués de Valdecilla • Psychiatry University of Cantabria
Elsa Gómez Ruíz Jana González Gómez César González-Blanch Bosch José Andrés Herrán Gómez Sara Herrera Castanedo Jacqueline María Mayoral Van Son María Soraya Otero Cuesta Consolidated group Gema Pardo García Beatriz Payá González, Mª Luz Ramírez Bonilla Researchers Paula Suárez Pinilla María Rosa Ayesa Arriola Javier Vázquez Bourgon Diana Tordesillas Gutiérrez Nurses Obdulia Martínez García Contributors Jesús Ángel Artal Simón Laura Carral Fernández Predoctoral Carlos Cobo Corrales Fulgencio Ruso Julve Javier Alejandro Cuartas Micieces Manuel Delgado Alvarado Technicians Luis Gaite Pindado Noemí de la Fuente González Andrés Gómez Del Barrio Víctor Ortíz García De La Foz 145
Research lines
lines of activity. Firstly, in the field The main objectives of this research of Pharmacogenetics, we work are: 1- Brain Neuroimaging in Non on the study of single nucleotide Affective Psychosis (NAP). polymorphisms (SNPs) of candidate a. To evaluate the course of early genes, specifically the genes involved cognitive function in a sample Responsibles: D. Roiz Santiáñez in dopaminergic neurotransmission, of first episodes of psychosis and D. Tordesillas Gutiérrez. serotonergic and candidate genes individuals. The techniques of brain imaging, in linking regions. The aim is to such as magnetic resonance determine whether single nucleotide b. To examine the relationship imaging (MRI), allow exploring the polymorphisms are associated with between cognitive functions and presence of structural alterations psychotic symptomatology, evolution clinical variables. from the first clinical phases of and response to treatment. Also, c. To evaluate the influence of the disease (neurodevelopmental we work in the field of “imaging cognitive function in the outcome abnomalies) and also study the genetics” genetic variations and prognosis of the disease. onset of morphological changes associated with brain alterations; In during the course of the disease particular, gene expression studies 5. Research and Intervention (neurodegeneration processes). Our are being carried out to identify program focused on the early work in this area aims to: genes whose expression is different phases of eating disorders. in people with a first psychotic a. To Compare the volume of gray episode with respect to people not Responsibles: Dr. J.A. Gómez and white matter in the cortex affected by the disease and also del Barrio. Barrio. It consists of a between patients and controls in possible differences in gene bio-psychosocial line of research b. To Determine the existence of expression in people with a first and a therapeutic intervention and differences in volume of the basal Psychotic episode before starting prevention focused on early phases ganglia between patients and treatment and after one year of of eating disorders: controls pharmacological treatment. a. Implement an early, c. A longitudinal study to detect 3- Epidemiology and Clinical multidisciplined and multi-factorial structural changes over time in characteristics of non-affective evaluation and intervention people with schizophrenia, and psychosis. protocol for all patients that develop an eating disorder in the d. To study the relationship Responsible: Dr. B. Crespo Facorro. area referenced by the Psychiatric between variables related to brain The main objectives of this research Service of Hospital Universitario structure and other clinical and / or are: Marqués de Valdecilla. genetic variables. a. To investigate the incidence of b. Research the early phases of psychosis in Cantabria and likely the disease— the psychological, related factors. biological, and social components of eating disorders. b. To identify the profile of symptoms during early phases of c. Identify and define the risk the illness. factors of developing eating disorders, as well as the nature c. To describe predictors of and characteristics of prodromal outcome. symptoms and earliest clinical d. To advance in the knowledge of manifestations. biological markers (neuroimage, d. Evaluate the response to biochemical, genetic) of interventions, as well as the Schizophrenia. At present, we are developing evolutionary course of the disease, research by DTI to explore alterations e. To study new short- and long- researching bio-psycho-social in the integrity of white matter tracts. term therapeutic, pharmacological, factors that condition them. Another line of recent research is psychotherapeutic interventions e. Evaluate the costs derived from the development of spectroscopy in the treatment of non-affective treatment, as well as the level of techniques to assess neuronal psychosis. Special interest in patient and family satisfaction.. processes genesis. treating metabolic side effects associated with antipsychotic The line of investigation incorporates 2- Genomic of non-affective treatments.s. psychosis. the following studies: 4- Cognition in non affective Intervention study focused on Responsible: Dr. B. Crespo psychosis. Facorro. In this field, our group cognitive processes in eating disorders. Responsible: Laura Carral has focused its work on two main Responsible: Dra. R. Ayesa Arriola. Fernandez y J.A. Gomez del Barrio. Activity Research Areas Report Neuroscience Area
This study is framed under an a first episode of psychosis from Renteria ME, Bis JC, Arias-Vasquez investigation contract Rio Hortega healthy controls, combinated with A, Ikram MK, Desrivières S, Vernooij (CM10/0017). clinical practice. MW, Abramovic L, Alhusaini S, Amin N, Andersson M, Arfanakis K, This program focuses on intervention b. Determine peripheral differences Aribisala BS, Armstrong NJ, Athanasiu and therapeutic strategies based between patients with an episode L, Axelsson T, Beecham AH, Beiser on new technology for early phases of non-affective psychosis and A, Bernard M, Blanton SH, Bohlken of eating disorders. Responsibles: healthy controls, from the onset MM, Boks MP, Bralten J, Brickman Dra. Jana Gonzalez Gomez and Dr. and over time. AM, ..., Ikram MA. Novel genetic J.A. Gomez del Barrio. This program loci associated with hippocampal c. Conduct a longitudinal study of integrates DETECTA (DEtecion volume. TEmprana en Cantabria de Trasornos the change in biomarkers over time Nat Commun. 2017;8:13624-13624. Alimentarios) and is framed under in people with schizophrenia. F.I.:12,124. [doi:10.1038/ a research scholarship, financed by ncomms13624] IDIVAL (Lopez Albo WLA 02/11). d. Study the relationship between changes in peripheral molecules 6.- Research and Pharmacological and correlate with longitudinal 3. Walton E, Hibar DP, van Erp TG, Interventions Program for Early severity scores. Potkin SG, Roiz-Santiañez R, Crespo- Phases of Psychoses in children Facorro B, Suarez-Pinilla P, Van Haren and adolescents population. e. Detect biomarkers to predict NE, de Zwarte SM, Kahn RS, Cahn W, treatment response. Doan NT, Jørgensen KN, Gurholt TP, Responsibles: Dra. S. Otero Cuesta Agartz I, Andreassen OA, Westlye LT, 9.- Classification and assessment and Dra. B. Payá González. This is a Melle I, Berg AO, Mørch-Johnsen L, of disability in mental health. research program focused on mental Faerden A, Flyckt L, Fatouros-Bergman health problems of young people. Responsibles: Dra. S. Herrera H, Karolinska Schizophrenia Project The main areas of interest are: Castanedo and dr. l. Gaite Pindado. Consortium (KaSP), Jönsson EG, Since 1993, our research group Hashimoto R, Yamamori H, Fukunaga a. Clinical trials on effectiveness M, Preda A, ..., Ehrlich S. and safety of new drugs for has been involved in the Positive symptoms associate with children and adolescents development, publication nad cortical thinning in the superior psychiatric disorders. dissemination of the International classification of Fucntionality temporal gyrus via the ENIGMA b. Research on Prevention (ICF) and related instruments of Schizophrenia consortium. Strategies and Bio-psycho-social assessment (i.e., World Health Acta Psychiatr Scand. Interventions for Early Phases Organization Disability Assessment 2017;135:439-447. of Psychosis in children and Schedule 11 (WHO-DAS 11). F.I.:6,790. [doi:10.1111/acps.12718] adolescents.. 4. Nieuwenhuis M, Schnack HG, 7.- 7.- Strategies of assessment van Haren NE, Lappin J, Morgan C, in mental health. Responsibles: • PUBLICATIONS: Reinders AA, Gutierrez-Tordesillas Dr. L. Gaite Pindado and Dra. S. D, Roiz-Santiañez R, Schaufelberger Herrera Castanedo. To develop MS, Rosa PG, Zanetti MV, Busatto and consolidate a network of health IMPACT FACTOR | 123,012 GF, Crespo-Facorro B, McGorry PD, professionals interested in investiga Velakoulis D, Pantelis C, Wood SJ, - ting mental health services and Kahn RS, Mourao-Miranda J, Dazzan P. needs. Multi-center MRI prediction models: Original articles Predicting sex and illness course To promote the development and in first episode psychosis patients. dissemination of investigations on Neuroimage. instruments of assessment and 1. Marshall CR, Howrigan DP, Merico 2017;145:246-253. indicators of outcome (including D, Thiruvahindrapuram B, Wu W, F.I.:5,835. [doi:10.1016/j. economic indicators). Greer DS, Antaki D, Shetty A, Holmans neuroimage.2016.07.027] PA, Pinto D, Gujral M, Brandler WM, 8. Molecular basis of non-affective Malhotra D, Wang Z, Fajarado KVF, 5. Hickling LM, Ortiz-García de la Foz psychosis. Maile MS, Ripke S, Agartz I, Albus M, V, Ayesa-Arriola R, Crespo-Facorro B, Alexander M, Amin F, Atkins J, Bacanu Responsibles: Dra. P. Suárez Pinilla McGuire P, Perez-Iglesias R. SA, Belliveau RA, Bergen SE, Bertalan and Dr. B Crespo Facorro. The The effects of tobacco smoking M, Bevilacqua E, Bigdeli TB, Black DW, range of clinical features shows on age of onset of psychosis and ..., CNV and Schizophrenia Working that schizophrenia affects multiple psychotic symptoms in a first- Groups of the Psychiatric Genomics brain circuits, and also peripheral episode psychosis population. Consortium. Contribution of copy pathways. Recently, we have been Addiction. 2017;112:526-532. number variants to schizophrenia developing the research in this F.I.:5,789. [doi:10.1111/add.13646] field through the study of serum from a genome-wide study of 41,321 subjects. and PBMCs (peripheral blood 6. Mellor-Marsá B, Caballero FF, Nat Genet. 2017;49:27-35. mononuclear cells). Our work in this Cabello M, Ayuso-Mateos JL, F.I.:27,959. [doi:10.1038/ng.3725] area aims to: Setién-Suero E, Vázquez-Bourgon J, Crespo-Facorro B, Ayesa-Arriola R. a. Detect blood biomarkers and 2. Hibar DP, Adams HH, Jahanshad Disability multilevel altered cellular signaling pathways N, Chauhan G, Stein JL, Hofer E, leading to diagnose patients with modelling in first episodes 147
of psychosis at 3-year Foz V, Martínez-García O, Tabarés- and Cognitive Trajectory (ENPACT) follow-up. Seisdedos R, Crespo-Facorro B, study. PLoS One. 2017;12:F.I.:2,806. Schizophr Res. 2017;185:101-106. Ayesa-Arriola R. [doi:10.1371/journal.pone.0188000] F.I.:3,986. [doi:10.1016/j. Rates and predictors of relapse in Martino J, Velasquez C, Vázquez- schres.2016.12.014] first-episode non-affective psychosis: Bourgon J, Marco de Lucas E, a 3-year longitudinal study in a Gomez E. Cross-Modal Recruitment 7. Crespo-Facorro B, Ortiz-Garcia de specialized intervention program of Auditory and Orofacial Areas la Foz V, Suarez-Pinilla P, Valdizan (PAFIP). During Sign Language in a Deaf EM, Pérez-Iglesias R, Amado-Señaris Eur Arch Psychiatry Clin Neurosci. Subject. JA, Teresa Garcia-Unzueta M, Labad 2017;267:315-323. WORLD NEUROSURG. 2017;105: J, Correll C, Ayesa-Arriola R. F.I.:3,569. [doi:10.1007/s00406-016- F.I.:2,592. [doi:10.1016/j. Effects of aripiprazole, quetiapine 0740-3] wneu.2017.05.170] and ziprasidone on plasma prolactin levels in individuals with first episode 12. Correa-Ghisays P, Balanzá- 16. Crespo-Facorro B, Bernardo M, nonaffective psychosis: Analysis of a Martínez V, Selva-Vera G, Vila-Francés Argimon JM, Arrojo M, Bravo-Ortiz randomized open-label 1year study. J, Soria-Olivas E, Vivas-Lalinde J, San MF, Cabrera-Cifuentes A, Carretero- Schizophr Res. 2017;189:134-141. Martín C, Borrás AM, Ayesa-Arriola Román J, Franco-Martín MA, F.I.:3,986. [doi:10.1016/j. R, Sanchez-Moreno J, Sánchez-Ort J, García-Portilla P, Haro JM, Olivares schres.2017.01.046] Crespo-Facorro B, Vieta E, Tabarés- JM, Penadés R, Del Pino-Montes J, Seisdedos R. Sanjuán J, Arango C. 8. López-Gimenez JF, de la Fuente Manual motor speed dysfunction as Effectiveness, efficiency and efficacy Revenga M, Ruso-Julve F, Saunders a neurocognitive endophenotype in in the multidimensional treatment JM, Moreno JL, Crespo-Facorro B, euthymic bipolar disorder patients of schizophrenia: Rethinking project. González-Maeso J. and their healthy relatives. Evidence Rev Psiquiatr Salud Ment. Validation of schizophrenia gene from a 5-year follow-up study. 2017;10:4-20. expression profile in a preclinical J Affect Disord. 2017;215:156-162. F.I.:2,227. [doi:10.1016/j. model of maternal infection during F.I.:3,432. [doi:10.1016/j. rpsm.2016.09.001] pregnancy. jad.2017.03.041] Schizophr Res. 2017;189:217- 17. Arango C, Bernardo M, Bonet P, 218.F.I.:3,986. 13. Juncal-Ruiz M, Ramirez-Bonilla Cabrera A, Crespo-Facorro B, Cuesta [doi:10.1016/j.schres.2017.02.005] M, Gomez-Arnau J, Ortiz-Garcia de MJ, González N, Parrabera S, Sanjuan la Foz V, Suarez-Pinilla P, Martinez- J, Serrano A, Vieta E, Lennox BR, 9. Guadalupe T, Mathias SR, vanErp Garcia O, Neergaard KD, Tabares- Melau M. TG, Whelan CD, Zwiers MP, Abe Y, Seisdedos R, Crespo-Facorro B. When the healthcare does not follow Abramovic L, Agartz I, Andreassen Incidence and risk factors of the evidence: The case of the lack OA, Arias-Vásquez A, Aribisala BS, acute akathisia in 493 individuals of early intervention programs for Armstrong NJ, Arolt V, Artiges with first episode non-affective psychosis in Spain. Rev Psiquiatr E, Ayesa-Arriola R, Baboyan VG, psychosis: a 6-week randomised Salud Ment. 2017;10:78-86. Banaschewski T, Barker G, Bastin study of antipsychotic treatment. F.I.:2,227. [doi:10.1016/j. ME, Baune BT, Blangero J, Bokde Psychopharmacology (Berl). rpsm.2017.01.001] AL, Boedhoe PS, Bose A, Brem S, 2017;234:2563-2570. Brodaty H, Bromberg U, Brooks S, F.I.:3,308. [doi:10.1007/s00213-017- 18. Ferro A, Bonivento C, Delvecchio Büchel C, ..., Francks C. 4646-1] G, Bellani M, Perlini C, Dusi N, Human subcortical brain asymmetries Marinelli V, Ruggeri M, Altamura AC, in 15,847 people worldwide reveal 14. Setién-Suero E, Neergaard K, Crespo-Facorro B, Brambilla P. effects of age and sex. Ramírez-Bonilla M, Correa-Ghisays P, Longitudinal investigation of the BRAIN IMAGING BEHAV. Fañanás L, Crespo-Facorro B, Ayesa- parietal lobe anatomy in bipolar 2017;11:1497-1514. Arriola R. disorder and its association with F.I.:3,985. [doi:10.1007/s11682-016- Cannabis use in male and female general functioning. 9629-z] first episode of non-affective Psychiatry Res. 2017;267:22-31. psychosis patients: Long-term F.I.:1,878. [doi:10.1016/j.pscychresns. 10. Pilar-Cuéllar F, Vidal R, Díaz Á, clinical, neuropsychological and 2017.06.010] Garro-Martínez E, Linge R, Castro E, functional differences. Haberzettl R, Fink H, Bert B, Brosda PLoS One. 2017;12: 19. Martino J, Caballero H, DE Lucas J, Romero B, Crespo-Facorro B, F.I.:2,806. [doi:10.1371/journal. EM, DA Silva-Freitas R, Velasquez Pazos Á. pone.0183613] C, Gomez E, Vazquez-Bourgon J, Enhanced Stress Response in 5-HT Vázquez-Barquero A. 1A R Overexpressing Mice: Altered 15. Maggioni E, Crespo-Facorro Recovery of long-term paresis HPA Function and Hippocampal B, Nenadic I, Benedetti F, Gaser C, following resection of WHO grade Long-Term Potentiation. ACS CHEM Sauer H, Roiz-Santiañez R, Poletti II gliomas infiltrating the pyramidal NEUROSCI. S, Marinelli V, Bellani M, Perlini C, pathway. 2017;8:2393-2401. Ruggeri M, Altamura AC, Diwadkar J NEUROSURG SCI. F.I.:3,883. [doi:10.1021/ VA, Brambilla P, ENPACT group. 2017;61:88-96. acschemneuro.7b00156] Common and distinct structural F.I.:1,522. [doi:10.23736/S0390- features of schizophrenia and bipolar 5616.16.03090-3] 11. Pelayo-Terán JM, Gajardo disorder: The European Network Galán VG, de la Ortiz-García de la on Psychosis, Affective disorders Activity Research Areas Report Neuroscience Area
Thesis Addressed 3. Benedicto Crespo Facorro. 2. Jesús Ángel Artal Simón. Ayudas para contratos predoctorales Estudio epidemiológico para la formación de doctores. observacional, transversal, 1. Montejo ÁL, Arango C, Bernardo BES-2014-070615. MINISTERIO DE multicéntrico e internacional para M, Carrasco JL, Crespo-Facorro ECONOMIA Y COMPETITIVIDAD. evaluar la prevalencia de las crisis de B, Cruz JJ, Del Pino-Montes J, agitación en pacientes psiquiátricos. García-Escudero MA, García-Rizo 4. Benedicto Crespo Facorro. FER-ANT-2013-01. C, González-Pinto A, Hernández AI, Tratamiento estratificado en FERRER INTERNACIONAL, S.A. Martín-Carrasco M, Mayoral-Cleries esquizofrenia: integrando resultados F, Mayoral-van Son J, Mories MT, de transcriptoma humano y celular Pachiarotti I, Pérez J, Ros S, Vieta E. en las estrategias de tratamiento Multidisciplinary consensus on antipsicotico. the therapeutic recommendations SAF2016-76046-R. MINISTERIO DE for iatrogenic hyperprolactinemia ECONOMIA Y COMPETITIVIDAD. secondary to antipsychotics. Front Neuroendocrinol. 5. Benedicto Crespo Facorro. 2017;45:25-34. Plataforma de Unidades de F.I.:9,425. [doi:10.1016/j. Investigación Clínica y Ensayos yfrne.2017.02.003] Clínicos (Scren). PT17/0017/0039. INSTITUTO DE 2. Santesteban-Echarri O, Paino M, SALUD CARLOS III. MINISTERIO DE Rice S, González-Blanch C, McGorry ECONOMÍA Y COMPETITIVIDAD. P, Gleeson J, Alvarez-Jimenez M. Predictors of functional recovery in 6. Benedicto Crespo Facorro. first-episode psychosis: A systematic Iniciativa de promoción a la review and meta-analysis of investigación europea Valdecilla longitudinal studies. (VALER H2020). CLIN PSYCHOL REV. ECT-2017-0371. MINISTERIO DE 2017;58:59-75. ECONOMIA Y COMPETITIVIDAD. F.I.:8,897. [doi:10.1016/j. cpr.2017.09.007] Clinical Trials Reviews 1. Beatriz Payá González. Estudio de fase III, abierto, 1. Maria Teresa Sainz Olavarría. multicéntrico, para proporcionar Estudio Transversal y Longitudinal acceso al clorhidrato de guanfacina de la Morfometría de la Corteza de liberación prolongada a sujetos Orbitofrontal en Pacientes con un europeos con trastorno por déficit Primer Episodio de Psicosis no de atención con hiperactividad Afectiva. Relación con Variables (TDAH) que participaron en el Sociodemográficas, Clínicas y estudio SPD503-315 o SPD503-316. Cognitivas. SPD503-318. Director/a:Benedicto Crespo Facorro. SHIRE PHARMACEUTICAL UNIVERSIDAD DE CANTABRIA. DEVELOPMENT LIMITED.
2. Benedicto Crespo Facorro. Estudio europeo de antipsicóticos de acción prolongada en esquizofrenia. • PROJECTS ABR49490. FOUNDATION EUROPEAN GROUP FOR RESEARCH IN SCHIZOPHRENIA Projects EGRIS.
1. Benedicto Crespo Facorro. Postmarketing Studies Centro de Investigación Biomédica and Other en Red de Salud Mental. CIBERSAM. INSTITUTO DE SALUD 1. Javier Vázquez Bourgon. CARLOS III. MINISTERIO DE Estudio transversal y revisión ECONOMÍA Y COMPETITIVIDAD. retrospectiva de los pacientes con síntomas persistentes de 2. Benedicto Crespo Facorro. esquizofrenia para estimar la Translating neuroimaging findings utilización de recursos médicos y from research into clinical practice. la carga de la enfermedad. ROC- EU12/01- PSYSCAN. COMISIÓN ESQ-2013-01. EUROPEA. ROCHE FARMA, S.A.U. 149 Activity Report 151
· Cancer Area
Fernando Rivera Herrero Coordinator of the Cancer Area.
Head of the Oncology Service. University Hospital Marqués de Valdecilla. Activity Research Areas Report Cancer Area
Group Responsible José Javier Gómez Román Pathology Service • Anatomical and Molecular University Hospital Marqués de Valdecilla Pathology University of Cantabria
Researchers José Fernando Val Bernal
Contributors Ainara Azueta Etxebarría Pablo Miguel Bueno Ortíz Clara Isabel Caballero Escudero Clara Isabel Esparza del Valle Francisco Javier Freire Salinas María Pilar García-Berbel Molina Sara Marcos González Javier Martín López Marta Mayorga Fernández Víctor Jacinto Ovejero Gómez Steliana Florina Racean Consolidated group Nurses Montserrat Fernández Álvarez María Montserrat Nicolás Martínez
Technicians María Dolores Herrera Cisneros Servando Lazuen Fernández 153
Research lines
1. Predictive markers and diagnostics in solid tumors based on techniques advanced molecular:
Our concern continues to be to establish the bridge between basic and clinical research by applying new technologies that help to make therapeutic decisions. Our work focuses on obtaining new markers that may be susceptible to their use in diagnosis and as predictive markers of response to drugs of different neoplasms (MAMACAN and TERPERAN projects based on epithelial-mesenchymal transition molecules such as Collagen XIalfa1 or CCR9).
2. Incorporation of the technology of massive sequencing (Next Generation Sequencing): The results of basic research take implemented BEAMING technology a long time until they can be used to diagnose mutations in colon The task of diagnosing neoplastic in practice. Our mission is to speed cancer in free DNA in plasma pathology goes from making up the use of biomarkers that have with a sensitivity of 0.01% allelic determinations on a single already proven their usefulness in frequency. We also have other molecule to panels of genes with assistance. Thus, we have already technologies for diagnosis in free repercussions on the therapy to incorporated several of the most DNA in plasma for lung cancer, be applied. We have incorporated prevalent tumors such as lung especially aimed at detecting the to the armamentarium of the cancer (mutations in EGFR, ALK resistance mutation T790M group the two most powerful and ROS1), breast cancer (Her2neu technologies at present in this overexpression), colon cancer 6. Development of sense as it is that of Illumina (mutations in KRAS, NRAS and Immunotherapy in cancer. and that of ThermoFisher with BRAF) and brain tumors ( allelic Immunotherapy is one of the which besides giving service to losses of 1p and 19q regions most promising fields in new the hospital routine we provide and methylation of the MGMT cancer therapies. collaborations to other units in promoter), malignant melanoma The use of the so-called research projects. (mutations in the BRAF oncogene) “companion tests” are mandatory and other tumor types where according to the regulatory 3. We incorporated the diagnosis there are treatments that improve agencies for the prescription. We of hereditary cancer associated the quality of life and survival of have developed all the markers with mutations in BRCA1 and 2 patients. with new technologies based on associated with specific anti massive sequencing, decreasing 5. Development of Liquid Biopsy: PD1 and anti PD-L1 therapies. the number of extrahospitalary For this, we are involved in the referrals and the waiting time of the The monitoring of patients with clinical establishment and in new patients of the hereditary cancer cancer is essential due to the models of anti PD-L1 antibodies unit of the Oncology Service. existence of new treatments and SP142, SP263, 22C3 and 28-8. The the development of resistance availability of all antibodies allows 4. Application of the results to them. It is necessary to the participation in new clinical obtained and implementation in detect these resistances in the trials in new tumor models. the clinical care routine. earliest possible way. We have Activity Research Areas Report Cancer Area
7. We actively collaborate with • PUBLICATIONS: 6. Val-Bernal JF, Malaxetxebarria S, groups from Cantabria, Spain and González-Rodilla I, Salas-García M. international in several lines of Woven coronary artery anomaly IMPACT FACTOR | 30,626 work. presenting as sudden cardiac death. With the University of Cantabria Cardiovasc Pathol. 2017;26:7-11. with active projects in relation to Original articles F.I.:2,359. [doi:10.1016/j. Legal Medicine (utility of DNA carpath.2016.10.002] extraction methods in old samples) and the IBBTEC in Genómica 1. Calderon-Gonzalez R, Terán- 7. Val-Bernal JF, Mayorga M, Ortega Navarro H, García I, Marradi M, C, Linares E. (Dr Ignacio Varela with several Salcines-Cuevas D, Yañez-Diaz S, Histiocytoid cardiomyopathy projects in execution using massive Solis-Angulo A, Frande-Cabanes and ventricular noncompaction sequencing procedures). With Dr. E, Fariñas MC, Garcia-Castaño A, presenting as sudden death in an Carmen Álvarez from IDIVAL in Gomez-Roman J, Penades S, Rivera adult male. the project for the development of F, Freire J, Álvarez-Domínguez C. Pathol Res Pract. 2017;213:1424-1430. nanoparticle-based vaccines against Gold glyconanoparticles coupled F.I.:1,543. [doi:10.1016/j. melanoma. The collaboration with to listeriolysin O 91-99 peptide prp.2017.09.002] national research groups is mainly serve as adjuvant therapy against with the CIMA of the University of melanoma. 8. Gómez-Román J, Zarrabeitia Navarra in its line of oncology led NANOSCALE. 2017;9:10721-10732. MT, Santurtún A, Parra JA, Azueta by Professor Luis Montuenga in the F.I.:7,367. [doi:10.1039/c7nr02494k] Etxebarría A, Cifrian JM, Freire field of lung cancer and with the Salinas J. University of Oviedo and various 2. Calderon-Gonzalez R, Frande- Pulmonary Langerhans cell hospitals of the national network Cabanes E, Teran-Navarro H, histiocytosis de novo after lung in the role of the epithelium- Marimon JM, Freire J, Salcines- transplantation. Cuevas D, Fariñas MC, Gonzalez- mesenchyme transition in breast Pathol Int. 2017;67:632-637. Rico C, Marradi M, Garcia I, F.I.:1,465. [doi:10.1111/pin.12597] cancer. Alkorta-Gurrutxaga M, San Nicolas- Gomez A, Castañeda-San Pedro A, 9. Rodríguez-Zarco E, Vallejo- We receive rotating professionals Yañez-Diaz S, Penades S, Punzon C, Benítez A, Umbría-Jiménez S, from different hospitals in the Gomez-Roman J, Rivera F, Fresno Pereira-Gallardo S, Pabón-Carrasco national network to deepen their M, Alvarez-Dominguez C. GNP- S, Azueta A, González-Cámpora teaching. The collaboration extends GAPDH1-22 nanovaccines prevent R, Espinal PS, García-Escudero A. to European countries as well as to neonatal listeriosis by blocking Immunohistochemical study of the microglial apoptosis and bacterial neural development transcription the group of Dr Julian Downward dissemination. factors (TTF1, ASCL1 and BRN2) in of the London Research Institute Oncotarget. 2017;8:53916-53934. neuroendocrine prostate tumours. investigating factors of resistance F.I.:5,168. [doi:10.18632/ Actas Urol Esp. to drugs that inhibit tyrosine kinase oncotarget.19405] 2017;41:529-534. activity in lung cancer. We also F.I.:1,181. [doi:10.1016/j. collaborated with MD Anderson 3. Fernando Val-Bernal J. acuro.2016.11.009] Hospital in a neuroendocrine tumor Primary pure lymphoepithelioma- evaluation project and its new like carcinoma of the ureter. 10. Val-Bernal JF, Hermana S, classification (Dr. Cesar Moran) Virchows Arch. 2017;471:559-559. Armesto S, González-Vela MC. F.I.:2,848. [doi:10.1007/s00428-017- Melanocytes Containing Large 2188-x] Nuclei and Abundant Pale Cytoplasm in Melanocytic Nevi. 4. Irure J, Asensio E, Rodrigo Am J Dermatopathol. E, Romón Í, Gómez J, Arias M, 2017;39:414-416. López-Hoyos M, San Segundo D. F.I.:1,095. [doi:10.1097/ Improvement in the definition of DAD.0000000000000644] anti-HLA antibody profile in highly sensitized patients. 11. Val-Bernal JF, González-Vela MC, PLoS One. 2017;12: León-Castillo A, Armesto S. F.I.:2,806. [doi:10.1371/journal. Papillary Dermal Elastosis. pone.0171463] Am J Dermatopathol. 2017;39:150- 152.F.I.:1,095. [doi:10.1097/ 5. Val-Bernal JF, Terán-Villagrá N, DAD.0000000000000653] García-Diego O, Sarralde JA. Lymphocyte-rich capillary- cavernous hemangioma of the Authorship Thesis mitral valve: a case report and review of the literature. 1. María Pilar García-Berbel Molina. Cardiovasc Pathol. 2017;28:59-63. Utilidad del COL11A1 como F.I.:2,359. [doi:10.1016/j. marcador pronóstico de infiltración carpath.2017.03.003] tumoral. 155
Director/es: Francisco Javier Freire 2. José Javier Gómez Román. • PROJECTS Salinas, José Javier Gómez Román. Desarrollo de anticuerpos UNIVERSIDAD DE CANTABRIA. terapéuticos anti-CCR9 para el Projects tratamiento personalizado de Thesis Addressed tumores- TERPERAN. RTC-2015- 3786-1. 1. José Javier Gómez Román. MINISTERIO DE ECONOMIA Y 1. Lucía García-Berbel Molina. Desarrollo y validación de métodos COMPETITIVIDAD. Determinación de Biomarcadores y productos de diagnóstico contra Pronósticos en Papilomas el carcinoma infiltrante de mama Intraductales Mamarios. Director/ (MAMACAN). IPT 2011-1817- es: Francisco Javier Freire Salinas, 900000. José Javier Gómez Román. MINISTERIO DE ECONOMIA Y UNIVERSIDAD DE CANTABRIA. COMPETITIVIDAD. Activity Research Areas Report Cancer Area
Group Responsible Juan M. Hurlé Gonzalez Department of Molecular Biology School of Medicine • Apoptosis University of Cantabria
Researchers Juan Antonio Montero Simón
Contributors Juan Antonio García-Porrero Pérez Carlos Ignacio Lordá Díez
Predoctoral Beatriz García-Riart Monzón Cristina Sánchez Fernández
Consolidated group
of skeletal progenitors and also of the embryonic limb bud follow two to provide information about limb alternative fates: in the future digit morphogenesis. Genesidentified regions, mesodermal cells aggregate Research by different molecular strategies and differentiate into cartilage, joints are functionally analyzed through and fibrous tissues such as tendons lines gain-of- and lossof-function or ligaments; in the interdigital experiments. Gain-of-function regions, cells do not condense experiments are performed through and instead undergo massive cell the overexpression of the selected death. The goal of these studies is genes employing viral infections or to obtain information of relevance We are interested in the development plasmid electroporation. Loss-of- in regenerative medicine to direct of the vertebrate limb using avian function experiments are made with the differentiation of stem cells into and mouse embryos as experimental short hairpin RNAi or CRISPR-Cas9 skeletal tissues and to provide basic models. The aim of our research approaches. Our major research field information about the mechanisms is to uncover molecular signals is the formation of the digits. During accounting for programmed cell which regulate the diffe rentiation this process mesodermal progenitors death. 157
• PUBLICATIONS: transcriptional upregulation of Esqueléticos de los Espacios RhoA. Interdigitales Embrionarios. IMPACT FACTOR: | 9,701 Oncogene. 2017;36:1733-1744. Director/es: Juan M Hurlé Gonzalez, F.I.:7,519. [doi:10.1038/onc.2016.341] Juan Antonio Montero Simón. UNIVERSIDAD DE CANTABRIA. 2. Garcia-Riart B, Lorda-Diez CI, Original articles Marin-Llera JC, Garcia-Porrero JA, Hurle JM, Montero JA. • PROJECTS Interdigital tissue remodelling in 1. Talamillo A, Grande L, Ruiz- the embryonic limb Ontañon P, Velasquez C, Mollinedo P, involves dynamic regulation Torices S, Sanchez-Gomez P, Aznar Projects of the miRNA profiles. A, Esparis-Ogando A, Lopez-Lopez J Anat. 2017;231:275-286. C, Lafita C, Berciano MT, Montero F.I.:2,182. [doi:10.1111/joa.12629] 1. Juan M. Hurlé Gonzalez. JA, Vazquez-Barquero A, Segura V, Mecanismo y nueva significación Villagra NT, Pandiella A, Lafarga M, biológica de la muerte celular Leon J, Martinez-Climent JA, Sanz- Authorship Thesis interdigital responsable de la Moreno V, Fernandez-Luna JL. separación de los dedos durante ODZ1 allows glioblastoma 1. Beatriz García-Riart Monzon. el desarrollo de las extremidades. to sustain invasiveness Análisis del Perfil de los Microrna en BFU2014-54026-P. through a Myc-dependent la Eliminación de los Progenitores MINISTERIO DE ECONOMIA Y COMPETITIVIDAD. Activity Research Areas Report Cancer Area
Group Responsible Alberto Gandarillas Solinis Valdecilla Biomedical • Cell Cycle, Determining Stem Reserch Institute Marqués de Valdecilla Cells and Cancer IDIVAL
Contributors Higinio Ayala Gutiérrez José Manuel Bernal Marco Natalia Castañeda Curto Ernesto de Diego García Isabel de Pedro González Verónica Fernández González Inmaculada Fernández Jiménez Ana Franco Gonzalez de Canales Ana Freije León María Fe García Reija María Teresa Gil Aguilar Patricia López Santos Carmelo Morales Angulo Sergio Obeso Aguera Ramón Sanz Giménez-Rico Consolidated group Ana Tardaguila Calvo María Soledad Trugeda Carrera Sandra Patricia Vergara Pastrana
Predoctoral Rut Molinuevo Llaria Natalia Sanz Gómez
Technicians Laura Ceballos Castillo
https://www.cancerresearchuk. in English) causes around 200,000 org/). SCC typically appears in the deaths per year in the world (Ferlay stratified epithelia of the skin, oral et al., 2010). In Spain, about 12,000 Research cavity, pharynx, larynx, esophagus, cases are diagnosed each year lines cervix, but is also common in some (SEOM, 2014). simple epithelia such as the lung. It constitutes 20% of epithelial There is growing evidence that cancer in the skin, 90% in the epidermoid epithelia may have a head and neck, 20-80% in the common regulation, and therefore Epithelia are the tissues most esophagus, or 25-30% in the lung. common alterations would give frequently affected by cancer. It is usually aggressive and has rise to epidermoid carcinomas. Among them, squamous cell a poor prognosis and treatment, These epithelia are continuously carcinoma (SCC) is the second except in the case of the skin where exposed to the action of mutagens most frequent and one of the it is usually detected early and such as ultraviolet light from leading causes of cancer death eliminated by surgery. Even so, in the sun, alcohol or tobacco. For (Ferlay et al., 2010; http://www. the skin, SCC metastasizes in 4-5% these reasons they need powerful wcrf.org; https: //www.cancer. of cases (Karia et al., 2013). Only cellular and molecular mechanisms. gov/; http://www.cancer.org; the head and neck SCC (HNSCC These mechanisms go through a 159
correct control of Stem Cells and EUR J CELL BIOL. 2017;96:632- • PUBLICATIONS: homeostasis. The main objective 641.F.I.:3,712. [doi:10.1016/j. of our group is the investigation ejcb.2017.03.011] of these mechanisms and their IMPACT FACTOR: | 18,856 alteration in hyperproliferative 4. Domínguez-Durán E, Domènech- problems, fundamentally those Vadillo E, Álvarez-Morujo de Sande that lead to cancer. We use and Original articles MG, González-Aguado R, Guerra- develop technologies in vitro, in situ Jiménez G, Ramos-Macías Á, and in vivo to study the different Morales-Angulo C, Martín-Mateos AJ, tissues and squamous carcinomas. 1. Molinuevo R, Freije A, de Pedro I, Figuerola-Massana E, Galera-Ruiz H. We seek to apply the knowledge Stoll SW, Elder JT, Gandarillas A. Analysis of risk factors generated through the reciprocal influencing the outcome of FOXM1 allows human transfer between the laboratory the Epley maneuver. Eur Arch keratinocytes to bypass the (molecular mechanisms of the cell Otorhinolaryngol. oncogene-induced differentiation cycle), the industry (exploitation of 2017;274:3567-3576. checkpoint in response to gain of the results) and the clinic (obtaining F.I.:1,660. [doi:10.1007/s00405-017- MYC or loss of p53. biopsies, characterization, 4674-9] Oncogene. 2017;36:956-965. monitoring, new diagnoses or F.I.:7,519. [doi:10.1038/onc.2016.262] therapies).
2. Alonso-Lecue P, de Pedro I, The main lines currently active • PROJECTS are: Coulon V, Molinuevo R, Lorz C, Segrelles C, Ceballos L, López- 1) Mechanisms of homeostasis of Aventín D, García-Valtuille A, Bernal Projects the epidermis and other epidermoid JM, Mazorra F, Pujol RM, Paramio epithelia against genetic damage. J, Ramón Sanz J, Freije A, Toll A, Gandarillas A. 1. Alberto Gandarillas Solinis. 2) Mechanisms of control of mitosis Inefficient differentiation response Nuevas Rutas y Estrategias Hacia and epidermoid differentiation. to cell cycle stress leads to el Cáncer de Células Escamosas. genomic instability and malignant PI14/00900. 3) Alterations of the control mitosis- progression of squamous INSTITUTO DE SALUD CARLOS differentiation in squamous cancer. carcinoma cells. III. MINISTERIO DE ECONOMÍA Y Cell Death Dis. 2017;8: COMPETITIVIDAD. 4) In vitro applications for F.I.:5,965. [doi:10.1038/ personalized medicine in: cddis.2017.259] 2. Alberto Gandarillas Solinis. Dianas terapéuticas causantes · Mother cells. 3. Purba TS, Brunken L, Peake M, de inestabilidad genómica y Shahmalak A, Chaves A, Poblet · Cancer. malignidad comunes al cáncer E, Ceballos L, Gandarillas A, Paus escamoso, para su aplicación R. Characterisation of cell cycle · Rare, hereditary diseases or en medicina personalizada. arrest and terminal differentiation developmental syndromes. PI17/01307. in a maximally proliferative human INSTITUTO DE SALUD CARLOS epithelial tissue: Lessons from III. MINISTERIO DE ECONOMÍA Y the human hair follicle matrix. COMPETITIVIDAD. Activity Research Areas Report Cancer Area
Group Responsible Santiago Montes Moreno Pathology • Translational Service University Hospital Hematopathology Marqués de Valdecilla
Contributors Ruth Alonso Alonso Julia García Reyero María del Carmen González Vela Nerea Martínez Magunacelaya María Martino González Arantza Onaindia Pérez
Technicians María Pilar Díaz García Ainara González Pereña Enriqueta Pumarejo Gómez
Emerging group
molecular markers of clinical utility. analysis and interpretation protocols The use of phenotyping techniques, of B and T lymphoid cloning of the Research new technologies such as mass European consortium Biomed2 and, sequencing, high sensitivity recently, has generated a protocol lines expression analysis techniques, of clinical diagnosis of somatic detection of circulating tumor DNA mutation detection MYD88L265P, in plasma (liquid biopsy) requires useful in small cell B lymphomas a rigorous preclinical validation with plasmacytic differentiation for its use as clinical diagnostic (lymphoplasmacytic B lymphoma / 1. New technologies useful tools. Our group generates Waldestrom’s disease) and diffuse for the molecular diagnosis of and validates clinical molecular large cell B-cell lymphoma of ABC patients with hematolymphoid diagnostic tools useful in the area phenotype. The inclusion of the neoplasms. of hematolymphoid pathology. He determination in the catalog of SCS has participated in the validation laboratory tests (November 2017) The field of hematopathology is of monoclonal antibodies useful has recently been approved and is in continuous development with in the diagnosis (ie GCET1, SPI-B), routinely performed as a molecular regard to the identification of new validation and standardization of the diagnostic method in our laboratory. 161
Currently, a line of progress is the The precise subclassification of optimization of a protocol for the the different entities of LBDCG • PUBLICATIONS: identification of somatic mutations has clinical relevance from the in free circulating tumor DNA in point of view of prognosis and IMPACT FACTOR: | 85,632 plasma of patients with LBDCG selection of therapy since there that serves as a screening to are a number of phenotypes of the diagnosis of the disease and aggressive clinical behavior (high clinical monitoring of patients. grade B lymphoma with “double / Original articles The implementation of this new triple hit”, LBDCG of subtype ABC, procedure is part of the PI16 / 1397 plasmablastic lymphoma) for which 1. Curiel-Olmo S, Mondejar R, project. standard immunochemotherapy is Almaraz C, Mollejo M, Cereceda L, ineffective. Recent studies using Marès R, Derdak S, Campos-Martín 2. Clinical validation of massive genome and exome Y, Batlle A, González de Villambrosía biomarkers in translational sequencing are identifying recurrent S, Gut M, Blanc J, Traverse-Glehen research projects linked to genetic alterations in the pathways A, Verney A, Baseggio L, Camacho multicenter clinical trials for of NFkB, BCR, JAK / STAT, histone FI, Wotherspoon A, Stamatopoulos patients with hematolymphoid modifying genes and genes related K, Xochelli A, Papadaki T, Kanellis neoplasms. to the immune response, among G, Ponzoni M, Garcia-Cosio M, others. Some of these alterations Vaque JP, Beltran S, Gut I, Piris MA, The clinical validation of molecular are associated with specific Martinez N. markers is concreted by analyzing phenotypes and may be targeted Splenic diffuse red pulp small therapy targets. the impact of these biomarkers B-cell lymphoma displays increased in clinical trials designed to test Recent data from our group (S expression of cyclin D3 and their predictive value of response recurrent CCND3 mutations. and prognosis. In this sense, Montes-Moreno, et al., Modern Pathology 2017) reinforce the Blood. 2017;129:1042-1045. our group, integrated with the relevance of the MYC oncogene F.I.:13,164. Pathological Anatomy Service of [doi:10.1182/blood-2016-11-751024] the HUMV, leads a centralized in plasmablastic lymphoma and describe, for the first time, somatic anatomopathological and molecular 2. Campos-Martín Y, Martínez N, mutations in PRDM1 / blimp1 in diagnostic platform for the samples Martínez-López A, Cereceda L, Casado this type of neoplasm, revealing of patients included in clinical F, Algara P, Oscier D, Menarguez FJ, new molecular mechanisms of the trials of the national cooperative García JF, Piris MA, Mollejo M. illness. group GELTAMO (Spanish Group Clinical and diagnostic relevance of of Lymphomas and Bone Marrow Additionally, the recent NOTCH2 -and KLF2 -mutations in Transplantation). , responsible implementation of NGS-directed splenic marginal zone lymphoma. for the centralized diagnosis sequencing technologies in cases of Haematologica. 2017;102: and generation of molecular LBDCG is revealing that mutational F.I.:7,702. [doi:10.3324/ study protocols of the different profiles are associated with specific haematol.2016.161711] open clinical trials in large cell B clinicopathological variants and lymphoma (GEL-BRCAP21 (EudraCT 3. Calvo-Río V, Santos-Gómez M, condition their phenotype. Recent Nº: 2012- 005138-12), GEL-RCOMP Calvo I, González-Fernández MI, López observations from our group 2013 (Nº EudraCT: 2013- 001065- Montesinos B, Mesquida M, Adán A, confirm that the application of 17), LR-ESHAP (Nº EudraCT: 2010- Victoria Hernández M, Maíz O, Atanes directed sequencing methods of 018463-41), IBDCL (Nº EudraCT: A, Bravo B, Modesto C, Díaz-Cordovés the exome using NGS allows us 2015-005390-21). This project G, Palmou-Fontana N, Loricera J, to trace the clonal evolution of has financing from national funds González-Vela MC, Demetrio-Pablo refractory LBDCG and may have an (MINECO, PI16 / 1397). R, Hernández JL, González-Gay MA, impact on the selection of optimal Blanco R. therapy (Garcia-Reyero et al., Clonal 3. Identification of markers Anti-Interleukin-6 Receptor Evolution in primary diffuse large of diagnostic, prognostic and Tocilizumab for Severe Juvenile B cell lymphoma of the Central predictive utility of response to Idiopathic Arthritis-Associated Nervous System, AIMM, 2018). therapy in patients with large cell Uveitis Refractory to Anti-Tumor B-cell lymphoma. Necrosis Factor Therapy: A Multicenter Study of Twenty-Five Diffuse large-cell lymphoma B Patients. (BDLL) is the most frequent form Arthritis Rheumatol. of non-Hodgkin’s lymphoma in 2017;69:668-675.F.I.:6,918. our country and accounts for 80% [doi:10.1002/art.39940] of aggressive lymphomas, with an upward-trend incidence that 4. González-Vela MC, Curiel-Olmo represents about 93,000 new cases S, Derdak S, Beltran S, Santibañez a year in Europe. (GLOBOCAN M, Martínez N, Castillo-Trujillo A, Gut (IARC). M, Sánchez-Pacheco R, Almaraz C, Cereceda L, Llombart B, Agraz-Doblas A, Revert-Arce J, López Guerrero JA, Mollejo M, Marrón PI, Ortiz-Romero Activity Research Areas Report Cancer Area
Figure A. Image depicting recurrent (Stratifying diffuse large B-cell Figure D. The complete molecular mutated genes in LBDCG. The new lymphoma patients treated with characterization (genotype and methods of directed sequencing of chemoimmunotherapy: GCB / Non- phenotype) of aggressive B-cell the exoma allow to generate mapping GCB by immunohistochemistry is subtypes such as plasmablastic of the cases in order to identify still a robust and feasible marker. lymphoma allows explaining the profiles that guide the optimal therapy Oncotarget 2016). interaction between neoplastic driver in each subject. genes (MYC) and other regulatory genes (PRDM1 / Blimp1) revealing Figure C. Clinical validation of new new molecular mechanisms of Figure B. The correlation of molecular diagnostic techniques disease (Plasmablastic Lymphoma expression data with global survival (identification of the mutation of phenotype is determined by genetic and progression-free survival in MYD88L265P by AS-PCR and direct alterations in MYC and PRDM1, LBDCG allows the identification sequencing in large cell type B Modern Pathology 2017). of patients who could benefit lymphoma is shown as an example) is from inclusion in clinical trials useful for proper subclassification of with new, more selective drugs each case. 163
P, Fernandez-Cuesta L, Varela I, Gut I, Dybkær K, Tam W, Bhagat G, Hsi ED, J, Hernández JL, González-Gay MÁ. Cerroni L, Piris MA, Vaqué JP. van Krieken JH, Ponzoni M, Ferreri Significant sE-Selectin levels Shared Oncogenic Pathways AJM, Wang S, Møller MB, Piris MA, reduction after 6 months of anti- Implicated in Both Virus-Positive Medeiros LJ, Li Y, Pham LV, Young KH. TNF-a therapy in non-diabetic and UV-Induced Merkel Cell AKT Hyperactivation and the patients with moderate-to-severe Carcinomas. Potential of AKT-Targeted Therapy psoriasis. J Invest Dermatol. in Diffuse Large B-Cell Lymphoma. J Dermatolog Treat. 2017;28:726-730. 2017;137:197-206.F.I.:6,287. Am J Pathol. F.I.:1,890. [doi:10.1080/09546634.20 [doi:10.1016/j.jid.2016.08.015] 2017;187:1700-1716. 17.1329498] F.I.:4,057. [doi:10.1016/j. 5. Visco C, Wang J, Tisi MC, Deng L, ajpath.2017.04.009] 15. González-López MA, Hernández D’Amore ESG, Tzankov A, Montes- JL, Vilanova I, Mata C, López-Escobar Moreno S, Dybkær K, Bhagat G, Hsi 10. Pardo A, Real E, Krishnaswamy V, M, González-Vela MC, López-Hoyos ED, van Krieken JH, Ponzoni M, Ferreri Lopez-Higuera JM, Pogue BW, Conde M, González-Gay MA, Blanco R. AJM, Møller MB, Piris MA, Medeiros OM. Thyroid autoimmunity in patients LJ, Xu-Monette ZY, Young KH. Directional Kernel Density with hidradenitis suppurativa: a Hepatitis C virus positive diffuse Estimation for Classification case-control study. large B-cell lymphomas have of Breast Tissue Spectra. IEEE Clin Exp Dermatol. distinct molecular features and lack Trans Med Imaging. 2017;36:64- 2017;42:642-644. BCL2 translocations. 73.F.I.:3,942. F.I.:1,589. [doi:10.1111/ced.13153] Br J Cancer. [doi:10.1109/TMI.2016.2593948] 2017;117:1685-1688. 16. Jiménez-Alonso M, Montes- F.I.:6,176. [doi:10.1038/bjc.2017.345] 11. Mondejar R, Pérez C, Onaindia Moreno S, Banzo I. Erdheim-Chester A, Martinez N, González-Rincón J, disease with isolated skeletal 6. Montes-Moreno S, Martinez- Pisonero H, Vaqué JP, Cereceda L, involvement in patient with Magunacelaya N, Zecchini-Barrese T, Santibañez M, Sánchez-Beato M, odontalgia. Gonzalez de Villambrosía S, Linares E, Piris MA. Med Clin (Barc). Ranchal T, Rodriguez-Pinilla M, Batlle Molecular basis of targeted therapy 2017;149:229-230. A, Cereceda-Company L, Revert-Arce in T/NK-cell lymphoma/leukemia: F.I.:1,125. [doi:10.1016/j. JB, Almaraz C, Piris MA. A comprehensive genomic and medcli.2017.03.018] Plasmablastic lymphoma phenotype immunohistochemical analysis of a is determined by genetic alterations panel of 33 cell lines. 17. Val-Bernal JF, Hermana S, in MYC and PRDM1. PLoS One. 2017;12: Armesto S, González-Vela MC. Mod Pathol. 2017;30:85-94. F.I.:2,806. [doi:10.1371/journal. Melanocytes Containing Large F.I.:5,728. [doi:10.1038/ pone.0177524] Nuclei and Abundant Pale modpathol.2016.162] Cytoplasm in Melanocytic Nevi. Am 12. Calvo-Río V, Blanco R, Santos- J Dermatopathol. 7. Manso R, Roncador G, Montes- Gómez M, Díaz-Valle D, Pato E, 2017;39:414-416. Moreno S, Rojo F, Pérez-Sáenz MÁ, Loricera J, González-Vela MC, F.I.:1,095. [doi:10.1097/ Mollejo M, Menárguez J, Carvajal N, Demetrio-Pablo R, Hernández JL, DAD.0000000000000644] García-Cosio M, Llamas P, Piris MA, González-Gay MA. Rodríguez-Pinilla SM. Efficacy of Anti-IL6-Receptor 18. Val-Bernal JF, González-Vela MC, p-MAPK1 expression associated Tocilizumab in Refractory Cystoid León-Castillo A, Armesto S. with poor prognosis in Macular Edema of Birdshot Papillary Dermal Elastosis. Am J angioimmunoblastic T-cell Retinochoroidopathy Report of Two Dermatopathol. lymphoma patients. Cases and Literature Review. 2017;39:150-152. Br J Haematol. 2017;176:661-664. OCUL IMMUNOL INFLAMM. F.I.:1,095. [doi:10.1097/ F.I.:5,670. [doi:10.1111/bjh.13972] 2017;25:604-609. DAD.0000000000000653] F.I.:2,453. [doi:10.1080/09273948.20 8. Remuzgo-Martínez S, Genre F, 16.1231331] Castañeda S, Corrales A, Moreno- Reviews Fresneda P, Ubilla B, Mijares V, Portilla 13. González-López MA, Consuegra V, González-Vela J, Pina T, Ocejo- G, Lacalle M, González-Vela MC. 1. Onaindia A, Medeiros LJ, Patel KP. Vinyals G, Irure-Ventura J, Blanco R, Unilateral angiokeratoma of the Clinical utility of recently identified Martín J, Llorca J, López-Mejías R, scrotum (Fordyce’s type) associated diagnostic, prognostic, and predictive González-Gay MA. with a contralateral varicocele. molecular biomarkers in mature Protein tyrosine phosphatase Indian J Dermatol Venereol Leprol. B-cell neoplasms. Mod Pathol. non-receptor 22 and C-Src tyrosine 2017;83:470-472. 2017;30:1338-1366. kinase genes are down-regulated in F.I.:1,948. [doi:10.4103/ijdvl. F.I.:5,728. [doi:10.1038/ patients with rheumatoid arthritis. IJDVL_850_14] modpathol.2017.58] Sci Rep. 2017;7:10525-10525. F.I.:4,259. [doi:10.1038/s41598-017- 14. Genre F, Armesto S, Corrales A, 2. Piris MA, Onaindía A, Mollejo M. 10915-9] López-Mejías R, Remuzgo-Martínez Splenic marginal zone lymphoma. S, Pina T, Ubilla B, Mijares V, Martín- Best Pract Res Clin Haematol. 9. Wang J, Xu-Monette ZY, Jabbar Varillas JL, Rueda-Gotor J, Portilla V, 2017;30:56-64.F.I.:2,000. KJ, Shen Q, Manyam GC, Tzankov A, Dierssen-Sotos T, González-López MA, [doi:10.1016/j.beha.2016.09.005] Visco C, Wang J, Montes-Moreno S, González-Vela MDC, Blanco R, Llorca Activity Research Areas Report Cancer Area
Thesis Addressed Antonio, Rodriguez Pinilla, Socorro • PROJECTS Maria, Mayordomo Aranda, Empar, 1. Glenda Mariuxi Bermudez BATLLE LOPEZ, MARIA ANA, Pinargote. Rozman, Maria, Garcia Sanz, Ramon. Projects Neoplasia folicular in situ y neoplasia Recomendaciones para el de células del manto in situ: estudio histopatologico, 1. SANTIAGO MONTES MORENO. incidencia y significado clínico. inmunohistoquimico, citogenetico y Targeted exonic next generation Director/es: Miguel Ángel Piris molecular e informe diagnostico de sequencing for the molecular Pinilla, Santiago Montes Moreno. los procesos neoplasicos linfoides. diagnosis and cell free tumor DNA UNIVERSIDAD DE CANTABRIA. Consenso SEAP_SEHH-GOTEL. analysis as screening method for Libro blanco de anatomía patológica patients with DLBCL. PI16/01397. Books and Book Chapters de la SEAP. 2017.65. INSTITUTO DE SALUD CARLOS III. MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD. 1. MONTES MORENO, SANTIAGO, MOLLEJO VILLANUEVA, MANUELA, Fraga, Maximo, Garcia, Juan Fernando, Jose Luis, Villar, Martinez, 165 Activity Research Areas Report Cancer Area
Group Responsible José Ignacio Banzo Marraco Nuclear Medicine Service University Hospital • Molecular Imaging Marqués de Valdecilla
Researchers Julio Francisco Jiménez Bonilla María Isabel Martínez Rodríguez
Contributors María de Arcocha Torres Iván García Martín María Teresa García Unzueta Néstor Anibal Martínez Amador Pedro José Prada Gómez Remedios Quirce Pisano María Ángeles Revilla García
Consolidated group
b. Assessment of the role of and inflammation of the carotid 18F-FDG PET/CT on the effect of atheroma plaque. biologic therapy in solid tumours. Research a. To define an acquisition lines c. Tissue characterization of protocol of 18F-FDG PET/CT pulmonary lesions by 18F-FDG to study the carotid plaque PET/CT. metabolism.
d. Assessment of the role of b. To assess the inflammation 1. Molecular Imaging od Glucose 18F-FDG PET/CT to the nodal process of the carotid plaque by Metabolism in Oncology. staging of lung cancer. 18F-FDG PET/CT. c. To assess the calcification a. Imaging Criteria for measuring process of the carotid plaque by the Metabolic Response to 18FNa PET/CT. treatment in Oncology. 2. Molecular Imaging in the study assessment of the mineralization 167
d. To monitor the response to of FDG in the large vessels was, Rodríguez A, Berciano J, Banzo I, anti-inflammatory treatment by to establish the optimum time for Infante J. 18F-FDG PET/CT image acquisition. Prospective clinical and DaT- To study the carotid plaque SPECT imaging in premotor LRRK2 c. To identify the normal uptake stability and to identify the G2019S-associated Parkinson patterns in different vascular vulnerable plaque by molecular disease. territories. imaging techniques Neurology. 2017;89:439-444. d. To quantify the arterial wall F.I.:7,592. [doi:10.1212/ 3. Assessment and evaluation activity in relation to the global WNL.0000000000004185] of the clinical impact of vascular activity. 18F-FNa PET/CT and 18F-FDG 2. Crespo-Facorro B, Ortiz-Garcia e. To calculate the standard PET/CT in the management de la Foz V, Suarez-Pinilla P, Valdizan uptake values ( SUV ) in normal of atherosclerosis in diabetic EM, Pérez-Iglesias R, Amado-Señaris subjects and in patients with patients. JA, Teresa Garcia-Unzueta M, Labad arterial wall inflammation. J, Correll C, Ayesa-Arriola R. 6. Research and Development Effects of aripiprazole, quetiapine a. To establish an acquisition and ziprasidone on plasma of new molecular imagen protocol for 18F-FNa PET/CT and prolactin levels in individuals radiotracers. 18F-FDG PET/CT for the study with first episode nonaffective of atherosclerosis in diabetic psychosis: Analysis of a patients. a. To study the application of randomized open-label 1year radiotracers for prostate cancer study. b. To identify uptake patterns in recurrence. Schizophr Res. 2017;189:134-141. different vascular territories of F.I.:3,986. [doi:10.1016/j. the body in diabetic patients. b. To assess the role of schres.2017.01.046] 11C-methionine in primary c. To evaluate the correlation hyperparathyroidism. between the arterial uptake of 3. Riancho J, Pozueta A, Santos M, 18F-Fna and cardiovascular risk c. To evaluate the role of Lage C, Carril JM, Banzo I, Martínez- factor of diabetes. 11C-methionine in the suspicion Rodriguez I, Gorno-Tempini M, of brain tumour recurrence. Sánchez-Juan P. 4. Molecular Imaging of the Logopenic Aphasia due to a protein b-amyloid in the study d. To carry out the synthesis and Strategic Stroke: New Evidence from of the cognitive impairment and clinical and to assess the clinical a Single Case. assessment of its clinical impact. contribution of 18F-FLT. J Alzheimers Dis. 2017;57:717-721. e. To carry out the synthesis and F.I.:3,731. [doi:10.3233/JAD-161267] a. Identification of patients with develop. Alzheimer´s disease. 4. Caresia Aroztegui AP, García Vicente AM, Alvarez Ruiz S, Delgado b. To establish an acquisition Bolton RC, Orcajo Rincon J, Garcia protocol for b-amyloid imaging Garzon JR, de Arcocha Torres M, using 11C-PIB PET/CT. Garcia-Velloso MJ, Oncology Task Force of the c. To determine the 11C-PIB Spanish Society of Nuclear retention patterns in the brain. Medicine and Molecular Ima. d. To study the contribution of 18F-FDG PET/CT in breast 11C-PIB PET/CT in the study of cancer: Evidence-based cognitive impairment. recommendations in initial staging. Tumour Biol. 2017;39:F.I.:3,650. e. To identify the patients with b [doi:10.1177/1010428317728285] amyloid deposit in the brain. f. To assess the role of 11C-PIB 5. Martínez-Rodríguez I, García- in differential diagnose of Castaño A, Quirce R, Jiménez-Bonilla dementias. J, Banzo I. Erythema Nodosum-Like g. To evaluate quantitatively the Panniculitis as a False-Positive contribution of 11C-PIB. • PUBLICATIONS: 18F-FDG PET/CT in Advanced 5. Molecular Imaging in the Melanoma Treated With early diagnosis and extension of IMPACT FACTOR | 46,242 Dabrafenib and Trametinib. vasculitis. Clin Nucl Med. 2017;42:44-46. F.I.:3,640. [doi:10.1097/ RLU.0000000000001448] a. To establish an acquisition Original articles protocol for 18F-FDG in patients 6. García-Hoyos M, García-Unzueta with suspicion of large vessel MT, de Luis D, Valero C, Riancho JA. vasculitis. 1. Sierra M, Martínez-Rodríguez I, Diverging results of areal and Sánchez-Juan P, González-Aramburu volumetric bone mineral density in b. To determine the biokinetics I, Jiménez-Alonso M, Sánchez- Down syndrome. Activity Research Areas Report Cancer Area
Osteoporos Int. 2017;28:965-972. 12. Martínez-Rodríguez I, Banzo I. Thesis Addressed F.I.:3,591. [doi:10.1007/s00198-016- Advances in PET: The success of 3814-1] multimodal molecular imaging. Med Clin (Barc). 2017;148:354-356. 1. Marcos Pajaron Guerrero. 7. Tenorio J, Álvarez I, Riancho- F.I.:1,125. [doi:10.1016/j. Auto-Administracion de Tratamiento Zarrabeitia L, Martos-Moreno GÁ, medcli.2016.11.020] Antimicrobiano Domiciliario Mandrile G, de la Flor Crespo M, Endovenoso (a-tade) en la Sukchev M, Sherif M, Kramer I, 13. Morán López JM, Beneítez Moralejo Endocarditis Infecciosa: Un modelo Darnaude-Ortiz MT, Arias P, Gordo G, B, Piedra León M, Enciso Izquierdo FJ, Asistencial Seguro y Eficiente. Dapía I, Martinez-Villanueva J, Gómez Luengo Pérez LM, Amado Señaris JA. Director/es: María Del Carmen R, Iturzaeta JM, Otaify G, García- Benefits of early specialized nutritional Fariñas Álvarez, José Ramón Unzueta M, Rubinacci A, Riancho JA, support in malnourished patients. De Berrazueta Fernández. Aglan M, Temtamy S, Hamid MA, Med Clin (Barc). 2017;148:303-307. UNIVERSIDAD DE CANTABRIA. Argente J, Ruiz-Pérez VL, Heath KE, F.I.:1,125. [doi:10.1016/j. Lapunzina P. medcli.2016.10.032] Other Publications Molecular and clinical analysis of
ALPL in a cohort of patients with 14. Jiménez-Alonso M, Montes- 1. Domínguez Rodríguez, F., Ramos, suspicion of Hypophosphatasia. Moreno S, Banzo I. A., Bouza, E., Munoz, P., Valerio, M. Am J Med Genet A. Erdheim-Chester disease with C., Farinas, C., De Berrazueta, J. R., 2017;173:601-610. isolated skeletal involvement in Zarauza, J., Pericas Pulido, J. M., F.I.:2,259. [doi:10.1002/ajmg.a.37991] patient Pare, J. C., De Alarcon, A., Sousa, with odontalgia. D., Rodriguez Bailon, I., Montejo-
8. Santurtún A, Riancho JA, Santurtún Med Clin (Barc). 2017;149:229-230. Baranda, M., Garcia-Pavia, P.. M, Richard C, Colorado MM, García F.I.:1,125. [doi:10.1016/j. Infective endocarditis in hypertrophic Unzueta M, Zarrabeitia MT. medcli.2017.03.018] cardiomyopathy: should antibiotic Genetic DNA profile in urine and prophylaxis be reconsidered?. Eur
hair follicles from patients who 15. Morán López JM, Luengo Pérez Heart J. have undergone allogeneic LM, Amado Señaris JA. 2016;37:1015-1015. hematopoietic stem cell Reply. transplantation. Med Clin (Barc). SCI JUSTICE. 2017;57:336-340. 2017;149:90-91. F.I.:1,992. [doi:10.1016/j. F.I.:1,125. [doi:10.1016/j. • PROJECTS scijus.2017.05.003] medcli.2017.03.024]
9. Martínez-Amador N, Jiménez- Projects Bonilla J, Martínez-Rodríguez I, Reviews De Arcocha-Torres M, Quirce R, 1. Julio Francisco Jiménez Bonilla.
Gómez-de la Fuente FJ, López-Defilló 1. García Vicente AM, Delgado- Estudio evolutivo a los 5 años en una JL, Banzo I. Bolton RC, Amo-Salas M, López- población con Deterioro Cognitivo Value of the visual and Fidalgo J, Caresia Aróztegui AP, Leve (DCL) evaluada previamente semiquantitative analysis of García Garzón JR, Orcajo Rincón J, con 11C-PIB y 18F-FDG PET/TAC. carbon-11-methionine PET/CT in García Velloso MJ, de Arcocha Torres PI16/01656. brain tumors’ recurrence M, Alvárez Ruíz S, Oncology Task INSTITUTO DE SALUD CARLOS versus post-therapeutic changes. Force of Spanish Society of Nuclear III. MINISTERIO DE ECONOMÍA Y Nucl Med Commun. Medicine and Molecular Imaging. COMPETITIVIDAD. 2017;38:1125-1132. 18 F-fluorodeoxyglucose positron F.I.:1,472. [doi:10.1097/ emission tomography in the 2. Pedro José Prada Gómez. MNM.0000000000000754] diagnosis of malignancy in patients Ensayo clínico de prueba de with paraneoplastic neurological concepto, multicéntrico, prospectivo,
10. Gómez-de la Fuente FJ, Martínez- syndrome: a systematic review and aleatorizado, abierto y paralelo, para Rodríguez I, Alonso-Martín J, meta-analysis. valorar la eficacia de la braquiterapia Jiménez-Bonilla J, Banzo I. Eur J Nucl Med Mol Imaging. con o sin tratamiento hormonal con A case report of penile metastases 2017;44:1575-1587. triptorelina 22,5mg semestral en from rectal carcinoma. F.I.:7,277. [doi:10.1007/s00259-017- pacientes con cáncer de próstata Cir Esp. 2017;95:116-118. 3722-4] recurrente previamente tratados con F.I.:1,276. [doi:10.1016/j. radioterapia.
ciresp.2016.05.018] 2. Riancho-Zarrabeitia L, IPS-TRI-2010-03. IPSEN PHARMA, Cubería M, Muñoz P, S.A. 11. Gómez-de la Fuente FJ, Jiménez- López-Hoyos M, García-Canale S, Bonilla J, Estévez J, Martínez- García-Unzueta M, Hernández JL, 3. Iván García Martín. Rodríguez I, Banzo I. Martínez-Taboada VM. RE-GENERATION: Estudio clínico Somatostatin receptors expression in Vitamin D and antiphospholipid sobre la seguridad y eficacia de breast cancer. syndrome: A retrospective RELAY-Pro y de RELAY NBS Pro Cir Esp. 2017;95:545-547. cohort study and meta-analysis. para el tratamiento de patologías en F.I.:1,276. [doi:10.1016/j. Semin Arthritis Rheum. aórtica torácica. ciresp.2016.12.010] 1;F.I.:0,000. [doi:10.1016/j. IP-0011-14. BOLTON MEDICAL semarthrit.2017.10.007] ESPAÑA, S.L.U. 169
Postmarketing Studies neurología de España. en la práctica clínica del cáncer de and Other BAY-ACO-2014-01. BAYER próstata localizado. HISPANIA, S.L.. ONC-MA-1003. ASTELLAS 1. María Ángeles Revilla García. PHARMA, S.A.. Validación del cuestionario ACTS 2. Pedro José Prada Gómez. en pacientes con Fibrilación Medida del impacto de la Auricular (FA) tratados con radioterapia coon intención curativa anticoagulantes orales (ACOs) en combinada o no con terapia consultas de medicina interna y hormonal sobre la calidad de vida Activity Research Areas Report Cancer Area
Group Responsible Samuel Cos Corral Department of Physiology • Melatonin and and Pharmacology School of Medicine Breast Cancer University of Cantabria
Contributors Carolina Alonso González Alicia Verónica González Cabeza Carlos Manuel Martínez Campa Noemí Rueda Revilla
Predoctoral Alicia González González Javier Menéndez Menéndez
Technicians José Antonio Cos Cossío Gema Viar Ruiz
Consolidated group
induced mammary tumors in rodents, years, research activity in our group while pinealectomy or experimental focuses on the description of a third Research conditions involving a reduction mechanism by which melatonin may lines in melatonin synthesis stimulate reduce the development of estrogen- mammary carcinogenesis. In vitro, dependent tumors, based on the melatonin inhibits proliferation and ability of melatonin to modulate invasiveness of human breast cancer estrogen synthesis in both tumoral cells. The antitumoral properties of and peritumoral surrounding tissues, Our group focuses its research melatonin are based on its ability behaving as a SEEM (selective on the actions of melatonin, the to interact with estrogen-signaling estrogen enzyme modulator) main hormone produced in the pathways. Two types of mechanisms pineal gland, on the genesis and have been proposed to explain these The research that we are currently development of hormone-dependent oncostatic actions of melatonin: a) developing centers on: mammary tumors. In vivo, either downregulation of the circulating experimental manipulations that levels of gonadal estrogens, and b) a) To study, on the one hand, activate the pineal gland or the direct actions at the tumoral level the ability of melatonin to exogenous administration of interfering with the activation of modulate the activity of melatonin, reduce the incidence the estrogen receptor, therefore some enzymes (aromatase, and development of spontaneous behaving as a SERM (selective sulfatase, 17β-dehydrogenase, mammary tumors or chemically- estrogen receptor modulator). In last sulfotransferase) involved in the 171
and Behavioural Disorders. synthesis of estrogens at tumor • PROJECTS level, and, then, to analyze the Curr Med Chem. 2017;24:3851-3878. possible intracellular mediators F.I.:3,249. [doi:10.2174/09298673246 through which melatonin 66170718105557] Projects regulates the activity and 3. Corrales A, Parisotto EB, Vidal V, expression of these enzymes. García-Cerro S, Lantigua S, Diego M, Wilhem Filho D, Sanchez-Barceló EJ, 1. Samuel Cos Corral. Martínez-Cué C, Rueda N. Efectos sensibilizadores de la b) To study the ability of Pre- and post-natal melatonin melatonina a la quimioterapia y la melatonin to modulate the administration partially regulates radioterapia: estudio de los cambios angiogenesis and to antagonize brain oxidative stress but does not moleculares que modulan este the effects of estrogens on improve cognitive or histological proceso. new blood vessel formation alterations in the Ts65Dn mouse SAF2013-42012-P. in hormone-dependent breast model of Down syndrome. cancer. Behav Brain Res. 2017;334:142-154. 2. Samuel Cos Corral y Carlos M. F.I.:3,002. [doi:10.1016/j. Martínez Campa. c) To study the ability of bbr.2017.07.022] Efectos beneficiosos de la melatonin to increase the melatonina como adyuvante en el sensibility of human breast cancer 4. González A, González-González tratamiento del cáncer de mama: cells to the action of radiotherapy A, Alonso-González C, Menéndez- regulación del microambiente in base to its actions modulating Menéndez J, Martínez-Campa C, tumoral. the enzymes that participate in Cos S. SAF2016-77103-P. the synthesis of estrogens and its Melatonin inhibits angiogenesis MINISTERIO DE ECONOMIA Y antiestrogenic actions. in SH-SY5Y human neuroblastoma COMPETITIVIDAD. cells by downregulation of VEGF. d) To study the protective Oncol Rep. 2017;37:2433-2440. 3. Noemí Rueda Revilla y Carmen effects of melatonin on the F.I.:2,662. [doi:10.3892/or.2017.5446] Martínez-Cué. molecular changes induced Efectos de la normalización del 5. Martínez-Campa C, Menéndez- número de copias de DYRK1A sobre by chemotherapy used in the Menéndez J, Alonso-González C, fenotipos cerebrales alterados y los treatment of breast cancer. González A, Álvarez-García V, Cos procesos neurodegenerativos en un S. What is known about melatonin, modelo de síndrome de Down. e) To study the protective chemotherapy and altered gene FUNDACIÓN TATIANA PÉREZ DE effects of chronic treatment expression in breast cancer. GUZMÁN EL BUENO. with melatonin on cognitive and ONCOL LETT. neuromorphological deficits in 2017;13:2003-2014. 4. Noemí Rueda Revilla. Ts65Dn mouse, a model of Down F.I.:1,390. [doi:10.3892/ol.2017.5712] Effects of the normalization syndrome. of Dyrk1A copy number on the cerebellar phenotypes and Thesis Addressed neurodegenerative profile of a mouse model of Down syndrome. 1. Sara Lantigua Romero. FUNDACION JÈRÔME LEJEUNE. • PUBLICATIONS: Efecto de distintas estrategias terapéuticas sobre los déficits IMPACT FACTOR | 15,323 cognitivos y las alteraciones neuromorfólogicas de un modelo de síndrome de down. Director/es: Noemí Rueda Revilla, Original articles Carmen Martínez-Cue Pesini. UNIVERSIDAD DE CANTABRIA. 1. García-Cerro S, Rueda N, Vidal V, Lantigua S, Martínez-Cué C. Books and Book Chapters Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several 1. C. Alonso-González, A. González, Alzheimer’s disease S. Cos, A. G Vonzález-González, J. phenotypes. Menéndez Menéndez, C. Martínez- Neurobiol Dis. 2017;106:76-88. Campa. F.I.:5,020. [doi:10.1016/j. Melatonin as modulator of nbd.2017.06.010] radiosensibility and chemosensibility in cancer. En: Pineal Gland: Research 2. Sanchez-Barcelo, Emilio J., Advances and Clinical Challenges. Rueda, Noemi, Mediavilla, Maria Ed. A. Catala. D., Martinez-Cue, Carmen, Reiter, Nova Science Publishers Inc, Russel J. Hauppauge, NY, (U.S.A.), págs. Clinical Uses of Melatonin in 291-325 (2017). Neurological Diseases and Mental Activity Research Areas Report Cancer Area
Group Responsible Mónica López Fanárraga Department of Molecular Biology School of Medicine • Nanomedicine University of Cantabria
Researchers Rafael Valiente Barroso
Contributors Íñigo Casafont Parra Fidel Ángel Fernández Fernández Jesús González Gómez Lorena González Legarreta Fernando González Martínez Rosa Martín Rodríguez Débora Muñoz Guerra Carlos Renero Lecuna Carmen Pesquera González Ciro Luis Salcines Suárez Nuria Terán Villagra Juan Carlos Villegas Sordo Group of new establishment Fernando Aguado Menéndez Ana Carmen Perdigón Aller
Grupo de nueva creación Predoctoral Eloísa González Lavado Nerea Iturrioz Rodríguez Elena María Navarro Palomares Esperanza Padín González Lourdes María Valdivia Fernández
organic levels. Our group nano-delivery systems customized investigates the application and directed, nano - functional of different nanomaterials as polymer systems, nanobiocides, Research nanomedicines or nanovehículos nanoteragnetic, nanovacunas, etc. carriers of drugs against cancer These lines of work are compatible lines or other pathologies. In addition, with the study of the toxicological we developed new contrast properties of nanomaterials and media for bioimaging based on nanoprevention. nanoparticles as fluorescent The Nanomedicine-IDIVAL probes, without, however, exploring Our work demonstrates how carbon group studies the biosynthetic other possibilities offered by nanotubes (NTC) can penetrate relationship and the biological nanomaterials applied in health, cells, interfering with microtubular response to different nanomaterials such as the development of dynamics and behaving like at the molecular, cellular and nanostructured materials and microtubule stabilizing drugs, 173
acting as mitotic spindle disrupters. • PUBLICATIONS: 5. González-Domínguez E, Iturrioz- NTC interacts biomimetically Rodríguez N, Padín-González E, with the microtubules causing IMPACT FACTOR | 63,375 Villegas J, García-Hevia L, Pérez- aberrant or catastrophic mitosis, Lorenzo M, Parak WJ, Correa-Duarte and triggering cell death. The MA, Fanarraga ML. advantage of NTC versus traditional Carbon nanotubes gathered onto cytotoxic chemotherapy is its large Original articles silica particles lose their biomimetic surface area interacting with the properties with the cytoskeleton microtubule, which makes the 1. Iturrioz-Rodríguez N, González- becoming biocompatible. appearance of resistance quite Domínguez E, González-Lavado E, Int J Nanomedicine. unlikely. Marín-Caba L, Vaz B, Pérez-Lorenzo 2017;12:6317-6328. M, Correa-Duarte MA, Fanarraga ML. F.I.:4,300. [doi:10.2147/IJN.S141794] Our most immediate objectives are A Biomimetic Escape Strategy for to generate a topical NTC-based Cytoplasm Invasion by Synthetic 6. Nataf, L., Aguado, F., Hernandez, cancer treatment and nanodelivery Particles. Angew Chem Int Ed Engl. I., Valiente, R., Gonzalez, J., Sanz- systems, for example, for use as 2017;56:13736-13740.F.I.:11,994. Ortiz, M. N., Wilhelm, H., Jephcoat, adjuvant or neoadjuvant treatment [doi:10.1002/anie.201707769] A. P., Baudelet, F., Rodriguez, F. in cancers that affect the skin, head Volume and pressure dependences neck cancers or topically accessible 2. Sanz B, Calatayud MP, Torres TE, of the electronic, vibrational, and cancers Or by injection (or reservoir) Fanarraga ML, Ibarra MR, Goya GF. crystal structures of Cs2CoCl4: in the area. This development we Magnetic hyperthermia enhances Identification of a pressure-induced have several patents. Currently we cell toxicity with respect to piezochromic phase at high work on the functionalisation of the exogenous heating. pressure. surface of the NTC to preferentially BIOMATERIALS. 2017;114:62-70. target them to the target cells and Phys Rev B. 2017;95: F.I.:8,402. [doi:10.1016/j. develop in the medium / long term F.I.:3,836. [doi:10.1103/ biomaterials.2016.11.008] a parenteral treatment and in the PhysRevB.95.014110] biocompatibilization of the NTC so that they are more biodegradable 3. Talamillo A, Grande L, Ruiz- 7. García-Calvo J, Ibeas S, Antón- through different treatments. Ontañon P, Velasquez C, Mollinedo P, García EC, Torroba T, González-Aguilar Recently we have undertaken a new Torices S, Sanchez-Gomez P, Aznar G, Antunes W, González-Lavado line of research using nanovesículas A, Esparis-Ogando A, Lopez-Lopez E, Fanarraga ML. Potassium-Ion- as liposomes or Niosomas to C, Lafita C, Berciano MT, Montero Selective Fluorescent Sensors To encapsulate different chemical and JA, Vazquez-Barquero A, Segura V, Detect Cereulide, the Emetic Toxin / or biological therapies as part of Villagra NT, Pandiella A, Lafarga M, of B-cereus, in Food Samples and nanostructured release systems. Leon J, Martinez-Climent JA, Sanz- HeLa Cells. ChemistryOpen. Moreno V, Fernandez-Luna JL. 2017;6:562-570. ODZ1 allows glioblastoma to F.I.:2,918. [doi:10.1002/ sustain invasiveness through a open.201700057] Myc-dependent transcriptional upregulation of RhoA. 8. Madiligama, A. S. B., Ari-Gur, P., Oncogene. 2017;36:1733-1744. Ren, Y., Koledov, V. V., Dilmieva, E. F.I.:7,519. [doi:10.1038/onc.2016.341] T., Kamantsev, A. P., Mashirov, A. V., Shavrov, V. G., Gonzalez-Legarreta, L., 4. Martín-Rodriguez, R., Valiente, R., Grande, B. H. Aguado, F., Perdigon, A. C.. Highly Thermal and magnetic hysteresis efficient photoluminescence from associated with martensitic and isolated Eu3+ ions embedded in magnetic phase transformations in high-charge mica. Ni52Mn25In16Co7 Heusler alloy. J Mater Chem C Mater. J MAGN MAGN MATER. 2017;5:10360-10368. 2017;442:25-35. F.I.:5,256. [doi:10.1039/c7tc01818e] F.I.:2,630. [doi:10.1016/j. jmmm.2017.06.080] Activity Research Areas Report Cancer Area
9. Val-Bernal JF, Terán-Villagrá N, F.I.:2,020. [doi:10.1007/s11051-017- Murino: Patogénesis y Prevención. García-Diego O, Sarralde JA. 3931-6] Director/es: Carmen Álvarez Lymphocyte-rich capillary-cavernous Domínguez, Mónica López hemangioma of the mitral valve: 15. Zhukov, Arcady, Ipatov, Mihail, Fanárraga. a case report and review of the Talaat, Ahmed, Blanco, Juan Maria, UNIVERSIDAD DE CANTABRIA. literature. Hernando, Blanca, Gonzalez- Cardiovasc Pathol. 2017;28:59-63. Legarreta, Lorena, Josep Sunol, Books and Book Chapters F.I.:2,359. [doi:10.1016/j. Joan, Zhukova, Valentina. carpath.2017.03.003] Correlation of Crystalline Structure 1. Riancho Zarrabeitia, Javier, Ruiz with Magnetic and Transport Soto, María Terán Villagra, Nuria, 10. Kaur, Amandeep, Khanna, Atul, Properties of Glass-Coated Berciano Blanco, José Ángel, Bhatt, Himal, Gonzalez-Barriuso, Microwires. Crystals (Basel). 2017;7: Berciano Blanco, María Teresa, Marina, Gonzalez, Fernando, Chen, F.I.:1,566. [doi:10.3390/cryst7020041] Lafarga Coscojuela, Miguel Ángel. Banghao, Deo, M. N. Compensatory motor neuron B-O and Te-O speciation in 16. Dilmieva, Elvina T., Koshkidko, response to chromatolysis in the bismuth tellurite and bismuth Yurii S., Kamantsev, Alexander P., murine hSOD1-G93-A model of borotellurite glasses by FTIR, Koledov, Victor V., Mashirov, Aleksey amytrophic lateral esclerosis. B-11 MAS-NMR and Raman V., Shavrov, Vladimir G., Khovaylo, Compensatory Mechanisms in spectroscopy. Vladimir V., Lyange, Mariya V., Cwik, Neurodegenerative Disorders. J Non Cryst Solids. 2017;470:19-26. J., Gonzalez-Legarreta, Lorena, 2017. F.I.:2,124. [doi:10.1016/j. Blanca Grande, Hernado. jnoncrysol.2017.04.028] Research of Magnetocaloric Effect For Ni-Mn-In-Co Heusler Alloys by 11. Kaur, Amandeep, Khanna, Atul, the Direct Methods in Magnetic • PROJECTS Gonzalez-Barriuso, Marina, Gonzalez, Fields Up to 14 T. Fernando, Chen, Banghao. IEEE Trans Magn. 2017;53: Short-range structure and thermal F.I.:1,243. [doi:10.1109/ Projects properties of alumino-tellurite TMAG.2017.2702577] glasses. 1. Mónica López Fanárraga. J Non Cryst Solids. 2017;470:14-18. 17. Marquina, J., Martin, J., Luengo, Diseño y evaluación antitumoral F.I.:2,124. [doi:10.1016/j. J., Vera, F., Roa, L., Delgado, G. E., de nano-dispensadores multi- jnoncrysol.2017.04.034] Rodriguez, F., Renero-Lecuna, C., terapéuticos basados en nanotubos Valiente, R., Gonzalez, J. de carbono. PI16/00496. 12. Gupta, Nupur, Kaur, Amandeep, Structural refinement, INSTITUTO DE SALUD CARLOS Khanna, Atul, Gonzalez, Fernando, photoluminescence and Raman III. MINISTERIO DE ECONOMÍA Y Pesquera, Carmen, Iordanova, Reni, spectroscopy of Wurtzite Mn-doped COMPETITIVIDAD. Chen, Banghao. ZnO pellets. Structure-property correlations REV MEX FIS. 2017;63:32-39. 2. Mónica López Fanárraga. in TiO2-Bi2O3-B2O3-TeO2 glasses. F.I.:0,482. Contrato Sara Borrell. CD17/00105. J Non Cryst Solids. INSTITUTO DE SALUD CARLOS 2017;470:168-177. 18. Dilmieva, E. T., Irzhak, A. V., III. MINISTERIO DE ECONOMÍA Y F.I.:2,124. [doi:10.1016/j. Kamantsev, A. P., Koledov, V. V., COMPETITIVIDAD. jnoncrysol.2017.05.021] Shavrov, V. G., Grechishkin, R. M., Krasnoperov, E. P., Dikan, V. A., 3. Mónica López Fanárraga. 13. Binns J, McIntyre GJ, Barreda- Albertini, F., Fabbrici, S., Gonzalez- Contrato Juan de la Cierva- Argüeso JA, González J, Aguado F, Legarreta, L., Hernando, B.. Rapidly Formación. FJCI-2015-25306. Rodríguez F, Valiente R, Parsons S. Quenched Ferromagnetic Ribbons MINISTERIO DE ECONOMÍA Y Phase transition sequences with Shape Memory for Magnetically COMPETITIVIDAD. in tetramethylammonium Controlled Micromechanic Devices. tetrachlorometallates by X-ray J COMMUN TECHNOL EL+. diffraction and spectroscopic 2017;62:809-819. measurements. F.I.:0,446. [doi:10.1134/ Acta Crystallogr B Struct Sci Cryst S106422691707004X] Eng Mater. 2017;73:844-855. F.I.:2,032. [doi:10.1107/ S2052520617006412] Thesis Addressed
14. de la Fuente Rodríguez, M., 1. Ricardo Calderon Gonzalez. Espeso, J. I., González, J. A., Vacunas Basadas en Listeria Rodríguez Fernández, J., Rojas, D. Monocytogenes. P., Rodríguez Fernández, L., García- Director/es: Carmen Álvarez Arribas, A., Fdez-Gubieda, M. L., Domínguez, Mónica López Echevarría-Bonet, C., Perigo, E. A., Fanárraga. Michels, A., Fernandez Barquin, L.. UNIVERSIDAD DE CANTABRIA. Surfactant-assisted production of TbCu2 nanoparticles. 2. Elisabet Frande Cabanes. J NANOPART RES. 2017;19: Listeriosis Cerebral en el Modelo 175 Activity Research Areas Report Cancer Area
Group Responsible Manuel Gómez Fleitas Surgery Service University Hospital • New Techniques in Marqués de Valdecilla Abdominal Surgery University of Cantabria
Researchers Luis Antonio Herrera Noreña
Contributors Joaquín Alonso Martín Federico Castillo Suescun Julio José del Castillo Diego Ramón Agustín Domínguez Díez Maria José Fernández Diaz Roberto Fernández Santiago Elena García Somacarrera Marcos Gómez Ruiz Associated group Mónica González Noriega Gonzalo Gutiérrez Fernández Fernando Luis Hernanz de La Fuente Antonio López Useros Cesar Baldomero Madrazo Leal José Carlos Manuel Palazuelos José Ignacio Martín Parra Dieter José Morales García Carlos Ortega Morales Rodrigo Perea Muñoz María Riaño Molleda Juan Carlos Rodríguez Sanjuan Isabel Seco Olmedo
Implementing new clinical surgical techniques for breast surgical procedures (Laparoscopic cancer surgery. choledocholithotomy). Research g. Research on new techniques d. Results in tumour for training surgeons. lines pathology. Thermal ablation of Development of simulators for hepatocellular carcinoma as a training in surgical and endoscopic bridge to transplantation and techniques. Impact of training with Xenotransplantation. simulation methods in the teaching a. Liver tumour pathology. of professionals. Development of Staging, new diagnosis and e. Obesity surgery. simulation models for training in therapeutic techniques. Effects of bariatric surgery teamwork, communication skills on the morbidity factors of obesity b. Pancreatic tumour pathology. and critical situations. in steatohepatitis and ghrelin Staging, new diagnosis and levels. Evaluation of results. therapeutic techniques. f. Breast cancer. c. Biliary tumour pathology and Tumour excision using image- nonneoplastic pathology. guided techniques. Oncoplastic 177
COLORECTAL DIS. • PUBLICATIONS: 2017;19:299-301. Thesis Addressed F.I.:2,689. [doi:10.1111/codi.13614] IMPACT FACTOR: | 16,310 1. Nerea Ruiz. 4. Pajarón-Guerrero M, Fernández- Trasplante hepático a partir de Miera MF, Dueñas-Puebla JC, donantes en asistolia controlada con Cagigas-Fernández C, Allende- uso de necmo. Original articles Mancisidor I, Cristóbal-Poch L, Director/a: Juan Carlos Rodríguez Gómez-Fleitas M, Manzano-Peral Sanjuan. 1. Miñambres E, Suberviola B, MA, Gonzalez-Fernandez CR, UNIVERSIDAD DE CANTABRIA. Dominguez-Gil B, Rodrigo E, Ruiz- Aguilera-Zubizarreta A, Sanroma- San Millan JC, Rodríguez-San Juan Mendizábal P, Hospital Valdecilla JC, Ballesteros MA. ERAS Study Group. Improving the Outcomes of Organs Early Discharge Programme on • PROJECTS Obtained From Controlled Donation Hospital-at-Home Evaluation After Circulatory Death Donors for Patients with Immediate Clinical Trials Using Abdominal Normothermic Postoperative Course after Regional Perfusion. Laparoscopic Colorectal Surgery. Am J Transplant. EUR SURG RES. 2017;58:263-273. 1. Julio José del Castillo Diego. 2017;17:2165-2172. F.I.:1,382. [doi:10.1159/000479004] Ensayo clínico multicéntrico, F.I.:6,165. [doi:10.1111/ajt.14214] prospectivo, controlado y 5. Gómez-de la Fuente FJ, Martínez- aleatorizado de no inferioridad, del 2. Baukloh JK, Reeh M, Spinoglio G, Rodríguez I, Alonso-Martín J, tratamiento del cáncer de recto Corratti A, Bartolini I, Mirasolo VM, Jiménez-Bonilla J, Banzo I. T2-T3s (superficial) N0, M0 mediante Priora F, Izbicki JR, Gomez Fleitas M, A case report of penile metastases quimioterapia preoperatoria y Gómez Ruiz M, Perez DR. from rectal carcinoma. microcirugía endoscópica transanal Evaluation of the robotic approach Cir Esp. 2017;95:116-118. (TEM) versus escisión total del concerning pitfalls in rectal surgery. F.I.:1,276. [doi:10.1016/j. mesorecto (ETM), versión 01 de 1 de Eur J Surg Oncol. ciresp.2016.05.018] julio de 2009. 2017;43:1304-1311. TAU-TEM-2009-01. SERRA, XAVIER. F.I.:3,522. [doi:10.1016/j. 6. Gómez Ruiz M, Cagigas Fernández ejso.2016.12.014] C, Alonso Martín J, Cristobal Poch 2. Julio José del Castillo Diego. L, Manuel Palazuelos C, Barredo Estudio multicéntrico, aleatorizado, 3. Gómez Ruiz M, Cristóbal Poch L, Cañibano FJ, Gómez Fleitas M, controlado con placebo y doble Alonso Martín J, Cagigas Fernández Castillo Diego J. ciego para evaluar la eficacia y la C, Barredo Cañibano FJ, Gómez Robotic Assisted Transanal tolerabilidad del hidrocloruro de Fleitas M, Castillo Diego J. Polypectomies: Is There Any diltiazem al 2 % en el tratamiento de Robotic-assisted dissection of Indication?. la fisura anal crónica, y un periodo metastatic lymph node recurrence Cir Esp. 2017;95:601-609. de seguimiento de 24 semanas. following rectal cancer resection - a F.I.:1,276. [doi:10.1016/j. 150601. video vignette. ciresp.2017.09.006] Activity Research Areas Report Cancer Area
Group Responsible José Luis Fernández Luna Molecular Genetics Unit University Hospital • Cell Signalling and Marqués de Valdecilla Therapeutic Targets in Cancer
Researchers Juan Martino González
Contributors Ana María Fontalba Romero Ana Antonia Talamillo Cancelo Alfonso Vázquez Barquero Carlos José Velásquez Rodríguez
Predoctoral María del Pilar Mollinedo Sedano
Technicians Consolidated group Eva Ferrández Fernández María Olga Gutiérrez Saiz Rebeca Madureira Rivero
resection nearly impossible. Among Most in vitro studies to measure the the GBM cells there is a small cellular response to chemotherapy population (<5%) with the capacity use cell cultures on 2D surfaces. Research to regenerate the tumor and with There are many evidences about lines features similar to those found the role of the biophysic features in adult stem cells. They are the of the microenvironment in so-called cancer stem cells. If the cellular processes studied in current hypothesis is right, this cell vitro (diferentiation, migration, population is the proper target for survival). In order to optimize more 1. Study of the invasive new therapeutic strategies. We aim physiological in vitro models of capacity of glioblastoma stem to identify molecular mediators of chemotherapy response, closer to cells (GSCs). The capacity of migration and invasion of GSCs. in vivo models, we are studying glioblastoma (GBM) cells to invade the behaviour of GBM cells the surrounding parenchyma is 2. Development of in vitro (GSCs and tumor parenchymal one of the main problems for models to study the response cells) following exposure to an efficient therapeutic strategy of GBM cells to chemotherapy chemotherapeutic agents in because it makes complete in physiological environments. different microenvironments. 179
3. Screening of novel compounds of proof of concept still persist, system, is being developed jointly addressed to cancer stem cells which means that there are no by IDIVAL (group of cell signaling by using computational and drugs approved for this indication. and therapeutic targets and group biologic platforms. Currently, This novel therapeutic area is of Medical Oncology), University there are different undergoing open to different experimental of Cantabria (optics group of the clinical trials addressed to kill approaches including combinatorial Faculty of Sciences), the center cancer stem cells. However, a lack chemistry, re - profiling and virtual Technological group IK4-TEKNIKER screening, among others. In co - (micro-manufacturing group) and llaboration with a start-up from the the Cantabrian biotech company Bioinformatics Unit at Centro de CELLBIOCAN. Currently, the Biologia Molecular Severo Ochoa assembly of an experimental (CSIC), we have established a prototype is being finalized, which platform that joints computational will be optimized until it reaches a screening of 5 million compounds final product with which a clinical with the validation of candidates in validation will be performed with biological mo - dels in vitro and in samples from cancer patients. The vivo. Target cells are cancer stem objective is to quantify blood CTCs cells from GBM and colon cancer. as a predictor, and to isolate them for further genetic analysis, which 4. Development of a biosensor will allow a personalized selection device to detect, quantify and of the treatment. isolate circulating tumor cells from cancer patients: SENTIR Project. This device, based on optical principles and a microfluidic
Figura. Esquema de trabajo que incluye los principales objetivos de esta línea de investigación. Activity Research Areas Report Cancer Area
• PUBLICATIONS: Bourgon J, Marco de Lucas E, 10. Hilis A, Roldan L, Fernandez D, Gomez E. Laez R, Agueros JA, Barquero A. Cross-Modal Recruitment of One-Shot CT image navigated IMPACT FACTOR: | 36,957 Auditory and Orofacial Areas During circumferential fusion in a single Sign Language in a Deaf Subject. lateral decubitus position: surgical WORLD NEUROSURG. technique. J NEUROSURG SCI. Original articles 2017;105: 2017;61:429-437.F.I.:1,522. F.I.:2,592. [doi:10.1016/j. [doi:10.23736/S0390-5616.16.03396-8] wneu.2017.05.170] 1. Talamillo A, Grande L, Ruiz- 11. Martino J, Caballero H, DE Lucas Ontañon P, Velasquez C, Mollinedo P, 6. Mandonnet E, Martino J, EM, DA Silva-Freitas R, Velasquez Torices S, Sanchez-Gomez P, Aznar Sarubbo S, Corrivetti F, Bouazza S, C, Gomez E, Vazquez-Bourgon J, A, Esparis-Ogando A, Lopez-Lopez Bresson D, Duffau H, Froelich S. Vázquez-Barquero A. C, Lafita C, Berciano MT, Montero Neuronavigated Fiber Dissection Recovery of long-term paresis JA, Vazquez-Barquero A, Segura V, with Pial Preservation: Laboratory following resection of WHO grade Villagra NT, Pandiella A, Lafarga M, Model to Simulate Opercular II gliomas infiltrating the pyramidal Leon J, Martinez-Climent JA, Sanz- Approaches to Insular Tumors. pathway. J NEUROSURG SCI. Moreno V, Fernandez-Luna JL. WORLD NEUROSURG. 2017;61:88-96. ODZ1 allows glioblastoma to 2017;98:239-242. F.I.:1,522. [doi:10.23736/S0390- sustain invasiveness through a F.I.:2,592. [doi:10.1016/j. 5616.16.03090-3] Myc-dependent transcriptional wneu.2016.10.020] upregulation of RhoA. 12. Martín-Láez R, Vázquez-Barquero A. Oncogene. 2017;36:1733-1744. 7. Zarrabeitia R, Fariñas-Álvarez C, Pronóstico a largo plazo de la F.I.:7,519. [doi:10.1038/onc.2016.341] Santibáñez M, Señaris B, Fontalba A, hidrocefalia crónica del adulto Botella LM, Parra JA. idiopática: I. Protocolo diagnóstico- 2. Pérez-Beteta J, Martínez-González Quality of life in patients with terapéutico del Hospital Universitario A, Molina D, Amo-Salas M, Luque B, hereditary haemorrhagic Marqués de Valdecilla. Neurocirugia Arregui E, Calvo M, Borrás JM, López telangiectasia (HHT). (Astur). C, Claramonte M, Barcia JA, Iglesias Health Qual Life Outcomes. 2017;28:141-156. L, Avecillas J, Albillo D, Navarro M, 2017;15:19-19. F.I.:0,548. [doi:10.1016/j. Villanueva JM, Paniagua JC, Martino F.I.:2,143. [doi:10.1186/s12955-017- neucir.2016.04.004] J, Velásquez C, Asenjo B, Benavides 0586-z] M, Herruzo I, Delgado MD, Del Valle A, Falkov A, Schucht P, Arana E, 8. Spena G, Schucht P, Seidel K, Reviews Pérez-Romasanta L, Pérez-García VM. Rutten GJ, Freyschlag CF, D’Agata Glioblastoma: does the F, Costi E, Zappa F, Fontanella M, 1. Wu Y, Vázquez Barquero A. pre-treatment geometry matter? Fontaine D, Almairac F, Cavallo M, De Stimulus-Evoked Electromyographic A postcontrast T1 MRI-based Bonis P, Conesa G, Foroglou N, Gil- Monitoring During Minimally study. Robles S, Mandonnet E, Martino J, Invasive Transpedicular Implantation Eur Radiol. 2017;27:1096-1104. Picht T, Viegas C, Wager M, Pallud J. of Screws in Lumbosacral Spine: F.I.:3,967. [doi:10.1007/s00330-016- Brain tumors in eloquent areas: Threshold Value, Methodology 4453-9] A European multicenter survey and Clinical Effectiveness. WORLD of intraoperative mapping NEUROSURG. 3. Torices S, Alvarez-Rodríguez L, techniques, intraoperative 2017;98:146-151. Varela I, Muñoz P, Balsa A, López- seizures occurrence, and F.I.:2,592. [doi:10.1016/j. Hoyos M, Martinez-Taboada V, antiepileptic drug prophylaxis. wneu.2016.10.122] Fernández-Luna JL. NEUROSURG REV. 2017;40:287-298. Evaluation of Toll-like-receptor F.I.:2,060. [doi:10.1007/s10143-016- 2. Delgado-López PD, Corrales- gene family variants as prognostic 0771-2] García EM, Martino J, Lastra-Aras E, biomarkers in rheumatoid Dueñas-Polo MT. arthritis. 9. Rofes A, Mandonnet E, Godden Diffuse low-grade glioma: a review Immunol Lett. 2017;187:35-40. J, Baron MH, Colle H, Darlix A, de on the new molecular classification, F.I.:2,860. [doi:10.1016/j. Aguiar V, Duffau H, Herbet G, Klein natural history and current imlet.2017.04.011] M, Lubrano V, Martino J, Mathew R, management strategies. Clin Transl Miceli G, Moritz-Gasser S, Pallud J, Oncol. 4. Molina D, Pérez-Beteta J, Papagno C, Rech F, Robert E, Rutten 2017;19:931-944.F.I.:2,353. Martínez-González A, Martino J, GJ, Santarius T, Satoer D, Sierpowska [doi:10.1007/s12094-017-1631-4] Velasquez C, Arana E, Pérez-García J, Smits A, Skrap M, Spena G, Visch VM. Lack of robustness of textural E, De Witte E, Zetterling M, Wager M. measures obtained from 3D brain Thesis Addressed Survey on current cognitive tumor MRIs impose a need for practices within the European Low- standardization. Grade Glioma Network: towards a 1. Wu Yunfen. PLoS One. 2017;12: European assessment protocol. Acta Aplicaciones de t-electromiografía F.I.:2,806. [doi:10.1371/journal. Neurochir (Wien). en la implantación transpedicular pone.0178843] 2017;159:1167-1178.F.I.:1,881. mínimamente invasiva de tornillos [doi:10.1007/s00701-017-3192-2] en la columna lumbosacra: - visión 5. Martino J, Velasquez C, Vázquez- neurofisiológica. 181
Director/a: Alfonso Vázquez en la memoria de trabajo verbal Barquero. • PROJECTS para evitar secuelas en la cirugía UNIVERSIDAD DE CANTABRIA. de gliomas en áreas elocuentes. Projects PI13/01249. INSTITUTO DE SALUD CARLOS Doctoral thesis III. MINISTERIO DE ECONOMÍA Y 1. José Luis Fernández Luna. COMPETITIVIDAD. 1. Gonzalo Fernández Ruíz. Relevancia pronóstica y terapéutica Contribución del microentorno a en glioblastoma de ODZ1, una 3. José Luis Fernández Luna. la quimiorresistencia de células nueva diana en cáncer. PI13/01760. Contribución del eje hipoxia- iniciadoras de glioblastoma en INSTITUTO DE SALUD CARLOS odz1 a la capacidad invasiva modelos in vitro. III. MINISTERIO DE ECONOMÍA Y del glioblastoma. PI17/01399. Director: José Luis Fernández Luna. COMPETITIVIDAD. INSTITUTO DE SALUD CARLOS UNIVERSIDAD DE CANTABRIA. III. MINISTERIO DE ECONOMÍA Y 2. Juan Martino González. COMPETITIVIDAD. Preservación de las áreas implicadas Activity Research Areas Report Cancer Area
Group Responsible Fernando Rivera Herrero Oncology Service University Hospital • Oncology Clinical Marqués de Valdecilla trials Unit
Contributors Yolanda Blasco Mesonero Ana de Juan Ferré Ignacio Durán Martínez Almudena García Castaño Carmen Hinojo González Carlos López López José Manuel López Vega Marta Francisca López-Brea Piqueras Eva Martínez de Castro Matilde Salledo Lambea Noelia Vega Gil
Technicians Associated group Fátima Antía Gesto Moral Elena Zarrabeitia Puente
This line of research is well 1. Gudmundsson J, Thorleifsson established, it is the basis of the G, Sigurdsson JK, Stefansdottir L, Jonasson JG, Gudjonsson SA, Research group’s publications and has an Gudbjartsson DF, Masson G, lines intense activity. Johannsdottir H, Halldorsson GH, Stacey SN, Helgason H, Sulem P, Senter L, He H, Liyanarachchi S, Ringel MD, Aguillo E, Panadero Clinical trials in solid tumors A, Prats E, Garcia-Castaño A, De Nowadays our Unit starts around Juan A, Rivera F, Xu L, Kiemeney thirty new clinical trials every LA, Eyjolfsson GI, Sigurdardottir year, many of them in Phases O, Olafsson I, Kristvinsson H, ..., • PUBLICATIONS: Stefansson K. II and III, becoming a leading A genome-wide association study center in Spain on development IMPACT FACTOR | 128,544 yields five novel thyroid cancer risk of some lines of new drugs, loci. particularly anti-EGFR Nat Commun. 2017;8:14517-14517. therapies, anti-VGF F.I.:12,124. [doi:10.1038/ Original articles ncomms14517] and anti-PD-L1. 183
2. Grasselli J, Elez E, Caratù G, Viudez A, Hernández R, Cano JM, Ramchandani A, Visa L, Viudez A, Matito J, Santos C, Macarulla T, Echavarria I, Pericay C, Mangas M, Buxó E, Díaz-Serrano A, López C, Vidal J, Garcia M, Viéitez JM, Paéz Visa L, Buxo E, García T, Rodríguez Azkarate A, Longo F, Castañón E, D, Falcó E, Lopez Lopez C, Aranda E, Palomo A, Álvarez Manceñido F, Sánchez Bayona R, Pimentel P, Limón Jones F, Sikri V, Nuciforo P, Fasani R, Lacalle A, Macias I, Azkarate A, ML, Cerdá P, Álvarez Llosa R, Serrano Tabernero J, Montagut C, Azuara D, Ramchandani A, Fernández Montes R, Lobera MP, ..., Gómez-Martin C. Dienstmann R, Salazar R, Vivancos A. A, López C, Longo F, Sánchez Prognostic significance of Concordance of blood- and tumor- Bayona R, Limón ML, Díaz-Serrano performing universal HER2 t based detection of RAS mutations A, Hurtado A, Madero R, Gómez C, esting in cases of advanced gastric to guide anti-EGFR therapy in Gallego J. cancer. metastatic colorectal cancer. Nomogram-based prediction of GASTRIC CANCER. Ann Oncol. 2017;28:1294-1301. survival in patients with advanced 2017;20:465-474. F.I.:11,855. [doi:10.1093/annonc/ oesophagogastric adenocarcinoma F.I.:5,454. [doi:10.1007/s10120-016- mdx112] receiving first-line chemotherapy: 0639-8] a multicenter prospective study 3. Talamillo A, Grande L, Ruiz- in the era of trastuzumab. 10. Calderon-Gonzalez R, Frande- Ontañon P, Velasquez C, Mollinedo P, Br J Cancer. 2017;116:1526-1535. Cabanes E, Teran-Navarro H, Torices S, Sanchez-Gomez P, Aznar F.I.:6,176. [doi:10.1038/bjc.2017.122] Marimon JM, Freire J, Salcines- A, Esparis-Ogando A, Lopez-Lopez Cuevas D, Fariñas MC, Gonzalez-Rico C, Lafita C, Berciano MT, Montero 7. Carrato A, Abad A, Massuti B, C, Marradi M, Garcia I, Alkorta- JA, Vazquez-Barquero A, Segura V, Grávalos C, Escudero P, Longo- Gurrutxaga M, San Nicolas-Gomez Villagra NT, Pandiella A, Lafarga M, Muñoz F, Manzano JL, Gómez A, Castañeda-San Pedro A, Yañez- Leon J, Martinez-Climent JA, Sanz- A, Safont MJ, Gallego J, García- Diaz S, Penades S, Punzon C, Moreno V, Fernandez-Luna JL. Paredes B, Pericay C, Dueñas R, Gomez-Roman J, Rivera F, Fresno ODZ1 allows glioblastoma to Rivera F, Losa F, Valladares-Ayerbes M, Alvarez-Dominguez C. GNP- sustain invasiveness through a M, González E, Aranda E, Spanish GAPDH1-22 nanovaccines prevent Myc-dependent transcriptional Cooperative Group for the Treatment neonatal listeriosis by blocking upregulation of RhoA. of Digestive Tumours (TTD). microglial apoptosis and bacterial Oncogene. First-line panitumumab plus dissemination. 2017;36:1733-1744. FOLFOX4 or FOLFIRI in Oncotarget. 2017;8:53916-53934. F.I.:7,519. [doi:10.1038/onc.2016.341] colorectal cancer with multiple F.I.:5,168. [doi:10.18632/ or unresectable liver metastases: oncotarget.19405] 4. Calderon-Gonzalez R, Terán- A randomised, phase II trial Navarro H, García I, Marradi M, (PLANET-TTD). 11. Andersson M, López-Vega Salcines-Cuevas D, Yañez-Diaz S, Eur J Cancer. 2017;81:191-202. JM, Petit T, Zamagni C, Easton V, Solis-Angulo A, Frande-Cabanes F.I.:6,029. [doi:10.1016/j. Kamber J, Restuccia E, Perez EA. E, Fariñas MC, Garcia-Castaño A, ejca.2017.04.024] Efficacy and Safety of Pertuzumab Gomez-Roman J, Penades S, Rivera and Trastuzumab Administered in F, Freire J, Álvarez-Domínguez C. 8. Irigoyen A, Gallego J, Guillén a Single Infusion Bag, Followed by Gold glyconanoparticles coupled to Ponce C, Vera R, Iranzo V, Ales I, Vinorelbine: VELVET Cohort 2 Final listeriolysin O 91-99 peptide serve as Arévalo S, Pisa A, Martín M, Salud A, Results. adjuvant therapy against melanoma. Falcó E, Sáenz A, Manzano Mozo JL, Oncologist. 2017;22:1160-1168. NANOSCALE. 2017;9:10721-10732. Pulido G, Martínez Galán J, Pazo-Cid F.I.:4,962. [doi:10.1634/ F.I.:7,367. [doi:10.1039/c7nr02494k] R, Rivera F, García García T, Serra theoncologist.2017-0079] O, Fernández Parra EM, Hurtado 5. Jiménez Fonseca P, Carmona- A, Gómez Reina MJ, López Gomez 12. García-Carbonero R, van Cutsem Bayonas A, Hernández R, Custodio LJ, Martínez Ortega E, Benavides E, Rivera F, Jassem J, Gore I, Tebbutt A, Cano JM, Lacalle A, Echavarria I, M, Aranda E, Spanish Cooperative N, Braiteh F, Argiles G, Wainberg Macias I, Mangas M, Visa L, Buxo Group of Treatment of Digestive ZA, Funke R, Anderson M, McCall B, E, Álvarez Manceñido F, Viudez A, Tumors (TTD). Stroh M, Wakshull E, Hegde P, Ye W, Pericay C, Azkarate A, Ramchandani Gemcitabine-erlotinib versus Chen D, Chang I, Rhee I, Hurwitz H. A, López C, Martinez de Castro gemcitabine-erlotinib-capecitabine Randomized Phase II Trial of E, Fernández Montes A, Longo in the first-line treatment of patients Parsatuzumab (Anti-EGFL7) or F, Sánchez Bayona R, Limón ML, with metastatic pancreatic cancer: Placebo in Combination with Diaz-Serrano A, Martin Carnicero A, Efficacy and safety results of a FOLFOX and Bevacizumab for First- Arias D, Cerdà P, Rivera F, Vieitez JM, phase IIb randomised study from the Line Metastatic Colorectal Cancer. Sánchez Cánovas M, ..., Gallego J. Spanish TTD Collaborative Group. Oncologist. 2017;22: Lauren subtypes of advanced Eur J Cancer. 2017;75:73-82. F.I.:4,962. [doi:10.1634/ gastric cancer influence survival and F.I.:6,029. [doi:10.1016/j. theoncologist.2016-0133] response to chemotherapy: real- ejca.2016.12.032] world data from the AGAMENON 13. Lope V, Martín M, Castelló A, National Cancer Registry. 9. Jiménez-Fonseca P, Carmona- Casla S, Ruiz A, Baena-Cañada JM, Br J Cancer. 2017;117:775-782. Bayonas A, Sánchez Lorenzo ML, Casas AM, Calvo L, Bermejo B, F.I.:6,176. [doi:10.1038/bjc.2017.245] Plazas JG, Custodio A, Hernández Muñoz M, Ramos M, de Juan-Ferré R, Garrido M, García T, Echavarría A, Jara C, Antón A, Jimeno MÁ, 6. Custodio A, Carmona-Bayonas I, Cano JM, Rodríguez Palomo Lluch A, Antolín S, García-Sáenz JÁ, A, Jiménez-Fonseca P, Sánchez ML, A, Mangas M, Macías Declara I, Estévez P, Arriola-Arellano E, Gavilá Activity Research Areas Report Cancer Area
J, Pérez-Gómez B, Carrasco E, Pollán F.I.:2,353. [doi:10.1007/s12094-016- 22. García-Carbonero R, Vera M, GEICAM, the Spanish Breast 1594-x] R, Rivera F, Parlorio E, Pagés M, Cancer Group. González-Flores E, Fernández-Martos Physical activity and breast cancer 18. Mestres JA, iMolins AB, Martínez C, Corral MÁ, Bouzas R, Matute risk by pathological subtype. LC, López-Muñiz JI, Gil EC, de Juan F. SEOM/SERAM consensus Gynecol Oncol. 2017;144:577-585. Ferré A, Del Barco Berrón S, Pérez statement on radiological diagnosis, F.I.:4,959. [doi:10.1016/j. YF, Mata JG, Palomo AG, Gregori JG, response assessment and follow-up ygyno.2016.12.014] Pardo PG, Mañas JJ, Hernández AL, in colorectal cancer. de Dueñas EM, Jáñez NM, Murillo Clin Transl Oncol. 2017;19:135-148. 14. Martínez-Rodríguez I, García- SM, Bofill JS, Auñón PZ, Sanchez- F.I.:2,353. [doi:10.1007/s12094-016- Castaño A, Quirce R, Jiménez-Bonilla Rovira P. 1518-9] J, Banzo I. Defining the optimal sequence for Erythema Nodosum-Like the systemic treatment of metastatic 23. Crespo G, Jiménez-Fonseca Panniculitis as a False-Positive breast cancer. P, Custodio A, López C, Carmona- 18F-FDG PET/CT in Advanced Clin Transl Oncol. 2017;19:149-161. Bayonas A, Alonso V, Navarro M, Melanoma Treated With Dabrafenib F.I.:2,353. [doi:10.1007/s12094-016- Aller J, Sevilla I, Grande E, Gajate P, and Trametinib. 1520-2] Alonso-Gordoa T, Matos I, Capdevila Clin Nucl Med. 2017;42:44-46. J, Nieto B, Barriuso J. F.I.:3,640. [doi:10.1097/ 19. Salvador J, Aparicio J, Baron FJ, Capecitabine and temozolomide in RLU.0000000000001448] García-Campelo R, Garcia-Carbonero grade 1/2 neuroendocrine tumors: R, Lianes P, Llombart A, Isla D, Piera a Spanish multicenter experience. 15. Tavera-Tapia A, Pérez-Cabornero JM, Muñoz M, Puente J, Rivera F, FUTURE ONCOL. 2017;13:615-624. L, Macías JA, Ceballos MI, Roncador Rodríguez CA, Virizuela JA, Martín M, F.I.:2,131. [doi:10.2217/fon-2016- G, de la Hoya M, Barroso A, Felipe- Garrido P. 0434] Ponce V, Serrano-Blanch R, Hinojo Erratum to: Equity, barriers and C, Miramar-Gallart MD, Urioste M, cancer disparities: study of the 24. Martín Algarra S, Soriano V, Caldés T, Santillan-Garzón S, Benitez Spanish Society of Medical Fernández-Morales L, Berciano- J, Osorio A. Oncology on the access to oncologic Guerrero MÁ, Mujika K, Manzano Almost 2% of Spanish breast cancer drugs in the Spanish Regions. Clin JL, Puértolas Hernández T, Soria A, families are associated to germline Transl Oncol. 2017;19:525-525. Rodríguez-Abreu D, Espinosa Arranz pathogenic mutations in the ATM F.I.:2,353. [doi:10.1007/s12094-017- E, Medina Martínez J, Márquez- gene. 1628-z] Rodas I, Rubió-Casadevall J, Ortega Breast Cancer Res Treat. ME, Jurado García JM, Lecumberri 2017;161:597-604. 20. González-Cao M, Arance A, Biurrun MJ, Palacio I, Rodríguez de F.I.:3,626. [doi:10.1007/s10549-016- Piulats JM, Marquez-Rodas I, la Borbolla Artacho M, Altozano JP, 4058-7] Manzano JL, Berrocal A, Crespo G, Castellón Rubio VE, García A, Luna Rodriguez D, Perez-Ruiz E, Berciano P, Ballesteros A, Fernández O, López 16. Rivera F, Karthaus M, Hecht M, Soria A, Castano AG, Espinosa Martín JA, Berrocal A, Arance A. JR, Sevilla I, Forget F, Fasola G, E, Montagut C, Alonso L, Puertolas Dabrafenib plus trametinib Canon JL, Guan X, Demonty G, T, Aguado C, Royo MA, Blanco for compassionate use in metastatic Schwartzberg LS. R, Rodríguez JF, Muñoz E, Mut P, melanoma: A STROBE-compliant Final analysis of the randomised Barron F, Martin-Algarra S, Spanish retrospective observational PEAK trial: overall survival and Melanoma Group. Pembrolizumab postauthorization study. tumour responses during first-line for advanced melanoma: experience Medicine (Baltimore). 2017;96: treatment with mFOLFOX6 plus from the Spanish Expanded Access F.I.:1,803. [doi:10.1097/ either panitumumab or bevacizumab Program. MD.0000000000009523] in patients with metastatic colorectal Clin Transl Oncol. 2017;19:761-768. carcinoma. F.I.:2,353. [doi:10.1007/s12094-016- INT J COLORECTAL DIS. 1602-1] Reviews 2017;32:1179-1190. F.I.:2,426. [doi:10.1007/s00384-017- 21. Carmona-Bayonas A, Jiménez- 1. Carmona-Bayonas A, Jiménez- 2800-1] Fonseca P, Virizuela J, Antonio M, Font Fonseca P, Custodio A, Grande C, Biosca M, Ramchandani A, Martinez- E, Capdevila J, López C, Teule 17. Hidalgo M, Álvarez R, Gallego Garcia J, Hernando J, Espinosa J, de A, Garcia-Carbonero R, Spanish J, Guillén-Ponce C, Laquente B, Castro EM, Ghanem I, Beato C, Blasco Neuroendocrine Tumor Group Macarulla T, Muñoz A, Salgado M, A, Garrido M, Mondéjar R, Arcusa (GETNE). Vera R, Adeva J, Alés I, Arévalo S, MÁ, Aragón I, Manzano A, Sevillano Optimizing Somatostatin Analog Use Blázquez J, Calsina A, Carmona A, de E, Castañón E, Ayala F, Supportive in Well or Moderately Differentiated Madaria E, Díaz R, Díez L, Fernández Care Working Group of the Spanish Gastroenteropancreatic T, de Paredes BG, Gallardo ME, Society of Medical Oncology (SEOM). Neuroendocrine Tumors. CURR González I, Hernando O, Jiménez Performance of the clinical index of ONCOL REP. P, López A, López C, López-Ríos F, stable febrile neutropenia (CISNE) 2017;19:72-72. Martín E, Martínez J, ..., Carrato A. in different types of infections and F.I.:2,608. [doi:10.1007/s11912-017- Consensus guidelines for diagnosis, tumors. 0633-2] treatment and follow-up of patients Clin Transl Oncol. 2017;19:386-395. with pancreatic cancer in Spain. F.I.:2,353. [doi:10.1007/s12094-016- 2. González A, Lluch A, Aba E, Clin Transl Oncol. 2017;19:667-681. 1540-y] Albanell J, Antón A, Álvarez I, Ayala 185
F, Barnadas A, Calvo L, Ciruelos E, más prednisona en pacientes GRUPO DE TRATAMIENTO DE LOS Cortés J, de la Haba J, López-Vega asintomáticos o con síntomas TUMORES DIGESTIVOS GRUPO JM, Martínez E, Muñoz M, Peláez I, leves que padecen cáncer de TTD. Redondo A, Rodríguez Á, Rodríguez próstata metastásico resistente CA, Ruíz A, Llombart A. a la castración, versión 1.0 del 7. Fernando Rivera Herrero. A definition for aggressive disease 11/02/2009. HIP/CI v 1.1 del Estudio SCOT - Tratamiento in patients with HER-2 negative 20/07/2009,. COU-AA-302. oncológico de corta duración - metastatic breast cancer: an expert JANSSEN-CILAG, S.A.. Estudio de Quimioterapia Adyuvante consensus of the Spanish Society en Cáncer Colorrectal. SCOT. of Medical Oncology (SEOM). Clin 2. José Manuel López Vega. FUNDACIO INSTITUT DE RECERCA Transl Oncol. Estudio fase III aleatorizado, abierto DEL HOSPITAL VALL D´HEBRON. 2017;19:616-624. de lapatinib, trastuzumab, la F.I.:2,353. [doi:10.1007/s12094-016- administración secuencial de ambos 8. Carlos López López 1571-4] y la administración combinada Estudio fase II aleatorizado de de ambos como tratamiento doble ciego de la combinaci6n de 3. Gallego J, López C, Pazo-Cid R, adyuvante en pacientes con cáncer Sandostatina LAR con Axitinib vs López-Ríos F, Carrato A. de maam HER2/ErbB2 positivo. Sandostatina LAR con placebo Biomarkers in pancreatic ductal EGF106708/CLAP016B2301. en pacientes con carcinomas adenocarcinoma. Clin Transl Oncol. GLAXOSMITHKLINE, S.A.. neuroendocrinos avanzados y 2017;19:1430-1437. bien diferenciados de origen no F.I.:2,353. [doi:10.1007/s12094-017- 3. Marta Francisca López-Brea pancreatico (Carcinoides), protocolo 1691-5] Piqueras. Vs. 1 de 3 de mayo de 2011, HIP y CI Estudio en fase 3, aleatorizado y Vs 3 de mayo de 2011. AXI-IIG-02. 4. Salvador J, Urtasun JA, Duart abierto, de la eficacia y seguridad de GRUPO ESPAÑOL DE TUMORES FJ, García-Campelo R, Carbonero PF-02341066 frente a quimioterapia NEUROENDOCRINOS, S.A. GETNE. RG, Lianes P, Llombart A, Casado estandar (pemetrexed o docetaxel) DI, Piera JM, Mateu MM, Puente J, en pacientes con cancer de pulmon 9. Fernando Rivera Herrero. Rivera F, Rodríguez CA, Virizuela JA, no microcitico (NSCLC) avanzado Estudio fase II con axitinib como Martín M, Garrido P. que presentan una translocacion tratamiento de mantenimiento en Equity, barriers and cancer o inversion en el locus del gen de pacientes con carcinoma colorrectal disparities: study of the Spanish la quinasa de linfoma anaplasico, metastásico. TTD-11-01/AXI-IIG-01. Society of Medical Oncology on the versión 3 de agosto de 2009,. GRUPO DE TRATAMIENTO DE LOS access to oncologic drugs in the A8081007. TUMORES DIGESTIVOS GRUPO Spanish Regions. PFIZER LIMITED. TTD. Clin Transl Oncol. 2017;19:341-356. F.I.:2,353. [doi:10.1007/s12094-016- 4. Marta Francisca López-Brea 10. Ana de Juan Ferré. 1535-8] Piqueras. Ensayo fase I/II multicéntrico Estudio en fase 2, abierto, con un y prospectivo de nilotinib y 5. Rivera F, Andres R, Felip E, solo grupo de tratamiento, de la adriamicina como tratamiento Garcia-Campelo R, Lianes P, Llombart eficacia y seguridad de PF02341066 neoadyuvante en liposarcomas y A, Piera JM, Puente J, Rodriguez en pacientes con cáncer de pulmón leiomiosarcomas retroperitoneo. CA, Vera R, Virizuela JA, Martin M, no microcítico (NSCLC) avanzado EC10-150 RETRONEO. Garrido P. que presentan una translocación MARTÍN BROTO, JAVIER. Medical oncology future plan of o inversión en el locus del gen de the Spanish Society of Medical la quinasa de linfoma anaplásico, 11. José Manuel López Vega. Oncology: challenges and future versión Enmienda 2 de 27 de agosto Estudio multicéntrico, doble needs of the Spanish oncologists. de 2009,. A8081005. ciego, randomizado, controlado Clin Transl Oncol. PFIZER LIMITED. con placebo, para comparar 2017;19:508-518. quimioterapia más trastuzumab F.I.:2,353. [doi:10.1007/s12094-016- 5. Fernando Rivera Herrero. y placebo con quimioterapia 1595-9] Estudio fase II de Capecitabina- más trastuzumab y pertuzumab, Oxaliplatino-Trastuzumab (Xelox- como tratamiento adyuvante en Trastuzumab)como tratamiento pacientes con cáncer de mama perioperatorio de pacientes con primario Her2-positivo operable. Adenocarcinoma Gástrico o de la BIG 4-11/BO25126/TOC4939G. F. unión Gastroesofágica, resecable HOFFMANN-LA ROCHE LTD. • PROJECTS (Estadios II a IV). ML25189. ROCHE FARMA, S.A.U.. 12. Marta Francisca López-Brea Piqueras. Clinical Trials 6. Fernando Rivera Herrero. Ensayo clínico fase Ilb, abierto, Ensayo fase IIb randomizado para aleatorizado de afatinib versus 1. Marta Francisca López-Brea evaluar la eficacia de Gemcitabina- gefitinib en primera línea de Piqueras. Erlotinib vs Gemcitabina-Erlotinib- tratamiento en pacientes con Estudio en fase 3, aleatorizado, Capecitabina en pacientes con denocarcinoma de pulmón avanzado con doble enmascaramiento, cáncer de páncreas metastático, con mutación del EGFR. 1200.123. controlado, con placebo, para el protocolo vs final de 2 de septiembre BOEHRINGER INGELHEIM ESPAÑA, acetato de abiraterona (CB7630) de 2010. TTD-10-01. S.A.. Activity Research Areas Report Cancer Area
13. José Manuel López Vega. ramas, que compara exemesrano hepatocelular avanzado (CHC) tras Ensayo fase II multicentrico, abierto, más placebo, frente a exemestano fracaso o intolerancia a sorafenib. de dos cohortes para determinar la más celecoxib y frente a placebo, Estudio ReLive. BA2011/03/04. eficacia y seguridad de pertuzumab en mujeres postmenopáusicas con ONXEO, S.A.. en combinación con trastuzumab y riesgo aumentado de desarrollar vinorelbine en pacientes de primera cáncer de mama. GEICAM/2003-08. 24. CarlosLópez López. línea de cáncer de mama avanzado FUNDACIÓN GRUPO ESPAÑOL DE Ensayo en fase 3, abierto, (localmente avanzado o metastasico) INVESTIGACIÓN EN CÁNCER DE multicéntrico y aleatorizado para HER-2 positivo. MO27782. MAMA FUNDACION GEICAM. evaluar la eficacia y la seguridad de F. HOFFMANN-LA ROCHE LTD. lenvatinib (E7080) en comparación 19. Fernando Rivera Herrero. con sorafenib en el tratamiento 14. José Manuel López Vega. Ensayo clínico abierto, multicéntrico, de primera línea de sujetos Estudio fase III prospectivo, de un único brazo, para evaluar con carcinoma hepatocelular no randomizado y abierto de la seguridad y Calidad de Vida irresecable. E7080-G000-304. EISAI dos cohortes, multicéntrico y Relacionada con la Salud de FARMACEUTICA, S.A.. multinacional para asegurar la aflibercept en pacientes con cáncer seguridad de administración colorrectal metastásico (CCRm) 25. FernandoRivera Herrero. asistida o autoadministración de previamente tratados con un Estudio de fase 3, multicéntrico, trastuzumab subcutáneo como régimen conteniendo oxaliplatino. abierto y aleatorizado de nab- tratamiento adyuvante en pacientes AFLIBC06097. paclitaxel más gemcitabina en con carcinoma de mama precoz SANOFI AVENTIS, S.A.. comparación con gemcitabina en operable HER-2+. MO28048. monoterapia como tratamiento ROCHE FARMA, S.A.U.. 20. Fernando Rivera Herrero. adyuvante en sujetos con Ensayo clínico abierto, aleatorizado, adenocarcinoma pancreático 15. Fernando Rivera Herrero. de fase III, de cisplatino y extirpado quirúrgicamente. ABI-007- Ensayo clínico fase III aleatorizado, 5-fluorouracilo con o sin PANC-003. para evaluar la eficacia de FOLFOX panitumumab, en pacientes con CELGENE CORPORATION. + bevacizumab versus FOLFOXIRI + carcinoma esofágico de células bevacizumab como tratamiento de escamosas (ESCC) avanzado o 26. Fernando Rivera Herrero. primera línea de pacientes con cáncer metastásico, no resecable. AIO- Ensayo IMPALA:Evaluación de colorrectal metastásico no tratado STO-0309. un tratamiento de mantenimiento previamente con tres o más células AIO-STUDIEN-GGMBH. inmunomodulador en pacientes tumorales circulantes. TTD-12-01. con cáncer colorrectal metastásico GRUPO DE TRATAMIENTO DE LOS 21. Ana de Juan Ferré. con reducción del tumor durante TUMORES DIGESTIVOS GRUPO Ensayo clínico fase II aleatorizado, el tratamiento de inducción. Un TTD. abierto y multicéntrico, para ensayo en fase III. MGN1703-C06. determinar la toxicidad y eficacia MOLOGEN AG. 16. Fernando Rivera Herrero. de quimioterapia pre-quirúrgica con Ensayo clínico fase II aleatorizado o sin Bevacizumab en pacientes 27. Marta Francisca López-Brea para explorar la influencia del con Cáncer de Ovario Avanzado. Piqueras. estado de BRAF y PI3K, en la GEICO-1205. Ensayo clínico de fase III aleatorizado eficacia de FOLFIRI + Bevacizumab GRUPO ESPAÑOL DE de comparación de pembrolizumab ó Cetuximab, como tratamiento INVESTIGACION EN CANCER DE (MK-3475) frente a paclitaxel, de primera línea de pacientes con OVARIO GEICO. docetaxel o vinflunina en pacientes cáncer colorrectal metastásico con con cáncer urotelial metastásico KRAS nativo y menos de tres células 22. Almudena garcía castaño. recidivante o progresivo. MK3475-045. tumorales circulantes. TTD-12-02. COMBI-AD: Estudio de fase III, MERCK, SHARP&DOHME CORP. GRUPO DE TRATAMIENTO DE LOS aleatorizado y doble ciego de (MERCK). TUMORES DIGESTIVOS GRUPO dabrafenib (GSK2118436) en TTD. COMBInación con trametinib 28. José Manuel López Vega. (GSK1120212) frente a dos placebos Estudio multicéntrico, abierto, 17. Fernando Rivera Herrero. en el tratamiento ADyuvante del de un único brazo de extensión Estudio en fase II, multicéntrico, melanoma de alto riesgo con de Pertuzumab administrado en aleatorizado, doble ciego y la mutación BRAF V600 tras monoterapia o en combinación con controlado con placebo para resección quirúrgica. BRF115532. otros tratamientos antitumorales evaluar la eficacia y la seguridad GLAXOSMITHKLINE, S.A.. en pacientes previamente incluidos de onartuzumab (MetMab) en en estudios de Pertuzumab combinación con 5-fluorouracilo, 23. CarlosLópez López. esponsorizados por Hoffmann-La ácido folínico y oxaliplatino Estudio abierto, controlado, Roche. MO29406. (mFolfox6) en pacientes con cáncer aleatorizado y multicéntrico que F. HOFFMANN-LA ROCHE LTD. gastroesofágico positivo para Met, compara la eficacia y la seguridad negativo para Her2, metastásico. de infusiones intravenosas 29. Marta Francisca López-Brea YO28322. lentas repetidas de 2 dosis de Piqueras. F. HOFFMANN-LA ROCHE LTD. doxorrubicina Transdrug (DT) (20 Estudio de fase IIIb, aleatorizado, mg/m2 o 30 mg/m2) con las del doble ciego, controlado con placebo, 18. José Manuel López Vega. mejor tratamiento de referencia para evaluar la eficacia y seguridad Estudio aleatorizado fase III de tres (MTR) en pacientes con carcinoma de continuar el tratamiento con 187
enzalutamida en pacientes con de primera línea con platino y 5-fluorouracilo frente a placebo + cáncer de próstata resistente a la fluoropirimidinas. MK3475-061. cisplatino + 5-fluorouracilo como castración metastásico, que no MERCK, SHARP&DOHME CORP. tratamiento de primera línea en han recibido quimioterapia previa, (MERCK). sujetos con adenocarcinoma gástrico que han experimentado progresión o de la unión gastroesofágica (UGE) al tratamiento con enzalutamida 35. Marta Francisca López-Brea avanzado. MK3475-062. sola, tratados con docetaxel más Piqueras. MERCK, SHARP&DOHME CORP. prednisolona. 9785-MA-1001. Estudio Fase III, abierto, aleatorizado, (MERCK). ASTELLAS PHARMA EUROPE, LTD. de MPDL3280A (Anticuerpo ANTI-PD-L1) en combinación 40. Fernando Rivera Herrero. 30. CarlosLópez López. con Carboplatino + Paclitaxel con Estudio de fase II, aleatorizado, Estudio fase II para evaluar la o sin Bevacizumab comparado doble ciego controlado con placebo actividad y seguridad de TH-302 con Carboplatino + Paclitaxel + de MM- 141 más nab-paclitaxel y en combinación con sunitinib Bevacizumab en pacientes con gemcitabina en comparación con para pacientes con tumores cáncer de Pulmón no epidermoide nab-paclitaxel y gemcitabina en el neuroendocrinos pancreáticos no microcítico en estadio IV que no tratamiento de primera línea para (pNET) bien o moderadamente han recibido quimioterapia previa. el cáncer de páncreas metastásico. diferenciados metastásicos no GO29436. MM-141-07-02-02. tratados previamente. F. HOFFMANN-LA ROCHE LTD. MERRIMACK PHARMACEUTICALS, GETNE-1408. GRUPO ESPAÑOL DE INC. TUMORES NEUROENDOCRINOS, 36. Marta Francisca López-Brea S.A. GETNE. Piqueras. 41. Fernando Rivera Herrero. Estudio fase III, Abierto, Ensayo aleatorizado de fase 2 en el 31. Fernando Rivera Herrero. Multicéntrico, Aleatorizado que que se evalúan dosis alternativas Nab-paclitaxel (Abraxane®) más evalúa la eficacia y seguridad de ramucirumab en combinación gemcitabina en sujetos con de MPDL3280A (Anticuerpo con paclitaxel como tratamiento cáncer pancreático localmente ANTI PD L1) en combinación de segunda línea en pacientes avanzado (CPLA): estudio de fase 2, con Carboplatino + Paclitaxel o con adenocarcinoma gástrico internacional, abierto y multicéntrico MPDL3280A en combinación o de la unión gastroesofágica, (LAPACT). ABI-007-PANC-007. con Carboplatino + Nab Paclitaxel localmente avanzado o metastásico CELGENE CORPORATION. comparado con Carboplatino + Nab e irresecable. I4T-MC-JVCZ. Paclitaxel en pacientes con cáncer LILLY, S.A.. 32. Almudena García Castaño. de pulmón no microcítico escamoso Estudio de extensión (transferencia) estadio IV que no han recibido 42. Marta Francisca López-Brea abierto, de Vemurafenib en pacientes quimioterapia previa. GO29437. Piqueras. con neoplasia maligna con la F. HOFFMANN-LA ROCHE LTD. Estudio en fase III, abierto y mutación BRAFV600 incluidos aleatorizado para investigar la previamente en un protocolo 37. CarlosLópez López. eficacia y seguridad de atezolizumab anterior de Vemurafenib. Estudio de fase 3, aleatorizado, (anticuerpo Anti-PD-L1) en GO28399. doble ciego, controlado con placebo, comparación con el tratamiento F. HOFFMANN-LA ROCHE LTD. de ramucirumab y las mejores de soporte optimo después de medidas complementarias frente quimioterapia adyuvante basada 33. Marta Francisca López-Brea a placebo y las mejores medidas en cisplatino en pacientes Piqueras. complementarias como tratamiento seleccionados por PD-L1 con Ensayo clínico abierto y de segunda línea en pacientes con cáncer de pulmón no microcitico en multicéntrico de nivolumab (BMS- carcinoma hepatocelular y con la estadio IB-IIIA totalmente resecado. 936558) en monoterapia en sujetos alfafetoproteína (AFP) basal elevada, GO29527. con cáncer de pulmón no microcítico tras un tratamiento de primera línea F. HOFFMANN-LA ROCHE LTD. (CPNM) epidermoide avanzado o con sorafenib. metastásico que han recibido al I4T-MC-JVDE. LILLY, S.A.. 43. Fernando Rivera Herrero. menos una línea de tratamiento Estudio en fase II de pembrolizumab sistémico previa para el tratamiento 38. CarlosLópez López. (MK 3475) en monoterapia en del CPNM epidermoide en estadio Ensayo para evaluar la eficacia sujetos tratados previamente por IIIb/IV. CA209-171. de lenvatinib en tumores un carcinoma colorrectal con alta BRISTOL-MYERS SQUIBB neuroendocrinos metastásicos inestabilidad de microsatélites INTERNATIONAL CORPORATION (Estudio Talent). GETNE1509. o con reparación de errores de (BMSIC). GRUPO ESPAÑOL DE TUMORES apareamiento deficiente, localmente NEUROENDOCRINOS, S.A. GETNE. avanzado irresecable o metastásico 34. Fernando Rivera Herrero. (estadio IV) (KEYNOTE 164). MK- Ensayo clínico de fase III, 39. Fernando Rivera Herrero. 3475-164. aleatorizado y abierto de Ensayo clínico de fase III, MERCK, SHARP&DOHME CORP. pembrolizumab (MK 3475) aleatorizado, controlado (MERCK). frente a paclitaxel en sujetos con tratamiento activo, con con adenocarcinoma gástrico enmascaramiento parcial y con 44. Fernando Rivera Herrero. o de la unión gastroesofágica detección de biomarcadores, de Estudio de fase III de pembrolizumab avanzado que han presentado pembrolizumab en monoterapia y (MK-3475) frente a quimioterapia progresión después del tratamiento en combinación con cisplatino + en el carcinoma colorrectal en Activity Research Areas Report Cancer Area
estadio IV con inestabilidad de 51. Marta Francisca López-Brea gemcitabina y nab-paclitaxel en microsatélites alta (MSI-H) o con Piqueras. pacientes con adenocarcinoma de defectos en la reparación de los Ensayo en fase III, aleatorizado, páncreas metastásico tratados en errores de emparejamiento (dMMR) multicéntrico, abierto y comparativo primera línea en la práctica clínica (KEYNOTE-177). MK3475-177. para determinar la eficacia de habitual. Estudio ANICE-PaC. MERCK, SHARP&DOHME CORP. durvalumab o durvalumab y GIT-ADE-2015-02. (MERCK). tremelimumab en combinación con quimioterapia basada en platino 5. Eva Martínez de Castro. 45. Carlos López López. como tratamiento de primera Estudio observacional retrospectivo Tratamiento de inducción con línea en pacientes con cáncer sobre el tratamiento del cáncer FOLFOX con o sin Aflibercept de pulmón microcítico (CPM) en colorrectal metastásico (CCRm) en seguido de quimio-radioterapia (QT/ enfermedad avanzada (estadio IV). España. BAY-ONC-2016-01. RT) en adenocarcinoma de recto D419QC00001. ASTRAZENECA BAYER HISPANIA, S.L.. localmente avanzado de alto riesgo. FARMACÉUTICA SPAIN, S.A.. Ensayo abierto, Fase II, aleatorizado. 6. Marta Francisca López-Brea GEMCAD-1402. 52. Marta Francisca López-Brea Piqueras. GRUPO ESPAÑOL Piqueras. Estudio observacional MULTIDISCIPLINAR EN CÁNCER Estudio de Fase III Multicéntrico, postautorización titulado:? DIGESTIVO GEMCAD. Randomizado, controlado con Estudio de biomarcadores no Placebo de Atezolizumab (anticuerpo intervencionista en pacientes con 46. Fernando Rivera Herrero. ANTIPD-L1) en monoterapia y en cáncer de pulmón no microcítico Ensayo clínico multicéntrico combinación con quimioterapia (NSCLC) del tipo histológico randomizado, de tratamiento basada en platino en pacientes adenocarcinoma elegibles para el de mantenimiento basado en con carcinoma urotelial localmente tratamiento con Vargatef® según Biomarcadores para primera línea avanzado o metastásico no tratado la ficha técnica autorizada (LUME de cáncer colorrectal metastásico previamente. WO30070. BioNIS). 1199.223. (Modul). MO29112. F. HOFFMANN-LA ROCHE LTD. BOEHRINGER INGELHEIM ESPAÑA, ROCHE FARMA, S.A.U. S.A.. Postmarketing Studies 47. Fernando Rivera Herrero. and Other Estudio en fase 1b/2 del tratamiento combinado con Ibrutinib en tumores 1. Almudena García Castaño. gastrointestinales y genitourinarios Estudio de la prevalencia, la avanzados seleccionados. PCYC- clasificación sindrómica y el control 1128-CA. del dolor mixto en pacientes INC RESEARCH UK LIMITED. atendidos en los servicios de oncología médica en España. SP- 48. Marta Francisca López-Brea GRT-EPI-2014-02. Piqueras. GRÜNENTHAL PHARMA, S.A.. Estudio abierto y multicéntrico en fase III de brigatinib (AP26113) 2. Marta Francisca López-Brea frente a crizotinib en pacientes con Piqueras. cáncer de pulmón avanzado con REASSURE – Estudio no ALK positiva. AP26113-13-301. intervencionista para la evaluación ARIAD PHARMACEUTICALS, INC.. a largo plazo de la seguridad del agente emisor de partículas alfa 49. Fernando Rivera Herrero. Radio-223 en pacientes con cáncer Estudio aleatorizado fase 2 de de próstata metastásico resistente comparación de diferentes dosis- a la castración (mCRPC). BAY- pautas de tratamiento de inducción RAD-2015-01. (primer ciclo) de regorafenib en BAYER HISPANIA, S.L.. pacientes con cáncer colorrectal metastasico (mCRC). TTD-16-01. 3. Marta Francisca López-Brea GRUPO DE TRATAMIENTO DE LOS Piqueras. TUMORES DIGESTIVOS GRUPO Detección de la mutación T790M TTD. mediante tecnología BEAMing en pacientes con CPCNP y EGFR 50. Fernando Rivera Herrero. mutado en estadio IV. Estudio fase II para evaluar la SYS-ONC-2015-001. eficacia de FOLFIRI + aflibercept en pacientes con cáncer colorrectal 4. Carlos López López. metastásico tratado previamente con Estudio epidemiológico, oxaliplatino con o sin polimorfismos observacional, retrospectivo y de ACE. TTD-16-02. multicéntrico para evaluar las GRUPO DE TRATAMIENTO DE LOS características del tratamiento con TUMORES DIGESTIVOS GRUPO TTD. 189 Activity Report 191
· Transversal Area
Javier Llorca Díez Coordinator of the Transversal Areal.
Professor of Preventive Medicine and Public Health. University of Cantabria. Activity Research Areas Report Transversal Area
Group Responsible Javier Llorca Díaz Department of Preventive Medicine and Public • Epidemiology and Health School of Medicine Public Health University of Cantabria
Researchers Trinidad Dierssen Sotos Paz Rodríguez Cundín
Contributors Jessica Alonso Molero Inés Gómez Acebo
Predoctoral Camilo Palazuelos Calderón
Research lines
1. Epidemiology of cancer:Development of methods for estimating confidence intervals of the population attributable fraction Figura. ROC Curves for the death day mortality and 0.8900 [95% CI 0.8311 outcomes at: (a) 30 days after to 0.9488] for 90-day mortality). Dashed (Stat Med) and its asignation when transplantation, and (b) 90 days after lines: artificial neural network (AUC is risk factors are not aditive (J Clin transplantation. Solid lines: logistic 0.8806 [95% CI 0.7551 to 1.00] for 30-day Epidemiol). Analysis of regression (area under ROC curve [AUC] is mortality and 0.8625 [95% CI 0.7865 to competing risks of death using 0.7246 [95% CI 0.6080 to 0.8913] for 30- 0.9389] for 90-day mortality Gompertzian models (Mech Ageing Develop; J Epidemiol Commun the MCC-Spain project. There have the project (Asturias, Cantabria, Health; Rev Esp Cardiol), Markov been recruited 10000 participants León, Guipúzcoa, Navarre, Gerona, chains with conditional independence between cases (breast, prostate, Barcelona, Valencia, Murcia, (Int J Epidemiol) and in lack of colorectal, stomach and Chronic Granada, Huelva and Madrid). The independence (J Clin Epidemiol). lymphocytic leukemia) and Cantabria node is the 4th in number Line started in 2009 when entering controls in the different nodes of of participants (after Of Madrid, 193
4. López-Mejías R, Carmona FD, Barcelona and Leon). • PUBLICATIONS: Castañeda S, Genre F, Remuzgo- Our group has obtained three FIS Martínez S, Sevilla-Perez B, Ortego- projects as IP for this project in IMPACT FACTOR | 68,865 Centeno N, Llorca J, Ubilla B, Mijares 2009 (5 Projects coordinated by the V, Pina T, Miranda-Filloy JA, Navas Cantabria node), 2012 (4 projects Parejo A, de Argila D, Aragües M, coordinated by The Madrid node) Original articles Rubio E, Luque ML, Blanco-Madrigal and 2015 (3 projects coordinated JM, Galíndez-Aguirregoikoa E, Jayne D, by the Cantabria node), In addition Blanco R, Martín J, González-Gay MA. to participating with collaborating 1. Romaguera D, Gracia-Lavedan E, A genome-wide association study researchers in projects of 2011 and Molinuevo A, de Batlle J, Mendez suggests the HLA Class II region as 2014 Led by CREAL, the National M, Moreno V, Vidal C, Castelló A, the major susceptibility locus for IgA Center for Epidemiology and the ICO- Pérez-Gómez B, Martín V, Molina AJ, vasculitis. Belvitge. Dávila-Batista V, Dierssen-Sotos T, Sci Rep. 2017;7:5088-5088. Gómez-Acebo I, Llorca J, Guevara M, F.I.:4,259. [doi:10.1038/s41598-017- MCC-Spain began publishing its Castilla J, Urtiaga C, Llorens-Ivorra C, 03915-2] results in mid-2015 and at the Fernández-Tardón G, Tardón A, Lorca moment Has published 27 articles, JA, Marcos-Gragera R, Huerta JM, 5. López-Mejías R, Corrales A, of which the node of Cantabria has Olmedo-Requena R, Jimenez-Moleon Vicente E, Robustillo-Villarino M, led 3 on Consumption of drugs and JJ, Altzibar J, de Sanjosé S, Pollán M, González-Juanatey C, Llorca J, breast cancer (BMC Cancer, PlosOne ..., Amiano P. Genre F, Remuzgo-Martínez S, and Breast Cancer Research and Adherence to nutrition-based Dierssen-Sotos T, Miranda-Filloy Treatment). cancer prevention guidelines and JA, Huaranga MA, Pina T, Blanco R, breast, prostate and colorectal Alegre-Sancho JJ, Raya E, Mijares With the 2015 project, a turn in the cancer risk in the MCC-Spain V, Ubilla B, Ferraz-Amaro I, Gómez- project is initiated to transform the case-control study. Vaquero C, Balsa A, López-Longo FJ, cases into Cohorts for the study of Int J Cancer. 2017;141:83-93. Carreira P, González-Álvaro I, Ocejo- prognostic factors. To this end, the F.I.:6,513. [doi:10.1002/ijc.30722] Vinyals JG, Rodríguez-Rodríguez L, Coordinating committee of MCC- Fernández-Gutiérrez B, Castañeda Spain, including from November 2. García-Gómez C, Martín-Martínez S, Martín J, González-Gay MA. 2016 to Javier Llorca as a follow-up MA, Castañeda S, Sanchez-Alonso F, Influence of coronary artery disease coordinator. Uriarte-Ecenarro M, González-Juanatey and subclinical atherosclerosis C, Romera-Baures M, Santos-Rey J, related polymorphisms on the risk 2. Epidemiology of rheumatic Pinto-Tasende JA, Quesada-Masachs of atherosclerosis in rheumatoid diseases: Line initiated in 2000 in E, Tornero-Molina J, Martínez-González arthritis. collaboration with the group of Dr. O, Cobo-Ibáñez T, Chamizo-Carmona Sci Rep. 2017;7:40303-40303. González-Gay (then, In the Hospital E, Manrique-Arija S, Fábregas-Canales F.I.:4,259. [doi:10.1038/srep40303] Xeral Calde de Lugo). We have D, Díaz-González F, Llorca J, González- worked on rheumatoid arthritis, Gay MA, CARMA Project Collaborative 6. Remuzgo-Martínez S, Genre F, arteritis Of giant cells, Schönlein- Group. Castañeda S, Corrales A, Moreno- Henoch’s disease, ankylosing Lipoprotein(a) concentrations in Fresneda P, Ubilla B, Mijares V, spondylitis, Psoriatic arthropathy rheumatoid arthritis on biologic Portilla V, González-Vela J, Pina T, among others, giving rise to a large therapy: Results from the Ocejo-Vinyals G, Irure-Ventura J, number of articles in first Decile / CARdiovascular in rheuMAtology Blanco R, Martín J, Llorca J, López- quartile and to the presentation of study project. Mejías R, González-Gay MA. 7 doctoral theses. At this point, we J CLIN LIPIDOL. 2017;11: Protein tyrosine phosphatase continue Fundamentally in two sub- F.I.:5,812. [doi:10.1016/j. non-receptor 22 and C-Src tyrosine lines: cardiovascular risk in diseases jacl.2017.02.018] kinase genes are down-regulated in Rheumatic and genetic factors that patients with rheumatoid arthritis. influence this risk. 3. Casabonne D, Gracia E, Espinosa Sci Rep. 2017;7:10525-10525. A, Bustamante M, Benavente F.I.:4,259. [doi:10.1038/s41598-017- 3. Clinical Epidemiology: In Y, Robles C, Costas L, Alonso 10915-9] these years, the line of clinical E, Gonzalez-Barca E, Tardón A, epidemiology has focused The Dierssen-Sotos T, Vázquez EG, 7. Ibáñez-Sanz G, Díez-Villanueva transplant, especially the lung, giving Aymerich M, Campo E, Jiménez- A, Alonso MH, Rodríguez-Moranta rise to 18 articles and 5 theses. Moleón JJ, Marcos-Gragera R, F, Pérez-Gómez B, Bustamante M, Castaño-Vinyals G, Aragones N, Martin V, Llorca J, Amiano P, Ardanaz 4. Epidemiological method: Our old Pollan M, Kogevinas M, Urtiaga C, E, Tardón A, Jiménez-Moleón JJ, line of epidemiological method has Amiano P, Moreno V, de Sanjose S. Peiró R, Alguacil J, Navarro C, Guinó been refocused towards the Research Fruit and vegetable intake and E, Binefa G, Navarro PF, Espinosa of new methods to study gene-gene vitamin C transporter gene A, Dávila-Batista V, Molina AJ, and gene-environment interaction; (SLC23A2) polymorphisms in Palazuelos C, Castaño-Vinyals G, This includes regression with lasso chronic lymphocytic leukaemia. Aragonés N, Kogevinas M, Pollán M, and ridge penalty, artificial neural EUR J NUTR. 2017;56:1123-1133. Moreno V. networks, and Bayesian networks. F.I.:4,370. [doi:10.1007/s00394-016- Risk Model for Colorectal Cancer This refocus should begin to 1162-8] in Spanish Population Using produce End of 2017. Environmental and Genetic Factors: Activity Research Areas Report Transversal Area
Results from the MCC-Spain study. Antibody reactivity against F.I.:2,343. [doi:10.1016/j. Sci Rep. 2017;7:43263-43263. Helicobacter pylori proteins canep.2017.08.002] F.I.:4,259. [doi:10.1038/srep43263] in a sample of the Spanish adult population in 2008-2013. 16. Alonso-Molero J, González- 8. Gómez-Acebo I, Dierssen-Sotos HELICOBACTER. 2017;22:F.I.:3,429. Donquiles C, Palazuelos C, T, Fernandez-Navarro P, Palazuelos [doi:10.1111/hel.12401] Fernández-Villa T, Ramos E, Pollán M, C, Moreno V, Aragonés N, Castaño- Aragonés N, Llorca J, Henar Alonso Vinyals G, Jiménez-Monleón JJ, 12. Castelló A, Boldo E, Pérez-Gómez M, Tardón A, Amiano P, Moleon Ruiz-Cerdá JL, Pérez-Gómez B, Ruiz- B, Lope V, Altzibar JM, Martín V, JJJ, Pérez RP, Capelo R, Molina AJ, Dominguez JM, Molero JA, Pollán M, Castaño-Vinyals G, Guevara M, Acebo IG, Guevara M, Gómez BP, Kogevinas M, Llorca J. Dierssen-Sotos T, Tardón A, Moreno Lope V, Huerta JM, Castaño-Vinyals Risk Model for Prostate Cancer V, Puig-Vives M, Llorens-Ivorra C, G, Kogevinas M, Moreno V, Martín V. Using Environmental and Genetic Alguacil J, Gómez-Acebo I, Castilla The RS4939827 polymorphism Factors in the Spanish Multi-Case- J, Gràcia-Lavedán E, Dávila-Batista V, in the SMAD7 GENE and its Control (MCC) Study. Kogevinas M, Aragonés N, Amiano P, association with Mediterranean diet Sci Rep. 2017;7:8994-8994. Pollán M. in colorectal carcinogenesis. BMC F.I.:4,259. [doi:10.1038/s41598-017- Adherence to the Western, Prudent Med Genet. 2017;18:122-122. 09386-9] and Mediterranean dietary patterns F.I.:2,198. [doi:10.1186/s12881-017- and breast cancer risk: MCC-Spain 0485-5] 9. Fernández de Larrea-Baz N, study. Michel A, Romero B, Pérez-Gómez Maturitas. 2017;103:8-15. 17. Amor-Dorado JC, Barreira- B, Moreno V, Martín V, Dierssen- F.I.:3,255. [doi:10.1016/j. Fernandez MP, Llorca J, Gonzalez- Sotos T, Jiménez-Moleón JJ, Castilla maturitas.2017.06.020] Gay MA. J, Tardón A, Ruiz I, Peiró R, Tejada Oculographic, Clinical Test of A, Chirlaque MD, Butt JA, Olmedo- 13. Huerta JM, Chirlaque MD, Sensory Integration and Balance Requena R, Gómez-Acebo I, Linares Molina AJ, Amiano P, Martín V, and Computerized Dynamic P, Boldo E, Castells A, Pawlita M, Fernández-Villa T, Pérez-Gómez B, Posturography Findings in Patients Castaño-Vinyals G, Kogevinas M, de Moreno V, Burgui R, Gómez-Acebo I, With Psoriatic Arthritis. Otol Sanjosé S, Pollán M, Del Campo R, Ramos-Lora M, Fernández-Tardón G, Neurotol. 2017;38:448- Waterboer T, Aragonés N. Peiró R, Olmedo-Requena R, Pollán 453.F.I.:2,024. [doi:10.1097/ Helicobacter pylori Antibody M, Kogevinas M, Castaño-Vinyals G, MAO.0000000000001296] Reactivities and Colorectal Cancer Aragonés N, Navarro. Risk in a Case-control Study in Physical activity domains and risk of 18. Genre F, Armesto S, Corrales A, Spain. gastric adenocarcinoma in the MCC- López-Mejías R, Remuzgo-Martínez Front Microbiol. 2017;8:888-888. Spain case-control study. S, Pina T, Ubilla B, Mijares V, Martín- F.I.:4,076. [doi:10.3389/ PLoS One. 2017;12: Varillas JL, Rueda-Gotor J, Portilla V, fmicb.2017.00888] F.I.:2,806. [doi:10.1371/journal. Dierssen-Sotos T, González-López MA, pone.0179731] González-Vela MDC, Blanco R, Llorca J, 10. Dierssen-Sotos T, Gómez-Acebo Hernández JL, González-Gay MÁ. I, Palazuelos C, Rodriguez-Moranta 14. Robustillo-Villarino M, Alegre- Significant sE-Selectin levels F, Gómez BP, Vazquez JP, Amiano P, Sancho JJ, Rodilla-Sala E, Corrales A, reduction after 6 months of anti- Barricarte A, Mirón-Pozo B, Tardon Llorca J, Gonzalez-Gay MA, Dessein TNF-a therapy in non-diabetic A, Capelo R, Pérez RP, Huerta JM, PH. patients with moderate-to-severe Andreu M, Sierra MÁ, López CC, Ruiz Pulse wave velocity and psoriasis. I, Moreno-Iribas C, Olmedo-Requena augmentation index are not J Dermatolog Treat. 2017;28:726- R, Castaño-Vinyals G, Aragonés N, independently associated with 730. Kogevinas M, Pollán M, Llorca J. carotid atherosclerosis in patients F.I.:1,890. [doi:10.1080/09546634.20 Relationship between drugs with rheumatoid arthritis. 17.1329498] affecting the renin-angiotensin Clin Rheumatol. 2017;36:2601-2606. system and colorectal cancer: F.I.:2,365. [doi:10.1007/s10067-017- 19. Aurrecoechea E, Llorca Díaz J, The MCC-Spain study. 3680-z] Diez Lizuain ML, McGwin G, Calvo- PREV MED. Alen J. 2017;99:178-184. 15. Fernández de Larrea-Baz N, Gender-associated comorbidities in F.I.:3,434. [doi:10.1016/j. Pérez-Gómez B, Michel A, Romero rheumatoid arthritis and their impact ypmed.2017.01.011] B, Lope V, Pawlita M, Fernández-Villa on outcome: data from GENIRA. T, Moreno V, Martín V, Willhauck- Rheumatol Int.2017; 11. Fernández-de-Larrea N, Michel A, Fleckenstein M, López-Abente G, F.I.:1,824. [doi:10.1007/s00296-016- Romero B, Butt J, Pawlita M, Pérez- Castilla J, Fernández-Tardón G, 3628-7] Gómez B, Castaño-Vinyals G, Moreno Dierssen-Sotos T, Santibáñez M, V, Martín V, Amiano P, Castilla J, Peiró R, Jiménez-Moleón JJ, Navarro 20. Holanda Peña MS, Talledo Fernández-Tardón G, Dierssen-Sotos C, Castaño-Vinyals G, Kogevinas M, NM, Ots Ruiz E, Lanza Gómez T, Clofent J, Alguacil J, Huerta JM, Pollán M, de Sanjosé S, Del Campo JM, Ruiz Ruiz A, García Miguelez Jiménez-Moleón JJ, Barricarte A, R, Waterboer T, Aragonés N. A, Gómez Marcos V, Domínguez Molinuevo A, Fernández-Villa T, Helicobacter pylori serological Artiga MJ, Hernández Casabonne D, Sierra Á, Kogevinas M, biomarkers of gastric cancer risk in Hernández MÁ, Wallmann R, de Sanjosé S, Pollán M, Del Campo the MCC-Spain case-control Study. Llorca Díaz J, Grupo HU-CIC. R, Waterboer T, Aragonés N. Cancer Epidemiol. 2017;50:76-84. Satisfaction in the Intensive 195
Care Unit (ICU). Patient opinion Miguel Ángel González-Gay • PROJECTS as a cornerstone. Mantecón. Med Intensiva. 2017;41:78-85. UNIVERSIDAD DE CANTABRIA. F.I.:1,231. [doi:10.1016/j. Projects medin.2016.06.007] 2. Beatriz Carnero López. Manifestaciones reumáticas de 1. Javier Llorca Díaz. los pacientes con cáncer. estudio Integración de big data genéticos Thesis Addressed observacional prospectivo. y datos clínicos: supervivencia con Director/es: Javier Llorca Díaz, cáncer de mama en el estudio MCC- 1. María Dolores Alonso Mesonero. Miguel Ángel González-Gay Spain. PI15/00069. Lupus Eritematoso Sistémico. Mantecón. UNIVERSIDAD DE INSTITUTO DE SALUD CARLOS Epidemiología y Presentación Clínica CANTABRIA. III. MINISTERIO DE ECONOMÍA Y en el Noroeste de España. COMPETITIVIDAD. Director/es: Javier Llorca Díaz, Activity Research Areas Report Transversal Area
Group Responsible Pedro Muñoz Cacho Teaching Unit of Family Medicine and Community • Community health Cantabrian Health Service
Contributors Héctor Alonso Valle María Andres Gómez Francisco Javier Ayesta Ayesta Yolanda Borrego Izquierdo Joaquín Cañal Villanueva José María Castillo Oti Rafael Julián Colás Chacartegui Lorena de Carlos Negro Ángel de la Mora Parra Mónica del Amo Santiago María Teresa Gil Urquiza Luis Gutiérrez Bardeci Mónica Hernández Herrero Associated group Fernando Martín Fuente Luis Otero García Álvaro Peña Irún Sandra Piris García Patricia Rodríguez Fernández Manuel Antonio Tazón Varela Carlos Teja Santamaría
evaluation. It has also collaborated Smoking. At present there is an in a genetic study related to the risk active follow-up project, which Research of developing diabetes in which includes patients who participated three Autonomous Communities in the groups of tobacco cessation lines participate at the national level in primary care from 2006 to (Madrid, Catalonia and Cantabria) the present, in the health center within CIBERDEM (CIBER of Diabetes of Puertochico; In these have The group currently has three and Associated Metabolic Diseases). participated something more than main lines of research: diabetes, In addition one of the areas of 520 people. The aim is to establish smoking and emergencies. interest of the group is diabetic long-term effectiveness, ie beyond retinopathy, in this sense has been the 12-month period commonly In the line of diabetes we are finalized in 2016, an epidemiological used as an international benchmark participating in the study PREDAPS, study in Cantabria to update the for evaluating the effectiveness which is a multicenter national prevalence of this complication. The of interventions. This would be a follow-up study of two cohorts of possible contribution of vitamin D novel contribution, and may serve patients (subjects with prediabetes deficiency as a risk factor for diabetic to establish the need to mark an criteria and healthy controls) started retinopathy and the possible use of assessment at three or five years as in 2012, consists of 1184 prediabetics certain micrornas as predictors of a standard. and 838 controls. Four articles have diabetic retinopathy are also being been published and are being drafted investigated. and are about to be submitted for 197
In the emergency and emergency Además nos proponemos con la Evaluation of Toll-like-receptor area, a cohort study is used to incorporación de dos enfermeras, gene family variants as prognostic establish the prognostic capacity of una de ellas matrona, iniciar biomarkers in rheumatoid arthritis. ultrasensitive troponin T for early una nueva línea en el área de la Immunol Lett. and late mortality in community lactancia matrerna, una de las 2017;187:35-40. acquired pneumonias, in which líneas prioritarias del Plan de Salud F.I.:2,860. [doi:10.1016/j. the emergency professionals de Cantabria. Se tiene experiencia imlet.2017.04.011] of the hospitals of Laredo And en este tema de investigación, en Valdecilla. The aim is to evaluate concreto se consiguió financiación 3. Demetrio Pablo R, Muñoz P, the predictive capacity of the en una convocatoria competitiva López-Hoyos M, Calvo V, Riancho L, aminoterminal fragment of the en el año 2008, que sirvió para Martínez-Taboada VM. Cerebral Natriuretic Pro-peptide verificar el buen funcionamiento Thrombocytopenia as a thrombotic in order to predict mortality in de la metodología de recogida y risk factor in patients with pneumonias. The objective of seguimiento de la cohorte. En la antiphospholipid antibodies without this study was to use the same actualidad estamos finalizando el disease criteria. protocol for the collection of análisis de la encuenta definitiva Med Clin (Barc). 2017;148:394-400. variables and follow-up of patients. del 2009 después del segumiento F.I.:1,125. [doi:10.1016/j. Acquired in the community, and que finalizó en el 2016. medcli.2016.11.026] which provided positive results. In this study we explored the Authorship Thesis utility of troponin T results, not significant because of the small • PUBLICATIONS: 1. María Teresa Gil Urquiza. sample number available for this Factores que intervienen en el inicio marker, but with a better diagnostic IMPACT FACTOR | 8,483 y mantenimiento de la lactancia yield curve than that of the main materna en cantabria. objective (NT Pro-BNP). Director/a: Pedro Muñoz Cacho. In addition we propose with the Original articles UNIVERSIDAD DE CANTABRIA. incorporation of two nurses, one of them matron, to initiate a new line in the area of breastfeeding 1. Riancho-Zarrabeitia L, Daroca G, matrerna, one of the priority lines Muñoz P, López-Hoyos M, Haya A, of the Health Plan of Cantabria. Martínez-Taboada VM. We have experience in this Serological evolution in women with research topic, in particular we positive antiphospholipid antibodies. Semin Arthritis Rheum. obtained funding in a competitive 2017;47:397-402. call in 2008, which served to F.I.:4,498. [doi:10.1016/j. verify the proper functioning of semarthrit.2017.05.001] the methodology of collection and monitoring of the cohort. At 2. Torices S, Alvarez-Rodríguez L, the moment we are finishing the Varela I, Muñoz P, Balsa A, López- analysis of the final survey of 2009 Hoyos M, Martinez-Taboada V, after the segumiento that ended in Fernández-Luna JL. 2016. Activity Research Areas Report Transversal Area
Group Responsible Joaquín Cayón de las Cuevas Head of Legal Councel Office • Law and Bioethics Ministry of Health
Contributors Elena Balmori Gómez Silvia de Diego Lagüera María Diez Sánchez Gustavo Merino Gómez Guillermina Navarro Caballero Daniel Pérez González Ángela Ruiz Sáenz
Emerging group
dimension of healthcare practice regulation of transplants, both and research activity. Within this living donor and deceased donor, Research line, the abandonment of the and the analysis that raises the conception of informed consent complex dynamic transplant, this lines as a defensive medicine tool line specifically addresses the so- and its redesign as a tool for called principle of self-sufficiency, empowerment and doctor-patient the problem of the shortage communication. of organs and tissues and the progressive integration of public 1.1.- Legal protection of health 1.3.- Reproductive rights policies regarding organ donation data. and assisted reproduction and transplantation. techniques. This line of research is part of the 1.5.- Legal aspects of vaccines. implementation of autonomous It confronts reproductive rights projects of a legal nature, or in from a double perspective: This line includes the dialectic the cross-sectional contribution to negative and positive. From the voluntary vaccination - biomedical projects that require first one, the scope of the “right compulsory vaccination, the the corresponding analysis of the to non-procreation” is examined problem of off-label vaccines, the impact of the right to privacy by with the links that this has with transparency and homogeneity the proposed actions. This line the problem of sterilization, both of the vaccination calendar includes the bio-legal analysis of voluntary and forced in case of and, finally, consent in minors the uses and applications of big incapacitated persons. From the and responsibility derived from data in health and the studies on positive side (“right to procreate”), vaccination (or, where appropriate, access and preservation of the the determination of the bio- non-vaccination). clinical history. legal scope of assisted human reproduction techniques forms part 1.6.- Medical responsibility. of this line of research. 1.2.- Informed consent in In this line, we address civil, the assistance and in the criminal and administrative investigation. 1.4.- Legal and ethical dimension of the transplanting activity. litigation liability for damages It addresses informed consent, caused by defective health services a legal figure from the double In addition to examining the and products. 199
2.- Sanitary rights as a tool • PUBLICATIONS: responsabilidad de la aseguradora de for optimizing the assistance asistencia sanitaria: daños médicos management y costes de la atención urgente de IMPACT FACTOR: | 1,675 carácter público en caso de doble 2.1.- Extrajudicial resolution of cobertura. conflicts in the sanitary field Culpa y responsabilidad, Thomson (health mediation). Original articles Reuters Aranzadi, Cizur Menor, 2017, 201-223. The articulation of hetero- 1. Cayon-De Las Cuevas J, Hervey T. compositive tools for extrajudicial A place in the sun? Healthcare rights 7. Merino Gómez Gustavo. resolution of health conflicts- of retired UK citizens in Spain post- Medicamentos falsificados: un internal and external-is studied, Brexit. problema a escala global presided over by the principles Health Econ Policy Law. Derecho fundamental a la salud of voluntariness, impartiality and 2017;12:297-307. ¿nuevos escenarios? agility. F.I.:1,675. [doi:10.1017/ Ed. Universidad Nacional de Colombia, Bogotá, 2017, 329-334. 2.2.- Normative articulation of S1744133117000147] waiting lists. Books and chapters of Projects >The normative approach of books the phenomenon of waiting 1. Cayón-De las Cuevas, Joaquín Projects lists is studied: La prestación de servicios sanitarios como relación jurídica de consumo, 1. Joaquín Cayón de las Cuevas. >Reimbursement of healthcare Thomson Reuters Civitas, Cizur Health Law and Policy Jean Monnet expenses in cases of assistance Menor, 2017. provided by means other Network. 587058-EPP-1-017-1-CA-EPPJMO- than the NHS compensation 2. Cayón-De las Cuevas, Joaquín NETWORK. for patrimonial liability of the Mutual recognition of cross-border COMISIÓN EUROPEA. Public Administrations, when prescriptions at EU level: concerns the delay has caused damage. and challenges. Cross-border health care and >Maximum time guarantee European Union law, Erasmus systems. University Press, Rotterdam, 2017, 117-127. 2.3.- Normative Impact Analysis of health programs. 3. Cayón-De las Cuevas, Joaquín Within the framework of these La responsabilité médicale et les policies to improve regulation, crimes d’omission selon le droit et la the Normative Impact Analysis is jurisprudence espagnole. configured as a method to assess Le droit français a l’aune du droit the different existing regulatory comparé: pour un droit pénal options to achieve a specific health médical rénové? Institut Universitaire Varenne, París, 2017, 141-148. objective, as well as the positive and negative effects of each one. 4. Cayón-De las Cuevas, Joaquín of them. Construyendo la salud como 2.4.- Health organization, hiring derecho autónomo: conexidad and human resources. constitucional, democracia sanitaria y health literacy. It addresses the study of flexible Derecho fundamental a la salud organizational and legal models in the ¿Nuevos escenarios?, field of human resources management Ed. Universidad Nacional models and health contracts, through de Colombia, Bogotá, the analysis of innovative public 2017, 73-88. procurement and HTA. 5. Cayón-De las Cuevas, Joaquín 2.5.-Globalization and Health Defectos de diseño de los Law: Global Health Law. medicamentos: bases del régimen de responsabilidad por daños en la The category of Global Health Unión Europea. Law is studied, the globalization O movimiento do saber: uma of the health phenomenon and its homenagem para Claudia Lima incidence in health care, especially Marqués, Editora RJR, Porto Alegre, through the international treaties 2017, 369-378. on cross-border assistance, pharmaceutical patents and foreign 6. Cayón-De las Cuevas, Joaquín trade of drugs. Títulos de imputación de la Activity Research Areas Report Transversal Area
Group Responsible José Miguel López Higuera Electronic Technology Dept. and systems engineering School of Industrial Engineering and • Photonic engineering group Telecommunications University of Cantabria
Researchers Olga María Conde Portilla Adolfo Cobo García
Contributors Gaspar Fernández Barreras Mauro Matías Lomer Barboza Francisco Javier Madruga Saavedra Jesús María Mirapeix Serrano Antonio Quintela Incera María Ángeles Quintela Incera Eusebio Real Peña Luis Rodríguez Cobo
Consolidated group
Group (PEG) of the University of training, during a period of time, Cantabria generates knowledge and the others, to the application Research and technique in the Photonic field of knowledge and technique with a special focus on solving performing development and lines real problems (not yet resolved innovation for the optimization or insufficiently determined) of their interaction and the and, in the search for their transference of results to the About PEG-JM-Review CHUs-JM solution, generate knowledge productive sector. This, in turn, (16-03-2017) and technique that gives rise to feedback the group with real publications, thesis and patents. problems to be solved and Photonics (Light Sciences and During this process Information resources to best carry out Technologies) has been declared and Communication Technologies their mission. PEG has a R&D&I by the European Union one of (ICT) can be used as an appropriate Photonics Laboratory (457 m2) its six Key Enabling Technologies supplement. equipped with facilities of Optical and by USA one of its essential Fiber, Optical, Opto-Electronic, technologies for its development. It PEG is formed by 26 research, Electronic, Climatic, Thermal is a horizontal (or transversal) field scientific and technical staff imaging characterization, Additive of knowledge with impact in all the following a dynamic model, Manufacturing, Lasers, etc. application sectors. where a part of the members are dedicated more intensively to More than 50 R&D&i projects have The Photonics Engineering the generation of knowledge and been carried out with companies to 201
improve their production processes interaction of laser-matter for 5. Rodríguez-Cuevas A, Peña ER, or the quality of their products; diagnosis and therapy; Rodríguez-Cobo L, Lomer M, or even, to innovate or to develop Higuera JM. new products. The developed 3. Optical devices without Low-cost fiber specklegram sensor (and transferred) knowledge and contact and Optoelectronic for noncontact continuous patient technique have been able to Efficient Systems (low cost or monitoring. improve their productivity and/or cost-effective) for quality and J BIOMED OPT. 2017;22:37001- ensure their qualities. In addition, safety and security of food. 37001. four spin-offs have emerged F.I.:2,530. [doi:10.1117/1. from PEG: TELNOS, Optical and JBO.22.3.037001] Telecommunications systems (2005); Empiric Technologies, SL 6. Ferreira MFS, Castro-Camus E, Ottaway DJ, López-Higuera JM, Feng (2010), Sadiq Engineering (2011) • PUBLICATIONS: and Edronica (2016). X, Jin W, Jeong Y, Picqué N, Tong L, Reinhard BM, Pellegrino PM, Méndez Main Research Lines IMPACT FACTOR | 18,599 A, Diem M, Vollmer F, Quan Q. Roadmap on optical sensors. Since its foundation (1992) PEG J Opt. 2017;19: has been focused on Photonic/ F.I.:1,741. [doi:10.1088/2040-8986/ Optical/Fiber optic sensors; fiber Original articles aa7419] light sources; Optoelectronics Instrumentation; Techniques 7. Ismail Laarossi, Ruben Ruiz- 1. Pardo A, Real E, Krishnaswamy of detection, Measurement Lombera, Maria Angeles Quintela, V, Lopez-Higuera JM, Pogue BW, Jesus Mirapeix, Domingo Lima, and Monitoring of events and Conde OM. David Solana, and Jose-Miguel processes using image for any Directional Kernel Density Estimation Lopez-Higuera. sector of application.Without for Classification of Breast Tissue Ultrahigh Temperature Raman-Based neglecting collaborations proposed Spectra. Distributed Optical Fiber Sensor from other sectors, PEG has very IEEE Trans Med Imaging. With Gold-Coated Fiber. recently decided to focus its 2017;36:64-73. IEEE J SEL TOP QUANT. 23:1-6; work on R&D&I, mainly, in life F.I.:3,942. [doi:10.1109/ F.I.: 3,971. [doi: 10.1109/ sciences and health. This decision TMI.2016.2593948] is backed by a great progress in JSTQE.2016.2633821] the Photonics knowledge, methods 2. Pallares-Aldeiturriaga, David, 8. Cobo A, García-Escárzaga and techniques able to be used in Rodriguez-Cobo, Luis, Quintela, A, Gutiérrez-Zugasti I, Setién J, biological sciences and health that Antonio, Lopez-Higuera, Jose M.. González-Morales MR, López- are significantly contributing to the Curvature Sensor Based on In-Fiber Higuera JM. solution of several of the “societal Mach-Zehnder Interferometer Automated Measurement of challenges” of our time [as defined Inscribed With Femtosecond Laser. Magnesium/Calcium Ratios in in the Lund Declaration www.vr.se/ J LIGHTWAVE TECHNOL. Gastropod Shells Using Laser- lunddeclaration2015 ]. 2017;35:4624-4628. Induced Breakdown Spectroscopy F.I.:3,671. [doi:10.1109/ for Paleoclimatic Applications. PEG has joined the Centro de JLT.2017.2756103] Investigación Biomédica en Red APPL SPECTROSC. 2017;71:591-599. F.I.:1,529. (CIBER-BBN) of IS Carlos III (2016), 3. Aporta Litago, Inaki, Leandro, Daniel, doi:10.1177/0003702816687570] and also joined at the Instituto de Angeles Quintela, Maria, Ana Perez- Investigación Sanitaria de Valdecilla Herrera, Rosa, Lopez-Amo, Manuel, 9. Ortíz D, Casas FJ, Ruiz-Lombera R, (IDIVAL) and set the “Photonics Miguel Lopez-Higuera, Jose. Mirapeix J. for the Life and Health” program Tunable SESAM-Based Mode-Locked Electro-optic correlator for large- which includes four strategic R&D Soliton Fiber Laser in Linear Cavity by format microwave interferometry: lines: Axial-Strain Applied to an FBG. Up-conversion and correlation stages J LIGHTWAVE TECHNOL. performance analysis. Medical diagnostic tools based 2017;35:5003-5009. REV SCI INSTRUM. 2017;88:44702- on Photonic Imaging (Multi, F.I.:3,671. [doi:10.1109/ 44702. Hyperspectral, OCT, Thermografy, JLT.2017.2769221] etc); F.I.:1,515. [doi:10.1063/1.4979811] 4. Ruben Ruiz-Lombera, Isamil 1. Devices and Systems 10. A. Boukhachem,M. Mokhtari, N. Laarossi, Luis Rodriguez-Cobo, (including those referred to as Benameur, A. Ziouche, M. Martínez, Maria Angeles Quintela, Jose-Miguel smart ) for a better diagnosis P. Petkova,M. Ghamnia, A. Cobo, M. López-Higuera; Jesús Mirapeix. and monitoring of diseases with Zergoug, M. Amlouk; Distributed high-temperature optical special emphasis in the elderly Structural optical magnetic fiber sensor based on a Brillouin properties of Co doped alfa-MoO3 population; optical time domain analyzer and sprayed thin films. multimode gold-coated fiber. 2. Interaction of light-matter as SENSOR ACTUAT A-PHYS. 253:198-209 IEEE SENS J. 2017; 17:2393-2397. a basis for new therapies based F.I.: 2,499 [doi: 10.1021/jp066897p]. F.I.:2,512 [doi: 10.1109/ on light and/or the manufacture JSEN.2017.2668844] of micro/nano structures by Activity Research Areas Report Transversal Area
Projects 4. Carlos Fernández Viadero. Thesis Addressed Investigador José Miguel López- Higuera y Luis Rodríguez Cobo. 1. Eusebio Real Peña Projects Valoración de Cronicidad, Sarcopenia Fotónica y Técnicas de Interpretación y Fragilidad, como Instrumento aplicadas al Diagnóstico de 1. Olga María Conde Portilla. para la Prevención del Deterioro de Patologías Cardiovasculares y Fusioderm, Fusión de tecnologías la Capacidad Intrínsica en Dermatológicas fotónicas para el diagnóstico Ancianos. Un Estudio en el Valle Del Directora: Olga M. Conde Portilla dermatológico. Nansa. UNIVERSIDAD DE CANTABRIA DTS15/00238. INCVAL17/03 INSTITUTO DE SALUD CARLOS III. IDIVAL MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD. 5. José Miguel López-Higuera y Adolfo Cobo García 2. Olga María Conde Portilla. SENSORES DE FIBRA ÓPTICA PARA Diseño y desarrollo de un dispositivo SEGURIDAD Y PROTECCIÓN multimodal para diagnóstico (TEC2013-47264-C2-1-R) cardiovascular intraoperatorio Ministerio de Economía y (IntraCardio). DTS17/00055. Competitividad INSTITUTO DE SALUD CARLOS III. MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD. Postmarketing Studies and Other 3. José Miguel López-Higuera y Adolfo Cobo García. 1. Olga María Conde Portilla. Sensores Fotónicos Para Seguridad Diagnóstico de aneurismas de aorta Y Protección mediante nuevas técnicas ópticas de TEC2016-76021-C2-2-R. AEI/FEDER, UE imagen (DA2TOI). 2010.013. AGENCIA ESTATAL DE INVESTIGACIÓN 2. José Miguel López-Higuera. Tecnologías para Sensores De Fibra Óptica II. (TEC2010-20224-C02-02). 2011 203 Activity Research Areas Report Transversal Area
Group Responsible Carmen María Sarabia Cobo Nursing Department Faculty of Nursing • Nursing research University of Cantabria group
Contributors Rebeca Abajas Bustillo Ana Rosa Alconero Camarero Francisco José Amo Setién María Jesús Dura Ros Rosario Fernández Peña Víctor Fradejas Sastre Silvia González Gómez, María Carmen Ortego Maté Paula Parás Bravo Isabel Pérez Loza María Sáenz Jalón Raquel Sarabia Lavín Tamara Silió García Eduardo Vázquez de Castro
Emerging group
L2. Care in aging and dementias. regarding the emotional processing IP Carmen Sarabia Cobo. of Emotional Facial Expressions. Research The most important contribution This line is especially productive is that this is one of the first lines with several contributions such as: studies carried out that values that the most prodromal phases of The validation in Spanish of the dementia affect the recognition of ICECAP-O questionnaire assessing facial expressions, something little L1. Nursing care in quality of life, adapted to the studied until now. This fact opens cardiovascular area. IP: Ana Rosa population with institutionalized an important door to research on Alzonero. Contributors: Víctor dementia. This instrument has communication with these patients Fradejas. Silvia González. special relevance because it is as well as the role that cognitive simple but provides valuable processing plays in emotional Research on the impact of gender information about the quality processing during dementias. on coronary disease stands out. of life of the people and can be The contributions in this sense answered by caregivers, something make it possible to specify the Another important contribution is decisive in the advanced stages of the use of new mechanisms in the treatment more effectively and dementia. to establish preventive measures improvement of stress and burnout in professionals and caregivers of aimed at the female group. It is a Also noteworthy is the research people with dementia, a group with pioneering research in our country, in the elderly population and high stress rates. First-time use of also led by a nurse. with slight Cognitive Impairment the Heart Coherence technique in 205
professionals and caregivers for Alconero, Silvia Gonázlez, María in the process of publication, will managing and managing stress Sáenz. benefit patients by highlighting has contributed to improving the major risk factors associated their quality of life and indirectly We have led for the first time in with surgery (as demonstrated by improving the care they provide. Spain the study of the application the use of anticoagulants, which On the other hand the use of this of clinical simulation in training has been scarcely investigated to technique has shown to have in palliative care, carrying out date). Also noteworthy is another longitudinal effects maintained in the creation and validation of pioneering research in our country, the time being easy and simple to the first battery of tests aimed at within the clinical safety in the apply. assessing satisfaction with own surgical field, as is the unnecessary learning in nursing students in study of surgical doors during the L3. Social networks and health. our country. Research in teaching interventions. This study, carried IP Rosario Fernández. methodologies is becoming out in collaboration with engineers, relevant in nursing faculties will determine the causes, times Particularly important are the work worldwide, especially in the and reasons for opening doors related to the study of personal application of new technologies with the consequent commitment networks in health, a very little such as clinical simulation. We of clinical safety of the patient explored area at the national level. have also carried out the Spanish during the intervention. The study The contributions of the group validation of the test. On the other will allow posteriori to carry out allow a better understanding of hand, regarding the use of new educational interventions with the the networks of social support of educational methodologies, our professionals of the operating room family caregivers contributing to group stands out as the most to sensitize to a problem not very improve the support that should be productive in Online Massive and visible, according to the literature. provided at the professional level. Open Online Courses (MOOCS) This line especially highlights the related to Clinical Safety and L8. Application of Artificial study of personal networks and psychosocial skills at the Spanish Intelligence to the field of health-related quality of life. speaking level, with more than Nursing. 200,000 students enrolled in their L4. Chronicity, dependency, courses in The MiriadaX Platform, IP Raquel Sarabia Lavín. caregivers. IP Carmen Ortego. having received a prize for the best Collaborators: Paula Parás, Eduardo Contributors: Carmen Sarabia, MOOC course in 2014 (Potencia tu Vázquez. Rosario Fernández, M Jesus mente course). Durá, Rebeca Abajas, Francisco Nursing as a profession, is not Amo). The MOOC courses contribute in exempt from the changes and a remarkable way to the scientific transformations originated by the This line has just been opened dissemination in the area of use of emerging technologies, thanks to funding from the health, having been cataloged by or the influence they have and University of Cantabria in a Universia, our courses as the ones will have about its development. competitive national call for with the greatest media impact on Specifically, the technologies emerging research groups. The health in 2015 and 2016. based on Artificial Intelligence funded project will work with are having a great impact in the chronicity and caregivers in Primary L7. Medical-surgical nursing and world of health. The conjunction Care through interventions based patient safety. IP María Sáenz of these technologies in Nursing on advanced practice nursing. Jalón. Collaborate with Carmen will allow us to build intelligent, Sarabia autonomous systems with the L5. Care in relation to capacity to prediction that help in nutrition. IP M Jesus Durá Ros. Our group has developed the their day to day, both professionals Contributors: Carmen Sarabia first global study led by nurses and patients. The objective is not Cobo, Rebeca Abajas, Francisco to assess the impact of the LOOP to replace the human character of Amo. ischemia technique versus the nursing, since we consider that traditional method in upper limb The main contribution of this the Technology and humanism are surgery, obtaining the second line has been a joint project with complementary elements in health National Nursing Research Award the University of Bradfrod (work care general and specifically in from HUMV in 2012. The LOOP pending publication) relating the nursing care. technique is Safer and more impact of stress on eating habits. effective for patients and our study This group has recently Collaboration will also be initiated has been presented at various collaborated in the definition and in a nationally funded competitive Traumatology congresses, leading development of an application project of the Department of to its implementation by different mobile and web, which provides Chemistry of the UC on the hospitals nationwide. an intelligent system for the wastage of nutrients in human food prevention of ulcers by pressure consumption. Another outstanding line of our (UPP). The project, aimed team is to have carried out the L6. Teaching, educational at helping and guiding non- second largest study in patients on innovation and scientific professional caregivers in the basic the characteristics and morbidity dissemination. IP Carmen care, provides a tool to prevent, factors in hip fracture in elderly Sarabia. Contributors: Ana Rosa patients at risk of suffer from UPP, people in our country. This study, Activity Research Areas Report Transversal Area
suffer this important ailment. The Judit, Pallisera, Maria, Perez-Burriel, 2. Santiago López González. project called “Smart UPP” has Marc, Serra, Laura. Una revisión sistemática de been one of the projects supported Improving and evaluating reflective la adherencia al tratamiento through the SODERCAN program narratives: A rubric for higher antihipertensivo y de las I + C = + C 2016 of support for R education students. intervenciones destinadas a & D projects in the field of ICT (Ref. TEACH TEACH EDUC. 2017;63:148-158. mejorarla. TI16-IN-026). In addition, since the F.I.:2,183. [doi:10.1016/j. Director/es: Tania Huedo Medina, application of these technologies tate.2016.12.015] Maria Carmen Ortego Maté. brings legal obligations with In UNIVERSIDAD DE CANTABRIA. relation to the protection, treatment 4. Fernández-Martínez E, Andina-Díaz and exploitation of personal data, E, Fernández-Peña R, García-López 3. Mónica Cueli Arce. there is a researchers specialized in R, Fulgueiras-Carril I, Liébana-Presa Adaptación transcultural de la the legal framework that regulates C. Social Networks, Engagement and “escala revisada de la evaluación these legal aspects. Resilience in University Students. de la percepción de los cuidadores Int J Environ Res Public Health. familiares [revised caregiving 2017;14: appraisal scale (rcas)]” en población F.I.:2,101. [doi:10.3390/ española. ijerph14121488] Directores y Codirectores: Miguel • PUBLICATIONS : Santibañez Margüello, Ana Rosa 5. Sarabia-Cobo CM, Suárez SG, Alconero Camarero y Juan Ramón Menéndez Crispín EJ, Sarabia Cobo Barrada González. IMPACT FACTOR | 19,125 AB, Pérez V, de Lorena P, Rodríguez UNIVERSIDAD DE CANTABRIA. Rodríguez C, Sanlúcar Gross L. Emotional intelligence and coping Original articles styles: An intervention in geriatric nurses. APPL NURS RES. 2017;35:94-98. 1. Parás-Bravo P, Paz-Zulueta M, F.I.:1,379. [doi:10.1016/j. Alonso-Blanco MC, Salvadores- apnr.2017.03.001] Fuentes P, Alconero-Camarero AR, Santibañez M. 6. Sarabia-Cobo CM, Sáenz-Jalón M, Association among presence of Vélez-Carrera B, Miguel Martín ME, cancer pain, inadequate pain control, Rodríguez Landeras G, Roscales San and psychotropic drug use. Bartolomé E, Santiago Fernández PLoS One. 2017;12: M, Higuero-Piris C, Artabe Pozas P, F.I.:2,806. [doi:10.1371/journal. Espeso Salas S, Briz Casares S. pone.0178742] Variables to Predict Mortality in Hip Fractures in Patients Over 65 Years 2. Parás-Bravo P, Salvadores-Fuentes of Age: A Study on the Role of P, Alonso-Blanco C, Paz-Zulueta Anticoagulation as a Risk Factor. M, Santibañez-Margüello M, J Trauma Nurs. 2017;24:326-334. Palacios-Ceña D, Boixadera-Planas F.I.:0,852. [doi:10.1097/ E, Fernández-de-Las-Peñas C. JTN.0000000000000313] The impact of muscle relaxation techniques on the quality of life of cancer patients, as measured by the Reviews FACT-G questionnaire. PLoS One. 2017;12: 1. Fernández-de-Las-Peñas C, F.I.:2,806. [doi:10.1371/journal. Fernández-Muñoz JJ, Palacios- pone.0184147] Ceña M, Parás-Bravo P, Cigarán- Méndez M, Navarro-Pardo E. 2. Sarabia-Cobo CM, Parás-Bravo Sleep disturbances in tension-type P, Amo-Setién FJ, Alconero- headache and migraine. Camarero AR, Sáenz-Jalón M, Ther Adv Neurol Disord. Torres-Manrique B, Sarabia-Lavín R, 2017;11:F.I.:4,192. Fernández-Rodríguez A, Silio-García [doi:10.1177/1756285617745444] T, Fernández-Peña R, Paz-Zulueta M, Santibáñez-Margüello M. Validation of the Spanish Version Thesis Addressed of the ICECAP-O for Nursing Home Residents with Dementia. 1. Tamara Silió García. PLoS One. 2017;12: La experiencia vivida de pacientes F.I.:2,806. [doi:10.1371/journal. valorados para trasplante de pulmón. pone.0169354] Director/es: Paloma Salvadores Fuentes, Maria Carmen Ortego Maté. 3. Alsina, Angel, Ayllon, Sara, Colomer, UNIVERSIDAD DE CANTABRIA. Jordi, Fernandez-Pena, Rosario, Fullana, 207 Activity Report 209
· Infectious Diseases and Immune System Area
María Carmen Fariñas Álvarez Coordinator of the Area of Infectious Diseases and Immune System.
Head of the Infectious Service. University Hospital Marqués de Valdecilla. Professor of the Department of Medicine and Psychiatry. University of Cantabria. Activity Research Areas Report Infectious Diseases and Immune System Area
Group Responsible Miguel Ángel González-Gay • Genetic epidemiology and Mantecón atherosclerosis in systemic Rheumatology Service University Hospital inflammatory diseases Marqués de Valdecilla
Víctor Manuel Mora Cuesta Natalia Palmou Fontana Mª Enriqueta Peiró Callizo Genma Pérez Paredes Trinitario Pina Murcia Consolidated group Federico Rehbergeer Bescos Sara Remuzgo Martínez Leyre Riancho Zarrabeitia Javier Rueda Gotor Researchers Nuria Vegas Revenga Alfonso Fernando Corrales Martínez Losune Vilanova Vadaniz Ricardo Blanco Alonso Lucía Cristina Domínguez Casas Raquel López Mejías Marta Drake Monfort Nurses Sonia María Fernández Rozas Virginia Portilla González Contributors José Héctor Fernández Llaca Patricia Vicente Gómez Pilar Alonso Lecue Virginia Franco Gutiérrez Susana Armesto Alonso Lorien García Cuello Belén Atienza Mateo Fernanda Genre Predoctoral Inés Margarita Ayerbe Cintra Marcos Antonio González López Verónica Pulito Cueto Luis Miguel Blasco Mata David Iturbe Fernández Vanesa Calvo del Río Marina Lacalle Calderon Technicians Benigno Casanueva Fernandez Javier Loricera García Javier García Fernández Beatriz Castro Gutiérrez María Marcellán Fernández, Leticia Lera Gómez José Manuel Cifrián Martínez Cristina Martínez Dubois Verónica Mijares Díaz Germana Consuegra Romero María Cristina Mata Arnaiz Enar Pons Sierra 211
indication for lack of response to Padyukov L, Worthington J, Vyse T, conventional standard therapy, Alarcón-Riquelme ME, Martín J. Research in those patients that due to the A combined large-scale meta- severity of the disease require analysis identifies COG6 as a novel lines biological treatments, we analyze shared risk locus for rheumatoid the impact of these therapies on arthritis and systemic lupus the progression of atherosclerotic erythematosus. disease, analyzing serum markers Ann Rheum Dis. 2017;76:286-294. and clinical parameters Associated F.I.:12,811. [doi:10.1136/ 1.- Epidemiology of autoimmune with an increased risk of CV annrheumdis-2016-209436] diseases (mainly rheumatoid mortality and the implication of 5. Agca R, Heslinga SC, Rollefstad arthritis (RA), giant cell arteritis, these drugs in their pathogenesis S, Heslinga M, McInnes IB, Peters scleroderma, spondyloarthropathies as potentially “protective” therapies MJ, Kvien TK, Dougados M, Radner (EspA), systemic lupus against the development of CV H, Atzeni F, Primdahl J, Södergren A, erythematosus (SLE), psoriasis, disease progression. Wallberg Jonsson S, van Rompay J, antisynthetic syndrome, interstitial Zabalan C, Pedersen TR, Jacobsson lung disease, Shöenlein-Henoch L, de Vlam K, Gonzalez-Gay MA, purpura PSH), aortitis, fibromyalgia Semb AG, Kitas GD, Smulders YM, and hidradenitis suppurativa). We Szekanecz Z, Sattar N, Symmons DP, analyze incidence, clinical spectrum Nurmohamed MT. and evolutionary course of these EULAR recommendations for diseases. In many cases, these • PUBLICATIONS: cardiovascular disease risk data are unknown in the Spanish management in patients with population, which puts our center rheumatoid arthritis and other forms IMPACT FACTOR: | 441,455 as a reference for the knowledge of inflammatory joint disorders: of these diseases in southern 2015/2016 update. European population. Ann Rheum Dis. 2017;76:17-28. F.I.:12,811. [doi:10.1136/ 2.- Cardiovascular risk (CV) and Original articles annrheumdis-2016-209775] vascular disease in autoimmune diseases (mainly RA, EspA, 1. Gladman D, Rigby W, Azevedo 6. Sieper J, Deodhar A, Marzo- SLE, psoriasis and hidradenitis VF, Behrens F, Blanco R, Kaszuba Ortega H, Aelion JA, Blanco R, A, Kudlacz E, Wang C, Menon S, suppurativa). Role of inflammation Jui-Cheng T, Andersson M, Porter Hendrikx T, Kanik KS. and genetics in their development B, Richards HB, MEASURE 2 Study Tofacitinib for Psoriatic Arthritis and clinical presentation. We Group. in Patients with an Inadequate analyzed the markers (analytical, Secukinumab efficacy in anti-TNF- Response to TNF Inhibitors. clinical and imaging) associated naive and anti-TNF-experienced N Engl J Med. with inflammation that may be subjects with active ankylosing 2017;377:1525-1536. involved in the development of spondylitis: results from the F.I.:72,406. [doi:10.1056/ CV events and early mortality in MEASURE 2 Study. NEJMoa1615977] patients with chronic inflammatory Ann Rheum Dis. 2017;76:571-592. rheumatologic diseases. F.I.:12,811. [doi:10.1136/ 2. Gonzáles-Gay MA, Loricera J, annrheumdis-2016-210023] 3.- Genetic, serum and gene Blanco R. expression profiles of autoimmune Trial of Tocilizumab in Giant-Cell 7. Burmester GR, Rigby WF, van Arteritis. diseases and their associated Vollenhoven RF, Kay J, Rubbert-Roth N Engl J Med. 2017;377:1493-1493. comorbidities (mainly RA, giant A, Blanco R, Kadva A, Dimonaco S. F.I.:72,406. [doi:10.1056/ cell arteritis, scleroderma, EspA, Tocilizumab combination therapy NEJMc1711031] SLE, psoriasis, antisynthetic or monotherapy or methotrexate syndrome, interstitial lung monotherapy in methotrexate-naive 3. González-Gay MA, González- disease, aortitis and PSH). Study patients with early rheumatoid Juanatey C. of the genetic predisposition arthritis: 2-year clinical and Inflammation: NSAIDs and pattern of susceptibility as well radiographic results from the cardiovascular risk in arthritis. NAT as analysis of serum biomarkers randomised, placebo-controlled REV CARDIOL. and gene expression profiles FUNCTION trial. 2017;14:69-70. in rheumatologic autoimmune Ann Rheum Dis. 2017;76:1279-1284. F.I.:14,299. [doi:10.1038/ inflammatory diseases and their F.I.:12,811. [doi:10.1136/ nrcardio.2016.208] associated comorbidities. annrheumdis-2016-210561]
4. Márquez A, Vidal-Bralo L, 4.- Therapeutic strategy with 8. Carmona FD, Vaglio A, Mackie SL, Rodríguez-Rodríguez L, González- biological agents in patients with Hernández-Rodríguez J, Monach PA, Gay MA, Balsa A, González-Álvaro I, autoimmune diseases (mainly Castañeda S, Solans R, Morado IC, Carreira P, Ortego-Centeno N, Ayala- RA, EspA and psoriasis). Effect Narváez J, Ramentol-Sintas M, Pease Gutiérrez MM, García-Hernández on clinical parameters of the CT, Dasgupta B, Watts R, Khalidi N, FJ, González-Escribano MF, Sabio disease and the development of CV Langford CA, Ytterberg S, Boiardi L, JM, Tolosa C, Suárez A, González A, disease. Based strictly on clinical Beretta L, Govoni M, Emmi G, Bonatti Activity Research Areas Report Infectious Diseases and Immune System Area
F, Cimmino MA, Witte T, Neumann T, T, Chamizo-Carmona E, Manrique-Arija Martínez S, Sevilla-Perez B, Ortego- Holle J, Schönau V, Sailler L, Papo T, S, Fábregas-Canales D, Díaz-González Centeno N, Llorca J, Ubilla B, Mijares Haroche J, ..., F, Llorca J, González-Gay MA, CARMA V, Pina T, Miranda-Filloy JA, Navas Martín J. A Genome-wide Project Collaborative Group. Parejo A, de Argila D, Aragües M, Association Study Identifies Risk Lipoprotein(a) concentrations in Rubio E, Luque ML, Blanco-Madrigal Alleles in Plasminogen and P4HA2 rheumatoid arthritis on biologic JM, Galíndez-Aguirregoikoa E, Jayne D, Associated with Giant Cell Arteritis. therapy: Results from the Blanco R, Martín J, González-Gay MA. Am J Hum Genet. CARdiovascular in rheuMAtology A genome-wide association study 2017;100:64-74. study project. suggests the HLA Class II region as F.I.:9,025. [doi:10.1016/j. J CLIN LIPIDOL. 2017;11: the major susceptibility locus for IgA ajhg.2016.11.013] F.I.:5,812. [doi:10.1016/j. vasculitis. jacl.2017.02.018] Sci Rep. 2017;7:5088-5088. 9. Calvo-Río V, Santos-Gómez M, F.I.:4,259. [doi:10.1038/s41598-017- Calvo I, González-Fernández MI, 13. López P, Rodríguez-Carrio J, 03915-2] López Montesinos B, Mesquida M, Martínez-Zapico A, Pérez-Álvarez ÁI, Adán A, Victoria Hernández M, Maíz López-Mejías R, Benavente L, Mozo 18. Carmona FD, Coit P, Saruhan- O, Atanes A, Bravo B, Modesto C, L, Caminal-Montero L, González-Gay Direskeneli G, Hernández-Rodríguez Díaz-Cordovés G, Palmou-Fontana MA, Suárez A. J, Cid MC, Solans R, Castañeda S, N, Loricera J, González-Vela MC, Serum Levels of Anti-PON1 Vaglio A, Direskeneli H, Merkel PA, Demetrio-Pablo R, Hernández JL, and Anti-HDL Antibodies as Boiardi L, Salvarani C, González-Gay González-Gay MA, Blanco R. Potential Biomarkers of Premature MA, Martín J, Sawalha AH, Spanish Anti-Interleukin-6 Receptor Atherosclerosis in Systemic Lupus GCA Study Group, Italian GCA Study Tocilizumab for Severe Juvenile Erythematosus. Group, Turkish Takayasu Study Idiopathic Arthritis-Associated Thromb Haemost. Group, Vasculitis Clinical Research Uveitis Refractory to Anti-Tumor 2017;117:2194-2206. Consortium. Necrosis Factor Therapy: A F.I.:5,627. [doi:10.1160/TH17-03- Analysis of the common genetic Multicenter Study of Twenty-Five 0221] component of large-vessel Patients. vasculitides through a meta- Arthritis Rheumatol. 2017;69:668-675. 14. Márquez A, Codero-Coma M, Immunochip strategy. F.I.:6,918. [doi:10.1002/art.39940] Martín-Villa JM, Gorroño-Echebarría Sci Rep. 2017;7:43953-43953. MB, Blanco R, Díaz Valle D, Del Rio F.I.:4,259. [doi:10.1038/srep43953] 10. Alonso-Lecue P, de Pedro I, MJ, Blanco A, Olea JL, Cordero Y, Coulon V, Molinuevo R, Lorz C, Capella MJ, Díaz-Llopis M, Ortego- 19. López-Mejías R, Corrales A, Segrelles C, Ceballos L, López- Centeno N, Ruiz-Arruza I, Llorenç V, Vicente E, Robustillo-Villarino M, Aventín D, García-Valtuille A, Bernal Adán A, Fonollosa A, Ten Berge J, González-Juanatey C, Llorca J, JM, Mazorra F, Pujol RM, Paramio Atan D, Dick AD, De Boer JH, Kuiper Genre F, Remuzgo-Martínez S, J, Ramón Sanz J, Freije A, Toll A, J, Rothova A, Martín J. Dierssen-Sotos T, Miranda-Filloy Gandarillas A. New insights into the genetic JA, Huaranga MA, Pina T, Blanco R, Inefficient differentiation response component of non-infectious uveitis Alegre-Sancho JJ, Raya E, Mijares to cell cycle stress leads to genomic through an Immunochip strategy. V, Ubilla B, Ferraz-Amaro I, Gómez- instability and malignant progression J Med Genet. 2017;54:38-46. Vaquero C, Balsa A, López-Longo FJ, of squamous carcinoma cells. F.I.:5,451. [doi:10.1136/ Carreira P, González-Álvaro I, Ocejo- Cell Death Dis. 2017;8: jmedgenet-2016-104144] Vinyals JG, Rodríguez-Rodríguez L, F.I.:5,965. [doi:10.1038/ Fernández-Gutiérrez B, Castañeda cddis.2017.259] 15. Conde J, Lazzaro V, Scotece M, S, Martín J, González-Gay MA. Abella V, Villar R, López V, Gonzalez- Influence of coronary artery disease 11. Rodríguez-Carrio J, Alperi-López Gay MÁ, Pino J, Gómez R, Mera A, and subclinical atherosclerosis M, López P, López-Mejías R, Alonso- Gualillo O. related polymorphisms on the risk Castro S, Abal F, Ballina-García FJ, Corticoids synergize with IL-1 in the of atherosclerosis in rheumatoid González-Gay MÁ, Suárez A. induction of LCN2. arthritis. High triglycerides and low high- Osteoarthritis Cartilage. Sci Rep. 2017;7:40303-40303. density lipoprotein cholesterol lipid 2017;25:1172-1178. F.I.:4,259. [doi:10.1038/srep40303] profile in rheumatoid arthritis: A F.I.:4,742. [doi:10.1016/j. potential link among inflammation, joca.2017.01.017] 20. Burillo-Sanz S, Montes-Cano MA, oxidative status, and dysfunctional García-Lozano JR, Ortiz-Fernández L, high-density lipoprotein. 16. Riancho-Zarrabeitia L, Daroca G, Ortego-Centeno N, García-Hernández J CLIN LIPIDOL. 2017;11: Muñoz P, López-Hoyos M, Haya A, FJ, Espinosa G, Graña-Gil G, Sánchez- F.I.:5,812. [doi:10.1016/j. Martínez-Taboada VM. Bursón J, Rosa Juliá M, Solans R, jacl.2017.05.009] Serological evolution in women with Blanco R, Barnosi-Marín AC, positive antiphospholipid antibodies. Gómez De la Torre R, Fanlo P, 12. García-Gómez C, Martín-Martínez Semin Arthritis Rheum. Rodríguez-Carballeira M, Rodríguez- MA, Castañeda S, Sanchez-Alonso 2017;47:397-402. Rodríguez L, Camps T, Castañeda F, Uriarte-Ecenarro M, González- F.I.:4,498. [doi:10.1016/j. S, Alegre-Sancho JJ, Martín J, Juanatey C, Romera-Baures M, semarthrit.2017.05.001] González-Escribano MF. Santos-Rey J, Pinto-Tasende JA, Mutational profile of rare variants Quesada-Masachs E, Tornero-Molina 17. López-Mejías R, Carmona FD, in inflammasome-related genes in J, Martínez-González O, Cobo-Ibáñez Castañeda S, Genre F, Remuzgo- Behçet disease: A Next Generation 213
Sequencing approach. Olmos JM, Hernández JL, González- Gutiérrez B, González López MA. Sci Rep. 2017;7:8453-8453. Gay MA, Ferraz-Amaro I. Photoallergic contact dermatitis. F.I.:4,259. [doi:10.1038/s41598-017- Incretins in patients with rheumatoid Eur J Intern Med. 2017;38: 09164-7] arthritis. F.I.:2,960. [doi:10.1016/j. Arthritis Res Ther. 2017;19:229-229. ejim.2016.08.013] 21. Remuzgo-Martínez S, Genre F, F.I.:4,121. [doi:10.1186/s13075-017- Castañeda S, Corrales A, Moreno- 1431-9] 31. Scotece M, Pérez T, Conde J, Fresneda P, Ubilla B, Mijares V, Abella V, López V, Pino J, Gonzalez- Portilla V, González-Vela J, Pina T, 26. Rúa-Figueroa I, de Castro MF, Gay MA, Gomez-Reino JJ, Mera A, Ocejo-Vinyals G, Irure-Ventura J, Andreu JL, Sanchez-Piedra C, Martínez- Gomez R, Gualillo O. Blanco R, Martín J, Llorca J, López- Taboada V, Olivé A, López-Longo Adipokines induce pro-inflammatory Mejías R, González-Gay MA. J, Rosas J, Galindo M, Calvo-Alén factors in activated Cd4+ T cells Protein tyrosine phosphatase J, Fernández-Nebro A, Alonso F, from osteoarthritis patient. non-receptor 22 and C-Src tyrosine Rodríguez-Lozano B, García Vadillo J ORTHOP RES. kinase genes are down-regulated in JA, Menor R, Narváez FJ, Erausquin C, 2017;35:1299-1303. patients with rheumatoid arthritis. García-Aparicio Á, Tomero E, Manrique- F.I.:2,692. [doi:10.1002/jor.23377] Sci Rep. 2017;7:10525-10525. Arija S, Horcada L, Uriarte E, Gil S, F.I.:4,259. [doi:10.1038/s41598-017- Blanco R, López-González R, Boteanu A, 32. Tejera-Segura B, de Vera- 10915-9] Freire M, Galisteo C, Rodríguez-Gómez González AM, López-Mejías R, M, ..., SJOGRENSER and RELESSER González-Gay MA. 22. Pavelka K, Kivitz A, Dokoupilova researchers and EAS-SER GROUP. Erratum corrige. E, Blanco R, Maradiaga M, Tahir H, Comorbidities in Patients With Clin Exp Rheumatol. 2017;35:874- Pricop L, Andersson M, Readie A, Primary Sjögren’s Syndrome and 874. Porter B. Systemic Lupus Erythematosus: A F.I.:2,634. Efficacy, safety, and tolerability of Comparative Registries-Based Study. secukinumab in patients with active Arthritis Care Res (Hoboken). 33. Sánchez-Pérez H, Tejera-Segura ankylosing spondylitis: a randomized, 2017;69:38-45. B, de Vera-González A, González- double-blind phase 3 study, F.I.:3,319. [doi:10.1002/acr.23015] Delgado A, Olmos JM, Hernández MEASURE 3. JL, Corrales A, López-Mejías R, Arthritis Res Ther. 27. Marzo-Ortega H, Sieper J, Kivitz González-Gay MA, Ferraz-Amaro I. 2017;19:285-285. A, Blanco R, Cohen M, Martin R, Insulin resistance in systemic lupus F.I.:4,121. [doi:10.1186/s13075-017- Readie A, Richards HB, Porter B, erythematosus patients: contributing 1490-y] MEASURE 2 study group. factors and relationship with Secukinumab and Sustained subclinical atherosclerosis. 23. Aterido A, Julià A, Carreira P, Improvement in Signs and Clin Exp Rheumatol. Blanco R, López-Longo JJ, Venegas Symptoms of Patients With Active 2017;35:885-892. JJP, Olivé À, Andreu JL, Aguirre- Ankylosing Spondylitis Through F.I.:2,634. Zamorano MÁ, Vela P, Nolla JM, Two Years: Results From a Phase III Marenco-de la Fuente JL, Zea A, Pego Study. 34. Calvo-Río V, Blanco R, Santos- JM, Freire M, Díez E, López-Lasanta Arthritis Care Res (Hoboken). Gómez M, Díaz-Valle D, Pato E, M, López-Corbeto M, Palau N, Tortosa 2017;69:1020-1029. Loricera J, González-Vela MC, R, Gelpí JL, Absher D, Myers RM, F.I.:3,319. [doi:10.1002/acr.23233] Demetrio-Pablo R, Hernández JL, Fernández-Nebro A, Marsal S. González-Gay MA. Genome-wide pathway analysis 28. Scirè CA, Gonzalez-Gay MA, Efficacy of Anti-IL6-Receptor identifies VEGF pathway association Selva-O’Callaghan A, Cavagna L. Tocilizumab in Refractory Cystoid with oral ulceration in systemic Clinical spectrum time course Macular Edema of Birdshot lupus erythematosus. of interstitial pneumonia with Retinochoroidopathy Report of Two Arthritis Res Ther. 2017;19:138-138. autoimmune features in patients Cases and Literature Review. F.I.:4,121. [doi:10.1186/s13075-017- positive for antisynthetase OCUL IMMUNOL INFLAMM. 1345-6] antibodies. Respir Med. 2017;25:604-609. 2017;132:265-266. F.I.:2,453. [doi:10.1080/09273948.20 24. Tejera-Segura B, Macía-Díaz F.I.:3,217. [doi:10.1016/j. 16.1231331] M, Machado JD, de Vera-González rmed.2017.03.028] A, García-Dopico JA, Olmos JM, 35. Robustillo-Villarino M, Alegre- Hernández JL, Díaz-González F, 29. Santurtún A, Rasilla DF, Riancho Sancho JJ, Rodilla-Sala E, Corrales A, González-Gay MA, Ferraz-Amaro I. L, Zarrabeitia MT. Llorca J, Gonzalez-Gay MA, Dessein HDL cholesterol efflux capacity Relationship Between Chronic PH. in rheumatoid arthritis patients: Obstructive Pulmonary Disease and Pulse wave velocity and contributing factors and relationship Air Pollutants Depending on the augmentation index are not with subclinical atherosclerosis. Origin and Trajectory of Air Masses independently associated with Arthritis Res Ther. 2017;19:113-113. in the North of Spain. carotid atherosclerosis in patients F.I.:4,121. [doi:10.1186/s13075-017- Arch Bronconeumol. with rheumatoid arthritis. 1311-3] 2017;53:616-621. Clin Rheumatol. F.I.:2,979. [doi:10.1016/j. 2017;36:2601-2606. 25. Tejera-Segura B, López-Mejías R, arbres.2017.03.017] F.I.:2,365. [doi:10.1007/s10067-017- Domínguez-Luis MJ, de Vera-González 3680-z] AM, González-Delgado A, Ubilla B, 30. Consuegra Romero G, Castro 36. Tenorio J, Álvarez I, Riancho- Activity Research Areas Report Infectious Diseases and Immune System Area
Zarrabeitia L, Martos-Moreno GÁ, 2017;37:1347-1356. Reply. Med Clin (Barc). Mandrile G, de la Flor Crespo M, F.I.:1,824. [doi:10.1007/s00296-017- 2017;148: Sukchev M, Sherif M, Kramer I, 3714-5] F.I.:1,125. [doi:10.1016/j. Darnaude-Ortiz MT, Arias P, Gordo G, medcli.2016.11.009] Dapía I, Martinez-Villanueva J, Gómez 41. Pato E, Martin-Martinez MA, R, Iturzaeta JM, Otaify G, García- Castelló A, Méndez-Fernandez R, 47. Demetrio Pablo R, Muñoz P, Unzueta M, Rubinacci A, Riancho JA, Muñoz-Fernández S, Cordero-Coma López-Hoyos M, Calvo V, Riancho L, Aglan M, Temtamy S, Hamid MA, M, Martinez-Costa L, Valls E, Reyes Martínez-Taboada VM. Argente J, Ruiz-Pérez VL, Heath KE, M, Francisco F, Esteban M, Fonollosa Thrombocytopenia as a thrombotic Lapunzina P. A, Sanchez-Alonso F, Fernández- risk factor in patients with Molecular and clinical analysis of Espartero C, Diaz-Valle T, Carrasco antiphospholipid antibodies without ALPL in a cohort of patients with JM, Beltran-Catalán E, Hernández- disease criteria. suspicion of Hypophosphatasia. Am Garfella M, Hernández MV, Pelegrin Med Clin (Barc). J Med Genet A. L, Blanco R, Diaz-Valle D. 2017;148:394-400. 2017;173:601-610. Development of an activity disease F.I.:1,125. [doi:10.1016/j. F.I.:2,259. [doi:10.1002/ajmg.a.37991] score in patients with uveitis medcli.2016.11.026] (UVEDAI). Rheumatol Int. 37. Amor-Dorado JC, Barreira- 2017;37:647-656. 48. Val-Bernal JF, Hermana S, Fernandez MP, Llorca J, Gonzalez- F.I.:1,824. [doi:10.1007/s00296-016- Armesto S, González-Vela MC. Gay MA. 3593-1] Melanocytes Containing Large Oculographic, Clinical Test of Nuclei and Abundant Pale Sensory Integration and Balance 42. Monforte V, Sintes H, López- Cytoplasm in Melanocytic Nevi. Am and Computerized Dynamic Gallo C, Delgado M, Santos F, J Dermatopathol. Posturography Findings in Patients Zurbano F, Solé A, Gavaldá J, Borro 2017;39:414-416. With Psoriatic Arthritis. JM, Redel-Montero J, Cifrian JM, F.I.:1,095. [doi:10.1097/ Otol Neurotol. Pastor A, Román A, Ussetti P. DAD.0000000000000644] 2017;38:448-453. Risk factors, survival, and F.I.:2,024. [doi:10.1097/ impact of prophylaxis length in 49. Val-Bernal JF, González-Vela MC, MAO.0000000000001296] cytomegalovirus-seropositive lung León-Castillo A, Armesto S. Papillary transplant recipients: A prospective, Dermal Elastosis. 38. González-López MA, Consuegra observational, multicenter study. Am J Dermatopathol. G, Lacalle M, González-Vela MC. Transpl Infect Dis. 2017;39:150-152. Unilateral angiokeratoma of the 2017;19: F.I.:1,095. [doi:10.1097/ scrotum (Fordyce’s type) associated F.I.:1,719. [doi:10.1111/tid.12694] DAD.0000000000000653] with a contralateral varicocele. Indian J Dermatol Venereol Leprol. 43. González-López MA, Hernández 50. Guidolin L, Noguera-Morel L, 2017;83:470-472. JL, Vilanova I, Mata C, López-Escobar Hernández-Martín A, Fernández-Llaca F.I.:1,948. [doi:10.4103/ijdvl. M, González-Vela MC, López-Hoyos H, Rodríguez-Peralto JL, Torrelo A. IJDVL_850_14] M, González-Gay MA, Blanco R. A Case with Juvenile Thyroid autoimmunity in patients Xanthogranuloma and Progressive 39. Genre F, Armesto S, Corrales A, with hidradenitis suppurativa: a case- Nodular Histiocytosis Overlap. López-Mejías R, Remuzgo-Martínez control study. Clin Exp Dermatol. Pediatr Dermatol. S, Pina T, Ubilla B, Mijares V, Martín- 2017;42:642-644. 2017;34: Varillas JL, Rueda-Gotor J, Portilla V, F.I.:1,589. [doi:10.1111/ced.13153] F.I.:0,990. [doi:10.1111/pde.13073] Dierssen-Sotos T, González-López MA, González-Vela MDC, Blanco R, Llorca 44. Gómez-Román J, Zarrabeitia J, Hernández JL, González-Gay MÁ. MT, Santurtún A, Parra JA, Azueta Reviews Significant sE-Selectin levels Etxebarría A, Cifrian JM, Freire reduction after 6 months of anti- Salinas J. 1. González-Gay MA, Matteson EL, TNF-a therapy in non-diabetic Pulmonary Langerhans cell Castañeda S. patients with moderate-to-severe histiocytosis de novo after lung Polymyalgia rheumatica. Lancet. psoriasis. transplantation. Pathol Int. 2017;390:1700-1712. J Dermatolog Treat. 2017;28:726- 2017;67:632-637. F.I.:47,831. [doi:10.1016/S0140- 730. F.I.:1,465. [doi:10.1111/pin.12597] 6736(17)31825-1] F.I.:1,890. [doi:10.1080/09546634.20 17.1329498] 45. Belmar Vega L, Fernández- 2. Abella V, Scotece M, Conde J, Díaz C, Palmou Fontana N, Rodrigo Pino J, Gonzalez-Gay MA, Gómez- 40. De Miguel E, Pecondón-Español Calabia E, Martin Penagos L, Arias Reino JJ, Mera A, Lago F, Gómez R, A, Castaño-Sánchez M, Corrales A, Rodríguez M, Fernández Fresnedo G. Gualillo O. Gutierrez-Polo R, Rodriguez-Gomez Pulmonary hemorrhage Leptin in the interplay of M, Pinto-Tasende JA, Rivas JL, Ivorra- in a patient with IgA nefropathy. inflammation, metabolism and Cortés J, ECO-DAI Group. Nefrologia. 2017;37:347-349. immune system disorders. Nat Rev A reduced 12-joint ultrasound F.I.:1,183. [doi:10.1016/j. Rheumatol. examination predicts lack of X-ray nefro.2016.12.001] 2017;13:100-109. progression better than clinical F.I.:12,188. [doi:10.1038/ remission criteria in patients with 46. Castañeda S, Vicente EF, nrrheum.2016.209] rheumatoid arthritis. Rheumatol Int. González-Gay MA. 215
3. Bartoloni E, Gonzalez-Gay MA, Scirè Editorials Systemic Autoimmune Diseases. C, Castaneda S, Gerli R, Lopez-Longo EU13/01- PRECISESADS. FJ, Martinez-Barrio J, Govoni M, Furini COMISIÓN EUROPEA, INNOVATIVE 1. González-Gay MA, Blanco R, F, Pina T, Iannone F, Giannini M, Nuño MEDICINES INITIATIVE. Castañeda S. L, Quartuccio L, Ortego-Centeno N, Henoch-Schönlein purpura (IgA Alunno A, Specker C, Montecucco C, 4. Miguel Ángel González-Gay vasculitis): the paradox of the Triantafyllias K, Balduzzi S, Sifuentes- Mantecón. different incidence and clinical Giraldo WA, Paolazzi G, Bravi E, Marcadores genéticos de spectrum in children and adults. Schwarting A, Pellerito R, Russo A, enfermedad aterosclerótica en la Clin Exp Rheumatol. 2017;35 Suppl Selmi C, Saketkoo LA, Fusaro E, ..., Artritis Reumatoide. 103:3-4. F.I.:2,634. Cavagna L. PI15/00525. INSTITUTO DE SALUD Clinical follow-up predictors of CARLOS III. disease pattern change in anti-Jo1 Authorship Thesis MINISTERIO DE ECONOMÍA Y positive anti-synthetase syndrome: COMPETITIVIDAD. Results from a multicenter, 1. Marta López Sánchez. international and retrospective study. Factores asociados a mortalidad en 5. Miguel Ángel González-Gay Autoimmun Rev. pacientes tratados con membrana de Mantecón. 2017;16:253-257. oxigenación extracorpórea (ECMO) Contratos para la Intensificación de F.I.:8,961. [doi:10.1016/j. en el trasplante de pulmón. la actividad investigadora en el SNS. autrev.2017.01.008] Director/a: Miguel Ángel González- INT16/00133. INSTITUTO DE SALUD Gay Mantecón. CARLOS III. 4. Abella V, Pino J, Scotece M, UNIVERSIDAD DE CANTABRIA. MINISTERIO DE ECONOMÍA Y Conde J, Lago F, Gonzalez-Gay MA, COMPETITIVIDAD. Mera A, Gómez R, Mobasheri A, 2. María Dolores Alonso Mesonero. Gualillo O. Lupus eritematoso sistémico. 6. Miguel Ángel González-Gay Progranulin as a biomarker and epidemiología y presentación clínica Mantecón. potential therapeutic agent. DRUG en el noroeste de españa. Red temática en Inflamación DISCOV TODAY. Director/es: Javier Llorca Díaz, y Enfermedades Reumáticas. 2017;22:1557-1564. Miguel Ángel González-Gay RD16/0012/0009. INSTITUTO DE F.I.:6,369. [doi:10.1016/j. Mantecón. SALUD CARLOS III. drudis.2017.06.006] UNIVERSIDAD DE CANTABRIA. MINISTERIO DE ECONOMÍA Y COMPETITIVIDAD. 5. Cavagna L, Nuño L, Scirè CA, 3. Beatriz Carnero Lopez. 7. Raquel López Mejías. Govoni M, Longo FJ, Franceschini Manifestaciones reumáticas de Contrato Miguel Servet Tipo I. F, Neri R, Castañeda S, Sifuentes los pacientes con cáncer. estudio CP16/00033. INSTITUTO DE SALUD Giraldo WA, Caporali R, Iannone observacional prospectivo. CARLOS III. MINISTERIO DE F, Fusaro E, Paolazzi G, Pellerito R, Director/es: Javier Llorca Díaz, ECONOMÍA YCOMPETITIVIDAD. Schwarting A, Saketkoo LA, Ortego- Miguel Ángel González-Gay Centeno N, Quartuccio L, Bartoloni Mantecón. 8. Miguel Ángel González-Gay E, Specker C, Pina Murcia T, La Corte UNIVERSIDAD DE CANTABRIA. Mantecón. R, Furini F, Foschi V, Bachiller Corral EU17/12. FOREUM (“Foundation for J, Airò P, Cavazzana I, Martínez- Research in Rheumatology”) Barrio J, Hinojosa M, ..., AENEAS Projects (American and European NEtwork of Antisynthetase Syndrome) Projects Clinical Trials Collaborative. Serum Jo-1 Autoantibody 1. Miguel Ángel González-Gay 1. Ricardo Blanco Alonso. and Isolated Arthritis in the Mantecón. Estudio abierto de seguimiento Antisynthetase Syndrome: Review Red de Investigación en Inflamación a largo plazo de Tofacitinib (CP- of the Literature and Report of the y Enfermedades Reumáticas. 690,550), para el tratamiento de la Experience of AENEAS Collaborative RD12/0009/0013. INSTITUTO DE artritis reumatoide. Group. Clin Rev Allergy Immunol. SALUD CARLOS III. A3921024. 2017;52:71-80. MINISTERIO DE ECONOMÍA Y PFIZER LIMITED. F.I.:5,263. [doi:10.1007/s12016-016- COMPETITIVIDAD. 8528-9] 2. Ricardo Blanco Alonso. 2. Miguel Ángel González-Gay Estudio prospectivo, Fase IIb/ 6. Sopeña B, Rivera A, Chamorro A, Mantecón. III, multicéntrico, randomizado, Freire M, Alende V, Seco E, González- Contratos Sara Borrell. doble ciego, controlado, de 3 Gay MA, González-Quintela A. CD15/0095. INSTITUTO DE SALUD grupos paralelos y 24 semanas de Clinical association between CARLOS III. duración con posible extensión, para Kikuchi?s disease and systemic MINISTERIO DE ECONOMÍA Y comparar la eficacia y seguridad lupus erythematosus: A systematic COMPETITIVIDAD. de masitinib, a la dosis de 3 y literature review. Semin Arthritis 4.5 mg/kg/día, con metotrexato, Rheum. 3. Miguel Ángel González-Gay con randomización 1:1:1, para 2017;47:46-52. Mantecón. el tratamiento de pacientes con F.I.:4,498. [doi:10.1016/j. Molecular Reclassification to Find artritis reumatoide activa y con semarthrit.2017.01.011] Clinically Useful Biomarkers for Activity Research Areas Report Infectious Diseases and Immune System Area
una respuesta inadecuada a 1. 8. Ricardo Blanco Alonso. 24 semanas y para evaluar la metotrexato, a 2. cualquier FAME Estudio Estudio multicéntrico, de seguridad, tolerabilidad y eficacia incluido al menos un fármaco grupos paralelos, de seguridad y a largo plazo hasta 3 años en biológico si previamente resultó eficacia a largo plazo de CNTO 136 pacientes con Artritis Psoriásica ineficaz en pacientes tratados con (sirukumab) en artritis reumatoide activa. metotrexato o a 3. metotrexato en en sujetos que han completado CAIN457F2318. combinación con cualquier FAME el tratamiento en los estudios NOVARTIS FARMACEUTICA, S.A.. incluidos fármacos biológicos. CNTO136ARA3002 (SIRROUND-D) AB06012. y CNTO136ARA3003 (SIRROUND-T). 13. Ricardo Blanco Alonso. AB SCIENCE. CNTO136ARA3004. Estudio abierto, de extensión, a JANSSEN-CILAG INTERNATIONAL, largo plazo, con Tofacitinib (CP- 3. Ricardo Blanco Alonso. NV. 690,550) para el tratamiento de la Estudio de extensión a largo artritis psoriásica. plazo de los estudios WA22762 y 9. Ricardo Blanco Alonso. A3921092. NA25220, multicéntrico, abierto Estudio multicéntrico, aleatorio, PFIZER, INC. para evaluar la seguridad y eficacia a doble ciego y comparativo con de tocilizumab subcutáneo en fármaco activo y con placebo de 14. Ricardo Blanco Alonso. pacientes con artritis reumatoide 24 semanas de duración, seguido Estudio de fase IIIB/IV aleatorizado, moderada a grave. ML28488. de una evaluación a largo plazo de criterios de valoración de la ROCHE FARMA, S.A.U.. de la eficacia y la seguridad seguridad, de 2 dosis de Tofacitinib de Ixekizumab (LY2439821) en en comparación con un inhibidor 4. Ricardo Blanco Alonso. pacientes con artritis psoriásica del factor de necrosis tumoral Estudio de fase III, multicéntrico, activa que nunca han recibido un (TNF) en pacientes con artritis aleatorizado, doble ciego, fármaco antirreumático biológico reumatoide. A3921133. controlado con placebo de modificador de la enfermedad. PFIZER, INC. secukinumab subcutáneo I1F-MC-RHAP (Reiteración). en jeringas precargadas para ELI LILLY & COMPANY. 15. Ricardo Blanco Alonso. demostrar la eficacia a las 16 Estudio multicéntrico, aleatorizado, semanas y evaluar la eficacia, 10. Ricardo Blanco Alonso. con doble enmascaramiento, seguridad y tolerabilidad a largo Estudio multicéntrico, controlado con placebo, de 24 plazo, hasta 5 años, en pacientes aleatorizado, doble ciego fase III semanas de duración, seguido con Espondilitis Anquilosante de Secukinumab, controlado con de una evaluación a largo plazo activa. placebo para demostrar la eficacia de la eficacia y la seguridad CAIN457F2310. a las 16 semanas y evaluar la de ixekizumab (LY2439821) en NOVARTIS FARMACEUTICA, S.A.. seguridad, tolerabilidad y eficacia pacientes con artritis psoriásica a largo plazo en un periodo de 3 activa que han recibido un fármaco 5. Ricardo Blanco Alonso. años en sujetos con espondilitis antirreumático modificador de la Estudio de fase 3, aleatorizado, anquilosante activa. enfermedad biológico. doble ciego, controlado con CAIN457F2314. I1F-MC-RHBE. placebo y un comparador activo, NOVARTIS FARMACEUTICA, S.A.. ELI LILLY & COMPANY. para evaluar la eficacia y seguridad de baricitinib en pacientes con 11. José Manuel Cifrián Martínez. 16. Ricardo Blanco Alonso.Estudio de artritis reumatoide con actividad Extensión del estudio AC-055-310, fase IIb, multicéntrico, aleatorizado, moderada-severa y respuesta Estudio fase IIIb con Macitentan, doble ciego, de ALX-0061 insuficiente al tratamiento con multicéntrico, abierto, de una administrado subcutáneamente metotrexato. única rama, en pacientes con como monoterapia, en sujetos con I4V-MC-JADV. hipertensión arterial pulmonar artritis reumatoide de moderada LILLY, S.A.. para validar psicométricamente a severa con intolerancia al las versiones francesa, italiana y metotrexato o para los que el 6. Ricardo Blanco Alonso. española de PAH-SYMPACT(tm). tratamiento continuado con Estudio fase 3, multicentrico para An extension of AC-055-310, a metotrexato es inadecuado. evaluar la seguridad y eficacia de multi-center, open-label, single-arm, ALX0061-C202. Baricitinib en pacientes con artritis Phase 3b study of macitentan in ABLYNX NV. reumatoide. patients with pulmonary arterial I4V-MC-JADY. hypertension to psychometrically 17. Ricardo Blanco Alonso. LILLY, S.A.. validate the French, Italian and Estudio de fase III, multicéntrico, Spanish versions of the PAH- aleatorizado, doble ciego, 7. Ricardo Blanco Alonso. SYMPACT(tm). controlado con placebo de Estudio de fase II, aleatorizado, AC-055-311. ACTELION secukinumab (150 mg) por vía doble ciego, controlado con PHARMACEUTICALS LTD. subcutánea con o sin una dosis placebo, de búsqueda de la dosis, de carga por vía subcutánea para sobre la eficacia y seguridad 12. Ricardo Blanco Alonso. evaluar la eficacia, la seguridad y la de tofacitinib en pacientes con Estudio multicéntrico, aleatorizado, tolerabilidad durante un máximo de espondilitis anquilosante (EA) doble ciego, controlado con 2 años en pacientes con espondilitis activa. placebo, de fase III de secukinumab anquilosante activa. A3921119. subcutáneo en autoinyectores, CAIN457F2320. PFIZER, INC. para demostrar la eficacia a las NOVARTIS FARMACEUTICA, S.A.. 217
18. Susana Armesto Alonso. doble ciego para comparar ABT-494 evaluar la eficacia en la semana 52 Optimización del tratamiento de con placebo en tratamiento estable de secukinumab en monoterapia por mantenimiento a largo plazo de con fármacos antirreumáticos vía subcutánea en comparación con la piel blanqueada en pacientes modificadores de la enfermedad adalimumab en monoterapia por vía con psoriasis crónica en placas sintéticos convencionales subcutánea en pacientes con artritis de moderada a grave: Estudio (FARMEsc) en sujetos con artritis psoriásica activa. randomizado, multicéntrico, abierto reumatoide de actividad moderada CAIN457F2366. con evaluación ciega, comparativo, a grave con respuesta insuficiente o NOVARTIS FARMACEUTICA, S.A.. de 52 semanas de seguimiento intolerancia a los FARME biológicos para evaluar la eficacia, seguridad y (FARMEb). 29. José Manuel Cifrián Martínez. tolerabilidad de secukinumab 300 M13-542. Estudio aleatorizado, doble ciego mg S.C. ABBVIE DEUTSCHLAND y controlado con placebo para CAIN457A3302. GMBH&CO K.G. evaluar la eficacia y la seguridad NOVARTIS FARMACEUTICA, S.A. del tratamiento oral con nintedanib 24. Ricardo Blanco Alonso. durante al menos 52 semanas 19. Ricardo Blanco Alonso. Estudio de Estudio multicéntrico, aleatorizado, en pacientes con «enfermedad extensión, de Fase II, multicéntrico, doble ciego, controlado con pulmonar intersticial asociada a abierto para evaluar la eficacia y placebo para evaluar la seguridad, esclerosis sistémica» (SSc-ILD). seguridad a largo plazo de ALX-0061 tolerabilidad y eficacia de 1199.214. BOEHRINGER INGELHEIM subcutáneo en sujetos con artritis secukinumab en pacientes con ESPAÑA, S.A.. reumatoide de moderada a severa spondiloartritis axial no radiográfica que hayan completado uno de los activa durante un periodo de 2 años. 30. José Manuel Cifrián Martínez. estudios anteriores de Fase IIb con CAIN457H2315. Ensayo en fase II, multicéntrico, ALX-006. NOVARTIS FARMACEUTICA, S.A.. internacional, doble ciego, de dos ALX0061-C203. grupos, aleatorizado y controlado ABLYNX NV. 25. José Manuel Cifrián Martínez. con placebo, de pirfenidona Estudio clínico de Fase III, en pacientes con epifibrosante 20. Cristina Martínez Dubois. Estudio controlado con placebo, doble ciego progresiva inclasificable. de Fase 3, aleatorizado, doble y aleatorizado para determinar la MA39189. ciego, controlado con placebo, eficacia, seguridad y tolerabilidad ROCHE PRODUCTS LIMITED. multicéntrico de la seguridad del óxido nítrico inhalado (NOi) y eficacia analgésicas de la pulsado frente al placebo en sujetos 31. José Manuel Cifrián Martínez. administración subcutánea de sintomáticos con hipertensión Estudio de Búsqueda de Dosis Tanezumab en sujetos con artrosis arterial pulmonar (HAP). de la Eficacia y la Seguridad de de cadera o de rodilla. PULSE-PAH-004. Bardoxolona de Metilo en Pacientes A4091057. BELLEROPHON PULSE con Hipertensión Pulmonar. PFIZER, INC. TECHNOLOGIES LLC. 402-C-1302. REATA PHARMACEUTICALS INC.. 21. Ricardo Blanco Alonso. 26. José Manuel Cifrián Martínez. Estudio de fase 3, aleatorizado, Estudio de la eficacia y la seguridad 32. José Manuel Cifrián Martínez. doble ciego comparando ABT-494 de bardoxolona metilo en pacientes Estudio de fase IIB multicéntrico, 15 mg una vez al día en monoterapia con hipertensión arterial pulmonar doble ciego, randomizado, y ABT-494 30 mg una vez al día en asociada a enfermedad del tejido controlado con placebo para evaluar monoterapia frente a metotrexato conectivo. la eficacia, seguridad y tolerancia (MTX) en monoterapia en sujetos no 402-C-1504. de Sildenafilo en combinación con tratados previamente con MTX con REATA PHARMACEUTICALS INC.. Pirfenidona en pacientes con fibrosis artritis reumatoide activa moderada pulmonar idiopática avanzada y a grave. 27. Ricardo Blanco Alonso. probabilidad intermedia o alta de M13-545. Maximise (Tratamiento de las desarrollar hipertensión pulmonar ABBVIE DEUTSCHLAND manifestaciones axiales en la Artritis grupo 3. GMBH&CO K.G. Psoriásica con Secukinumab), MA29957. estudio multicéntrico, aleatorizado, ROCHE FARMA, S.A.U.. 22. Ricardo Blanco Alonso. doble ciego, controlado con placebo, Estudio de fase 3, aleatorizado, de 52 semanas de seguimiento para 33. José Manuel Cifrián Martínez. doble ciego comparando ABT-494 evaluar la eficacia y seguridad de Programa de acceso al estudio de con placebo y con adalimumab en secukinumab 150 mg o 300 mg s.c. extensión para evaluar la seguridad sujetos con artritis reumatoide activa en pacientes con artritis psoriásica a largo plazo de bardoxolona metilo moderada a grave en tratamiento activa y afección del esqueleto axial en pacientes con hipertensión con metotrexato (MTX) en dosis que no respondan adecuadamente pulmonar. estables y que no han respondido a antiinflamatorios no esteroideos 402-C-1602. de forma adecuada a MTX (MTX-IR). (AINEs). REATA PHARMACEUTICALS INC.. M14-465. CAIN457F3302. ABBVIE DEUTSCHLAND NOVARTIS FARMACEUTICA, S.A.. 34. David Iturbe Fernández. GMBH&CO K.G. Ensayo clínico con enmascaramiento 28. Ricardo Blanco Alonso. doble, multicéntrico y controlado 23. Ricardo Blanco Alonso. Estudio multicéntrico, aleatorizado, con placebo para investigar la Estudio de Fase 3, aleatorizado, doble ciego, con control activo para eficacia y seguridad de 12 meses Activity Research Areas Infectious Diseases and Report Immune System Area
de terapia con Promixin® inhalado 3. Mª Enriqueta Peiró Callizo. observacional (EPA-OD), (colistimetato de sodio) para el Seguimiento y control en multicéntrico, en pacientes con HAP tratamiento de pacientes con Reumatología-Enfermería. tratados con Opsumit® (macitentan) bronquiectasia no debida a fibrosis SCORE-2010-01. según práctica clínica habitual en quística con infección crónica por FUNDACIÓN ESPAÑOLA DE España. Pseudomonas aeruginosa REUMATOLOGÍA F.E.R.. PRACMA. AC-055-507. (P. aeruginosa). ACTELION PHARMACEUTICALS Z7224L01. 4. Ricardo Blanco Alonso. ESPAÑA, S.L.. ZAMBON SPA. Registro observacional prospectivo a 5 años para evaluar los 7. José Manuel Cifrián Martínez. Postmarketing Studies acontecimientos adversos de interés Estudio retrospectivo, de revisión and Other y la eficacia en adultos con lupus de historias clínicas, multicéntrico eritematoso sistémico activo, con para describir el perfil clínico de los 1. Mª Enriqueta Peiró Callizo. autoanticuerpos positivos, tratados pacientes diagnosticados con FPI Evaluación del riesgo cardiovascular, con o sin BENLYSTA (belimumab). tratados con Nintedanib (OFEV®) y de sus determinantes, en pacientes HGS1006-C1124. en la práctica clínica habitual en con artritis reumatoide, espondilitis GLAXOSMITHKLINE RESEARCH & España. anquilosante y artritis psoriásica. DEVELOPMENT LIMITED. 1199-0295. CARMA. BOEHRINGER INGELHEIM ESPAÑA, FUNDACIÓN ESPAÑOLA DE 5. Cristina Martínez Dubois. S.A.. REUMATOLOGÍA F.E.R.. Estudio de prevalencia de las enfermedades reumáticas en la 2. José Héctor Fernández Ilaca. población adulta española. Registro epidemiológico FER-COR-2016-01. observacional para evaluar el perfil FUNDACIÓN ESPAÑOLA DE clínico de los pacientes con psoriasis REUMATOLOGÍA F.E.R.. moderada a grave en España. Estudio ARIZONA. 6. José Manuel Cifrián Martínez. JAN-PSO-2010-01. Estudio retrospectivo, JANSSEN-CILAG, S.A.. posautorización de tipo 219 Activity Research Areas Report Infectious Diseases and Immune System Area
Group Responsible María Del Carmen Fariñas Álvarez • Pathogenic Epidemiology and Infectious Diseases Service Mechanisms of Infectious University Hospital Marqués de Valdecilla Diseases University of Cantabria
Contributors Carlos Armiñanzas Castillo Ana Mª Arnaiz García Francisco Arnaiz De Las Revillas Almajano Mª Concepcion Fariñas Álvarez Marta Fernández Sampedro Lorien García Cuello Claudia González Rico Manuel Gutiérrez Cuadra Javier Gonzalo Ocejo Viñals Borja Suberviola Cañas Consolidated group
Research in Infectious Pathology API 11/09, are there more accurate Researcher (REIPI) and European Projects Systemic Markers in the diagnosis of (Increment-SOT). Knee Prosthesis Infection (IPRC) prior lines to Implant withdrawal?, the study of Systemic Markers is being carried 2. The study of Articular Prosthesis out in the diagnosis of Infection of Infections. Knee Prosthesis or Hip (IPRC) prior to 1. Infections in Transplanted Solid the withdrawal of the Implant such Organs. This line began in 2009 with the as IL6, Procalcitonin, VEGF (Vascular execution of the Research Project: PI Endothelial Growth Factor) or NETs 08/0609 where the study of the role (Neutrophils extracellular traps). This line of research started in 2012 of sonication in the diagnosis of joint is being consolidated in our group prosthesis infections was introduced. 3. Optimization of antimicrobial. mainly through the acquisition of The results have had as a positive competitive funding research projects result the incorporation into the (FIS - PI13 / 01191 - PI16 / 01415 laboratory routine of Microbiology of Treatment and its impact of antibiotic and Mutua Madrileña FMM 14/01. this technique. Then, and thanks to consumption on cost savings and 221
bacterial resistance. Initiated in 2006 The study of alleles and haplotypes 3. Parker A, Irure Ventura J, Sims D, with the granting of two research of the major histocompatibility Echeverría de Carlos A, Gómez de projects (FIS: PI06 / 90094 and API: complex between healthy controls, la Torre R, Tricas Aizpún L, Ocejo- 06/01). This project has received the individuals with latent tuberculosis Vinyals JG, López-Hoyos M, Wallis ValdecillaACaja Cantabria Teaching and individuals with active pulmonary G, Harding S. Measurement of the Excellence Award in 2013. Since tuberculosis in the population of IgG2 response to Pneumococcal then, the experience accumulated at Cantabria, is one of the lines initiated capsular polysaccharides may the Marqués de Valdecilla Hospital is in 2008 and later consolidated with identify an antibody deficiency being transferred to other hospitals the obtaining Of an API1010 Grant. in individuals referred for through the teaching of professional Currently still active. Likewise, immunological investigation. specialists of staff from National the search for other genes for J Immunoassay Immunochem. Hospitals that go to Diseases susceptibility or resistance to 2017;38(5):514-522. Infectious. progression, from a latent state of F.I.: 7,727. doi: tuberculosis infection to disease, is 10.1080/15321819.2017.1340897. another objective of the group. The excessive and inadequate 4. Calderon-Gonzalez R, Terán- use of antimicrobials is currently Navarro H, García I, Marradi M, an important economic and Salcines-Cuevas D, Yañez-Diaz S, public health problem due to the Solis-Angulo A, Frande-Cabanes • PUBLICATIONS: emergence of microorganisms E, Fariñas MC, García-Castaño A, that are increasingly resistant to Gomez-Roman J, Penades S, Rivera available antibiotics. This study is IMPACT FACTOR: | 93,662 F, Freire J, Álvarez-Domínguez C. part of an attempt to achieve these Gold glyconanoparticles coupled objectives through recommendations to listeriolysin O 91-99 peptide on the use of antimicrobials in a Original articles serve as adjuvant therapy against standardized way by a person with melanoma. NANOSCALE. experience in this area, the result of a 2017;9:10721-10732. multidisciplinary collaboration. F.I.:7,367. [doi:10.1039/c7nr02494k] 1. Lora-Tamayo J, Senneville É, Ribera A, Bernard L, Dupon M, 5. Ramos-Martínez A, Roque F, Zeller V, Li HK, Arvieux C, Clauss M, 4. Epidemiology of Infective Fariñas MC, Muñoz P, Verde E, Uçkay I, Vigante D, Ferry T, Iribarren Endocarditis. Cuerpo GP, de Alarcón A, Lepe JA, Peel TN, Sendi P, Miksic NG, JA, Miró JM, Plata A, Goenaga Rodríguez-Pardo D, Del Toro MD, MÁ, García-Rosado D, Martínez- With the creation of the Endocarditis Fernández-Sampedro M, Dapunt Monzonis A, de la Torre J, García- Management Assistance Group U, Huotari K, Davis JS, Palomino Pavía P, Spanish Collaboration on in Spain (GAMES) in 2007, which J, Neut D, Clark BM, Gottlieb T, Endocarditis — Grupo de Apoyo al comprises 35 hospitals, a better Trebše R, Soriano A, Bahamonde A, Manejo de la Endocardi. knowledge of this disease is being ..., and the Group of Investigators Prognostic factors of infective achieved, which is having an for Streptococcal Prosthetic Joint endocarditis in patients on impact on a better diagnostic and Infection.. hemodialysis: A case series from a therapeutic approach. Our group The Not-So-Good Prognosis of National Multicenter Registry. manages one of the 7 nodes in which Streptococcal Periprosthetic Joint Int J Cardiol. the participating Hospitals have Infection Managed by Implant 2017;241:295-301. been divided and has contributed Retention: The Results of a Large F.I.:6,189. [doi:10.1016/j. to the formation of the HUMV Multicenter Study. ijcard.2017.04.086] Multidisciplinary Endocarditis Group, Clin Infect Dis. 2017;64:1742-1752. H. Sierrallana and H. de Laredo, in F.I.:8,216. [doi:10.1093/cid/cix227] 6. Miñambres E, Suberviola B, which the Cardiology, Cardiovascular Dominguez-Gil B, Rodrigo E, Ruiz- Surgery, Home Hospitalization, 2. Cordero E, Roca-Oporto C, San Millan JC, Rodríguez-San Juan Bulnes-Ramos A, Aydillo T, Gavaldà Internal Medicine and Microbiology. JC, Ballesteros MA. J, Moreno A, Torre-Cisneros J, Improving the Outcomes of Montejo JM, Fortun J, Muñoz P, Organs Obtained From Controlled 5. Research in the field of sepsis. Sabé N, Fariñas MC, Blanes-Julia Donation After Circulatory M, López-Medrano F, Suárez- Death Donors Using Abdominal Benjumea A, Martinez-Atienza J, Study of sepsis in a global way, both Normothermic Regional Perfusion. Rosso-Fernández C, Pérez-Romero P, from the point of view of predisposing Am J Transplant. 2017;17:2165-2172. TRANSGRIPE 1–2 Study Group. factors and the optimization of its F.I.:6,165. [doi:10.1111/ajt.14214] treatment and the identification Two Doses of Inactivated Influenza Vaccine Improve of prognostic factors. This line of 7. Calderon-Gonzalez R, Frande- Immune Response in Solid Organ research began with research projects Cabanes E, Teran-Navarro H, Transplant Recipients: Results of with competitive funding: PI07/0723, Marimon JM, Freire J, Salcines- TRANSGRIPE 1-2, a Randomized PI10/01497 and API11/35. Cuevas D, Fariñas MC, Gonzalez-Rico Controlled Clinical Trial. C, Marradi M, Garcia I, Alkorta- Clin Infect Dis. Gurrutxaga M, San Nicolas-Gomez 6. Tuberculosis (Infection / Disease) 2017;64:829-838. A, Castañeda-San Pedro A, Yañez- and Genetic Alterations. F.I.:8,216. [doi:10.1093/cid/ciw855] Diaz S, Penades S, Punzon C, Activity Research Areas Report Infectious Diseases and Immune System Area
Gomez-Roman J, Rivera F, Fresno A, Medini D, Pizza M, Vázquez JA. 16. Suberviola B, Rellan L, Riera M, Alvarez-Dominguez C. GNP- Potential impact of the 4CMenB J, Iranzo R, Garcia Campos A, GAPDH1-22 nanovaccines prevent vaccine on oropharyngeal carriage Robles JC, Vicente R, Miñambres E, neonatal listeriosis by blocking of Neisseria meningitidis. Santibanez M. microglial apoptosis and bacterial J Infect. 2017;75:511-520. Role of biomarkers in early dissemination. F.I.:4,201. [doi:10.1016/j. infectious complications after lung Oncotarget. 2017;8:53916-53934. jinf.2017.09.021] transplantation. F.I.:5,168. [doi:10.18632/ PLoS One. 2017;12: oncotarget.19405] 12. Arnáiz-García ME, González- F.I.:2,806. [doi:10.1371/journal. Santos JM, Arnáiz-García AM, López- pone.0180202] 8. Del Barrio-Tofiño E, López- Rodríguez J, Arnáiz J. Causapé C, Cabot G, Rivera A, Acute Type A Aortic Dissection 17. Fernández-Sampedro M, Benito N, Segura C, Montero MM, After Sternal Bone Marrow Fariñas-Alvarez C, Garces-Zarzalejo Sorlí L, Tubau F, Gómez-Zorrilla S, Puncture. C, Alonso-Aguirre MA, Salas-Venero Tormo N, Durá-Navarro R, Viedma Ann Thorac Surg. 2017;104: C, Martínez-Martínez L, Fariñas MC. E, Resino-Foz E, Fernández-Martínez F.I.:3,700. [doi:10.1016/j. Accuracy of different diagnostic M, González-Rico C, Alejo-Cancho athoracsur.2017.07.039] tests for early, delayed and late I, Martínez JA, Labayru-Echverria C, prosthetic joint infection. Dueñas C, Ayestarán I, Zamorano L, 13. Martín-Loeches I, Muriel-Bombín BMC Infect Dis. 2017;17:592-592. Martínez-Martínez L, Horcajada JP, A, Ferrer R, Artigas A, Sole-Violan J, F.I.:2,768. [doi:10.1186/s12879-017- Oliver A. Lorente L, Andaluz-Ojeda D, Prina- 2693-1] Genomics and Susceptibility Mello A, Herrán-Monge R, Suberviola Profiles of Extensively Drug- B, Rodriguez-Fernandez A, Merino 18. Zarrabeitia R, Fariñas-Álvarez C, Resistant Pseudomonas P, Loza AM, Garcia-Olivares P, Anton Santibáñez M, Señaris B, Fontalba A, aeruginosa Isolates from Spain. E, Tamayo E, Trapiello W, Blanco J, Botella LM, Parra JA. Antimicrob Agents Chemother. Bermejo-Martin JF, GRECIA group. Quality of life in patients with 2017;61:F.I.:4,302. [doi:10.1128/ The protective association hereditary haemorrhagic AAC.01589-17] of endogenous immunoglobulins telangiectasia (HHT). Health Qual against sepsis mortality Life Outcomes. 2017;15:19-19. 9. López-Mejías R, Corrales A, is restricted to patients F.I.:2,143. [doi:10.1186/s12955-017- Vicente E, Robustillo-Villarino M, with moderate organ 0586-z] González-Juanatey C, Llorca J, Genre failure. F, Remuzgo-Martínez S, Dierssen- Ann Intensive Care. 2017;7:44-44. 19. Fernández-Cruz A, Muñoz P, Sotos T, Miranda-Filloy JA, Huaranga F.I.:3,656. [doi:10.1186/s13613-017- Sandoval C, Fariñas C, Gutiérrez- MA, Pina T, Blanco R, Alegre-Sancho 0268-3] Cuadra M, Pericás Pulido JM, JJ, Raya E, Mijares V, Ubilla B, Miró JM, Goenaga-Sánchez MÁ, Ferraz-Amaro I, Gómez-Vaquero C, 14. Fariñas MC, Campo A, Duran R, de Alarcón A, Bonache-Bernal F, Balsa A, López-Longo FJ, Carreira P, Sarralde JA, Nistal JF, Gutiérrez-Díez Rodríguez M, Noureddine M, Bouza González-Álvaro I, Ocejo-Vinyals JG, JF, Fariñas-Álvarez C. Santiago E, Spanish Collaboration on Rodríguez-Rodríguez L, Fernández- Risk factors and outcomes Endocarditis (GAMES). Gutiérrez B, Castañeda S, Martín for nosocomial infection after Infective endocarditis in patients J, González-Gay MA. Influence prosthetic vascular grafts. with cancer: a consequence of of coronary artery disease and J Vasc Surg. 2017;66:1417-1426. invasive procedures or a harbinger subclinical atherosclerosis related F.I.:3,536. [doi:10.1016/j. of neoplasm?: A prospective, polymorphisms on the risk of jvs.2017.06.078] multicenter cohort. atherosclerosis in rheumatoid Medicine (Baltimore). arthritis. 15. López-Aladid R, Guiu A, 2017;96: Sci Rep. 2017;7:40303-40303. Sanclemente G, López-Medrano F.I.:1,803. [doi:10.1097/ F.I.:4,259. [doi:10.1038/srep40303] F, Cofán F, Mosquera MM, Torre- MD.0000000000007913] Cisneros J, Vidal E, Moreno A, 10. Remuzgo-Martínez S, Genre F, Aguado JM, Cordero E, Martin- 20. Parker AR, Skold M, Ramsden Castañeda S, Corrales A, Moreno- Gandul C, Pérez-Romero P, Carratalá DB, Ocejo-Vinyals JG, López-Hoyos Fresneda P, Ubilla B, Mijares V, J, Sabé N, Niubó J, Cervera C, M, Harding S. Portilla V, González-Vela J, Pina T, Cervilla A, Bodro M, Muñoz P, The Clinical Utility of Measuring Ocejo-Vinyals G, Irure-Ventura J, Fariñas C, Codina MG, Aranzamendi IgG Subclass Immunoglobulins Blanco R, Martín J, Llorca J, López- M, Montejo M, Len O, Marcos During Immunological Mejías R, González-Gay MA. MA, Group for Study of Infection Investigation for Suspected Protein tyrosine phosphatase in Transplantation of the Spanish Primary Antibody Deficiencies. non-receptor 22 and C-Src tyrosine Society of Infect. Lab Med. kinase genes are down-regulated Detection of cytomegalovirus 2017;48:314-325. in patients with rheumatoid drug resistance mutations F.I.:1,265. [doi:10.1093/labmed/ arthritis. Sci Rep. 2017;7:10525- in solid organ transplant lmx058] 10525.F.I.:4,259. [doi:10.1038/ recipients with suspected s41598-017-10915-9] resistance. 21. Parker AR, Skold M, Ramsden J Clin Virol. 2017;90:57-63. DB, Ocejo-Vinyals JG, López-Hoyos 11. Abad R, Medina V, Fariñas MDC, F.I.:3,051. [doi:10.1016/j. M, Harding S. Martínez-Martínez L, Bambini S, Dari jcv.2017.03.014] The Clinical Utility of Measuring 223
IgG Subclass Immunoglobulins 27. Lisa-Gracia M, Martín-Rivas B, multirresistentes en las infecciones During Immunological Pajarón-Guerrero M, Arnáiz-García A. sistémicas, enfermedad de Investigation for Suspected Abdominal actinomycosis in the injerto contra huésped (EICH) y Primary Antibody Deficiencies. last 10 years and risk factors for mortalidad de pacientes receptores Lab Med. 2017;48:314-325. appendiceal actinomycosis: review de trasplante alogénico de F.I.:1,265. [doi:10.1093/labmed/ of the literature. progenitores hematopoyéticos lmx058] TURK J MED SCI. (Alo-TPH). PI16/01415. 2017;47:98-102. INSTITUTO DE SALUD CARLOS 22. Suberviola B, Rodrigo E, F.I.:0,710. [doi:10.3906/sag-1511-52] III. MINISTERIO DE ECONOMÍA Y González-Castro A, Serrano M, Heras COMPETITIVIDAD. M, Castellanos-Ortega Á. 28. Arnáiz-García ME, Arnáiz- Association between exposure to García AM, Gutierrez-Diez F, Nistal 3. María del Carmen Fariñas Álvarez. angiotensin-converting enzyme JF, González-Santos JM, Pulitani I, Red Temática de Enfermedades inhibitors and angiotensin receptor Amado-Diago C, Arnáiz J. Infecciosas. blockers prior to septic shock and Mutilating Purpura Fulminans in an RD16/0016/0007. INSTITUTO DE acute kidney injury. Adult with Meningococcal SALUD CARLOS III. MINISTERIO DE Med Intensiva. 2017;41:21-27. Sepsis. P ECONOMÍA Y COMPETITIVIDAD. F.I.:1,231. [doi:10.1016/j. R HEALTH SCI J. medin.2016.07.010] 2017;36:179-182. Clinical trials F.I.:0,581. 23. Arnáiz-García ME, Arnáiz-García AM, Gutiérrez-Diez JF, González- 1. María del Carmen Fariñas Álvarez. Santos JM, García-Martín A, Alonso- Editorials Ensayo prospectivo, aleatorizado, Peña D, Arnáiz J. comparativo de la eficacia y Vasopressor-induced peripheral 1. Arnáiz-García ME, González- seguridad del levofloxacino versus skin necrosis after shock. Santos JM, Arnáiz-García AM, isoniazida en el tratamiento de la Rev Port Cardiol. Arnáiz J. infección latente tuberculosa del 2017;36:573-574. Endovascular repair or trasplante hepático. F.I.:1,195. [doi:10.1016/j. best medical treatment: what FLISH-ILT. repc.2016.07.016] is the optimal management of FUNDACIÓN PÚBLICA ANDALUZA uncomplicated Type-B PARA LA GESTIÓN DE LA 24. Belmar Vega L, Rodrigo Calabria acute aortic dissection?. INVESTIGACIÓN EN SALUD DE E, Gutiérrez Fernández G, Casanova J Thorac Dis. 2017;9:3458-3462. SEVILLA FISEVI. Rituerto D, González Sánchez FJ, F.I.:2,365. [doi:10.21037/ Armiñanzas Castillo C, Roiz Mesones jtd.2017.08.145] 2. María del Carmen Fariñas Álvarez. MP, Arias Rodriguez M. Ensayo clínico prospectivo Actinomyces viscosus infection 2. Castellanos-Ortega Á, aleatorizado comparativo de in a kidney-pancreas trasplanted Cañas BS. Has the Surviving la eficacia y seguridad de una patient. Nefrologia. Sepsis Campaign been successful dosis de vacuna estacional 2017;37:431-432. in Spain?. respecto a dos dosis de vacunas F.I.:1,183. [doi:10.1016/j. Med Intensiva. 2017;41:1-2. como prevención de la gripe nefro.2017.01.001] F.I.:1,231. [doi:10.1016/j. en receptores de trasplante de medin.2016.11.001] órgano sólido. TRANSGRIPE 1-2. 25. Goenaga Sánchez MÁ, FUNDACIÓN PÚBLICA ANDALUZA Kortajarena Urkola X, Bouza Santiago PROGRESO Y SALUD. E, Muñoz García P, Verde Moreno E, Fariñas Álvarez MC, Teira Cobo 3. María del Carmen Fariñas Álvarez. R, Pericás Pulido JM, de Alarcón Projects Ensayo clínico de fase III González A, Sousa Regueiro D, Ruiz multicéntrico, aleatorizado, abierto Morales J, Rodríguez-Álvarez RJ, Projects de Telavancina en comparación Antorrena Miranda I, Iribarren Loyarte con la terapia intravenosa JA, Grupo GAMES. convencional en el tratamiento Aetiology of renal failure 1. María del Carmen Fariñas Álvarez. de pacientes con bacteriemia por in patients with infective Colonización intestinal por Staphylococcus aureus, incluyendo endocarditis. The role of enterobacterias multirresistentes la endocarditis infecciosa. antibiotics. en pacientes con trasplante renal 0112. Med Clin (Barc). 2017;149:331-338. y hepático: estudio multicéntrico THERAVANCE BIOPHARMA F.I.:1,125. [doi:10.1016/j. de cohortes y ensayo clínico ANTIBIOTICS, INC. medcli.2017.03.009] aleatorizado, controlado y abierto. PI13/01191. 4. María del Carmen Fariñas Álvarez. 26. Arnáiz-García AM, Arnáiz-García INSTITUTO DE SALUD CARLOS Estudio Fase III, aleatorizado, ME, Arnáiz J. III. MINISTERIO DE ECONOMÍA Y multicéntrico, abierto, de grupos Primary amyloidosis. COMPETITIVIDAD. paralelos, para evaluar la eficacia, Rev Clin Esp. seguridad y tolerabilidad de una 2017;217:238-239. 2. María del Carmen Fariñas Álvarez. pauta de tratamiento intramuscular F.I.:0,971. [doi:10.1016/j. Impacto de la colonización de acción prolongada con rce.2016.12.006] intestinal por enterobacterias cabotegravir y rilpivirina en el Activity Research Areas Report Infectious Diseases and Immune System Area
mantenimiento de la supresión pacientes adultos infectados por perfil del paciente naive que inicia virológica, tras una inducción con el VIH-1 que no han recibido un el tratamiento antirretroviral en un tratamiento de comprimido tratamiento antirretroviral previo España. único con un inhibidor de la pacientes adultos infectados por JAN-VIH-2009-04/TMC114HIV4051. integrasa en Estudio Fase III, el VIH-1 que no han recibido un JANSSEN-CILAG, S.A. aleatorizado, multicéntrico, abierto, tratamiento antirretroviral previo. de grupos paralelos, para evaluar la 201584. eficacia, seguridad y tolerabilidad LABORATORIOS VIIV HEALTHCARE, de una pauta de tratamiento S.L. intramuscular de acción prolongada con cabotegravir y Postmarketing Studies rilpivirina en el mantenimiento and Other de la supresión virológica, tras una inducción con un tratamiento 1. María del Carmen Fariñas Álvarez. de comprimido único con un Estudio epidemiológico no inhibidor de la integrasa en intervencionista para conocer el 225 Activity Research Areas Report Infectious Diseases and Immune System Area
Group Responsible Carmen • Nanovaccines and cellular Álvarez Domínguez vaccines based on Listeria Valdecilla Biomedical Research Institute monocytogenes and their Marqués de Valdecilla applications in biomedicine IDIVAL
Contributors Ricardo Calderón González Susana Gómez Salces Salcines Cuevas, David Hector Terán Navarro Sonsoles Yáñez Diaz
Technicians Milagros González Toca
Emerging group
08695, SAF2012-34203). To 2.- Listeria based dendritic establish cerebral and neonatal vaccines loaded with peptides listeriosis models to analyze against infectious agents. Research specific virulence factors of the lines pathogen targeted to microglia and design a cerebral listeriosis vaccine. (PI: Dr. C. Alvarez Dominguez and Co-PI: Dra. S. Ya- ñez Diaz/Grants: SAF2009-08695 y SAF2012-34203 This study implies the and Approved Clinical Study: 1.- Cerebral listeriosis and characterization of microglia CEIC-Acta 19/2014- 2014.228). A neonatal listeriosis models: phagosomes using differential Listeria based dendritic vaccine proteomics (col. C. Gil. UCM) loaded with peptides from virulence and examine new adyuvants for factors specific of Listeria (LLO) (PI: Dr. C. Alvarez Domínguez/ neonatal vaccines (col. M. Fresno, and common to Mycobacterium Grants: SAF2006- 08968, SAF2009- CBMSO). smegmatis (GAPDH) will be
Figura1. Listeriosis cerebral neonatal y papel de microglía 227
Figura 2. Vacuna dendrítica con un nuevo antígeno de Listeria monocytogenes: GAPDH.
used to examine experimental biomaGUNE collaborates with our dissemination. prophylactic measures against group preparing AuGNP (cols. Dr. Oncotarget. 2017;8:53916-53934. both bacteria. Moreover, we are M. Marradi, Dr. I. Garcia and Dr. F.I.:5,168. [doi:10.18632/ performing a clinical study with S. Penades). We have performed oncotarget.19405] listeriosis patients from a 2014 studies with a prophylactic outbreak with Dr. C. Fariñas experimental nanovaccine (Infectious Section-HUMV) and against listeriosis and a non- Authorships thesis Dr. Martinez (Microbiology Dpt- pathogenic tuberculosis model. HUMV) and Biodonostia Group of The efficiency of nanovaccine 1. Ricardo Calderon Gonzalez. Microbiologists (col. Dr. E. Trallero, is based in their targeting to Vacunas basadas en Listeria Dr. J. Marimon and Dr. CG. Cilla) dendritic cells, lack of toxicity, Monocytogenes. to elaborate a human vaccine for biocompatibility and induction Director/es: Carmen Álvarez patients at high risk of listeriosis. of a cytotoxic cellular immune Domínguez, Mónica López response. Other applications with Fanárraga. these Nanovaccines and their UNIVERSIDAD DE CANTABRIA. 3.- Listeria based dendritic modifications are tumor therapies. vaccines loaded with peptides against melanoma. Thesis Addressed
• PUBLICATIONS: (IP: Dr. C. Alvarez Dominguez 1. Elisabet Frande Cabanes. y Dra. S. Yañez Diaz/Proyectos: Listeriosis Cerebral en el modelo SAF2009-08695 y SAF2012-34203 IMPACT FACTOR | 12,535 Murino: patogénesis y prevención. y Estudio Clínicos aprobado: Director/es: Carmen Álvarez CEIC-Acta 30/2012). Se utiliza Domínguez, Mónica López una vacuna DC basada en Listeria Fanárraga. cargada con el péptido LLO91-99 Original articles UNIVERSIDAD DE CANTABRIA. como terapia anti-adhesiva para el melanoma en modelos murinos 1. Calderon-Gonzalez R, Terán- (col. Dr. J. Gomez-Roman, S. Navarro H, García I, Marradi M, Anatomia Patologica) y preparar Salcines-Cuevas D, Yañez-Diaz S, en pacientes con melanomas una Projects Solis-Angulo A, Frande-Cabanes vacuna DC anti-melanoma en E, Fariñas MC, Garcia-Castaño A, colaboración con los Servicios Gomez-Roman J, Penades S, Rivera Projects de Oncología y Dermatología del F, Freire J, Álvarez-Domínguez C. HUMV (melanoma metastatico) Gold glyconanoparticles coupled to (cols. Dr. H. Fernandez-Llaca y Dra. 1. Carmen Álvarez Domínguez. A. Garcia) y el Grupo de Melanoma listeriolysin O 91-99 peptide serve as Estudio de diferentes vectores Humano de UPV (col. Dra. D. adjuvant therapy against melanoma. vacuna basados en Listeria Boyano Lopez). NANOSCALE. monocytogenes frente a distintos 2017;9:10721-10732. procesos inflamatorios, infecciosos y F.I.:7,367. [doi:10.1039/c7nr02494k] cancerosos. 4.- Listeria based Nanovaccines SAF2012-34203. and their applications. 2. Calderon-Gonzalez R, Frande- MINISTERIO DE ECONOMIA Y Cabanes E, Teran-Navarro H, COMPETITIVIDAD. (PI: Dr. C. Alvarez Dominguez, Dr. Marimon JM, Freire J, Salcines- S. Gomez Salces and Dr. S. Yañez Cuevas D, Fariñas MC, Gonzalez-Rico Diaz/Grants: SAF2012-34203, C, Marradi M, Garcia I, Alkorta- and Approved Clinical Study: Gurrutxaga M, San Nicolas-Gomez CEIC-Acta 1/2016-2015.177). In A, Castañeda-San Pedro A, Yañez- this study we used as vaccine Diaz S, Penades S, Punzon C, vectors gold glyconanoparticles Gomez-Roman J, Rivera F, Fresno (AuGNP) of 2 nm size conjugated M, Alvarez-Dominguez C. GNP- to Listeria peptides, LLO91-99 and GAPDH1-22 nanovaccines prevent GAPDH1-22. The group of CIC- neonatal listeriosis by blocking microglial apoptosis and bacterial Activity Research Areas Report Infectious Diseases and Immune System Area
Group Responsible Jesús Merino Pérez Department of Molecular • Immunopathology of Biology School of Medicine Rheumatic Diseases University of Cantabria
Contributors Elena Aurrecoechea Aguinaga Manuel Ignacio González Carreró Marcos Iglesias Lozano Marta Muñoz Ruiz Jorge Postigo Fernández Teresa Ruiz Jimeno Esther Tamayo Revuelta Juan Ignacio Villa Blanco
Predoctoral Pilar Álvarez Sáinz de la Maza
Consolidated group Technicians María Aramburu Landeras Yordana Vega Miranda
involved in rheumatic inflammatory Torrelavega. Jesus Merino, in diseases. Our final aims are the close collaboration with Dr. Ramon identification and characterization Merino (IBBTEC), is studying Research of potential therapeutic targets for several molecules involved in the lines the treatment of these diseases. control of inflammatory responses, We undertake these tasks from a such as BAMBI (BMP and activin basic approach, coordinated by Dr. membrane bound inhibitor) and Jesus Merino at the University of BCL2A1 (a cell death regulator). We The research activity of our group Cantabria, and a clinical approach maintain also collaborations with focuses on the study of the cellular coordinated by Dr. Jaime Calvo other Spanish groups to evaluate and molecular mechanisms at the Hospital Sierrallana of the role in inflammation of the 229
immunomodulatory molecules, CD38 (Dr. Jaime Sancho, Granada), • PUBLICATIONS: Authorship Thesis CD5 and CD6 (Dr Francisco Lozano, Barcelona), the transcriptional IMPACT FACTOR | 9,641 1. Pilar Álvarez Sáinz De La Maza. factors E2F1 and E2F2 (Dr. Bambi, una nueva diana terapéutica Ana Zubiaga, UPV) and GPBP para el tratamiento de enfermedades (Goodpasture antigen binding autoinmunes. protein), a protein-kinase that Original articles Director/es: Ramón Merino Pérez, forms quaternary protein structures Jesús Merino Pérez. UNIVERSIDAD DE CANTABRIA. (Dr Juan Saus, Fibrostatin SL, 1. Rúa-Figueroa Í, López-Longo J, Valencia). Galindo-Izquierdo M, Calvo-Alén J, Del Campo V, Olivé-Marqués A, Thesis Addressed Overall, this research activity Pérez-Vicente S, Fernández-Nebro pretends to validate these Juan Jesús Augustin Rodríguez. A, Andrés M, Erausquin C, Tomero 1. molecules as therapeutic targets E, Horcada L, Uriarte E, Freire Papel de bambi en la regulación de la in inflammation and autoimmune M, Montilla C, Sánchez-Atrio A, respuesta inmune humoral. diseases. For this purpose we use Director/es: Ramón Merino Pérez, Santos G, Boteanu A, Díez-Álvarez murine models of these diseases, Jesús Merino Pérez. E, Narváez J, Martínez-Taboada such as the collagen-II-induced UNIVERSIDAD DE CANTABRIA. V, Silva-Fernández L, Ruiz-Lucea arthritis, adriamycin or bleomycin- E, Andreu JL, Hernández-Beriain induced pulmonary fibrosis, the JÁ, Gantes M, Hernández-Cruz Collaborations colitis induced by sodium dextran B, Pérez-Venegas J, Pecondón- sulphate, or the psoriasis caused Español Á, ..., Pego-Reigosa JM. 1. Joven BE, Navarro-Compán V, by local application of Imiquimod Incidence, associated factors Rosas J, Fernandez Dapica P, Zarco P, or i.p. injection of Saccharomyces and clinical impact of severe de Miguel E. cerevisiae mannan. infections in a large, multicentric Diagnostic Value and Validity of Early cohort of patients with systemic Spondyloarthritis Features: Results lupus erythematosus. Semin From a National Spanish Cohort. > Impact of gender on Arthritis Rheum. Arthritis Care Res (Hoboken). prognosis of rheumatoid 2017;47:38-45. 2017;69:938-942. arthritis, with particular F.I.:4,498. [doi:10.1016/j. F.I.:3,319. [doi:10.1002/acr.23017] emphasis on quality of life. semarthrit.2017.01.010] > Influence of treatment with 2. Fernández-Carballido C, Navarro- TNF inhibitors in the oxidative 2. Rúa-Figueroa I, de Castro Compán V, Castillo-Gallego C, Castro- phenotype of HDL cholesterol MF, Andreu JL, Sanchez-Piedra Villegas MC, Collantes-Estévez E, de C, Martínez-Taboada V, Olivé A, and its influence on their anti- Miguel E. Disease Activity As a Major López-Longo J, Rosas J, Galindo atherogenic capacity in patients Determinant of Quality of Life and M, Calvo-Alén J, Fernández-Nebro with rheumatoid arthritis. Physical Function in Patients With A, Alonso F, Rodríguez-Lozano Early Axial Spondyloarthritis. > Lipoprotein profiles and HDL B, García Vadillo JA, Menor R, Arthritis Care Res (Hoboken). phenotypes in patients with Narváez FJ, Erausquin C, García- 2017;69:150-155.F.I.:3,319. systemic lupus erithematosus Aparicio Á, Tomero E, Manrique- [doi:10.1002/acr.22908] (SLE) in correlation with Arija S, Horcada L, Uriarte E, Gil inter-ethnic differences, in S, Blanco R, López-González R, collaboration with the University Boteanu A, Freire M, Galisteo of Puebla (Mexico). C, Rodríguez-Gómez M, ..., Projects SJOGRENSER and RELESSER > Prospective evaluation of researchers and EAS-SER GROUP. individuals with high titers of Comorbidities in Patients With Projects antinuclear antibodies (>1280) Primary Sjögren’s Syndrome and without clinical symptoms of Systemic Lupus Erythematosus: 1. Jesús Merino Pérez. autoimmune diseases. A Comparative Registries- BAMBI, un regulador de la > Evaluation of new criteria Based Study. Arthritis Care Res señalizacion por TGFβ, en for clinical classification of (Hoboken). inflamación cutánea y en SLE patients (SLICC criteria), 2017;69:38-45. diferenciacion de linfocitos T CD4 in collaboration with Dr. Luis F.I.:3,319. [doi:10.1002/acr.23015] humanos. Ines (University of Coimbra, SAF2016-75195-R. Portugal). 3. Aurrecoechea E, Llorca Díaz J, Diez Lizuain ML, McGwin G, Calvo- > Co-chairman in the Alen J. Clinical trials RELESSER-PROS registration Gender-associated comorbidities for the follow-up of SLE in rheumatoid arthritis and their 1. Elena Aurrecoechea Aguinaga. patients. impact on outcome: data from Estudio fase 3, multicéntrico, GENIRA. Rheumatol Int. 2017; > Phase 3 Clinical trials: two aleatorizado, doble ciego, controlado F.I.:1,824. [doi:10.1007/s00296- trials in rheumatoid arthritis and con placebo y de grupos paralelos 016-3628-7] one in psoriatic arthritis. para evaluar la eficacia y la seguridad Activity Research Areas Report Infectious Diseases and Immune System Area
de dos dosis de Apremilast (CC- 4. Juan Ignacio Villa Blanco. 2. Jaime Calvo Alén. 10004) en pacientes con artritis SKIPPAIN (Rapidez en el alivio Preferencias de reumatólogos y psoriásica activa. CC-10004- del dolor en pacientes con pacientes por los atributos de los PSA-003. espondiloartritis axial inducido por agentes biológicos empleados en CELGENE CORPORATION. secukinumab) Estudio multicéntrico, el tratamiento de enfermedades aleatorizado, doble ciego, controlado reumáticas en España. MSD- 2. Elena Aurrecoechea Aguinaga. con placebo, de 24 semanas de BIO-2012-01. Estudio Fase IIIb para evaluar la duración para evaluar la eficacia MERCK SHARP & DHOME ESPAÑA. eficacia, seguridad y tolerabilidad de y seguridad de secukinumab en Tocilizumab (TCZ) subcutáneo (SC) el control del dolor espinal en 3. Juan Ignacio Villa Blanco. administrado en monoterapia o en pacientes con espondiloartritis axial. Estudio retrospectivo sobre la combinación con metotrexato (MTX) CAIN457H3301. eficaciaen práctica clínica de en pacientes con artritis reumatoide. NOVARTIS FARMACEUTICA, S.A.. golimumab tras el fracaso de un ML28709. primer anti-TNF-? en pacientes con ROCHE FARMA, S.A.U.. Postmarketing Studies espondiloartritis (Go-Beyond spain). and Other MSD-GOL-2016-01. 3. Juan Ignacio Villa Blanco. MERCK SHARP & DHOME ESPAÑA. Estudio multicéntrico, aleatorizado, 1. Jaime Calvo Alén. doble ciego, controlado con placebo Evaluación del riesgo cardiovascular, para demostrar la eficacia de y de sus determinantes, en pacientes secukinumab subcutáneo hasta 1 con artritis reumatoide, espondilitis año en el tratamiento de la entesitis anquilosante y artritis psoriásica. del tendón de Aquiles en pacientes CARMA. adultos con Artritis Psoriásica (APs) FUNDACIÓN ESPAÑOLA DE activa y Espondiloartritis axial (EspA REUMATOLOGÍA F.E.R.. axial) (ACHILLES). CAIN457F3301. NOVARTIS FARMACEUTICA, S.A.. 231 Activity Research Areas Report Infectious Diseases and Immune System Area
Group Responsible Jorge Calvo Montes • Clinical and Molecular Microbiology Service University Hospital Microbiology Marqués de Valdecilla
Contributors María Eliecer Cano García Itziar Chapartegui González Marta Fernandez Martínez Marina Fernández Torres Mónica Gozalo Margüello Consolidated group Pablo Jorrín Lozano María Lázaro Díez Jesús Navas Méndez Daniel Pablo Marcos Inmaculada Concepción Pérez Del Molino Bernal María José Reina Rodríguez Researchers María Pía Roiz Mesones Jesús Agüero Balbín Carlos Ruíz De Alegría Puig María Victoria Francia Gil Ana Sáez López Alain Antonio Ocampo Sosa Carlos Salas Venero José Ramos Vivas Jesús Rodríguez Lozano
antimicrobial agents (with emphasis is contributing to the “Resistance on beta-lactams, quinolones and Program” of the Spanish network aminoglycosides) in gram-negative for research on infection diseases Research bacteria of medical importance. (Red Española de Investigación lines We consider both Enterobacteria en RESEARCH AREAS Infection (Escherichia coli, Klebsiella and Immunity Area Patología pneumoniae, Enterobacter spp., etc.) Infecciosa, REIPI, http://reipi.org/) and non-fermenters (Pseudomonas supported by the Institute of Health aeruginosa, Actinetobacter Carlos III (ISCIII). This network has 1. Antimicrobial resistance in baumannii, Stenotromophomonas developed and is developing different gramnegative bacteria of medical maltophilia, Burkholderia cepacia multicenter studies on clinical and interest. complex, among others). Within this microbiological aspects of infections problem, we are particularly focused caused by resistant bacteria of Antimicrobial resistance is a current on multiresistance and low-level clinical relevance, a major problem major health problem. A large resistance. The clinical importance in many Spanish hospitals. Our proportion of the research activities of multiresistant bacteria is capital, collaboration on the study of the in our group is related to the study as there are quite few new agents molecular bases of resistance has of genetic and biochemical aspects under development aimed to fight allowed obtaining new information of the mechanisms of resistance to against these pathogens. Our group on infections caused by Escherichia 233
coli, Klebsiella pneumoniae, in gram-negative organisms). We We are interested in deciphering Pseudomonas aeruginosa and were involved in the discovery the molecular me - chanisms Acinetobacter baumannii. Our of qnr genes, and the group is implicated in the infections caused group is also participating in still active in the analysis of these by Pseudomonas aeruginosa and another REIPI research program genes and others causing plasmid- Burkholderia cepacia. These bacteria related to infections in transplanted mediated quinolone resistance. The are able to release huge quantities patients. Our objectives include study of aminoglycoside-resistance of hydrolytic enzymes inside host characterization of genes and mobile in gram-negative bacteria (both cells by means of complex secretion elements (plasmids, transposons, Enterobacteria and non-fermenters) is systems (TSS) partially inserted integrons, gene cassettes, etc.) another objective of our group. into the bacterial membrane. involved in antimicrobial resistance. One of these systems is the type We are particularly interested in VI secretion system (T6SS), first Our studies have contributed to the (1) aminoglycoside-modifying identified in 2006. The T6SS is a one discovery of new beta-lactamases enzymes [N-acetyltransferases (AAC), step mechanism that is used widely (i.e., the new oxacillinase OXA-207 in O-phosphotransferases (APH) and throughout gram-ne - gative bacterial Acinetobacter pittii -a microorganism O-nucleotidyltransferases (ANT)] species in injecting effector proteins related to A. baumannii, which is also which interferes with the ability and virulence factors from across important as a nosocomial pathogen). of the corresponding substrate the cytoplasm of a bacterial cell Beta-lactams continue to be very to interact with the ribosome, into a target cell (both bacterial and frequently prescribed antibacterials. impairing its activity, and (2) ARN 16S eukaryotic cells). Protein secretion Among them, carbapenems (very methyl-transferases, which cause is a key issue in bacterial pathoge broad-spectrum beta-lactams) are methylation at certain positions of - nesis and many of the proteins often considered the preferred the ribosome and cause high-level secreted by the cu - rrently known therapeutic option against infections resistance to many clinically used T6SS are also implicated in bacterial caused by different resistant gram- aminoglycosides. adherence and invasion, as well as negative pathogens. Unfortunately, growth and intra - cellular survival acquired resistance to carbapenems Genes coding for these enzymes inside macrophages. We focus on has been well documented, are frequently included in plasmid, new T6SS effector proteins of P. and is increasingly recognized which favors their dissemination aerugi - nosa and several species among different gram-negative among different bacterial hosts. of the B. cepacia complex. On the species. This is due very frequently An additional objective for us other hand, it is well known that to the production of enzymes is the evaluation of the role of the T6SS of P. aeruginosa is also (carbapenemases) hydrolyzing these active efflux pumps in the intrinsic implicated in biofilm formation and agents. We are applying phenotypic resistance of gram-negative bacteria antimicrobial resistance. A biofilm and genotypic methods for study to clinically relevant antimicrobial can be defined as a structured and characterization of carbapenem- agents (including beta-lactams, community of bacterial cells enclosed resistance caused by metallo-beta- quinolones, aminoglycosides in a self-produced polymeric lactamases (MBL; including IMP-, and other families). Similarly, the matrix and adherent to an inert or VIM-, SPM- and NDM-types), or group has great experience on living surface. Growth in biofilms serine beta-lactamases of Ambler the study of the importance of enhan - ces the survival of bacterial classes A and D. We are also porins of enterobacteria (mainly K. populations in hospital environments interested in the characterization pneumoniae, E. coli, Enterobacter and during host infections (i.e., of these enzymes in environmental spp.) in low-level resistance and in in the presence of antibiotics), organisms, such as Pseudomonas the evaluation of the regulation of the increasing the probability of causing putida and other taxonomically- gene coding for the OprD porin of P. nosocomial infections. Our group is related species such as P. monteilii, aeruginosa, involved in carbapenem also implicated in the discovery and which represent reservoirs of resistance. Finally, in the context of characterization of quorum sensing multiresistance genes (including the previously detailed information regulators that may play a role in genes coding for MBL). We have on mechanisms of antimicrobial biofilm formation and dispersion. reported nosocomial infections resistance, we are also considering: We use genomic and transcriptomic caused by strains of the later tools to understand the molecu - lar organisms producing the VIM-2 MBL > Analysis of the relationship determinants that contribute to the in severely ill/immunocompromised between antimicrobial resistance virulence and antimicrobial resistance patients. Fluoroquinolones are and virulence. in these pathogens. broad-spectrum antimicrobial agents. They are clinically useful > Study of the molecular 3. Host-Pathogen Interactions. for treating infections caused by epidemiology of resistant (among others) gram-positive and bacteria, in particular on the Acinetobacter spp. have become gram-negative organisms. Because problem of multiresistance in major pathogens in hospital- they are synthetic compounds, it was nosocomial infections. associated infections, especially in thought that transferable resistance critical care settings such as intensive was extremely unlike, as there are > Implementation of massive care units (ICUs). They can survive (presumably) not environmental sequencing technology for a in the hospital environment for producer organisms, which could better understanding of both long periods and have a remarkable represent a source of resistance resistance and virulence. propensity to develop resistan - ce genes. However, multiple variants to multiple classes of antibiotics. of qnr (quinolone resistance) genes 2. Mechanisms of pathogenicity in This antibiotic re - sistance trend have been identified worldwide in a gram-negative bacteria of medical is a serious concern given the great variety of bacteria (particularly interest. prospect of a further reduction Activity Research Areas Report Infectious Diseases and Immune System Area in therapeutic options for infec - tions by these multi-drug-resistant bacteria. While the epidemiology and antibiotic resistance of the species A. baumannii have been extensively studied, the molecu - lar and genetic basis of A. baumannii, A. nosocomialis and A. pittii virulence remains poorly understood, and there is still lack of knowledge in host cell response to these bacteria. Answering the need for studies of the mechanisms involved in the antimicrobials and host-pathogen (H-P) relationship, we seek to develop a multi-disciplinary research on host-pathogen inte - ractions in these clinically relevant Acinetobacter spe - cies by using cell sorting, advanced microscopy, qPCR arrays, and, more recently, next generation sequencing.
Our main objectives are:
1) To develop new tools for the study of host-pa - thogen interactions in Acinetobacter.
2) To study the impact of different antibiotics at subMICs on Acinetobacter species, biofilms, and on relevant host-pathogen interactions in vitro. tract infections, endocarditis and samples. In the last years, we have bacteriemia. We study horizontal studied several aspects related to 3) To unravel the dynamics and gene transfer (conjugation) of diverse coryneform bacteria: antimicrobial roles of vesi - cle-like droplets mobile genetic elements such as the resistance me - chanisms, their produced by Acinetobacter sex pheromone plasmids (present spread and their interactions with the species on biofilms and during in 95% of clinical isolates of E. host. host-pathogen interactions. faecalis associated with hospital outbreaks with a transference rate 6. Diagnostic Methodology and 4) To perform a detailed analysis near 100%). Also, we are studying Epidemiology of the immune responses of the mechanisms of gene expres human immune and non-immune - sion regulation (activation or Our team is also implicated in the cells against Acinetobacter strains repression) in these sex pheromone development and application of with diffe - rent phenotypes. plasmids, as the mechanisms that new diagnostic methods in clinical coordi - nately regulate basic plasmid mi - crobiology, using genomic 4. Antimicrobial Resistance processes (replication, partition, and proteomic techniques and mechanisms in gran-positive conjugation). We also perform the nanotechnology. Molecular infectious bacteria. identification and characterization of disease testing has become an plasmids present in multirresistant outstanding arm of our Service of We currently face multiresistant E. faecium clini - cal isolates carrying Microbiology, in - cluding sequencing infectious disease or - ganisms vancomycin resistant genes (and also or direct detection of genes re - that are difficult and, sometimes, resistance to aminoglycosides and lated to microbial identification impossible to treat successfully. macrolides). and resistance me - chanisms. For Multiresistance or multiple drug over 100 years, infectious diseases resistance (MDR) is often associated 5. Infections caused by coryneform agents have been identified after with mobile ge - netic elements bacteria. they were growth in culture and their implicated in horizontal gene transfer. phenotypic traits were considered. This occurs both in gram-negative We focus on antimicrobial In the mole - cular era, there is an and gram-positive bacteria. For resistance in several spe - cies of opportunity to detect pathogens gram-positive bacteria, we focus our corynebacteria. These bacteria are more rapidly and accurately based on activity on ba - sic plasmid biology widely dis - tributed in nature, and are their genetic signatures. Molecular as well as in factors that allow the found in the soil, water and on the methods, essentially those based appearance and spread of multidrug skin of humans and animals. Several upon the polymerase chain reaction resistant bacteria. Our model is species cause disease in humans. (PCR), have become an indispensable Enterococcus, mainly E. faecalis The most important is C. diphteriae, tool in the diagnosis of infectious and E. faecium. The most common but C. amycolatum, C. urealyticum, diseases. Over the past decade, nosocomial infections pro - duced C. jeikeium and C. striatum are also there has been an explosion in the by these organisms are urinary oc - casionally cultured from clinical use of molecular tests to diagnose 235
and manage infectious diseases. As - gi), multilocus sequence typing a result, the Clinical Microbiology (MLST), and variable number tandem • PUBLICATIONS: laboratory of the HUMV offers a repeat typing (VNRT). These typing growing and consolidated number methods are also performed in diffe IMPACT FACTOR: | 58,337 of nucleic acid amplification - rent specific areas of our Clinical tests (NAATs) for detec - tion and laboratory, and are useful in hospital identification of bacterial, viral and infection control, epidemiological fungal pathogens. A good example studies, and understanding the Original articles is the expertise we have acquired in pathogenesis of in - fection. gene amplification and sequencing of the 16S rDNA gene and of genes 7- in vitro activity of new 1. Aguirre-Quiñonero A, Cano ME, related with antibiotic resistance. antimicrobials. Gamal D, Calvo J, Martínez-Martínez L. We understand that, given the Evaluation of the carbapenem complexity of the mi - crobial world Different organizations, including the inactivation method (CIM) for and the increasing sophistication WHO, have alerted that antimicrobial detecting carbapenemase activity in of NAATs, the expertise is required resistance is one of the main health enterobacteria. not only for assay development and problems in the world. One of the Diagn Microbiol Infect Dis 2017. 88: performance, but also for consul hi - gh-priority strategies to confront 214-218. - tation. This rational improves this menace is the development FI: 2,401 10.1016/j. patient care, reduces antibiotic of new antimicrobial agents. Our diagmicrobio.2017.03.009 usage, enhances test utilization, and group participates in multicenter in - creases laboratory and hospital studies pursuing the eva - luation of 2. Aguirre-Quiñonero A, Martínez- efficiency. Recently, we have also new antimicrobials, challenging a Martínez L. incorporated an automated mass wide co - llection of bacterial clinical Non-molecular detection spectrometry microbial identification isolates. Also, we participate in the system that uses Matrix Assisted evaluation of reference automated of carbapenemases in Laser Desorption Ioniza - tion Time- methods that incorporate new Enterobacteriaceae clinical isolates.. of-Flight (MALDI-TOF) technology antimi - crobial agents. In the last J Infect Chemother 2017. 23: 1-11. and a comprehensive database of years, we have studied the activity FI: 1,826 10.1016/j.jiac.2016.09.008 clinically relevant spe - cies for results of daptomycin, linezolid, chelocardin 3. Alibi S, Ferjani A, Boukadida J, Cano in minutes. On the other side, it is and cef - taroline, collaborating to ME, Fernández-Martínez M, Martínez- sometimes important to analyze establish MIC breakpoints and the Martínez L, Navas J. Occurrence multiple isolates within a given interpretation of in vitro susceptibility of Corynebacterium striatum as species to determine whether they tests to define clinical categories. an emerging antibiotic-resistant represent a single strain or multiple Our group has also collaborated nosocomial pathogen in a Tunisian strains. The process of differentiating in the study of the variables that hospital.. strains based on their phenotypic influence the in vitro activity of cef Sci Rep 2017. 7: 9704-0. and genotypic di - fferences is known - taroline, a new broad-spectrum FI: 4,259 10.1038/s41598-017-10081-y as ‘typing’. Genotyping methods cephalosporin with activity against involve the study of the microbial methicillin resistant Staphylococcus 4. Alibi S, Ferjani A, Boukadida J, Ruiz DNA. The develo - 189 Activity report aureus (MRSA). We have also de Alegría C, Martínez-Martínez L, 2015 188 Valdecilla Biomedical contributed to the in vitro study of Navas J. Research Institute Santander, Spain a new antimicrobial, chelocardin, Evaluation of the VITEK-MS matrix- pment of molecular genotyping whose synthesis has been improved assisted laser desorption/ionization methods has revolu - tionized the by genetic engineering and with time-of-flight mass spectrometry possibility for classification of microor promising in vitro activity against system for the identification of - ganisms at the sub-species level, several species of multidrug resistant clinical Corynebacterium species.. which is crucial for deciding the bacteria. These studies have been Rev Esp Quimioter 2017. 30: 57-58. FI: molecular relatedness of isolates for developed in collaboration with 0,750(Q4) epidemiological studies. In this aim, members of the University of new PCR-based typing methods Cantabria and the University of Lu - 5. Angulo López I, Aguirre Quiñonero A, in the last years have supposed an bljana (Slovenia). Fernández Torres M, Alegría Echauri E. important advance in determining Chorioamnionitis and neonatal the molecular epi - demiology of septicaemia due to Eikenella microorganisms. Major advantages corrodens.. of these methods are flexibility, Enferm Infecc Microbiol Clin 2017. 35: technical simplicity and high 266-267. discriminatory power. Although most FI: 1,714(Q3) of these PCR-based typing methods are less time-consuming and easy to 6. Angulo López I, Fernández Torres M, perform and of interpretation, other approaches, however, depending Baldeón Conde C, Alonso Buznego L. on the species stu - died, are Disseminated maculo-papular lesions required to the study of the clonal in a patient in contact with cattle.. relations - hip among microbial Enferm Infecc Microbiol Clin 2017. isolates. These include the pul - 35: 603-604. sed-field gel electrophoresis (PFGE, FI: 1,714 10.1016/j.eimc.2016.03.006 the current gold standard method for typing most bacterium and fun Activity Research Areas Report Infectious Diseases and Immune System Area
7. Angulo López I, González Escartín E, Pseudomonas aeruginosa Isolates Á, Martínez-Martínez L. Aguirre Quiñonero A, Ots Ruiz E. from Spain.. Prevalence of quinolone Meningitis simultánea por Antimicrob Agents Chemother 2017. . resistance mechanisms in neumococo y enterovirus en FI: 4,302 10.1128/AAC.01589-17 Enterobacteriaceae producing lactante.. acquired AmpC ß-lactamases and/or Enferm Infecc Microbiol Clin 2017. 35: 13. Fernández-Sampedro M, Fariñas- carbapenemases in Spain.. 128-130. Alvarez C, Garces-Zarzalejo C, Alonso- Enferm Infecc Microbiol Clin 2017. 35: FI: 1,714 10.1016/j.eimc.2016.05.005 Aguirre MA, Salas-Venero C, Martínez- 487-492. Martínez L, Fariñas MC. FI: 1,714 10.1016/j.eimc. 8. Belmar Vega L, Rodrigo Calabria Accuracy of different diagnostic 2016.05.006 E, Gutiérrez Fernández G, Casanova tests for early, delayed and late Rituerto D, González Sánchez FJ, prosthetic joint infection.. 19. Perez Del Molino Bernal IC, Agüero Armiñanzas Castillo C, Roiz Mesones BMC Infect Dis 2017. Balbin J. MP, Arias Rodriguez M. 17: 592-0. seqA1 Is a Useful Target for Actinomyces viscosus infection in a FI: 2,768 10.1186/s12879-017-2693-1 Identification of Tsukamurella kidney-pancreas trasplanted patient.. pulmonis.. Nefrologia 2017. 37: 431-432. 14. González-Escartín E, Angulo J Clin Microbiol 2017. 55: 1591-0. FI: 1,183 10.1016/j.nefro.2017.01.001 López I, Ots Ruiz E, Martínez- FI: 3,712 10.1016/j. Martínez L, Cabero Pérez MJ. eimc.2016.03.00410.1128/JCM.00198-17 9. Chapartegui-González I, Lázaro-Díez Pneumococcal meningitis M, Redondo-Salvo S, Alted-Pérez L, in Cantabria (Spain) in the 20. Rodríguez-Arce I, Martí S, Euba B, Ocejo-Vinyals JG, Navas J, Ramos- pneumococcal conjugate vaccine Fernández-Calvet A, Moleres J, López- Vivas J. era (2001-2015).. López N, Barberán M, Ramos-Vivas J, Whole-Genome Sequence of ARCH ARGENT PEDIATR 2017. 115: Tubau F, Losa C, Ardanuy C, Leiva J, Acinetobacter pittii HUMV-6483 160-164. Yuste JE, Garmendia J. Isolated from Human Urine.. FI: 0,403 10.5546/aap.2017.eng.160 Inactivation of the Thymidylate Genome Announc 2017. . Synthase thyA in Non-typeable 10.1128/genomeA. 15. Lázaro-Díez M, Chapartegui- Haemophilus influenzae Modulates 00658-17 González I, Redondo-Salvo S, Leigh Antibiotic Resistance and Has a C, Merino D, Segundo DS, Navas J, Strong Impact on Its Interplay with 10. Corlouer C, Lamy B, Desroches Icardo JM, Acosta F, Ocampo-Sosa the Host Airways.. M, Ramos-Vivas J, Mehiri-Zghal E, A, Martínez-Martínez L, Ramos-Vivas Front Cell Infect Microbiol 2017. 7: Lemenand O, Delarbre JM, Decousser J. Human neutrophils phagocytose 266-0. JW, Collège de Bactériologie-Virologie- and kill Acinetobacter baumannii FI: 4,300 10.3389/fcimb.2017.00266 Hygiène des Hôpitaux de France. and A. Stenotrophomonas maltophilia pittii.. Sci Rep 2017. 7: 4571-0. 21. Ruiz de Alegría Puig C, Pilares L, healthcare-associated infections: FI: 4,259 10.1038/s41598-017-04870-8 Marco F, Vila J, Martínez-Martínez L, identification of two main Navas J. pathogenic genetic backgrounds.. 16. López-Causapé C, Sommer LM, Comparison of the Vitek MS and J Hosp Infect 2017. 96: 183-188. Cabot G, Rubio R, Ocampo-Sosa AA, Bruker Matrix-Assisted Laser FI: 3,126 10.1016/j.jhin.2017.02.003 Johansen HK, Figuerola J, Cantón R, Desorption Ionization-Time of Flight Kidd TJ, Molin S, Oliver A. Mass Spectrometry Systems for 11. De Mendoza C, Cabezas T, Evolution of the Pseudomonas Identification of Rhodococcus Caballero E, Requena S, Amengual MJ, aeruginosa mutational resistome equi and Dietzia spp.. Peñaranda M, Sáez A, Tellez R, Lozano in an international Cystic Fibrosis J Clin Microbiol 2017. 55: 2255- AB, Treviño A, Ramos JM, Pérez JL, clone.. 2260. Barreiro P, Soriano V, Spanish HIV-2 Sci Rep 2017. 7: 5555-0. FI: 3,712 10.1128/JCM.00377-17 Network. FI: 4,259 10.1038/s41598-017- HIV type 2 epidemic in Spain: 05621-5 22. Santos CS, Ramos JN, Vieira challenges and missing VV, Pinheiro CS, Meyer R, Alcantara- opportunities.. 17. López-Hernández I, Alonso N, Neves NM, Ramos RT, Silva A, Hirata AIDS 2017. 31: 1353-1364. Fernández-Martínez M, Zamorano R, Felicori L, de Alegría Puig CR, FI: 5,003 10.1097/ L, Rivera A, Oliver A, Conejo MC, Navas J, Azevedo V, Mattos-Guaraldi QAD.0000000000001485 Martínez-Martínez L, Navarro F, AL, Pacheco LGC. Pascual A. Efficient differentiation of 12. Del Barrio-Tofiño E, López- Activity of ceftazidime-avibactam Corynebacterium striatum, Causapé C, Cabot G, Rivera A, Benito against multidrug-resistance Corynebacterium amycolatum and N, Segura C, Montero MM, Sorlí L, Enterobacteriaceae expressing Corynebacterium xerosis clinical Tubau F, Gómez-Zorrilla S, Tormo N, combined mechanisms of isolates by multiplex PCR using Durá-Navarro R, Viedma E, Resino-Foz resistance.. novel species-specific primers.. E, Fernández-Martínez M, González- Enferm Infecc Microbiol Clin 2017. J Microbiol Methods 2017. 142: Rico C, Alejo-Cancho I, Martínez 35: 499-504. 33-35. JA, Labayru-Echverria C, Dueñas C, FI: 1,714 10.1016/j.eimc.2016.09.013 FI: 1,790 10.1016/j. Ayestarán I, Zamorano L, Martinez- mimet.2017.09.002 Martinez L, Horcajada JP, Oliver A. 18. Machuca J, Agüero J, Miró E, Genomics and Susceptibility Profiles Conejo MD, Oteo J, Bou G, González- 23. Rodríguez-Lozano J, de Malet A, of Extensively Drug-Resistant López JJ, Oliver A, Navarro F, Pascual Cano ME, de la Rubia L, Wallmann R, 237
Martínez-Martínez L, Calvo J. 2. José Ramos Vivas. 2. Belinda Vega Gutierrez, José Ramos Antimicrobial susceptibility of Biología integrada de la infección Vivas. microorganisms that cause urinary y la resistencia antimicrobiana de NUEVOS ASPECTOS EN LA tract infections in pediatric patients. Acinetobacter baumannii y A. pittii. BIOLOGÍA DE PHOTOBACTERIUM Enferm Infecc Microbiol Clin. PI16/01103. INSTITUTO DE SALUD DAMSELAE SUBSP PISCICIDA. 2017 Oct 7. [doi:10.1016/j. CARLOS III. MINISTERIO DE PILI, MOTILIDAD Y ADHERENCIA eimc.2017.08.003]. pii: S0213- ECONOMÍA Y COMPETITIVIDAD. A SUPERFICIES SÓLIDAS. 005X(17)30223-9. UNIVERSIDAD LAS PALMAS DE F.I.: 1,714. 3. María Victoria Francia Gil. GRAN CANARIA. 17/07/2017 Inducción de la transferencia conjugativa de los plásmidos de respuesta a feromonas. Projects PI16/01535. INSTITUTO DE SALUD CARLOS III. MINISTERIO DE Projects ECONOMÍA Y COMPETITIVIDAD. Doctoral Thesis 1. Alain Antonio Ocampo Sosa. Identificación y caracterización funcional de nuevos componentes 1. Sana Alibi ep Othmen, Jalel de sistemas de secreción tipo VI y las Boukakida, Jesús Navas Méndez. bases moleculares de su regulación CARACTERIZACIÓN GENÓMICA en cepas clínicas de Pseudomonas DE CEPAS CLÍNICAS DE aeruginosa. CORINEBACTERIAS. PI15/00009. INSTITUTO DE SALUD Túnez. Université de Carthage CARLOS III. MINISTERIO DE République Tunisienne. ECONOMÍA Y COMPETITIVIDAD. 01/07/2017 Activity Report 239
· Metabolism, Diseases of Ageing and Lifestyle Habits Area
José Antonio Riancho Moral Coordinator of the Area of Metabolism, Diseases of Aging and Habits of Life.
Head of Section of the Internal Medicine Service. University Hospital Marqués de Valdecilla. Professor of the Department of Medicine and Psychiatry. University of Cantabria. Activity Research Areas Report Metabolism, Diseases of Aging and Life Habits Area
Group Responsible José Antonio Parra Blanco • Diagnosis and Treatment Radiology Service University Hospital Using Imaging Marqués de Valdecilla (Radiology) University of Cantabria
Yasmina Lamprecht Rosa María Landeras Álvaro Pedro Lastra García-Barón Elena López Uzquiza Gerardo López Rasines Enrique Marco de Lucas Elena Marín Díez, Sarah Marqués Llano Paula Merino Rasillo Enrique Montes Figueroa José María Navasa Melado Estrella Ortega García Luis Antonio Ortiz Rivas María Macarena Otero Fernández Marta Peláz Esteban Associated group Raúl Pellón Daben María Elena Peña Gómez Mariano Rico Gutiérrez Contributors Marta Drake Perez Eva Ruiz Pérez, María Mercedes Acebo García Rosa Fabregat Borrás Alba Salvador Errasti María Pilar Alonso Bartolomé Alejandro Fernández Flórez Sonia Sánchez Gómez Eva Alonso Fernández Ana García Bolado Elena Sánchez Salmón Gerardo Blanco Rodríguez Mª Del Rosario García-Barredo Pérez Sergio Tapia Concha Ana Canga Villegas Vanesa Gómez Dermit Torres Díez, Eduardo Juan Crespo del Pozo Francisco José González Sánchez Natalia Valle San Roman Alexandra de Diego Diez Agustín Gutiérrez Gutiérrez Alfonso Vega Bolivar Javier Valentin de La Calle Lorenzo Carlos Jiménez Zapater Héctor Vidal Trueba María Rosa de La Puente Formoso Jordá Lope, Juan Cristina Villaespesa Diaz María Díez Blanco Angélica Lamagrande Obregón Elena Yllera Contreras 241
7. Pariente-Rodrigo E, Sgaramella GA, • PUBLICATIONS: Olmos-Martínez JM, Pini-Valdivieso SF, Landeras-Alvaro R, Hernández- Research IMPACT FACTOR: | 13,478 Hernández JL. Relationship lines between diffuse idiopathic skeletal hyperostosis, abdominal aortic calcification and associated Original articles metabolic disorders: Data from the Camargo Cohort. Active research lines: 1. Berciano J, Gallardo E, Orizaola P, Med Clin (Barc). 2017;149:196-202. >Evaluation of new low Marco de Lucas E, García A, Pelayo- F.I.:1,125. [doi:10.1016/j. percutaneous breast biopsy devices Negro AL, Sedano MJ. medcli.2017.01.030] Image control. Comment on paraparetic Guillain-Barré syndrome: Thesis Addressed >Study of arteriovenous Non-demyelinating reversible malformations in patients with conduction failure restricted to the Telangiectasia Hemorrhagic lower limbs. 1. Monica Rubio Lorenzo. Hereditary (THH). Muscle Nerve. 2017;55:445-446. Estudio comparativo de cirugía F.I.:2,605. [doi:10.1002/mus.25425] percutánea del tendón de aquiles >Quantification of coronary calcium asistida ecográficamente con la and carotid ultrasonography and as 2. Martino J, Velasquez C, Vázquez- cirugía abierta convencional en predictors of cardiovascular risk. Bourgon J, Marco de Lucas E, roturas de tendón de aquiles. Gomez E. Director/es: María Isabel Pérez >Development of hybrid Cross-Modal Recruitment of Auditory Nuñez, Mª Del Rosario García- techniques: surgical-radiological in and Orofacial Areas During Sign Barredo Pérez. the treatment of Vascular pathology. Language in a Deaf Subject. WORLD UNIVERSIDAD DE CANTABRIA. NEUROSURG. 2017;105: >Evaluation of the usefulness and F.I.:2,592. [doi:10.1016/j. complications of thermoablation wneu.2017.05.170] treatments In patients with neoplastic disease 3. Pariente E, Olmos JM, Landeras R, Projects Nan D, González-Macías J, Hernández >Ultrasonic contrasts in the study JL. of hepatic, renal and intestinal Projects Relationship between spinal pathology. osteoarthritis and vertebral fractures 1. José Antonio Parra Blanco. >Study of cerebral connectivity with in men older than 50 years: data Malformaciones arteriovenosas diffusion tensor MRI. from the Camargo Cohort Study. J Bone Miner Metab. 2017;35:114-121. en pacientes con Telangiectasia >Anatomic-radiological correlation F.I.:2,423. [doi:10.1007/s00774-016- Hemorrágica Hereditaria (THH): studies in cutaneous pathology. 0735-1] Estudio de optimización de las técnicas de diagnóstico y >Ultrasound in the diagnosis 4. Zarrabeitia R, Fariñas-Álvarez C, seguimiento. PI11/02426. and follow-up of hidradenitis Santibáñez M, Señaris B, Fontalba A, INSTITUTO DE SALUD CARLOS suppurativa. Botella LM, Parra JA. III. MINISTERIO DE ECONOMÍA Y Quality of life in patients with COMPETITIVIDAD. >Anatomical-radiological (MR) hereditary haemorrhagic correlation in corpse. telangiectasia (HHT). Clinical Trials Health Qual Life Outcomes. 2017;15:19- >Contribution of multi-cut CT in the 19. 1. Ana Canga Villegas. evaluation of perforating arteries F.I.:2,143. [doi:10.1186/s12955-017- Estudio de seguridad prior to Plastic reconstructive 0586-z] surgery. poscomercializaciôn en pacientes con insuficiencia renal moderada a 5. Gómez-Román J, Zarrabeitia MT, >Imaging study of diffuse liver los que se administra Omniscan™ Santurtún A, Parra JA, Azueta Etxebarría disease (NASH) (inyecciôn de gadodiamida) para A, Cifrian JM, Freire Salinas J. la adquisiciôn de imâgenes de RM Pulmonary Langerhans cell (IRM) realzada con contraste. Version histiocytosis de novo after lung 1.0 de 03.Mar.2009,. GE-041-075. transplantation. GE HEALTHCARE LTD.. Pathol Int. 2017;67:632-637. F.I.:1,465. [doi:10.1111/pin.12597]
6. Peña Gomez E, Vidal Trueba H. Complications of sickle cell disease. Med Clin (Barc). 2017;148:481-481. F.I.:1,125. [doi:10.1016/j. medcli.2016.07.008] Activity Research Areas Report Metabolism, Diseases of Aging and Life Habits Area
Group Responsible Jesús González Macías Internal Medicine Service • Mineral and Lipid University Hospital Marqués de Valdecilla Metabolism University of Cantabria
Researchers José Luís Hernández Hernández José Manuel Olmos Martínez José Antonio Riancho Moral José Carlos Rodríguez Rey
Contributors Consolidated group Alvaro del Real Bolt Mª Carmen García Ibarbia Marta Martín Millán Josefina Micaela Martínez García Daniel Narcis Nan Nan Flor María Pérez Campo Ana Santurtun Zarrabeitia Carmen Valero Díaz De Lamadrid María Teresa Zarrabeitia Cimiano
Nurses Isabel Sierra Setién
Technicians Estefanía Escalante Lanza María Luisa Junco Martín Carolina Sañudo Campo 243
mineral and bone metabolism Service for the study of mineral diseases, mainly (but not only) metabolism and cardiovascular risk Research osteoporosis. This includes the in systemic inflammatory diseases. prevalence of osteoporosis, the lines incidence of osteoporotic fractures 4. Line of lipid metabolism (vertebral and hip fractures), genomic. and the prevalence of low The Group of Molecular Biology vitamin D levels and secondary (Prof. Rodriguez Rey) investigates hyperparathyroidism, as well as the 1. Línea de genética/genómica. on the molecular mechanisms analysis of those factors influencing of mesenchymal stem cells the response to treatment. The It studies the genetic and epigenetic differentiation into adipose tissue. relationship between osteoporosis mechanisms involved in prevalent Firstly, the group studies the role of and other disorders, such as skeletal diseases like osteoarthritis epigenetic regulation in the process dyslipidemias, diabetes, obesity, and osteoporosis. The following of progenitor cell differentiation and metabolic syndrome should issues are addressed:, into adipocytes and its possible also be studied. Of particular relationship with obesity, with Genetic polymorphisms that interest is the follow-up of the particular emphasis on the role of influence bone mass, the risk cohort of Camargo, which allows microRNAs (in collaboration with Dr of fractures and large joint the analysis of the association Carlos Fernandez of Yale University). osteoarthritis, using candidate between various manifestations Secondly, the group investigates genes and genome-wide of bone and mineral metabolism the role of other epigenetic association studies. diseases with their risk factors. mechanism, the methylation of Mortality rate will be considered DNA, in the modulation of gene • The role of DNA methylation in in the study. Prominent among expression during the process of the differentiation of bone cells as the factors to be analyzed is the adipocyte differentiation. Besides well as in the modulation of the trabecular bone score (TBS), a that, and in collaboration with expression of genes which play a new tool to evaluate the risk of the Group of Professor Carmen key role in skeletal homeostasis. osteoporotic fractures.On the other Évora (Pharmaceutical Technology hand, we have participated in the The possible role of the differential Department, Univesidad de la Spanish Registry of Osteoporotic expression of microRNAs in bone Laguna) and Dr. Gomez-Cimiano Fractures of Fémur, sponsored changes that characterize these (Servicio de Traumatología by SEFRAOS, which has already disorders. del HUMV) it is developing an concluded and we will participate in experimental model consisting the new National Fracture Fracture Molecular and functional study of using mesenchymal stem Registry in which more than 90 of mesenchymal stem cells as cells modified in the treatment of Hospitals have been registered precursors of bone-forming cells. fractures of critical size Spanish people 2. Clinical and epidemiological line. 3. Mineral metabolism and Its objective is to study in Cantabria, cardiovascular risk in systemic as well as in the whole Spain (the inflammatory diseases. latter by means of multicenter studies), the prevalence and A line of collaboration has been incidence of different aspects of initiated with the Rheumatology
Figure. Imágenes de hueso por micro TC de animales OVX y control. Activity Research Areas Report Metabolism, Diseases of Aging and Life Habits Area
• PUBLICATIONS: J CLIN LIPIDOL. 2017;11:532-542. Incretins in patients with rheumatoid F.I.:5,812. [doi:10.1016/j. arthritis. jacl.2017.02.004] Arthritis Res Ther. 2017;19:229-229. IMPACT FACTOR | 110,070 F.I.:4,121. [doi:10.1186/s13075-017- 5. Del Real A, Pérez-Campo FM, 1431-9] Fernández AF, Sañudo C, Ibarbia Original articles CG, Pérez-Núñez MI, Criekinge WV, 10. Villaescusa P, Illescas MJ, Braspenning M, Alonso MA, Fraga Valverde L, Baeta M, Nuñez C, MF, Riancho JA. Martínez-Jarreta B, Zarrabeitia 1. Robinson-Cohen C, Lutsey PL, Differential analysis of genome-wide MT, Calafell F, de Pancorbo MM. Kleber ME, Nielson CM, Mitchell BD, methylation and gene expression in Characterization of the Iberian Y Bis JC, Eny KM, Portas L, Eriksson J, mesenchymal stem cells of patients chromosome haplogroup R-DF27 in Lorentzon M, Koller DL, Milaneschi with fractures and osteoarthritis. Northern Spain. Y, Teumer A, Pilz S, Nethander M, Epigenetics. 2017;12:113-122. Forensic Sci Int Genet. Selvin E, Tang W, Weng LC, Wong F.I.:4,394. [doi:10.1080/15592294.20 2017;27:142-148. HS, Lai D, Peacock M, Hannemann 16.1271854] F.I.:3,911. [doi:10.1016/j. A, Völker U, Homuth G, Nauk M, fsigen.2016.12.013] Murgia F, Pattee JW, Orwoll E, 6. Solé-Morata N, Villaescusa P, Zmuda JM, ..., Kestenbaum B. García-Fernández C, Font-Porterias 11. Cardoso S, Sevillano R, Gamarra Genetic Variants Associated with N, Illescas MJ, Valverde L, Tassi D, Santurtún A, Martínez-Jarreta B, Circulating Parathyroid Hormone. F, Ghirotto S, Férec C, Rouault K, de Pancorbo MM. J AM SOC NEPHROL. 2017;28:1553- Jiménez-Moreno S, Martínez-Jarreta Population genetic data of 38 1565. B, Pinheiro MF, Zarrabeitia MT, insertion-deletion markers in six F.I.:8,966. [doi:10.1681/ Carracedo Á, de Pancorbo MM, populations of the northern fringe of ASN.2016010069] Calafell F. the Iberian Peninsula. Analysis of the R1b-DF27 Forensic Sci Int Genet. 2017;27:175-179. 2. Calvo-Río V, Santos-Gómez M, haplogroup shows that a large F.I.:3,911. [doi:10.1016/j. Calvo I, González-Fernández MI, fraction of Iberian Y-chromosome fsigen.2016.12.014] López Montesinos B, Mesquida M, lineages originated recently in situ. Adán A, Victoria Hernández M, Maíz Sci Rep. 2017;7:7341-7341. 12. García-Hoyos M, García-Unzueta O, Atanes A, Bravo B, Modesto C, F.I.:4,259. [doi:10.1038/s41598-017- MT, de Luis D, Valero C, Riancho JA. Díaz-Cordovés G, Palmou-Fontana 07710-x] Diverging results of areal and N, Loricera J, González-Vela MC, volumetric bone mineral density in Demetrio-Pablo R, Hernández JL, 7. De-Ugarte L, Caro-Molina E, Down syndrome. González-Gay MA, Blanco R. Rodríguez-Sanz M, García-Pérez MA, Osteoporos Int. 2017;28:965-972. Anti-Interleukin-6 Receptor Olmos JM, Sosa-Henríquez M, Pérez- F.I.:3,591. [doi:10.1007/s00198-016- Tocilizumab for Severe Juvenile Cano R, Gómez-Alonso C, Del Rio L, 3814-1] Idiopathic Arthritis-Associated Mateo-Agudo J, Blázquez-Cabrera JA, Uveitis Refractory to Anti-Tumor González-Macías J, Pino-Montes JD, 13. Ferreño D, Sainz-Aja JA, Necrosis Factor Therapy: A Muñoz-Torres M, Diaz-Curiel M, Malouf Carrascal IA, Diego S, Ruiz E, Casado Multicenter Study of Twenty-Five J, Cano A, Pérez-Castrillon JL, Nogues JA, Riancho JA, Sañudo C, Gutiérrez- Patients. X, Garcia-Giralt N, Diez-Perez A. Solana F. Arthritis Rheumatol. 2017;69:668-675. SNPs in bone-related miRNAs are Orientation of whole bone samples F.I.:6,918. [doi:10.1002/art.39940] associated with the osteoporotic of small rodents matters during phenotype. bending tests. 3. Lamiquiz-Moneo I, Baila-Rueda Sci Rep. 2017;7:516-516. J Mech Behav Biomed Mater. L, Bea AM, Mateo-Gallego R, F.I.:4,259. [doi:10.1038/s41598-017- 2017;65:200-212. Pérez-Calahorra S, Marco-Benedí V, 00641-7] F.I.:3,110. [doi:10.1016/j. Martín-Navarro A, Ros E, Cofán M, jmbbm.2016.08.025] Rodríguez-Rey JC, Pocovi M, Cenarro 8. Tejera-Segura B, Macía-Díaz M, A, Civeira F. Machado JD, de Vera-González 14. García Ávila S, Urbina L, Garmilla ABCG5/G8 gene is associated with A, García-Dopico JA, Olmos JM, P, Valero C. hypercholesterolemias without Hernández JL, Díaz-González F, Síndrome de fuga capilar sistémica: mutation in candidate genes and González-Gay MA, Ferraz-Amaro I. una causa rara de shock. noncholesterol sterols. HDL cholesterol efflux capacity Emergencias. 2017;29:357-357. J CLIN LIPIDOL. 2017;11: in rheumatoid arthritis patients: F.I.:3,028. F.I.:5,812. [doi:10.1016/j. contributing factors and relationship jacl.2017.09.005] with subclinical atherosclerosis. 15. Córdoba Alonso AI, Arlabán Arthritis Res Ther. 2017;19:113-113. Carpintero M, Olmos Martínez JM. 4. Pérez-Campo FM, De Castro-Orós F.I.:4,121. [doi:10.1186/s13075-017- Giant Pulmonary Bulla I, Noriega A, Cofán M, Lamiquiz- 1311-3] Superinfection. Moneo I, Cenarro A, Ros E, Civeira Arch Bronconeumol. 2017;53:395-395. F, Pocoví M, Rodríguez-Rey JC. 9. Tejera-Segura B, López-Mejías F.I.:2,979. [doi:10.1016/j. Functional analysis of new 3’ R, Domínguez-Luis MJ, de Vera- arbres.2016.12.010] untranslated regions genetic variants González AM, González-Delgado A, in genes associated with genetic Ubilla B, Olmos JM, Hernández JL, 16. Santurtún A, Rasilla DF, Riancho hypercholesterolemias. González-Gay MA, Ferraz-Amaro I. L, Zarrabeitia MT. 245
Relationship Between Chronic Tocilizumab in Refractory Cystoid stem cell transplantation. Obstructive Pulmonary Disease and Macular Edema of Birdshot SCI JUSTICE. 2017;57:336-340. Air Pollutants Depending on the Retinochoroidopathy Report of Two F.I.:1,992. [doi:10.1016/j. Origin and Trajectory of Air Masses Cases and Literature Review. scijus.2017.05.003] in the North of Spain. OCUL IMMUNOL INFLAMM. Arch Bronconeumol. 2017;53:616-621. 2017;25:604-609. 28. Genre F, Armesto S, Corrales A, F.I.:2,979. [doi:10.1016/j. F.I.:2,453. [doi:10.1080/09273948.20 López-Mejías R, Remuzgo-Martínez arbres.2017.03.017] 16.1231331] S, Pina T, Ubilla B, Mijares V, Martín- Varillas JL, Rueda-Gotor J, Portilla V, 17. Castro B, Rivero M, Crespo J, 23. Pérez-Campo FM, May T, Zauers Dierssen-Sotos T, González-López MA, Riancho JA, Valero C. J, Sañudo C, Delgado-Calle J, González-Vela MDC, Blanco R, Llorca J, Influence of anti-TNF therapy on Arozamena J, Berciano MT, Lafarga Hernández JL, González-Gay MÁ. bone metabolism in patients with M, Riancho JA. Significant sE-Selectin levels inflammatory bowel disease. Generation and characterization reduction after 6 months of anti- Eur J Intern Med. 2017;39: of two immortalized human TNF-a therapy in non-diabetic F.I.:2,960. [doi:10.1016/j. osteoblastic cell lines useful for patients with moderate-to-severe ejim.2017.01.024] epigenetic studies. psoriasis. J Bone Miner Metab. 2017;35:150-160. J Dermatolog Treat. 2017;28:726-730. 18. Olmos-Martínez JM, Córdoba AI, F.I.:2,423. [doi:10.1007/s00774-016- F.I.:1,890. [doi:10.1080/09546634.20 Olmos JM. 0753-z] 17.1329498] Large subcutaneous tumor of the left shoulder. 24. Pariente E, Olmos JM, Landeras 29. García-Ibarbia C, Neila S, Garcés Eur J Intern Med. 2017;42: R, Nan D, González-Macías J, C, Alonso MA, Zarrabeitia MT, Valero F.I.:2,960. [doi:10.1016/j. Hernández JL. C, Ortiz F, Riancho JA. ejim.2016.10.002] Relationship between spinal Non-synonymous WNT16 osteoarthritis and vertebral polymorphisms alleles are 19. Santurtún A, Ruiz PB, López- fractures in men older than 50 associated with different Delgado L, Sanchez-Lorenzo A, years: data from the Camargo osteoarthritis phenotypes. Riancho J, Zarrabeitia MT. Cohort Study. Rheumatol Int. 2017;37:1667-1672. Stroke: Temporal Trends and J Bone Miner Metab. 2017;35:114-121. F.I.:1,824. [doi:10.1007/s00296-017- Association with Atmospheric F.I.:2,423. [doi:10.1007/s00774-016- 3783-5] Variables and Air Pollutants in 0735-1] Northern Spain. 30. González-López MA, Hernández CARDIOVASC TOXICOL. 25. Santurtún A, Riancho JA, JL, Vilanova I, Mata C, López-Escobar 2017;17:360-367. Arozamena J, López-Duarte M, M, González-Vela MC, López-Hoyos F.I.:2,712. [doi:10.1007/s12012-016- Zarrabeitia MT. M, González-Gay MA, Blanco R. 9395-6] Indel analysis by droplet digital Thyroid autoimmunity in patients PCR: a sensitive method for DNA with hidradenitis suppurativa: a 20. Santurtún A, Sánchez-Lorenzo A, mixture detection and chimerism case-control study. Villar A, Riancho JA, Zarrabeitia MT. analysis. Clin Exp Dermatol. 2017;42:642-644. The Influence of Nitrogen Dioxide Int J Legal Med. 2017;131:67-72. F.I.:1,589. [doi:10.1111/ced.13153] on Arrhythmias in Spain and Its F.I.:2,382. [doi:10.1007/s00414-016- Relationship with Atmospheric 1422-4] 31. Gómez-Román J, Zarrabeitia Circulation. MT, Santurtún A, Parra JA, Azueta CARDIOVASC TOXICOL. 2017; 26. Tenorio J, Álvarez I, Riancho- Etxebarría A, Cifrian JM, Freire 17:88-96.F.I.:2,712. [doi:10.1007/ Zarrabeitia L, Martos-Moreno GÁ, Salinas J. s12012-016-9359-x] Mandrile G, de la Flor Crespo M, Pulmonary Langerhans cell Sukchev M, Sherif M, Kramer I, histiocytosis de novo after lung 21. Sánchez-Pérez H, Tejera-Segura Darnaude-Ortiz MT, Arias P, Gordo G, transplantation. B, de Vera-González A, González- Dapía I, Martinez-Villanueva J, Gómez Pathol Int. 2017;67:632- Delgado A, Olmos JM, Hernández R, Iturzaeta JM, Otaify G, García- 637.F.I.:1,465. [doi:10.1111/ JL, Corrales A, López-Mejías R, Unzueta M, Rubinacci A, Riancho JA, pin.12597] González-Gay MA, Ferraz-Amaro I. Aglan M, Temtamy S, Hamid MA, Insulin resistance in systemic Argente J, Ruiz-Pérez VL, Heath KE, 32. Pariente-Rodrigo E, Sgaramella lupus erythematosus patients: Lapunzina P. GA, Olmos-Martínez JM, Pini- contributing factors and Molecular and clinical analysis of Valdivieso SF, Landeras-Alvaro relationship with subclinical ALPL in a cohort of patients with R, Hernández-Hernández JL. atherosclerosis. suspicion of Hypophosphatasia. Relationship between diffuse Clin Exp Rheumatol. 2017;35:885-892. Am J Med Genet A. 2017;173:601-610. idiopathic skeletal hyperostosis, F.I.:2,634. F.I.:2,259. [doi:10.1002/ajmg.a.37991] abdominal aortic calcification and associated metabolic disorders: Data 22. Calvo-Río V, Blanco R, Santos- 27. Santurtún A, Riancho JA, from the Camargo Cohort. Gómez M, Díaz-Valle D, Pato E, Santurtún M, Richard C, Colorado MM, Med Clin (Barc). 2017;149:196-202. Loricera J, González-Vela MC, García Unzueta M, Zarrabeitia MT. F.I.:1,125. [doi:10.1016/j. Demetrio-Pablo R, Hernández JL, Genetic DNA profile in urine and medcli.2017.01.030] González-Gay MA. hair follicles from patients who have Efficacy of Anti-IL6-Receptor undergone allogeneic hematopoietic 33. Lisa Gracia M, Córdoba Alonso Activity Research Areas Report Metabolism, Diseases of Aging and Life Habits Area
A, Hernández Hernández JL, Pérez Director/es: José Luís Hernández Clinical Trials Montes R, Napal Lecumberri JJ. Hernández, Emilio Pariente Rodrigo, Cardiovascular risk factors, José Manuel Olmos Martínez. 1. Jesús González Macías. nonvalvular atrial fibrillation and UNIVERSIDAD DE CANTABRIA. Estudio multicéntrico, internacional, retinal vein occlusion. aleatorizado, doble ciego, controlado Rev Clin Esp. 2017;217:188-192. con alendronato para determinar la F.I.:0,971. [doi:10.1016/j. eficacia y seguridad de AMG 785 rce.2016.10.013] Projects en el tratamiento de mujeres con osteoporosis postmenopáusica. 20110142. AMGEN, S.A.. Reviews Projects Postmarketing Studies 1. García-Hoyos M, Riancho JA, 1. Jesús González Macías. Valero C. Vía canónica de wnt en el and Other Bone health in Down syndrome. osteoclasto: estudio de su Med intervención en la regulación de la 1. José Luís Hernández Hernández. masa ósea. XALIA - Xarelto® para la Thesis Addressed PI12/01405. INSTITUTO DE SALUD Anticoagulación a Largo plazo e CARLOS III. MINISTERIO DE Inicial en el Tromboembolismo ECONOMÍA Y COMPETITIVIDAD. Venoso (TEV). BAY-RIV-2012-01. 1. Miguel Ángel Hernández BAYER HISPANIA, S.L.. Hernández. 2. José Manuel Olmos Martínez. Persistencia de actividad eléctrica Estudio del metabolismo óseo y 2. José Antonio Riancho Moral. cerebral tras el diagnóstico clínico mineral de la población femenina Registro internacional prospectivo de muerte encefálica: incidencia, postmenopáusica y masculina y multicéntrico de pacientes impacto y análisis comparativo mayor de 50 años atendida por hombres y mujeres que han sido del electroencefalograma frente un Centro de Salud en Cantabria. diagnosticados recientemente a la angiografía por tomografía PI15/00521. con fibrilación auricular y reciben computarizada. INSTITUTO DE SALUD CARLOS tratamiento con Rivaroxabán. Director/es: José Luis Fernández III. MINISTERIO DE ECONOMÍA Y TRI08890. Torre, José Luís Hernández COMPETITIVIDAD. THE TROMBOSIS RESEARCH Hernández. INSTITUTE. UNIVERSIDAD DE CANTABRIA. 3. José Antonio Rancho Moral. Estudio de las células troncales 2. Giusi Alesia Sgaramella. mesenquimales en la osteoporosis: Análisis de la concentración Papel de los RNAs largos no plasmática de tirotropina como codificantes (lncRNAs) y potencial variable predictora de enfermedad regenerativo. PI16/00915. cardiovascular en los varones INSTITUTO DE SALUD CARLOS mayores de 50 años: la cohorte III. MINISTERIO DE ECONOMÍA Y Camargo. COMPETITIVIDAD.
Activity Report 249
· Associated Groups
Roberto Zarrabeitia Puente
Hereditary Hemorrhagic Telangiectasia Unit Hospital of Sierrallana Activity Research Areas Report Hereditary hemorrhagic telangiectasia
Responsible Roberto Zarrabeitia Puente • Hereditary hemorrhagic Hereditary hemorrhagic telangiectasia (Rendu Osler telangiectasia Service Hospital of Sierrallana Weber) Study Group
Contributors Jesús Bueno López Ana José Bustamante Ruiz Manuel Secundino Bustamante Sánchez José Luis Fernández Forcelledo José Luis Martín Gurpegui Roberto Megía López Cristina Menéndez García Julio Rodríguez Iglesias Sara Rodríguez Prado, Blanca Señaris González
Nurses Associated group Elena Barahona Bustamante Mar Rodriguez Garrido María Valdor Arriaran
Technicians Teresa Dosal Josefa Hernández
Study of new therapies for HHT: receptors and beta-blockers, in selective modulators of estrogen collaboration with the Center for Research lines
1. Epidemiology of hereditary haemorrhagic telangiectasia in Spain (phenotype-genotype correlation, validity of diagnostic tests, radiological and clinical findings). 251
Mutation affecting the proximal Vascular diseases of the liver. promoter of Endoglin as the Clinical Guidelines from the origin of hereditary hemorrhagic Catalan Society of Digestology telangiectasia type 1. BMC Med and the Spanish Association Genet. for the Study of the Liver. 2017;18:20-20. Gastroenterol Hepatol. F.I.:2,198. [doi:10.1186/s12881- 2017;40:538-580. 017-0380-0] F.I.:0,917. [doi:10.1016/j. gastrohep.2017.03.011] 2. Zarrabeitia R, Fariñas-Álvarez C, Santibáñez M, Señaris B, Fontalba 4. Albinana, Virginia, Recio-Poveda, Biological Research (CIB) of the A, Botella LM, Parra JA. Lucia, Zarrabeitia, Roberto, Botella, Center for Scientific Research Quality of life in patients Luisa M.. (CSIC) in the basic area. with hereditary haemorrhagic Current and emerging telangiectasia (HHT). Health Qual pharmacotherapies for hereditary Life Outcomes. hemorrhagic telangiectasia. • PUBLICATIONS: 2017;15:19-19. Expert Opin Orphan Drugs. F.I.:2,143. [doi:10.1186/s12955- 2017;5:665-675. 017-0586-z] F.I.:0,559. [doi:10.1080/21678707.2 IMPACT FACTOR: | 5,817 017.1353417] 3. Martín-Llahí M, Albillos A, Bañares R, Berzigotti A, García- Original articles Criado MÁ, Genescà J, Hernández- Gea V, Llop-Herrera E, Masnou- Ridaura H, Mateo J, Navascués CA, 1. Albiñana V, Zafra MP, Colau Puente Á, Romero-Gutiérrez M, J, Zarrabeitia R, Recio-Poveda L, Simón-Talero M, Téllez L, Turon F, Olavarrieta L, Pérez-Pérez J, Botella Villanueva C, Zarrabeitia R, García- LM. Pagán JC.